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Summary 
The MRN complex (consisting of Mre11 Rad50 and Nbs1), and CtIP, functions to repair 
DNA double strand breaks. They are also known to have a role in the removal of 
topoisomerases from DNA, and can therefore provide resistance to topoisomerase inhibitors, 
such as camptothecin, which are used as anti-cancer drugs and function by increasing the 
half-life of topoisomerase-DNA cleavage complexes leading to the persistence of DNA 
breaks which can lead to cell death. Therefore it has been hypothesised that patient mutations 
in the MRE11, RAD50, NBS1 and CtIP genes can confer an increased sensitivity to 
topoisomerase inhibitors.  
A recent study, the NWCOG-2 trial, involving the treatment of colorectal carcinomas with 
irinotecan (a topoisomerase inhibitor) and capecitabine (which is metabolised to form the 
nucleoside analogue 5-FU) showed a pathological complete response in 22% of patients and 
a three year survival of 88%, it is unknown which genetic factors influence the response this 
method of treatment. The aforementioned genes are known to be mutated at high frequency 
in colorectal cancers associated with microsatellite instability. 
 In this study, mutations in these genes which have been previously identified in tumours 
have been recreated in Schizosaccharomyces pombe, using the Cre-lox system, and tested for 
sensitivity to camptothecin and MMS. The results show that many of these mutants exhibit a 
severe sensitivity to these drugs. The nbs1-MSI mutant, which encodes a mutant protein 
lacking the C-terminal Mre11 and Tel1
ATM
 binding domains appeared to show an increased 
sensitivity to MMS, with only a slight increase in sensitivity to camptothecin. This mutant is 
a separation of function mutant and shows that the Mre11 and Tel1
ATM
 binding domains of 
Nbs1 may not be essential for topoisomerase removal, but are required for downstream repair 
of MMS induced lesions. 
Sequencing of 25 NWCOG-2 patient tumour samples initially identified the presence of 30 
somatic mutations in. However, identification of all but one of these mutations, the CtIP-
poly(A)9 1 bp deletion of patient R48, was irreproducible and were not found in subsequent 
resequencing reactions. Fluorescent fragment analysis of the MRE11-poly(T)11 tract revealed 
the presence of a single base-pair deletion in one patient (patient R12). Fluorescent fragment 
analysis of CtIP-poly(A)9 tract confirmed the presence of a single base-pair deletion in 
patient R48 and identified patient R51 to possible harbour the mutation also. Bothe patients 
R12 and R48 responded well to the treatment regimen of irinotecan, capecitabine, radiation 
and excision; however it cannot be confirmed that this response was due to the presence of 
the mutations. 
S. pombe mre11Δ, rad50Δ, nbs1Δ and ctp1Δ strains were also tested for sensitivity to 5-FU, 
these strains showed no increase in sensitivity to 5-FU compared to the wild-type, suggesting 
that these genes may not confer sensitivity to 5-FU in tumours. A screen of the Bioneer 
genome wide deletion library was carried out to identify other genes for which mutations 
could potentially confer increased sensitivity or resistance to 5-FU. This identified a total of 
181 mutations which confer increased 5-FU sensitivity, and 316 which conferred an 
increased resistance. Many of the genes found to sensitise to 5-FU when deleted function in 
chromatin remodelling and centromere function, suggesting a possible role for the centromere 
in 5-FU sensitivity. Many of the genes found to confer resistance to 5-FU function in the 
processing of uridine in tRNA; this suggests that the processing of incorporated fluorouridine 
in tRNA may be a significant contributing factor to 5-FU cytotoxicity in S. pombe. 
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1 Introduction 
1.1 The Roles of the MRN Complex and CtIP 
1.1.1 The MRN complex and DNA double strand break repair 
DNA double strand breaks (DSBs) are the most cytotoxic form of DNA damage that occurs 
within cells. There are many agents that may induce DSBs including exogenous factors such 
as ionising radiation (IR) and certain chemotherapeutic drugs, such as radiomimetic drugs 
(e.g. bleomycin) and topoisomerase inhibitors. DSBs can also occur due to the endogenous 
production of reactive oxygen species [1] [2]. DSBs may also be induced by the cells in order 
to initiate various forms of recombination including V(D)J recombination [3], 
immunoglobulin class-switch recombination and meiotic homologous recombination. DSBs 
can also occur during DNA replication (known as replication mediated DSBs (Rep-DSBs)) 
by collisions of DNA polymerase enzymes with a single strand break (SSB), which convert 
single strand breaks (SSBs) into DSBs; and replication fork collapse [4]. 
DSBs are initially detected by the MRN complex [5], this complex is composed of three 
different proteins: Meiotic recombination 11 (Mre11), Rad50 and Nijmegen breakage 
syndrome 1 (Nbs1; also known as NBN). This complex consists of four structural domains, 
one of which is the “head” region which consists of an Mre11 dimer and two ABC ATPase 
domains of Rad50, this region is responsible for the 3′-5′ endonuclease and exonuclease 
activities of this complex. The coil and hook regions consist of the Rad50 coiled-coil 
domains connected by a Zn
+
-hook domain. The fourth region is the flexible adapter that is 
formed by Nbs1 and performs roles in signalling and protein recruitment [6]. Phosphorylation 
of Nbs1 has been shown to regulate the accumulation of the MRN complex and ATM at 
DSBs [7]. The structure of the MRN complex is shown in Figure 1.  
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(Tsutsui, Kawasaki & Iwasaki 2011) [8]  
 
 
 
The MRN complex binds to the broken DNA by the Mre11 DNA binding motifs and tethers 
the two broken ends in order to stabilise the broken chromosomes [5] [9]. Following the 
detection of DSBs, the Nbs1 subunit of the MRN complex then recruits and activates the 
Ataxia Telangiectasia mutated (ATM) protein kinase [10] [11]. ATM is activated via 
autophosphorylation [12]. This in turn leads to the phosphorylation of a range of substrates 
which lead to an arrest of the cell cycle, DNA repair or apoptosis by ATM [5] (See Figure 2). 
These substrates include the histone H2AX [13], which provides docking sites for proteins 
involved in DNA repair and activates checkpoint proteins [14], such as DNA damage 
checkpoint protein 1 (MDC1) [14]; Chk1 [15] and Chk2 [16]; p53 [17], Mdm2 and Mdmx, 
which also aid the stabilisation of p53. Once p53 has been expressed at high levels, it can 
either promote the production of p21/WAF1, which prevent cells from progressing into S-
Figure 1. Model of the MRN complex.  This shows the “head region” consisting of the Mre11 
dimer and the two Rad50 ATPase domains. The coil and hook regions are shown extending from the 
head region. The flexible adapter region consisting of Nbs1 is shown bound to Mre11. The ATM and 
CtIP/Ctp1 proteins are shown bound to the ATM binding and FHA domains respectively.  
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phase from G1 by the inhibition of cycline kinases; or induce the Bax, Noxa and Puma 
proteins which lead to initiation of the caspase cascade and apoptosis [18]. 
There are many pathways which the cell can utilise in order to repair the DSB. One of the 
most important of these pathways is homologous recombination (HR), which is a highly 
accurate mechanism of DNA repair that utilises a sister chromatid, or a homologous 
chromosome, as a template for repair; however, due to the requirement of a sister chromatid, 
this pathway can only take place during the S- and G2-phases of the cell cycle. Another 
highly important DSB repair mechanism, which can occur during the G1-, G0- and M-phases, 
is the non-homologous end joining (NHEJ) pathway which is error prone and can result in 
nucleotide loss and chromosomal translocations [5] [19]. 
Following the detection of DSBs in the NHEJ pathway the Ku heterodimer (consisting of 
Ku70 and Ku80 subunits) binds to the deoxyribose phosphate backbone of both ends of the 
broken DNA [20] (See Figure 3). The DNA dependent protein kinase subunit (DNA-PKcs) 
then binds to the Ku heterodimer thus forming the DNA-dependent protein kinase (DNA-PK) 
[21]. Both broken ends of the DSB are then tethered by DNA-PK, the DNA is then processed 
by a variety of nuclease and polymerase enzymes, including Pol-λ [22] and Pol-μ [23], which 
function to fill in or remove any overhangs of single stranded DNA, this is the stage at which 
errors are thought to occur [24]. The nucleases involved in the processing of the overhangs 
include Artemis which forms a complex with DNA-PK and possesses exonuclease activity 
required to process 5ʹ and 3ʹ overhangs [25] [26]; and Fen1 which plays a role in the 
processing of 5ʹ flaps [27]. Mre11 nuclease activity and Carboxy-Terminal Binding protein 
(CtBP) Interacting Protein (CtIP, also known as RBBP8) aid the dissociation of the Ku 
heterodimer from the DNA [28]. Prior to ligation the 5ʹ hydroxyl groups are phosphorylated 
by polynucleotide kinase (PNK), a process required for XRCC4 activity [29] [30]. The ends 
are then ligated by the LigIV/XRCC4 complex, which is believed to be stimulated by the 
XLF protein (also known as Cernunnos) in an ATP dependent manner [31] [32] (See Figure 
3). Studies have found that in Schizosaccharomyces pombe MRN and checkpoint proteins are 
not required for NHEJ, and no XRCC4 homologue is present [33] [34]. 
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During the HR pathway (see Figure 4) the broken ends must be resected, a process mediated 
by the MRN complex in cooperation with CtIP [35], following CtIP phosphorylation and 
deacetylation by Cdk1 and SIRT6 respectively [36] [37]. Mre11 endonuclease activity is 
required to induce HR by the initiation of resection [38]. It has been shown that in the 
budding yeast Saccharomyces cerevisiae resection is carried out by the Sgs1(Rqh1 in S. 
pombe, BLM in human) helicase which unwinds the DNA; the Dna2 nuclease which digests 
the DNA to create ssDNA overhangs and the replication protein A (RPA) which coats the 
newly formed ssDNA [39]. Exonuclease 1 (Exo1) also plays a role in DNA resection at DSBs 
during HR to generate ssDNA [40] and is required for the recruitment of RPA and Rad51 
[41]. The breast cancer 2 (BRCA2) protein transports the Rad51 recombinase to the ssDNA 
at the break where it replaces the RPA protein to form a polymer which winds around the 
DNA creating a nucleoprotein filament [42]. The replacement of RPA for Rad51 is 
stimulated by Rad52 [43]. The nucleoprotein then searches for homology and initiates strand 
invasion resulting in recombinant DNA molecules [44] (see Figure 4). 
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Figure 2. The DNA double strand break detection mechanism by the MRN complex. This figure 
shows the sequence of events which occur following the formation of a DSB the detection by MRN 
and the subsequent activation of ATM leading to cell cycle arrest, DNA repair and apoptosis, as 
described in section 1.1.1. 
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Figure 3. The non-homologous end-joining (NHEJ) pathway which can occur following 
DSB detection and ATM activation. This figure shows the sequence of events involved in non-
homologous end joining as described on page 3. Mre11 nuclease activity  also aids the 
dissociation of the Ku hetorodimer from DNA (not shown in figure). 
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     (Stracker & Petrini et al 2011) [45] 
 
 
  
Figure 4. The homologous recombination (HR) pathway which can occur following DSB detection 
and ATM activation. This figure shows the events in homologous recombination, as described on pages 
3-4. Rad51is transported by BRCA2 to the ssDNA where is replaces RPA, in a process stimulated by 
Rad52. Rad51 binds to the ssDNA and forms the nucleoprotein filament (not shown in figure). 
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1.1.2 The role of the MRN complex in telomere maintenance 
During DNA replication in eukaryotic cells, genetic material, around 50-200 bp [46], is lost 
from the 5ʹ terminus of the lagging strand thus posing the problem of chromosome shortening 
and potential loss of genes following numerous mitoses [47]. To prevent this from occurring, 
structures known as telomeres are present at the ends of chromosomes. These structures 
consist of guanine rich non-coding repeat sequences bound by proteins forming a T-loop in 
higher eukaryotes. These structures are created by the enzyme telomerase, which in 
vertebrates creates telomeres long enough so that the progeny may go through limited rounds 
of cell division, before the telomeres shorten to the critical length, inducing senescence and 
apoptosis. This process also carries a tumour suppressive effect as cancer cells proliferating at 
an uncontrolled high rate undergo senescence when the telomeres reach critical length [47], 
therefore telomerase reactivation and immortalisation are believed to be important events in 
carcinogenesis as they allow the cancer cells to avoid senescence and to continue 
proliferating [48] [49]. Telomerase has been shown to be expressed at high levels in 90% of 
human cancers [49] [50]. 
In S. cerevisiae, the MRX complex (homologue of the MRN complex) was shown to 
associate with telomeres during the time of the cell cycle in which telomeres are synthesised, 
thus suggesting that the MRX complex may have a role in telomere synthesis [51]. The 
human MRN complex was then also found to localise to the telomeres of human fibroblasts 
during meiosis, suggesting that the MRN complex is also involved in the synthesis of 
telomerase in higher eukaryotes [52]. The exact role of MRN in telomere maintenance 
remains unknown; MRN may aid telomerase through a direct interaction, or indirectly by 
modifying the structure of the telomeres so that telomerase may bind [47]. MRX mutants in S. 
cerevisiae are known to have shortened telomeres [53] [54]. 
9 
 
1.2 Mismatch Repair and Microsatellite Instability  
1.2.1 The roles of mismatch repair 
During DNA replication, polymerase errors can cause DNA base mismatches and base 
insertions and deletions to occur [55]. These mismatches are repaired by the mismatch repair 
(MMR) mechanism in order to prevent these acquired mutations from persisting into the 
daughter cells. Defects of the MMR pathway can lead to an increased rate of spontaneous 
mutations and an increased risk of cancer development [56]. 
In response to the DNA mismatches in human cells, the hMSH2 and hMSH6 proteins 
(homologues of the E. coli MutS protein) form a heterodimer known as the MutSα complex 
which detects mismatch lesions of 1-2 bp in length, larger lesions are detected by MutSβ, a 
heterodimer consisting of hMSH2 and hMSH3 [55] [57]. Following mismatch recognition, 
MutSα recruits the MutLα complex, a heterodimer formed by MLH1 and PMS2 (homologues 
of E.coli MutL) (see Figure 5). The MutLα complex then aids the recruitment of other 
proteins which are involved in the repair of the mismatch, in addition to stabilising the 
interaction between MutSα and the DNA [57]. It is believed that the MutSα/MutLα complex 
then travels along the DNA in 3ʹ-5ʹ direction until it reaches a break in one of the DNA 
strands, at this point the exonuclease, Exo1, is loaded in order to degrade the strand 
containing the error [58]. RPA then binds the ssDNA created by Exo1 prior to the repair of 
the strand by DNA polymerase δ, DNA ligase I then seals the nick [59] (see Figure 5). 
There is evidence to suggest that the MMR pathway plays a role in DNA-damage signalling 
and apoptosis [60]. It is thought that many consecutive failed MMR attempts at the same 
locus can lead to the formation of replication blocks which can in turn trigger cell cycle arrest 
[61]. It has been shown that when cells deficient in the MMR protein complexes MutSα and 
MutLα are treated with certain DNA damaging agents they exhibit a lower level of cell cycle 
arrest, a lower level of p53 and p73 phosphorylation and a greater survival than MMR 
proficient cells [56] [62]. There is evidence to suggest that the MutSα and MutLα proteins 
can recruit Ataxia Telangiectasia Related (ATR) kinase and ATR-Interacting Protein 
(ATRIP) at sites of damage, which then phosphorylates Chk1 [63], the ATR-Chk1 pathway 
causes the cell cycle to arrest at the G2/M transition [64]. Nbs1 may function in the activation 
of ATR at sites of stalled DNA replication forks [65], independent of Mre11 [66]. 
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Figure 5. The Mismatch Repair (MMR) pathway which can occur following the formation of a DNA base 
mismatch as a result of DNA replication, as described on page 9.  
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1.2.2 Mismatch repair deficiency, microsatellite instability and cancer 
A deficiency of MMR can be caused by defects within the genes of the proteins involved in 
MMR, such as CpG island hypermethylation of the MLH1 gene promoter region [67] [68] 
and germline and sporadic mutations in MLH1 and MSH2 [69]. MMR deficiency results in an 
increased rate of mutagenesis which can lead to the deactivation of tumour suppressor genes 
and the activation of oncogenes thus promoting carcinogenesis [70].The most significant 
characteristic of MMR deficiency is microsatellite instability (MSI) in which there is a 
greater rate of unrepaired replication errors which occur within short repetitive sequences 
[71] [72]. MSI usually occurs within intergenic regions and non-coding parts of genes, 
however it has also been found to occur within coding regions [70]. 
Tumour cells showing a high level of MSI (MSI-H) exhibit defects within many genes which 
have microsatellites including genes which function in cell signalling, DNA repair, apoptosis, 
transcription and protein modification [67].  
MSI is known to occur and play an important role in various cancers such as gastric cancer 
[73], endometrial cancer [74] and pancreatic cancer [75], however it is most commonly 
reported in colorectal cancer in which it occurs in 20% of all cases [76].Tumours with MSI-
H, including sporadic and hereditary cases, show many genotypic and phenotypic 
characteristics which differ from microsatellite stable (MSS) tumours due to the distinct 
carcinogenic pathway of these tumours caused by their highly specific mutation spectrum 
[77]. The MSI-H tumours show phenotypes of a high level of mucin secretion, lymphocytic 
infiltration, a poor differentiation and occur most commonly within the proximal region of 
the colon [77] [78]. MSI-H caused by germline mutations within the genes involved in MMR 
is the underlying causes of colorectal cancers (CRCs) associated with Lynch Syndrome (also 
known as hereditary non-polyposis colorectal cancer (HNPCC)) [77] [79], the most common 
form of hereditary colorectal cancer [80]. In Lynch syndrome the aforementioned mutations 
alone do not directly lead to MSI-H and cancer and a “second hit” is required to inactivate the 
remaining wild-type allele, this can occur by a loss of heterozygosity (LOH), somatic 
mutations or DNA methylation of the MLH1 and p14
ARF
 promoters [81].  
MMR deficiency and MSI is also known to occur in around 15-20% of all sporadic colorectal 
cancers [82] [83]. Mutations within the genes involved in MMR are rarely found and it is 
believed that the epigenetic CpG island methylation, known as the CpG island methylator 
phenotype (CIMP) [84], of the hMLH1 promoter, is responsible for MSI in these tumours 
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[83]. Methylation of the promoters of the tumour suppressor genes p16 and THBS1 also 
occurs with a high incidence within CIMP+ (Exhibiting CpG island methylator phenotype) 
cells [84]. CIMP+ has been shown to have a strong association with BRAF and K-RAS 
mutations [85]. Both the K-RAS and BRAF proteins are involved in the mitogen activated 
protein kinase (MAPK) pathway in which these proteins play a role in the transduction of 
signals from a tyrosine kinase receptor in response to binding exogenous growth factors, this 
pathway leads to the activation and translocation of extracellular signal-related kinase (ERK) 
to the nucleus where it up-regulates the transcription of genes that promote cellular growth 
and proliferation [86]. 
Despite the fact that MMR deficiency and MSI are mostly associated with mutagenesis 
within repetitive sequences some mutations which occur in non-repetitive sequences, such as 
mutations which activate BRAF, K-RAS and PIK3CA, also occur frequently within MMR 
deficient tumours [87]. Mutations within the BRAF and K-RAS genes which arise from MSI 
are known to play a role in carcinogenesis by the serrated pathway [86]. The BRAF activating 
(BRAF-V600E) mutation induces a period in which the cell exhibits hyperproliferation and a 
resistance to apoptosis [88] due to an increase in signalling by the MAPK pathway resulting 
in hyperplasia of the crypts, this process is also associated with the MAPK/ERK dependent – 
Akt independent phosphorylation of Gsk3β causes β-catenin to translocate to the nucleus 
[89]. The increased activation of BRAF also up-regulates the production and secretion of 
Insulin-like growth factor binding protein 7 (IGFBP7) which acts via an autocrine/paracrine 
pathway which causes the inhibition of the BRAF-MEK-ERK signalling pathway leading to 
senescence and apoptosis of the affected cells [90]. 
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1.3 Topoisomerases as Targets for Cancer Therapy Using Topoisomerase 
Inhibitors 
 
1.3.1 Topoisomerases and Topoisomerase Inhibitors 
Certain processes, such as DNA replication, transcription and recombination require the 
unwinding of the helical DNA structures. This requirement for unwinding presents the cell 
with a topological issue, as the unwinding at the required site would lead to an over-winding 
of the chromosome. This issue is solved by the creation of transient breaks in the DNA which 
allows for the DNA to be unwound without causing excess winding. These breaks are 
induced by the topoisomerase enzymes type I which induces single-strand breaks, and type II 
which induces DSBs [91] [92] [93]. During the formation of the breaks, topoisomerases 
become covalently bound to DNA and are then released from the DNA following ligation of 
the break [93] [94]. 
If a topoisomerase persists at DNA then the associated break can lead to disruptions of 
transcriptions and replication leading to cell death [94]. The topoisomerase inhibitors, 
camptothecins (CPT) and etoposide derivatives are anti-cancer drugs which exploit the 
consequences of topoisomerase persistence by increasing the half-life of topoisomerase-DNA 
cleavage complex, leading to their retention during replication and transcription leading to 
the death of the cancer cells [94]. 
 
1.3.2 Uses of topoisomerase inhibitors in the treatment of colorectal cancer 
Currently surgery is used as the main treatment for colorectal cancer, the outcome of this 
treatment is improved when adjuvant chemoradiotherapy (combination of radiation and an 
anti-cancer drug, such as irinotecan) is administered. When given postoperatively, adjuvant 
chemoradiation has been found to improve the local control of the disease and increase the 
disease-free survival rate when compared to surgery alone [95]. One study showed that 
preoperative chemoradiotherapy provides greater local control and a reduction in adverse 
toxicity, when compared with postoperative chemoradiotherapy [96]. 
Topoisomerase inhibitors can also be given in combination with radiotherapy as the 
topoisomerase I inhibitors, camptothecins, have been shown to increase the sensitivity of 
cancer cells to radiation [97]. One study by Klautke et al (2011) involving patients with 
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locally advanced rectal adenocarcinoma showed that the camptothecin derivative irinotecan 
when used in conjunction with radiotherapy and the radiation sensitizing drug 5-fluorouracil 
to treat rectal cancer gives good results with a pathologic complete response (pCR) observed 
in 22% of patients, and a four year survival rate of 66% [98]. A pathologic complete response 
is defined as showing no residual invasive tumour or lymph node metastasis following 
treatment [99]. The North West/North Wales Clinical Oncology Group (NWCOG) -2 trial, a 
2011 study by Gollins et al involving 110 adenocarcinoma patients showed that preoperative 
chemoradiotherapy with capecitabine and irinotecan can be used as an effective method of 
downstaging for colorectal cancer prior to surgery with the T-stage downstaged in 67% of 
patients and the N stage downstaged in 80% of patients; this has shown to improve prognoses 
giving increased response rates and improved long-term survival, with a three year local 
recurrence free survival of 96.9%, a metastasis free survival of 71.1%, a disease free survival 
of 63.5% and an overall survival of 88.2%. 22% of patients showed a pathologic complete 
response [100]. Only around 15-30% of colorectal cancers are hypersensitive to 
camptothecins [101] [102]. The aforementioned observations suggest the involvement of 
cellular mechanisms that remove the covalently bound topoisomerases from DNA, even in 
the presence of inhibitors, to aid the survival of the cell. 
 
1.3.3 Mechanisms of topoisomerase removal 
The Tyrosyl-DNA phosphodiesterase (Tdp1) enzyme has been found to hydrolyse the 
topoisomerase-DNA bond to remove top1 from DNA at transcription stalls [94] [103]. 
However, deletions of the tdp1 gene in yeast have shown to only provide a mild sensitivity to 
CPT, suggesting that there are other proteins involved in the removal of topoisomerases and 
the resistance to topoisomerase inhibitors [94]. 
During meiotic recombination in S. pombe the topoisomerase-like protein Rec12 (homologue 
of S. cerevisiae Spo11) covalently binds to DNA to induce a DSB, Rec12 is then removed 
prior to end resection. One study showed that this process was carried out by the nuclease 
activity of Mre11 and Ctp1
CtIP
 [104]. Another study showed that Mre11 together with 
Ctp1
CtIP
 are also involved in the removal of covalently bound topoisomerases from DNA, 
Mre11 was shown to aid the removal of Top1 and Top2 from DNA in vivo, Ctp1
CtIP
 was 
shown to be involved in the removal of Top2 but inhibited the removal of Top1 from DNA, 
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these results and a survival assay showed a role for these proteins in the resistance to 
topoisomerase inhibitors. [94].  
As the MRN complex and CtIP proteins are involved in topoisomerase inhibitor resistance, it 
was theorised that mutations within the genes which encode these proteins could present 
affected cells with an increased sensitivity to topoisomerase inhibitors. Mutations in these 
genes frequently occur in MSI tumours due to the presence of repeat sequences within the 
genes, studies have shown an increase in sensitivity of MSI colorectal tumour cells to the 
camptothecin derivative Irinotecan [102] [105] [67]. CRC patients with MSI-H showed a 
greater response to irinotecan therapy over patient’s with MMR proficient tumours, but 
showed no greater sensitivity to fluorouracil [67]. One study found that the S. pombe rad50S 
(rad50-K81I, separation-of-function mutant that retains the ability to form meiotic DNA 
breaks, but loses resection and repair abilities [106]) and the nuclease dead mre11-D65N 
confer a high sensitivity to topoisomerase inhibitors but only mild sensitivity to other agents 
that damage the DNA [94]. Another study in human cells demonstrated that a specific mutant 
of MRE11, the Δ5-7MRE11 mutant conferred hypersensitivity to camptothecin when 
transfected into a camptothecin resistant cell line and acts in a dominant negative manner 
[107]. These results suggest that mutations of the MRE11, RAD50, NBS1 and CtIP genes may 
provide targets for drugs that increase sensitivity to topoisomerase inhibitors through 
inhibition of MRN or CtIP. For example, mirin has been identified as an inhibitor of Mre11 
nuclease activity [108] and therefor may sensitise cells to topoisomerase inhibition. 
Mutations within these genes may provide prognostic markers to cancers treated with 
topoisomerase inhibitors and that certain specific mutations may confer a higher degree of 
sensitivity over other mutations. Many mutations in MRE11, RAD50, NBS1 and CtIP have 
been identified so-far and are described in section 1.5. These mutations require further 
investigation to identify the specific prognostic value which may be carried by each 
individual mutation. 
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1.4 The use of Nucleoside Analogues in Cancer Therapy 
 
1.4.1 Colorectal cancer treatment using nucleoside analogues 
Nucleoside analogues are a class of drugs that have been administered to treat cancer and 
viral disease for over half a century [109]. The NWCOG-2 trial (as mentioned in section 
1.3.2) utilised the drug capecitabine along with irinotecan, radiotherapy and excision [110] 
[100]. Capecitabine is an orally administered prodrug that is metabolised into the base 
analogue 5-fluorouracil (5-FU) inside the body [111]. This trial showed a pCR in 22% of all 
patients and a three year survival rate of 88% [100]. Another study using a similar regimen 
also showed a pCR in 22% of patients [98]. 
Radiosensitisation of colorectal cancer cells can be induced by administration of nucleoside 
analogues such as gemcitabine [112] and nucleobase analogues such as 5-FU [113] and 5-
fluorocytosine [114], and thus facilitates treatment using radiotherapy. 
 
1.4.2 The mechanisms of action of nucleoside analogues 
Nucleoside analogues are known to cause cytotoxicity through three main mechanisms, by 
incorporation into DNA, incorporation into RNA, or by inhibiting enzymes which function in 
nucleic acid and nucleotide synthesis [115]. 
 
1.4.2.1 DNA incorporation 
For some nucleoside analogues, such as fludarabine and gemcitabine, DNA incorporation is 
required for cytotoxicity [116]. Once the nucleosides have entered a cell, they are converted 
into their respective triphosphate forms through phosphorylation and are subsequently 
incorporated into DNA [117] [118]. The base excision repair (BER) proteins Polymerase β 
and XRCC1 have been found to function in the incorporation of the nucleoside analogues 
gemcitabine and cytarabine into DNA. Following the recognition of DNA damage during 
BER, the damaged base is excised, creating gap which is subsequently filled and ligated by 
Polymerase β and XRCC1 respectively, during which a nucleoside analogue can be 
misincorporated into the DNA [119]. The MMR pathway can also lead to the 
misincorporation of nucleoside analogues into DNA, as MMR creates a nick in the DNA 
250-100 bp from the mismatch, which is subsequently degraded and then filled by DNA 
17 
 
synthesis, which can misincorporated nucleoside analogues [120]. Nucleoside analogues can 
also be incorporated into nuclear and mitochondrial DNA during DNA replication [121]. 
Nucleoside analogues cause the steric hindrance of replication forks when incorporated into 
DNA, this causes the replication forks to stall, which activates the S-phase checkpoint 
leading to cell cycle arrest and apoptosis [122] [123]. Blocking of cell cycle progression 
through S-phase has been found to induce radiosensitivity in cells treated with gemcitabine 
[124].  
DNA incorporation of the active metabolite of the nucleoside analogue 5-fluorouracil (5-FU), 
has also been shown to contribute to cytotoxicity by inducing mutations that lead to aberrant 
protein synthesis  [125] [126]. 
 
1.4.2.2 RNA incorporation 
Nucleoside analogue incorporation into mRNA can also lead to cytoxicity through the 
synthesis of aberrant proteins through miscoding and defective splicing [125] [127]. 
Nucleoside analogues can also be incorporated into tRNA [128], and inhibit 
posttranscriptional modification, and rRNA, which can inhibit pre-rRNA processing [129]. 
These mechanisms are known to contribute to the cytotoxicity of 5-FU [125] [127] [128] 
[129]. 
 
1.4.2.3 Inhibition of enzymes involved in nucleic acid synthesis 
Nucleoside analogues can also exert cytotoxicity through the inhibition of enzymes that 
function in the synthesis of nucleotides. Gemcitabine is known to inhibit ribonucleotide 
reductase (RNR) [130] [131], an enzyme required to synthesise deoxyribonceotides. 
Inhibition of RNR leads to depletion of cellular nucleotide pools. [131] [132]. An active 
metabolite of 5-FU is known to inhibit the enzyme thymidylate synthase (TS), an enzyme 
which functions in the synthesis of dTMP, which is required for dTTP synthesis. TS inhibiton 
leads to thymidineless death through the depletion of cellular thymidine pools and the 
misincorporaton of dUTP into DNA [133]. 
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1.4.3 Roles of the MRN complex and CtIP in nucleoside analogue resistance 
The MRN and ATM proteins have been found to function in the resistance to nucleoside 
analogues by responding to stalled replication forks that have occurred due to the 
incorporation of nucleoside analogues into DNA [134]. MRN and ATM have been found to 
co-localise with γ-H2AX in response to nucleoside analogue induced replication fork stalling, 
even in the absence of DSBs [135]. Poly-(ADP-ribose) polymerase 1 (PARP1) binds to 
stalled replication forks following nucleoside analogue treatment [136] and recruits Mre11 to 
the replication fork to promote resection of DNA and initiate repair of the stalled fork [137]. 
Unpublished research data from the Hartsuiker lab suggests that mutations in MRE11 confer 
hypersensitivity to nucleoside analogues such as gemcitabine, suggesting that the MRN 
complex is required to maintain resistance to nucleoside analogues. Therefore mutations 
within the MRN encoding genes, and also CtIP may confer increased sensitivity in tumours 
to treatment with nucleoside analogues. 
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1.5 Known Mutations of MRE11, RAD50, NBS1 and CtIP 
 
1.5.1 Syndromes associated with germline mutations in MRE11, NBS1, RAD50 and 
CtIP  
Mutations within the MRE11 gene are known to be aetiologically linked to ataxia 
telangiectasia-like disorder (AT-LD) which is an extremely rare progressive disease similar 
to ataxia telangiectasia (AT) and presents with progressive cerebellar ataxia, oculomotor 
apraxia, increased sensitivity to radiation, cell cycle checkpoint defects and chromosomal 
instability [138], however, unlike AT, AT-LD does not present with telangiectasia or severe 
immunodeficiency [139] [140] and has not been shown to cause an increased risk of cancer 
[139] [141]. One study showed that mice heterozygous for an AT-LD causing mutation did 
not exhibit cancer predisposition [142]. The MRE11 N117S [143], W210C [139], T481K, 
[144], R572X [144] [145] and R633X [143] [146] mutations are associated with AT-LD. The 
locations of the aforementioned AT-LD related mutations on the human MRE11 gene and 
Mre11 protein amino acid sequence are shown in Figure 6 and Figure 7 respectively. Table 1, 
on page 29 shows the known MRE11 mutations. Figure 16 on page 87 shows the domain 
structure of human Mre11 in comparison to mutants, including the Mre11-R572X protein. 
The germline MRE11 R633X mutation, when present heterozygously, has been found to 
cause an increased predisposition to breast cancer, this was also found of the R202G mutation 
[146]. 
Germline mutations within NBS1 are known to cause Nijmegen breakage syndrome (NBS), a 
rare autosomal recessive disease which presents with microcephaly, radiosensitivity, 
impaired growth, immunodeficiency and an increased risk of developing cancer [147] [148]. 
Over 90% of the mutations in NBS1 that are responsible for NBS are the founder mutation, 
657del5 [148] [149], a 5 base pair deletion causing a frameshift and a premature stop codon 
resulting in a truncated protein which contains the N-terminal fork-head-associated (FHA) 
and the domain required for BRCA1 interaction however the domain required for Mre11 
interaction is not present [150]. Compound heterozygotes of 657del5 and another NBS 
related mutation, R215W, exhibit a phenotype which is more severe that those homozygous 
for 657del5 [151, 152, 153]. The R215W mutation affects the BRCT (BRCA1 Carboxyl 
Terminal) domains causing impairment in the protein’s ability to bind to histone γ-H2AX 
resulting in a delay in DNA-DSB repair [153]. Other mutations associated with NBS include 
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the nonsense mutations Q326X and Y363X and the frameshift truncations 681delT, 698del4, 
742insGG, 835del4, 842insT, 900del25 and 1142delC [149] [154]. 
Heterozygous mutations in NBS1, particularly the 657del5, I171V, R215W and IVS11+2insT 
mutations, have also been found to cause an increase in cancer predisposition, particularly to 
tumours of the colon and rectum, breast, prostate, lymphoblastic leukaemia and non-
Hodgkin’s lymphoma due to haploinsufficiency of Nbs1 [149]. A study has shown that the 
NBS1-I171V mutation functions in a dominant negative manner, impairing DNA repair 
leading to chromosomal instability [155]. A homozygous germline mutation of E185Q was 
thought to increase cancer predisposition [156] [157] [158], however a recent meta-analysis 
has suggested that there is no association between this variant and overall cancer risk [159] 
[160]. The locations of aforementioned NBS related mutations on the human NBS1 gene and 
Nbs1 protein and amino acid sequence are shown in Figure 10 and Figure 11 respectively. A 
table showing the known NBS1 mutations is shown in Table 3. 
There currently is no syndrome attributed to mutations in RAD50, however one patient with 
compound heterozygous mutations of RAD50 was described with an NBS-like disorder 
(NBS-LD). The two mutations identified were the R1093X truncation and the 
X1313YextX*66 mutation in which the stop codon is replaced by a tyrosine residue leading 
to the translation of an additional 66 amino acids [161]. The locations of aforementioned 
NBS-LD related mutations on the human RAD50 gene and Rad50 protein and amino acid 
sequence are shown in Figure 8 and Figure 9 respectively. A table showing the known 
RAD50 mutations is shown in Table 2. 
Homozygous mutations of CtIP have recently been identified to cause Seckel syndrome, a 
disorder characterised by neurological and growth syndromes. An increase in cancer risk has 
also been attributed to this disorder although few malignancies have been reported in Seckel 
syndrome. CtIP has also been linked to the Seckel-like microcephalic disorder Jawad 
syndrome. The Seckel Syndrome mutation (CtIP
S
) occurs at the 15
th
 splice donor site, 
causing the insertion of the sequence from intron 15 and a premature stop codon. The Jawad 
syndrome mutation (CTIP
J
) is a 2bp deletion causing a frameshift and truncation [162]. The 
locations of aforementioned Seckel syndrome and Jawad syndrome related mutations on the 
human CtIP gene and CtIP protein and amino acid sequence are shown in figures 12 and 13 
respectively. A table showing the known CtIP mutations is shown in Table 4. 
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1.5.2 MSI associated mutations of MRE11, RAD50, NBS1 and CtIP 
There have been many different mutations of the MRE11, RAD50, NBS1 and CtIP genes 
found within colorectal cancer cells. Many of these mutations occur within short repeating 
sequences with cancer cells which exhibit MSI. One of these repeat sequences which is 
commonly effected is the poly(T)11 repeat located within intron 4 of the MRE11 gene in 
which 1 or 2 bp deletions were found within 93% of all MMR deficient colorectal cancers 
[163] (see Figure 6 and Figure 7). These mutations are believed to interfere with the splicing 
process following transcription leading to the generation of a truncated Mre11 protein [163] 
[164] as this poly(T)11 repeat sequence provides an accessory splicing signal for the MRE11 
intron 4 (IVS-4) 3ʹ-splice acceptor site which can lead to the removal of exon 5 by the 
splicing process [164]. It is thought that the number of deletions of T bases within this 
sequence can greatly affect the expression of the Mre11 protein as it was shown that most 
cells carrying a wild type or a single base pair deletion show a normal level of Mre11 
expression whereas the level of Mre11 expression is greatly reduced in cells carrying a 2 bp 
deletion with a complete absence occurring in 56% of cases [164]. 
There are two known transcripts which arise due to these mutations one of which is the 
MRE11-484del88 mutant gene generated by a complete deletion of exon 5 and frameshift 
which causes a premature stop codon to occur within the transcript, leading to the synthesis 
of a 105 amino acid (out of 708) protein [4] [163]. This mutant protein is associated with a 
reduction in the expression of the other two proteins which constitute the MRN complex 
[165]. The Mre11-484del88 mutant protein is only found in colorectal cancer cells with 
MMR deficiency, in which one study identified this transcript in 98% of MMR deficient 
colorectal cancers [163] [165]. Mre11-484del88 has never been found within the 
microsatellite stable colorectal cells, non-cancerous surrounding colonic mucosa or within the 
peripheral blood [163]. 
The other mutant transcript that arises due to deletions within the poly(T)11 sequence of 
MRE11 intron-4 is that of Δ5-7MRE11 in which exons 5-7 are deleted resulting in a 593 amino 
acid protein in which the 3
rd
 and 4
th
 highly conserved phosphodiesterase domains, which are 
required for 3ʹ-5ʹ exonuclease activity, are removed [107]. The domain structure of wild-type 
Mre11 and Δ5-7Mre11 is shown in figure 16. A loss of nuclease activity is characteristic of the 
Mre11-D65N nuclease dead mutant protein in S. pombe (see page 15) suggesting a possibility 
that Δ5-7MRE11 may encode a separation of function mutant protein. This mutant protein, like 
the Mre11-484del88 protein, is found only within MMR deficient colorectal cancer cells and 
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has not been identified in any MMR proficient cells. This mutant protein has been shown to 
have decreased levels of interaction with Rad50 and decreased affinity for Nbs1 in 
comparison to wild-type Mre11, however the affinity for ssDNA regions is greater in this 
mutant than the wild-type suggesting a possibility that Δ5-7Mre11 persists at DNA following 
stress at the replication fork [107]. Cells expressing the Δ5-7Mre11 mutant have shown an 
increased sensitivity to the topoisomerase inhibitor camptothecin (see page 15) and 
thymidine, a drug which interferes with the cellular nucleotide balance by inhibiting the 
ribonucleotide reductase enzyme, causing an increase in the cellular concentration of 
deoxythymidine triphosphate (dTTP) and a decrease in the deoxycytosine triphosphate 
(dCTP) levels, thus disrupting DNA synthesis and the cell’s progression through to S-phase. 
Thymidine induces homologous recombination, it has been shown that cells expressing Δ5-
7MRE11 are defective in thymidine induced homologous recombination [107]. Following 
thymidine treatment in Δ5-7MRE11 expressing cells, ATM autophosphorylation is impaired, 
however the phosphorylation of Chk1, Chk2 and Nbs1 is not. Δ5-7 Mre11 containing cells 
were found to be defective at forming Mre11 foci and showed a slightly higher sensitivity to 
high doses of ionising radiation than the wild-type cells [107]. Cells expressing Δ5-7MRE11 
have been shown to exhibit hypersensitivity to inhibition of poly(ADP-ribose)polymerase 
(PARP-1), an enzyme which functions to repair DNA single-stranded breaks with ends that 
require processing, inhibition of this enzyme can lead to the accumulation of DNA single-
stranded breaks which can form DSBs as a result of DNA replication [166] [167]. 
Transfection of the Δ5-7MRE11 transcript into the HR proficient U937 cell had a detrimental 
effect on HR, as shown by an increase in the number of phosphor-γH2AX foci and a decrease 
in the number of Rad51 foci, following inhibition of PARP [167]. 
The frequencies of mutations in the aforementioned poly(T)11 mutation of Mre11 in MMR 
deficient colorectal cancers has been found to decrease with stage, with one study showing 
100% of MMR deficient tumours of stage A and B, whereas this was only found in 68.8% of 
tumours at grade C and D. The biallelic mutation frequency was also found to differ by grade 
with 55.6% of grade G1 and G2 patients having biallelic MRE11 mutations, this decreased to 
37.5% in grade G3 [165]. 
Repeat sequences located within coding regions can also be subject to mutation in cells with 
MSI, as is the case with the poly(A)9 repeat sequence in exon 13 of the RAD50 gene (see 
Figure 8 and Figure 9). This region has been found to be affected by single base pair 
deletions and insertions [70] [168] [169] which result in frameshifts that give rise to truncated 
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proteins consisting of 734 and 726 amino acids (out of 1312) respectively, both of which lack 
the C-terminal heptad repeat and therefore are unable to bind to Mre11 [168]. 2 bp deletions 
within this repeat have also been reported, these cause a frameshift similar to that of the 1 bp 
insertion but with a loss of a lysine residue, resulting in a 733 amino acid protein [70]. The 
aforementioned mutations have been found to occur in 33% of colon cancers and 38% of 
gastric cancers with MSI [70]. These mutations only occur within MSI-H cells, in which they 
were identified in 60% of MSI-H colorectal cancer cell lines and 46% of primary colorectal 
carcinomas with MSI-H and where not found in any MSI-S or MSI-L cell lines or primary 
tumour samples [168]. The aforementioned mutations were thought to only occur 
heterozygously within cells, as it is thought that a homozygous phenotype would be 
incompatible for cell survival [168], however one study showed a homozygous poly(A)8 
mutation within the LoVo cell line [169]. These mutations occur at high frequencies 
throughout the different stages of colorectal cancer, with frequencies of 57.1%, 71.4% and 
40% at Dukes A, B and C stages respectively in tumours from patients with HNPCC [170].  
A second repeat sequence, the poly(A)8 repeat in exon 17, that may be affected by MSI and 
lead to the generation of a mutated protein is present within Rad50 [169] [171] (see Figure 8 
and Figure 9). A homozygous single base pair deletion in this repeat sequence was identified 
in the LS411N cell line. A single base pair deletion causes a frameshift with a premature stop 
codon, leading to the expression of a truncated 938 (out of 1312) amino acid protein [169] 
(see figure 17 on page 89) 
The NBS1 gene contains a poly(A)7 repeat within exon 11 that is known to be subject to a 
single A base deletion, also referred to as the 1651delA mutation, in MSI tumours (see Figure 
10 and Figure 11). This mutation gives rise to a truncated protein that is 577 amino acids in 
length (see figure 18 on page 91). This mutation is found only in MSI-H tumours, in which it 
occurs within 3% of MSI-H colorectal cancers and 3.3% of MSI-H gastric cancers, and is not 
found in any MSI-S or MSI-L tumour cells [172]. 
Microsatellite instability can also affect the microsatellites of the CtIP gene with the 
poly(A)9 sequence of exon 12 being a frequent target for mutation (see Figure 12). This 
mutation leads to the expression of a truncated protein that consists of the N-terminal 357 
amino acid region [173] (see figure 19 on page 93). This mutation is also known to confer 
hypersensitivity to PARP inhibition [167]. In one study, this mutation was found in 22.9% of 
MSI colorectal tumours, significantly higher than the mutation frequency of intronic 
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poly(A)9 repeats (approximately 5%). Tumours containing this mutation were most common 
in the proximal region of the colon, similar to that of other MSI colorectal tumours. The 
occurrence of this mutation differed by the grade of the tumour, with 16%, 52%, 28% and 4% 
of cases of tumours with this mutation in grades I, II, III and IV respectively, which was 
similar to other MSI tumours (occurring at 8%, 72%, 20% and 0% at grades I, II, III and IV 
respectively) [174].  
 
1.5.3 Other mutations of the MRE11, RAD50, NBS1 and CtIP found in cancers 
Mutations in MRE11, RAD50, NBS1 and CtIP that are not associated with MSI have also 
been found to occur in various cancers. The locations of these mutants on the MRE11, 
RAD50, NBS1 and CtIP genes are shown in figures 6, 8, 10 and 12 respectively. The 
locations of these mutants on the Mre11, Rad50, Nbs1 and CtIp protein amino acid sequences 
are shown in figures 7, 9, 11 and 13 respectively. Full lists of the mutations, and their 
associated diseases, are shown in tables 1-4.  
Seven different MRE11 mutations, W210X, C249X, Q459X, E460X, L473F, M523K, Q629K 
and M675I, have been identified in colorectal cancers with chromosomal instability (CIN) 
[175]. Tumours with CIN are characterized by aneuploidy and the high rate of which affected 
cells gain and lose whole, or large parts of, chromosomes [175] [176]. Tumours with CIN 
carry a poor prognosis, worse than that of MSI tumours [176] [177]. A figure showing the 
domain structure of wild-type Mre11 and Mre11-W210X is shown in figure 16. 
MRE11 mutations can also arise in cancers of other organs, such as the breast in which the 
missense mutations S104C [178], F237C, H302Y [179] and R503H [178] have been 
identified. A mutation in which a 63bp sequence from intron 20 is inserted between codons 
690 and 691 was identified in a breast cancer cell line, this inserted sequence codes for a 
premature stop codon leading to a truncated MRE11 protein that lacks the C-terminal charged 
amino acid domain. This transcript is thought to occur due to a splicing error as no mutations 
on the DNA have been attributed [178]. 
Other cancers in which MRE11 has been found to be mutated include ovarian cancer and 
lymphoma, in which the mutations R305W [180] and R572Q [178] have been identified 
respectively. 
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Mutations in RAD50 have also been identified in cases of breast and ovarian cancer, one such 
mutation is the 687delT frameshift that leads to the production of Rad50 proteins that are 
approximately 80% shorter than that of the wild type, only containing the N-terminal domain 
required for binding to MRE11. One study found this mutation in around 2.5% of breast 
cancer cases [180]. Two missense mutations of RAD50 have also been found in breast and 
ovarian cancer, the I94L and R224H mutations that affect the amino-terminal and coiled coil 
domain of Rad50 respectively [180]. 
One study identified three novel NBS1 mutants found in breast, ovarian, colorectal and 
gastric cancer. These mutations were R43X, a truncation within the first exon found in more 
than half of all sequenced alleles; Ins 50 bp from Intron 2, a splicing error in which leading to 
a premature in-frame stop codon; and Δ13 NBS1, a splicing error which leads to the deletion 
of exon 13 in the transcript. No splice donor or acceptor site mutations have been identified 
for the latter two mutations [181]. 
Other mutations in NBS1 have been found in breast cancer, L150F [180]; renal cancer, 
Y679H [182]; ALL and lymphoma, S93L, D95N and V210F [183] [184]. 
Mutations in CtIP have been found in cells of colorectal cancer, V394M, P436S and Y819S 
[185]; pancreatic cancer, K337E [185]; ovarian cancer and breast cancer, R589H [173] [185]. 
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1.6 Figures Showing the Mutations Mapped to the Genes and Proteins 
1.6.1 MRE11
Figure 6. A map of the human MRE11 gene showing the exon/intron structure of the gene and the locations of the mutations which have been 
identified in tumour cell lines, cancer patient samples and patients with Ataxia Telangiectasia-like Disorder (AT-LD). 
hMRE11 
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Alignment of the Human Mre11 Protein with the Mouse, Chicken, S. pombe and S. cerevisiae Homologues 
 
 
 
 
hMre11   1 -----MSTADALDDENTFKILVATDIHLGFMEKDAVRGNDTFVTLDEILRLAQENEVDFILLGGDLFHENKPSRKTLHTCLELLRKYCMGDRPVQFEILSDQSVNFGFSKFPW 
mMre11   1 -----MSPTDPLDDEDTFKILVATDIHLGFMEKDAVRGNDTFVTFDEILRLALENEVDFILLGGDLFHENKPSRKTLHSCLELLRKYCMGDRPVQFEVISDQSVNFGFSKFPW 
gMre11   1 -----MSAVSLQDDEDTFKILIATDIHLGYLEKDAVRGNDTFVTFNEILEHAQKNEVDFILLGGDLFHENKPSRKTIHTCLESLRKYCMGDRPVSFEVLSDQAVNFQLSKFPW 
pMre11   1 MPNDPSDMNNELHNENTIRILISSDPHVGYGEKDPVRGNDSFVSFNEILEIARERDVDMILLGGDIFHDNKPSRKALYQALRSLRLNCLGDKPCELELLSDTSLTTGDTAVCN 
cMre11   1 ---------MDYPDPDTIRILITTDNHVGYNENDPITGDDSWKTFHEVMMLAKNNNVDMVVQSGDLFHVNKPSKKSLYQVLKTLRLCCMGDKPCELELLSDPSQVFHYDEFTN 
 
 
 
 
 
hMre11 109 VNYQDGNLNISIPVFSIHGNHDDPTGADALCALDILSCAGFVNHFGRSMSVEKIDISPVLLQKGSTKIALYGLGSIPDERLYRMFVNKKVTMLRPKEDENSWFNLFVIHQNRS 
mMre11 109 VNYQDGNLNISIPVFSIHGNHDDPTGADALCALDVLSCAGFVNHFGRSMSVEKVDISPVLLQKGSTKLALYGLGSIPDERLYRMFVNKKVTMLRPKEDENSWFNLFVIHQNRS 
gMre11 109 VNYQDENLNIFMPIFSIHGNHDDPTGVDALCALDILSCAGLLNHFGRSTSVEKIDISPILLRKGRTKIALYGLGAIPDERLYRMFVNKQVTMLRPKEDEDSWFNMFVIHQNRS 
pMre11 114 INYLDPNINVAIPVFSIHGNHDDPSGDGRYSALDILQVTGLVNYFGRVPENDNIVVSPILLQKGFTKLALYGISNVRDERLYHSFRENKVKFLRPDLYRDEWFNLLTVHQNHS 
cMre11 105 VNYEDPNFNISIPVFGISGNHDDASGDSLLCPMDILHATGLINHFGKVIESDKIKVVPLLFQKGSTKLALYGLAAVRDERLFRTFKDGGVTFEVPTMREGEWFNLMCVHQNHT 
 
 
 
  
 
hMre11 222 KHGSTNFIPEQFLDDFIDLVIWGHEHECKIAPTKNEQQLFYISQPGSSVVTSLSPGEAVKKHVGLLRIK-GRKMNMHKIPLHTVRQFFMEDIVLANHPDIFNPDNPKVTQAIQ 
mMre11 222 KHGNTNFIPEQFLDDFIDLVIWGHEHECKIGPIKNEQQLFYVSQPGSSVVTSLSPGEAVKKHVGLLRIK-GRKMNMQKLPLRTVRRFFIEDVVLANHPNLFNPDNPKVTQAIQ 
gMre11 222 KHGATNYIPEQFLDDFINLAVWGHEHECKITPAQNEQQHFYVTQPGSSVVTSLSPGEAVKKHIGLLRVK-GKKMKMQRIALETVRTFYMEDVVLADHPELFNPDNPKVTQAIQ 
pMre11 227 AHTPTSYLPESFIQDFYDFVLWGHEHECLIDGSYNPTQKFTVVQPGSTIATSLSPGETAPKHCGILNIT-GKDFHLEKIRLRTVRPFIMKDIILSEVSSIPPM--VENKKEVL 
cMre11 208 GHTNTAFLPEQFLPDFLDMVIWGHEHECIPNLVHNPIKNFDVLQPGSSVATSLCEAEAQPKYVFILDIKYGEAPKMTPIPLETIRTFKMKSISLQDVPHLRP----HDKDATS 
 
 
 
 
 
hMre11 334 SFCLEKIEEMLENAERERLGNSH---------QPEKPLVRLRVDYSG--------GFEPFSVLRFSQKFVDRVANPKDIIHFFRHREQKEKTGEEINFGKLITKPS-EGTTLR 
mMre11 334 SFCLEKIEEMLDSAERERLGNPQ---------QPGKPLIRLRVDYSG--------GFEPFNVLRFSQKFVDRVANPKDVIHFFRHREQKGKTGEEINFGMLITKPASEGATLR  
gMre11 334 AFCMEKVEMMLDNAERERLGNPR---------QPQKPLIILRVDYTG--------GFEPFIVHRFSQKYMDRVANPKDIIHFFRHREQKEKNDNDINFGKLLSRPASEEVTLR  
pMre11 338 TYLISKVEEAITEANAQWYEAQG-TVPVVENEKPPLPLIRLRVDYTG--------GYQTENPQRFSNRFVGRVANATDVVQFYLKKKYTRSKRNDGLYTSAVEDIKIN-----  
sMre11 328 KYLIEQVEEMIRDANEETKQKLADDGEGDMVAELPKPLIRLRVDYSAPSNTQSPIDYQVENPRRFSNRFVGRVANGNNVVQFYKKRSPVTRSKKSGINGTSISDRDVEKLFSE 
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hMre11 429 --VEDLVKQYFQTAEKNVQLSLLTERGMGEAVQEFVDKEEKDAIEELVKYQLEKTQRFLKERHIDALEDKIDEEVRRFRETRQKNTNEEDDEVREAMTRARALRSQSEESASA 
mMre11 430 --VEDLVKQYFQTAEKNVQLSLLTERGMGEAVQEFVDKEEKDAIEELVKYQLEKTQRFLKERHIDALEDKIDEEVRRFRESRQRNTNEEDDEVREAMSRARALRSQSETSTSA 
gMre11 430 --VEDLVKQYFQTAEKKVQLSLLTERRMGEAVQEFVDKEEKDAIEELVKFQLEKTQRFLKERHIDAEEEKIDEEVRKFRESRRKNTEEEDEEVREAMTRARAHRSEGVVLDSA 
pMre11 436 ---SLRVESLVNEYLKTNRLECLPEDSLGEAVVNFVEKDDRDAIKECVETQLNKQINLLVK-KRVTEENLEQEISSIINDLPKISTTK---------------RKDYEELPEE 
cMre11 440 SGGELEVQTLVNDLLNKMQLSLLPEVGLNEAVKKFVDKDEKTALKEFISHEISNEVGILSTNEEFLRTDDAEEMKALIKQVKRANSVRP------------TPPKENDETNFA 
 
 
 
 
 
hMre11 540 FSADDLMSIDLAEQMANDSDDSISAATNKGRGRGRGRRGGRGQNSASRGGSQRGRADTGLETSTRSRNSKTAVSASRNMSIIDAFKSTRQQPSRNVTTKNYSEVIEVDESDVE 
mMre11 541 FSAEDLS-FDTSEQTANDSDDSLSAVPSRGRGRGRGRRGARGQSSAPRGGSQRGR-DTGLEITTRGRSSKATSSTSRNMSIIDAFRSTRQQPSRNVAPKNYSETIEVDDSD-E  
gMre11 541 SSDEGLM--DTGMKASGDSDDDIPTTLSRGRGRGRAR-GARGQNSAARGSSRRGRGNTSQGSSTSSRTYKSVP--DKNSSIMDAFRSLKPEPSQ-STSKFFSEDIIDDEMDLE 
pMre11 530 VSET------SINIAEHTPVLKHTSSLLDH------------HSPLATSSSEHEMEATPSPALLKKTNKRRE-------LPSSLTKKNTRTPQRSKEVKKVPARKLSQSTKKS 
cMre11 541 FNGNGLDSFRSSNREVRTGSPDITQSHVDN------------ESRITHISQAESSKPTSKPKRVRTATKKKIPAFSDSTVISDAENELGDNNDAQDDVDIDENDIIMVSTDEE 
 
 
 
 
 
hMre11 653 EDIFPTTSKTDQRWSSTSS-SKIMSQSQVSKGVDFESSEDDDDDPFMNTSSLRRNRR 
mMre11 651 DDIFPTNSRADQRWSGTTS-SKRMSQSQTAKGVDFESDEDDDDDPFMSSSCPRRNRR 
gMre11 648 ESPISLSSKTNQRSSAMSSFSKRGSQSQMSRGVDFESDE---DDPFKNTATSRRKK- 
pMre11 618 DK-----NTQSTLLFYDPS-----STTEAQYLDNE-------DDEILDD-------- 
cMre11 642 DASYGLLNGRKTKTKTRPA-----ASTKTASRRGKGRASRTPKTDILGSLLAKKRK- 
 
 
 
Figure 7. Mre11 amino acid alignment. An alignment of the amino acid sequences of the human, mouse, chicken, Schizosaccharomyces pombe and Saccharomyces cerevisiae Mre11 
proteins (hMre11, mMre11, gMre11, pMre11 and cMre11 respectively).The sequence is shaded to show the similarities between the sequences of the aforementioned proteins. The 
mutations found in human tumour cell lines and patient samples as well as those found in AT-LD are labelled at their positions on the protein. The area of red text corresponds to the 
exons 5-7 in the human Mre11 as this is the deleted region in the Δ5-7MRE11 mutation. 
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Table 1: Mutations Found Within the Human MRE11 Gene 
 
Mutation Associated Condition(s) Association with MSI or CIN References 
S104C Breast cancer No [178] 
1 or 2 bp deletions in the poly(T)11 repeat in 
intron 4 creating the splice variants MRE11-
484del88 and Δ5-7MRE11 
Colorectal cancer MSI [4], [163], [165] 
N117S AT-LD No [143] 
R202G Breast cancer No [146] 
W210C AT-LD No [139] 
W210X Colorectal cancer CIN [175] 
F237C Breast cancer No [179] 
C249X Colorectal cancer CIN [175] 
H302Y Breast cancer No [179] 
R305W Ovarian cancer No [180] 
Q459X Colorectal cancer CIN [175] 
E460X Colorectal cancer CIN [175] 
L473F Colorectal cancer CIN [175] 
T481K AT-LD No [143] 
R503H Breast cancer No [178] 
M523K Colorectal cancer CIN [175] 
R572X AT-LD No [144], [145] 
R572Q Lymphoma No [178] 
Q629K Colorectal cancer CIN [175] 
R633X AT-LD, Breast cancer No [143], [146] 
M675I Colorectal cancer CIN [175] 
690-691 63 bp Insertion Breast cancer No [178] 
 
Table 1. Table describing the MRE11 mutations shown on Figure 6 and Figure 7. This table shows the amino acid changes for each mutation and the condition for which 
they are associated. The poly(T)11 mutations are also associated with MSI. 
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1.6.2 RAD50
Figure 8. A map of the human RAD50 gene showing the exon/intron structure of the gene and the locations of the mutations which have been 
identified in tumour cell lines, cancer patient samples and patients with Nijmegen Breakage Syndrome-like Disorder (NBS-LD).  
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Alignment of the Human Rad50 Protein with the Mouse, Chicken, S. pombe and S. cerevisiae Homologues 
  
 
 
 
hRad50   1 MSRIEKMSILGVRSFGIEDKDKQIITFFSPLTILVGPNGAGKTTIIECLKYICTGDFPPGTKGNTFVHDPKVAQETDVRAQIRLQFRDVNGELIAVQRSMVCTQKSKKTEFKT 
mRad50   1 MSRIEKMSILGVRSFGIEDKDKQIISFFSPLTILVGPNGAGKTTIIECLKYICTGDFPPGTKGNTFVHDPKVAQETDVRAQIRLQFRDVNGEMVAVHRSMLCSQKNKKTEFKT 
gRad50   1 MAKIEKMSILGVRSFGVEDKDKQIITFFNPLTILVGPNGAGKTTIIECLKYISTGDFPPGTKGNSFVHDPKVANETDVRAQIRLQFRDVSGELIAVQRSMVCTQKSKKTEFKT 
pRad50   1 MSCIDRMSIMGIRSF--DNRSRESIQFFSPLTLIVGQNGSGKTTIIECLKYATTGILPPNTKGGAFIHDPKICGEKEVLAQVKLAFRNTNQVKMICTRSLQLSVKKTTRQQKT 
cRad50   1 MSAIYKLSIQGIRSFD--SNDRETIEFGKPLTLIVGMNGSGKTTIIECLKYATTGDLPPNSKGGVFIHDPKITGEKDIRAQVKLAFTSANGLNMIVTRNIQLLMKKTTTTFKT 
 
 
 
 
 
hRad50  114 LEGVITRTKH-GEKVSLSSKCAEIDREMISSLGVSKAVLNNVIFCHQEDSNWPLSEGKALKQKFDEIFSATRYIKALETLRQVRQTQGQKVKEYQMELKYLKQYKEKACEIRD 
mRad50  114 LEGVITRMKH-GEKVSLSSKCAEIDREMISCLGVSKSVLNNVIFCHQEDSNWPLSEGKALKQKFDEIFSATRYIKALDTLRQVRQTQGQKVKECQTELKYLKQNKEKACEIRD 
gRad50  114 LEGVITRTKH-GEKVSLSSKCAEIDREMISALGVSKSVLNNVIFCHQEESNWPLSEGKALKQKFDEIFSATRYIKALETLRQVRLKQGTKVKECQTELKYLKQNKEKAQEIQD 
pRad50  112 LDGQLLILKD-NERTTISNRCAELDSQVPLSLGVSKALLDYVIFCHQEESFWPLSEPANLKKRFDEIFESLRYAKALDQIKGLKRDQETQVKVDQATLTHYRSDKERAEKIEL 
cRad50  112 LEGQLVAINNSGDRSTLSTRSLELDAQVPLYLGVPKAILEYVIFCHQEDSLWPLSEPSNLKKKFDEIFQAMKFTKALDNLKSIKKDMSVDIKLLKQSVEHLKLDKDRSKAMKL 
 
 
 
 
 
hRad50  226 QITSKEAQLTSSKEIVKSYENELDPLKNRLKEIEHNLSKIMKLDNEIKALDSRKKQMEKDNSELEEKMEKVFQGTDEQLNDLYHNHQRTVREKERKLVDCHRELEKLNKESRL 
mRad50  226 QITSKEAQLASSQEIVRSYEDELEPLKNRLKEIEHNLSKIMKLDNEIKALESRKKQMEKDNSELEQKMEKVFQGTDEQLNDLYHNHQRTVREKERRLVDCQRELEKLNKEARL 
gRad50  226 NLANREAQLSASKENIKSIESQLDPLKSSLAAVEKNLMEVMSLDNNVKALESRRIQMEKDNQDLQRKMEKVFQGTDEQLKDRYHNHQRTVKEKEKRLSDCKRELDRASKECQR 
pRad50  224 RVHESLKRISCIRSKVEELDQEITETARLQDELFKSTEEYEQQMITIRHLESQSDIINTTINDLKSQMTITDE-SSEDLEKLHSNFAEKVKEEQELYKSLEKKRSDLESLLKS 
cRad50  225 NIHQLQTKIDQYNEEVSEIESQLNEITEKSDKLFKSNQDFQKILSKVENLKNTKLSISDQVKRLSNSIDILDL-SKPDLQNLLANFSKVLMDKNNQLRDLETDISSLKDRQSS 
 
 
 
 
 
hRad50  339 LNQEKSELLVEQGRLQLQADRHQEHIRARDSLIQSLATQLELDGFERGPFSERQIKNFHKLVRERQEGEAKTANQLMNDFAEKETLKQKQIDEIRDKKTGLGRIIELKSEILS 
mRad50  339 LNQEKAELLVEQGRLQLQADRHQEHIRARDSLIQSLATHLELDGFERGPFSERQIKNFHELVKERQEREAKTASQLLSDLTDKEALKQRQLDELRDRKSGLGRTIELKTEILT 
gRad50  300 FNSEKSELLIERGRLQLQADRHQEHIKVRDSLIQALSAQLELDGFEQAPFNDRQIAVFHELLKERQKSDTEAANQLMREFTKEAMKQEQIDQKIRDRKTGLERSIDLKSDIQN 
pRad50  336 RRELLEKLTGDLGKIQGEIESLEKLKVKKSTMINEIVHRYNINEINEEGIMT-EVSKYASLVN-------KNYEISSGKLKERQVAVRARIEGIKAHEMFLNNRVSEINSSLE 
cRad50  337 LQSLSNSLIRRQGELEAGKETYEKNRNHLSSLKEAFQHKFQGLSNIENSDMAQVNHEMSQFKAFISQDLTDTIDQFAKDIQLKETNLSDLIKSITVDSQNLEYNKKDRSKLIH 
 
 
 
R224H 
687delT 
Start of Coiled-
coil Domain II 
 
 
 
I94L 
ABC ATPase N 
(Continued)  
Walker A                     
Motif  
ABC ATPase N  Nucleotide Binding    
Domain I  
 
Mre11 Interacting    
Domain I  
 
 
32 
 
 
 
 
 
 
hRad50  452 KKQNELKNVKYELQQLEGSSDRILELDQELIKAERELSKAEKNSNVETLKMEVISLQNEKADLDRTLRKLDQEMEQLNHHTTTRTQMEMLTKDKADKDEQIRKIKSRHSDELT 
mRad50  452 KKQSELRHVRSELQQLEGSSDRILELDQELTKAERELSKAEKNSSIETLKAEVMSLQNEKADLDRSLRKLDQEMEQLNHHTTTRTQMEMLTKDKTDKDEQIRKIKSRHSDELT 
gRad50  452 KRLAELKNVKYELCQLEGSSDRIAELDREIVKMEHELEKAERNSNVETLEQEVQTLQNEKINLDKVLRRLDQEMEQLNLHTTTITQMEMLKKDKADKEEQIRKVKLRHSEELT 
pRad50  441 KQLTTQKELRSRFEILFPVKLQREDFTKDVEKSDLWIKSLRQEYESKNLLELLDKHQTALSSVENRLDEISEIVDSYHKYSGVRTKLQVFEENKTNKSAILANQLMTLKSSFS 
cRad50  448 DSEELAEKLKSFKSLS--TQDSLNHELENLKTYKEKLQSWESENIIPKLNQKIEEKNNEMIILENQIEKFQDRIMKTNQQADLYAKLGLIKKSINTKLDELQKITEKLQNDSR 
 
 
 
 
 
hRad50  566 SLLGYFPN--------KKQLEDWLHSKSKEINQTRDRLAKLNKELASSEQNKNHINNELKRKEEQLSSYEDKLFDVCGSQD-FESDLDRLKEEIEKSSKQRAMLAG-ATAVYS 
mRad50  566 SLLGYFPN--------KKQLEDWLHSKSKEINQTRDRLAKLNKELASAEQNKNHINNELKKKEEQLSSYEDKLFDVCGSQD-LESDLGRLKEEIEKSSKQRAMLAG-ATAVYS 
gRad50  566 LLLGYFPN--------KKQLEDWLHGKSTEINETRSRHALLNKQLASAEQQKNYISAELRKKEEQLSNYEAKLFDVCGSQD-FDSNLNKLQDEIEKSSKQRAVLAG-ATAVYS 
pRad50  551 EVMSYELKDDDN---YNEELDKLVEDVRKKLQEKEEAESSLRSVRERLEIRISLSVQSINDLTENKKIKTKTLKSYSGTFASMISEIKALESEIEENRKTLHSLQF-GSTFYE 
cRad50  561 IRQVFPLTQEFQRADLEMDFQKLFINMQKNIAINNKKMHELDRRYTNALYNLNTIEKDLQDNQKSKEKVIQLLSENLPEDCTIDEYNDVLEETELSYKTALENLKMHQTTLEF 
 
 
 
 
 
hRad50  668 QFITQLTDENQSCCPVCQRVFQTEAELQEVISDLQSKLRLAPDKLKSTESELKKKEKRRDEMLGLVPMRQSIIDLKEKEIPELRNKLQNVNRDIQRLKNDIEEQETLLGTIMP 
mRad50  668 QFITQLTDENQSCCPVCQRVFQTEAELQEVISDLQSKLRLAPDKLKSTESELKKKERRRDEMLGLVPVRQSIIDLKEKEIPELRNRLQSVNRDIQRLKNDIEEQETLLGTIMP 
gRad50  668 QFITQLTEENQSCCPVCQRVFQTEAELQDVISDLQSKLRLAPDKLKSTESELKKREKKRDEMIGLKPIRQTVVELQERDIPDLRNRLQTVNRDFARLKGEIEEQETLLQTVLS 
pRad50  662 KAIEICVD--QHACQLCQRSLDKEEE-KLFVEHCHSMIDVIPSKSAEVYSHLETLTKTFKNLSEAKPIFD-EIELLDKRLSETKTELSDLQGDLQGLDIRKDIQSELDTLYEL 
cRad50  674 NRKALEIAERDSCCYLCSRKFENESFKSKLLQELKTKTDAN---FEKTLKDTVQNEKEYLHSLRLLEKHIITLNSINEKIDNSQKCLEKAKEETKTSKSKLDELEVDSTKLKD 
 
 
 
 
 
hRad50  781 EEESAK-VCLTDVTIMERFQMELKDVERKIAQQAAKLQGIDLD----RTVQQVNQEKQEKQHKLDTVSSKIELNRKLIQDQQEQIQHLKSTTNELKSEKLQISTNLQRRQQLE 
mRad50  781 EEESAK-VCLTDVTIMERFQMELKDVERKIAQQAAKLQGVDLD----RTVQQVNQEKQEKQHRLDTVTSKIELNRKLIQDQQEQIQHLKSKTNELKSEKLQIATNLQRRQQME 
gRad50  781 EKEGAN-ACLQDITLMERYQTDIRDVERKIAQQEAKLLGVDLN----RTVLQVSQEKQAKKHLWDTVTSKIELNQKMKQDQQNQIQELKSTVNELRAEKLQISSSVQRRQQLE 
pRad50  772 RRANLE-KLQLLVKDISNLEEEIRTIDRETEVLRIELPSSIAH----HNLDEIYAEREKLLEKRGYLRKQIERTKLEETSFKKKIDDAVLANNEQKLKLTKLNFQVNELEQLE 
cRad50  784 EKELAESEIRPLIEKFTYLEKELKDLENSSKTISEELSIYNTSEDGIQTVDELRDQQRKMNDSLRELRKTISDLQMEKDEKVRENSRMINLIKEKELTVSEIESSLTQKQNID 
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hRad50  889 EQTVELSTEVQSLYREIKDAKEQVSPLETTLEKFQQEKEELINKKNTSNKIAQDKLNDIKEKVKNIHGYMKDIENYIQDGKDDYKKQKETELNKVIAQLSECEKHKEKINEDM 
mRad50  889 EQSVELSTEVQSLNREIKDAKEQISPLETALEKLQQEKEELIHRKHTSNKMAQDKINDIKEKVKNIHGYMKDIENYIQDGKDDYKKQKETELNGVAVQLNECEKHREKINKDM 
gRad50  889 EQTVELTTEVQSLSREIKEEKEQVFPLDATLEKLQQDKEDLINKRTASNKEIQEKMNAIKEKVKDINKYTKEIENYIQQGKEEYKKQKECELDEVNSQLVACEKQKEKISKEM 
pRad50  880 KDINKSSEDCDLQKKKLLEVSSKQGSQAPFLNELESEYEKLEADIQEMAQKSRTEILEANEYLHQLNEWNSELRIDVSTKFKCIKEKK----SNIGEEVRIIASKIESTDDNL 
cRad50  897 DSIRSKRENINDIDSRVKELEARIISLKNKKDEAQSVLDKVKNERDIQVRNKQKTVADINRLIDRFQTIYNEVVDFEAKGFDELQTTIK-ELELNKAQMLELKEQLDLKSNEV 
 
 
 
 
 
hRad50 1002 RLMRQDIDTQKIQERWLQDNLTLRKRNEELKEVEEERKQHLKEMGQMQVLQMKSEHQKLEENIDNIKRNHNLALGRQKGYEEEIIHFKKELREPQFRDAEEKYREMMIVMRTT 
mRad50 1002 GTMRQDIDTQKIQERWLQDNLTLRKRRDELKEVEEEPKQHLKEMGQMQVLQMKNEHQKLEENIDTIKRNHSLALGRQKGYEDEILHFKKELREPQFRDAEEKYREMMIVMRTT 
gRad50 1002 EIIRQDIDTQKIQERWLEDNLTLRERNKELKGVEDNIKELVKKMGEMKVPQLKNEQKHLEEKIEALKRNHHVALGRQRGFEEEIVRFKKELRESQFKDAEEKHREMMIVMRTT 
pRad50  989 RKLQERLADLRTRERNASDNLRLRALMRQLEEAVTQKNYLLSQQSHDDRESFRERMQILKSKYGALNAERAGLLGECKQLENSITKDKEELN-MEFKDADERFRRQLIKTKTT 
cRad50 1009 NEEKRKLADSNNEEKNLKQNLELIELKSQLQHIESEISRLDVQNAEAERDKYQEESLRLRTRFEKLSSENAGKLGEMKQLQNQIDSLTHQLR-TDYKDIEKNYHKEWVELQTR 
 
 
 
 
 
hRad50 1115 ELVNKDLDIYYKTLDQAIMKFHSMKMEEINKIIRDLWRSTYRGQDIEYIEIRSDADENVSASDKRRNYNYRVVMLKGDTALDMRGRCSAGQKVLASLIIRLALAETFCLNCGI 
mRad50 1115 ELVNKDLDIYYKTLDQAIMKFHSMKMEEINKIIRDLWRSTYRGQDIEYIEIRSDADENVSASDKRRNYNYRVVMLKGDTALDMRGRCSAGQKVLASLIIRLALAETFCLNCGI 
gRad50 1115 ELVNKDLDIYYKALDKAIMTFHSMKMQEINKIIRDLWRSTYRGQDIEYIEIRSDADENVSASDKRRSYNYRVVMIKGDTALDMRGRCSAGQKVLASLIIRLALAETFCLNCGI 
pRad50 1101 GKANEDLGKYAKALDVAIMQLHSMKMNEINRIVDELWKQTYCGTDIDTILIRSDSEG-----KGNRTYNYRVCMVKGDAELDMRGRCSAGQKVLACIIIRLALAECLGVNCGI 
cRad50 1121 SFVTDDIDVYSKALDSAIMKYHGLKMQDINRIIDELWKRTYSGTDIDTIKIRSDEVS---STVKGKSYNYRVVMYKQDVELDMRGRCSAGQKVLASIIIRLALSETFGANCGV 
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hRad50 1228 IALDEPTTNLDRENIESLAHALVEIIKSRSQQRNFQLLVITHDEDFVELLGRSEYVEKFYRIKKNIDQCSEIVKCSVSSLGFNVH 
mRad50 1228 LALDEPTTNLDRENIESLAHALVEIIKSRSQQRNFQLLVITHDEDFVELLGRSEYVEKFYRVKKNMDQCSEIVKCSISSLGSYVH 
gRad50 1228 LALDEPTTNLDRENIESLAHALVEIIKSRSRQRNFQLLVITHDEDFVELLGRSEYVETFYRIRKNIDQCSEIMKCSVSSLGSYVH 
pRad50 1209 LALDEPTTNLDEENICSLAKNLSRIVEFRRKQANFQLIVITHDEQFIRLVNSDAYCSYYYRVKRDTNQKSMIVKEPL-------- 
cRad50 1231 IALDEPTTNLDEENIESLAKSLHNIINMRRHQKNFQLIVITHDEKFLGHMNAAAFTDHFFKVKRDDRQKSQIEWVDINRVTY--- 
 
 
Figure 9. Rad50 amino acid alignment. An alignment of the amino acid sequences of the human, mouse, chicken, Schizosaccharomyces pombe and Saccharomyces cerevisiae Rad50 
proteins (hRad50, mRad50, gRad50, pRad50 and cRad50 respectively). The sequence is shaded to show the similarities between the sequences of the aforementioned proteins. The mutations 
found in human tumour cell lines and patient samples as well as those found in NBS-LD are labelled at their positions on the protein.  
 
Table 2: Mutations Found Within the Human RAD50 Gene 
 
Mutation Associated Condition(s) Association with MSI References 
I94L Ovarian cancer, breast cancer No [180] 
R224H Ovarian cancer, breast cancer No [180] 
687delT Ovarian cancer, breast cancer No [180] 
Poly(A)9 1 bp deletion Gastric cancer, colorectal cancer Yes [70], [168], [169] 
Poly(A)9 1 bp insertion Gastric cancer, colorectal cancer Yes [70], [168], [169] 
Poly(A)9 2 bp deletion Gastric cancer, colorectal cancer Yes [70], [168], [169] 
Poly(A)8 1 bp deletion Colorectal cancer Yes [169], [171] 
R1093X NBS-LD No [161] 
X1313YextX*66 NBS-LD No [161] 
X1313YextX*66 
Table 2. Table describing the RAD50 mutations shown on Figure 8 and Figure 9. This table shows the amino acid changes for each mutation and the condition for which they are 
associated. The poly(A)9 and poly(A)8 mutations are also associated with MSI. 
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1.6.3 NBS1
 Figure 10.  A map of the human NBS1 gene showing the exon/intron structure and the locations of the mutations which have been identified in 
tumour cell lines, cancer patient samples and patients with Nijmegen Breakage Syndrome (NBS). 
hNBS1 
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Alignment of the Human Nbs1 Protein with the Mouse, Chicken, S. pombe and S. cerevisiae Homologues 
 
 
 
 
hNbs1    1 MWKL----LPAAGPAGGEPYRLLTGVEYVVGR---KNCAILIENDQSISRNHAVLTANFSVTNLSQTDEIPVLTLKD-NSKYGTFVNEEKMQNGFSRTLKSGDGITFGVFGSKF 
mNbs1    1 MWKL----LPAAGAAPGEPYRLLAGVEYVVGR---KNCGILIENDQSISRNHAVLTVNFPVTSLSQTDEIPTLTIKD-NSKYGTFVNEEKMQTGLSCTLKTGDRVTFGVFESKF 
gNbs1    1 MWKL----VPAAG--PGEPFRLLVGTEYVVGR---KNCAFLIQDDQSISRSHAVLTVSRPETTHSQSVSVPVLTIKD-TSKYGTFVNGSKLS-GASRSLQSGDRVNFGVFESKF 
pNbs1    1 MWII----EAEGDILKGKSRILFPG-TYIVGRNVSDDSSHIQVISKSISKRHARFTILTPSEKDYFTGGPCEFEVKDLDTKFGTKVNEKVVGQNGDSYKEKDLKIQLGKCPFTI 
cXrs2    1 MWVVRYQNTLEDGSISFISCCLQAFKTYSIGR--SSKNPLIIKNDKSISRQHITFKWEINNSSDLKHSSLCLVNKGKLTSLNKKFMKVGETFTINASDVLKSTIIELGTTP--I 
 
 
 
 
 
hNbs1  107 RIEYEPLVACSSCLDVSGKTALNQAILQLG-GFTVNNWTEECTHLVMVSVK----VTIKTICALICGRPIVKPEYFTEFLKAVESKKQP---------------------PQIE 
mNbs1  107 RVEYEPLVVCSSCLDVSGKTVLNQAILQLG-GLTANNWTEECTHLVMSAVK----VTIKTICALICGRPIIKPEYFSEFLKAVESKKQP---------------------PDIE 
gNbs1  103 RVEYESLVVCSSCLDVAQKTALNEAIQQLG-GLVVNEWTKECTHLIMESVK----VTVKTICALICGRPIVKPEFFSELMKAVQSRQQL---------------------PTPE 
pNbs1  110 NAYWRSMCIQFDNPEMLSQWASNLNLLGIPTGLRDSDAT---THFVMNRQAGSS-ITVGTMYAFLKKTVIIDDSYL-------------------------------------- 
cXrs2  111 RIEFEWINEVWNIPPHLTQFRTMLSEYGISTEISINDIPANLMISDYPKSEDNSIRELYALVSTIPMKKSRFLMELCNTLLPTSKTNLKFDEMWNDMISNPEYNVFDFDPNILL 
 
 
 
 
 
hNbs1  195 SFYPPLDEPSIGSKNVDLSGRQERKQIFKGKTFIFLNAKQHKKLSSAVVFGGGEARLITEENEEEHNFFLAPG-----------TCVVDTGITNSQTLIPDCQKKWIQSIMDML 
mNbs1  195 SFYPPIDEPAIGSKSVDLSGRHERKQIFKGKTFVFLNAKQHKKLSSAVAFGGGEARLMAEDDEEEQSFFSAPG-----------TCVVDVGITNTQLIISHSQKKWIHLIMDTL 
gNbs1  192 SFYPSVDEPAIGIDNMDLSGHPERKKIFSGKTFVFLTAKQHKKLGPAVILGGGEAKLMAEE-RKETSLLVSPE-----------VCVVDVGVTNSQILGSESMRNWTDSILAVL 
pNbs1  182 QYLSTVKESVIEDASLMPDALECFKNIIK----------------------------------NNDQFPSSPE-----------DCINSLEGFSCAMLNTSSES---HHLLELL 
cXrs2  225 SKFMRLNNIRVLTTIKSEPRLSSLLRTFNINLFAFDNIDSLYKYVDSLEASTEYLILTTTDKKENGKILCTIKTMLTSIIDGTLSAVINMKGASSRTLDNGKFDQISEGMSTIL 
 
 
 
 
 
hNbs1  298 QR------------------QGLRPIPEAEIGLAVIFMTTKNYCDPQGHPSTGLKTTTPG----PSLSQGVSVDEKLMPSAPVNTTTY-VADTESEQADTWD-LSERPKEIKVS 
mNbs1  298 QR------------------NGLRPIPEAEIGLAVIFMTTENYCNPQGQPCTELKTTTPG----PSLSQVLSANGKIIPSAPVNMTTY-VADTESEPADTCMPLSERPEEVKIP 
gNbs1  294 ES------------------NNLRAIPEAEIGLAVIFMSTEIYCNPQRQPDNKAVTASTASKVRPVSSQSSTVDETIMPTAAADYSTLNVADTEIEEQTCMEIERTTSQTTRRE 
pNbs1  248 GL------------------RISTFMSLGDIDKELISKTDFVVLNNAVYD-----------------SEKISFPEGIFCLTIEQLWKIIIERNSRE------------------ 
cXrs2  339 KTSRAPEVEASPVVSKKRKLNRRRVLPLDSLDFFAGGLSTKTLSENRSLTDAKRLNCGAESKTVISSPNIAEADEKHAPFLQNALKPTEDIGKKSGHSSPGAIIVSSPNLGTVN 
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G 
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hNbs1  388 KMEQ----------KFRMLSQDAPTVKESCKTSSNNNSMVS--NTLAKMRIPNYQLSPTKLPSINKSKDRASQQQQTNSIRNYFQPSTKKRERDEENQEMSSCKSARIETS-CS 
mNbs1  389 GLEQ----------SSRKLSQETFNIKEAPKPSSKANNVAS--DTLVRGKTPSYQLSPMKFPVANKNKDWTSQQQQ-NSIKNYFQPCTRKRERDEDNPELSSCKSSRMELS-CS 
gNbs1  390 KVA---------------FQQAAVRENPSTSGTVNAGMLISRVNRTSGFGQKNHPHSPSKILEVDKPRECTPRQQS-NSITNYFH-VARKRERAEEGEETSLSKQAKLEKKPLP 
pNbs1  291 -----------------LISKEIERLKYATASNSTPQKIIQPQRHIQKNIVDDLFSVKKPLPCSPKSKRVKTLENL--SIMDFVQPKQMFGKEPEGYLSNQSNNGSAQNKK--- 
cXrs2  417 TSEDSLDKSLQSHKLPQPSLPEVAGIGSQTISSNSADYETAAVNSMDDAEVTKNFRVNHHQNIEQPSKNIRKLSNYSREISSPLQENCKSPVKELSIKEKSGTPHAFVEAIQET 
 
 
 
 
 
hNbs1  489 LLEQTQPATPSLWKNKEQHLSENEPVDTNSDNNLFTDTDLKSIVKNSASKSHAAEKLRSN---------KKREMDDVAIEDEVLEQLFKDTKPELEIDVKVQKQEEDVNVRKRP 
mNbs1  488 LLEQTQPAGPSLWKSKE-HQSQNATLDREADTSSVGGMDIELNRKSPDRKPLPTETLRPR---------KRKDVD-LATEEEVLEELLRSTKPELAVQVKVEKQEADDTIRKKP 
gNbs1  487 VSECTESSASSAWNSEKEQHGKGNNIQLGRESG-------ELASDKTDIKITFSENPAPK---------KRKELDDVSEDVETLEMVFESRDLDWEEQTANGDQEAQSNKRKKR 
pNbs1  401 SGDNSEKTKNSLKSSSKKSANTGSGQG-------------KTKVEYVSYNSVDKGNSSPF---------KPLELNVVGEKKANAEVDSLPSE---NVQESEDDKAFEENRRLRN 
cXrs2  567 KNREVKRVKSTIVELKDEELSEEAINQLKNLAIVEPSNNLLRKSFDSEGNKTSRTTEKWENSLMEPEWHKRKNFKTFVKVRPKSKAHKEEGKNNTQSSDFIRNAAFLITRNYVP 
 
 
 
 
 
hNbs1  592 RMDIETNDTFSDEAVP-ESSKISQENEI------GKKRELKEDS-LWSAKEISNNDKLQDDSEMLPKKLLLTEFRSLVIKNSTSRNPSGINDDYGQLKNFKKFKKVTYPGAGKL 
mNbs1  590 RMDAERNRPLNGGSEP-ESNSALQEDER------EKKDELQTES-WSTKHEIANSDGLQDSSEELPRKLLLTEFRSLVVSNHNSTSRNLCVNECGPLKNFKKFKKATFPGAGKL 
gNbs1  585 CLETKGSRTEEGNTKQREENEMLRKEEVGSVLTLEDKSKIKEESSVSIRNKLINHNKLEDDSSRLPSKLLLTEFRSLVVSCPRSNSPTMRNTKCRGQNNFKTFRKVPYPGAGQL 
pNbs1  490 LGSVEYIRIMSSEKSN--------------------ANSRHTSKYYSGRKNFKKFQKKASQKAPLQAFLSLSEHKKTEVFDQDDTDLEPVP---------RLMSKVESIPAGAS 
cXrs2  681 LKKYSKKDTTTKWGTEENEDMFALTEMERFGSNTFMSDNINSNTIQKRSQALNRFTNEDSSNEGEEDSFSFSRCSGTAASVQPLKNKIFITDEDDLGDIDDKSDRLNHRENNRN 
 
 
 
 
 
hNbs1  700 PHIIGGSDLIAHHARKNTELEEWLRQEMEVQ------NQHAKEESLADDLFRYNPYLKRRR 
mNbs1  688 PHIIGGSDLVGHHARKNTELEEWLKQEMEVQ------KQQAKEESLADDLFRYNPNVKRR- 
gNbs1  689 PYIIGGSDLVAHQARKNSELEEWLREELEEQ------NRRAREESLADDLFRYDPNVKRRR 
pNbs1  578 SDKSGKSSISKKSSNS--------FKELSPK------TNNDEDDEFNDLKFHF-------- 
cXrs2  795 LFVVKEMNLRPNLSEECSKQSRHSRSATSRSRGSFGASNNGDGDDDDDDGPKFTFKRRKG- 
 
 
Figure 11. Nbs1 Amino acid alignment.  An alignment of the amino acid sequences of the human, mouse, chicken and Schizosaccharomyces pombe Nbs1 proteins (hNbs1, mNbs1, gNbs1 
and pNbs1 respectively) and the Saccharomyces cerevisiae Xrs2 protein (cXrs2). The sequence is shaded to show the similarities between the sequences of the aforementioned proteins. The 
mutations found in human tumour cell lines and patient samples as well as those found in NBS are labelled at their positions on the protein. The area of red text corresponds to exon 13 in the 
human Nbs1 as this is the deleted region in the Δ13NBS1 mutation.
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Table 3: Mutations Found Within the Human NBS1 Gene 
 
Mutation Associated Condition(s) Association with MSI References 
R43X Breast cancer, ovarian cancer, colorectal cancer No [181] 
Ins 50 bp from intron 2 Colorectal cancer No [181] 
S93L Lymphoma, ALL No [183], [184] 
D95N Lymphoma, ALL No [183], [184] 
L150F Breast cancer No [180] 
I171V 
Lymphoma, ALL, colorectal cancer, breast 
cancer, laryngeal cancer 
No [149], [155] 
E185Q Lung cancer, ALL No [156], [157], [158] 
V210F ALL No [183], [184] 
R215W NBS, ALL, colorectal cancer, breast cancer No [149] 
657del5 
NBS, colorectal cancer, gastric cancer, 
melanoma, non-Hodgkin lymphoma, prostate 
cancer 
No [148], [149], [151], [152], [153] 
681delT NBS No [149], [154] 
698del4 NBS No [149], [154] 
742insGG NBS No [149], [154] 
835del4 NBS No [149], [154] 
842insT NBS No [149], [154] 
900del25 NBS No [149], [154] 
Q326X NBS No [149], [154] 
Y363X NBS No [149], [154] 
1142delC NBS No [149], [154] 
1651delA Colorectal cancer, gastric cancer Yes [172] 
Ivs11+2insT Colorectal cancer, gastric cancer No [149] 
Δ13 Nbs1 Ovarian cancer No [181] 
Y679H Renal cancer No [182] 
Table 3. Table describing the NBS1 mutations shown on Figure 10 and Figure 11. This table shows the amino acid changes for each mutation and the condition for which they 
are associated. The 1651delA mutation is also associated with MSI. 
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1.6.4 CtIP
CtIP 
Figure 12. A map of the human CtIP gene showing the exon/intron structure and the locations of the mutations which have been identified in 
tumour cell lines, cancer patient samples and patients with Seckel and Jawad syndromes. 
 
40 
 
Alignment of the Human CtIP Protein with the Mouse, Chicken, S. pombe and S. cerevisiae Homologues 
 
 
 
 
hCtIP     1 MNISGSSCGSPNSADTSSD-FKDLWTKLKECHDREVQGLQVKVTKLKQERILDAQRLEEFFTKNQQLREQQKVLHETIKVLEDRLRAGLCDRCAVTEEHMRKKQQEFENIRQQ 
mRBBP8    1 MSISGSGCGSPNSADASND-FKELWTKLKEYHDKEVQGLQVKVTKLKKERILDAQRLEEFFTKNQQLRDQQKVLQETIKILEDRLRAGLCDRCAVTEEHMHKKQQEFENIRQQ 
gRBBP8    1 MNASGGTCGSPSSAEPAGDFFKELWSKLKECHDKEVQGLQLKISKLKKERCLDAERLEEFYTKNQQLREQQKALHDTIKVLEDRLRAGLCDRCAVTEEHMRKKQLEFENIRQQ 
pCtp1     1 ----------MNEEEHNKS---VHWSIVYRQLGNLLEQYEVEIARLKSQ-----------------------------LVLEKKLRI--------------QVEKELESVKTK 
cSae2     1 -----------MVTGEENVYLKSSLSILKELSLDELLNVQYDVTTLIAKR---------------------------VQALQNRNKCVLE-----------EPNSKLAEILCH 
 
 
 
 
 
hCtIP   113 NLKLITELMNERNTLQEENKKLSEQLQQKIENDQQHQAAELECEEDVIPDSPITAFSFSGVNRLRRK-ENPHVRYIEQTHTKLEHSVCANEMRKVSKSSTHPQHNPNENEILV 
mRBBP8  113 NLKLITELMNEKNTLQEENKKLSEQLQQKMENGQQDQVAELACEENIIPDSPVTSFSFSGINRLRKK-ENLHVRYVEQTHTKLERSLCTNELRKISKDSAPAPVNSEEHEILV 
gRBBP8  114 NLKLITELMNEKNSLQDENKKISEQFQQLQKELEEQKQQALDVEEGVIPDSPVLTSSFSMVNRMRRKKENRHIRYTEHTHPDLELAKSNSEFQIPLYSTQASSHH--EEEILV 
pCtp1    58 QISSSASSKVSSNTIQELDS---------------------TTDEDEIPGS-------------------------------------------------------------- 
cSae2    65 EKNAPQQSSQTSAGPGEQDS---------------EDFILTQFDEDIKKES-------------------------------------------------------------- 
 
 
 
 
 
hCtIP   225 ADTYDQSQSPMAKAHGTSSYTPDKSSFNLATVVAETLGLGVQEESETQG-PMSP------LGDELYHCLEGNHKKQPFEESTRNTEDSLRFSDSTSKTPPQEELPTRVSSPVF 
mRBBP8  225 ADTCDQNHSPLSKICETSSYPTDKTSFNLDTVVAETLGLNGQEESEPQG-PMSP------LGSELYHCLKEDHKKHPFMESARSKEDSLRFSDSASKTPPQE-FTTRASSPVF 
gRBBP8  226 ADTCDPQLSPVPNKPRMGGYPVPKPSFNLAAVVAETIGLAVQDESESQS-VLSSPHTSTAMNQAPEGIRSEDSRKHSASES-RNEDNSSGLSGPSQNTPPRVDWDSQVVSPVF 
pCtp1    88 -DTVDEEDPSLN--LPLVTMPPNRHKRKISEFSSPLNGLNNLSDLEDCS---------------------------------------------------------------- 
cSae2   101 AEVHYRNENKHTVQ---APFSEKNQSVKIP---PHSPTLPVQNASAFVKP--------------------------------------------------------------- 
 
 
 
 
 
hCtIP   331 GATSSIKSGLDLNTSLSPSLLQPGKKKHLKTLPFSNTCISRLEKTRSKSEDSALFTHHSLGSEVN-KIIIQSSNKQILINKN---ISESLGEQNRTEYGKDSNTDKHLEPLKS 
mRBBP8  330 GATSTVKAHLGLNTSFSPSLLDIGKKNLLKTAPFSNIAVSRSEKVRSKSEDNALFTQHSLGSEVK-VISQSFSSKQILTNKT---VSDSVDEQCSADHMNTTVADKYLVPLKS 
gRBBP8  337 GASSNTRN--NSSTSHAPCILDSNSKPNVKVNLFNNPSSSRSHKNRSKSEDVAFVAPLNLGTEINSVISQVSINRQMVVKKNSNEVVTSVGNTCAAKN-EVIKSDFLLAHQKQ 
pCtp1   129 ---------------ISVPLGNVKEEKFLDTNPIG------------------------------------------------------------------------AESFES 
cSae2   150 ----------------DTVIHEKDNDKENKTRKLLG---------------------------------------------------------------------IELENPES 
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hCtIP   440 LGGRTSKRKKTEEESEHEVSCPQASFDKENAFPFPMDNQFSMNGDCVMDKPLDLSDRFSAIQRQEKSQGSE-TSKNKFRQVTLYEAL----KTIPKGFSSSRKASDGNCTLPK 
mRBBP8  439 LGGKASKRKRTEEESEHAVKCPQACFDKENALPFPMENQFSMNGDHVMDKPLDLSDRFAATQRQEKNHGNE-TSKNKLKQATIYEAL----KPIPKGSSSGRKALSGDCMPAK 
gRBBP8  444 PEGRCAKRKKAED--EHAISCENASFNKENSVPFRSDIQH-MNGEHTGDKPLDLSDRFCGVRCQEKKQGSEETCKNKLKQVTLYDVFLQLGKPIHEGSSSVQNANNERSLFGR 
pCtp1   155 SDGEMHLRARSPE---------------------------------------------------------------------------------------------------- 
cSae2   178 TSPNLYKNVKDNFLFDFNTN--------------------------------------------------------------------------------------------- 
 
 
 
 
 
hCtIP   548 DSPGEPCSQECIILQPLNKCSPDNKPSLQIKEENAVFKIPLRPRESLETENVLDDIKSAGSHEPIKIQTRSDHGGCELASVLQLNPCRTGKIKSLQNNQDVS---FENIQWSI 
mRBBP8  547 DS-WETYCLQPRSLQSSSKFSPDQKTPLQIKEENPVFKTPPCSQESLETENLFGDVKGTGSLVPTKVKSRAVHGGCELASVLQLNPCRVAKTKALPSNQDTS---FENIQWSV 
gRBBP8  556 DMQEEPYVQEAV----LAKTFADTKKQVQMKEEVPPLKITPLP-STVDTEQLFNDMKVASDHVPNRKKTRTGHGESEPASVLQPNPCRLSKNKVQPNEQDLKEKPLENLQWSI 
pCtp1   168 -------------------------DMILLRETQP-----------------------------------------------------------------------------L 
cSae2   198 ---------------------PLTKRAWILEDFRP------------------------------------------------------------------------------ 
 
 
 
 
 
hCtIP   658 DPGADLSQYKMDVTVIDTKDGSQSKLGGETVDMDCTLVSETVLLKMKKQEQKGEKSSNEERKMNDSLEDMFDRTTHEEYESCLADSFSQAADEEEE---------LSTATKKL 
mRBBP8  756 DPGADLSQYKMDVTVIDTKDSSHSRLGGETVDMDCTLVSETVLLKMKKQEQK-ERSPNGDIKMNDSLEDMFDRTTHEEYESCLADSFSQVPDEEE----------LPDTTKKT 
gRBBP8  664 DPGADLAQYKMDVTVIDTKDDSQSRIGGEAVDMDYTYVSENVLLKMKNQEQTQESSPRREKKMNDTITEMFDRTADEEYESCLPEDSLSACDEKETVHGEEQNKEITVASKKL 
pCtp1   179 AP--------LDINTLGVSDN-------------------------RQKKGTEKKRPFEPEFLNDDVIRGNKRKALPAYECPDCQKFYELHGPVKE----------------- 
cSae2   212 -----------NEDIAPVKRG-------------------------RRKLERFYAQVGKPEDSKHRSLSVVIESQNSDYEFAFDNLRNRSKSPPG------------------ 
 
 
 
 
 
hCtIP   762 HTHGDKQDKVKQKAFVEPYFKGDERETSLQNFPHIEVVRKKEERRKLLGHTCKECEIYYADMPAEEREKKLASCSRHRFRYIPPN-TPENFWEVGFPSTQTCMERGYIKEDLD 
mRBBP8  758 NIPADKQDGVKQKAFVGPYFKDKERETSIQNFPHIEVVRKKEERRKLLGHTCKECEIYYADLPAEEREKKLASCSRHRFRYIPPN-TPENFWEVGFPSTQTCLERGYIKEDLD 
gRBBP8  777 KKHEDKQDKAKQKAFVEPYFKSDERKNTMLDFPHIEVIRKKEERRKLPGHTCKECEIYYADIPEEEREKKLAACSRHRFRYIPPN-TPENFWEVGFPSTQTCMERGYIKEDVA 
pCtp1   242 -------------SSVAPTWNDENR-------------------------------LGGGSLPNCKHQPLVQKVGRHRKLNIPKP-IPNGFWESDFVD--------------- 
cSae2   271 --------------FGRLDFPSTQE----------------------------------GNEDKKKSQEIIRRKTKYRFLMASNNKIPPYEREYVFKREQ----LNQIVDDGC 
 
 
 
 
 
 
R589H 
Y819S 
CtIP
J 
CtIP
S 
  
 
 
 
CtBp Binding          
Domain Site 
DNA Binding          
Domain PCNA                      
Binding Site 
DNA Binding          
Domain (Continued) 
CxxC                            
Motif 
Start of MRN Binding                       
Domain II 
Phosphoserine     
ATM Binding 
Phosphoserine     
ATM Binding 
Phosphothreonine 
CDK Binding 
 
 
42 
 
 
 
 
 
hCtIP   874 PCPRPKEQKTYNAVFSPKGKEQRT 
mRBBP8  870 LSPRPKRRQPYNAVFSPKGKEQRT 
gRBBP8  889 PCQRPKRRQPYAVMFSPKGKEQKT 
pCtp1       ------------------------ 
cSae2   324 FFWSDKLLQIYARC---------- 
 
 
Figure 13. CtIP amino acid alignment. An alignment of the amino acid sequences of the human CtIP (hCtIP), mouse and chicken RBBP8 proteins (mRBBP8 and gRBBP8 respectively), the 
Schizosaccharomyces pombe Ctp1(pCtp1) and the Saccharomyces cerevisiae Sae2 protein (cSae2). The sequence is shaded to show the similarities between the sequences of the 
aforementioned proteins. The mutations found in human tumour cell lines and patient samples as well as those found in Seckel and Jawad syndromes are labelled at their positions on the 
protein. 
 
 
Table 4: Mutations Found Within the Human CtIP Gene 
 
Mutation Associated Condition(s) Association with MSI References 
K337E Pancreatic cancer No [185] 
Poly(A)9 1 bp deletion Colorectal cancer, endometrial cancer Yes [163], [167], [174] 
V394M Colorectal cancer No [185] 
P436S Colorectal cancer No [185] 
R589H Ovarian cancer, breast cancer No [173], [185] 
CtIP
j 
Jawad syndrome No [162] 
CtIP
s 
Seckel syndrome No [162] 
Y819S Colorectal cancer No [185] 
 
Table 4. Table describing the RAD50 mutations shown on Figure 12 and Figure 13. This table shows the amino acid changes for each mutation and the condition for which they 
are associated. The poly(A)9 mutation is also associated with MSI. 
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1.7 Aims of the Project 
This project aimed to identify genetic markers that predict colorectal cancer patient response 
following chemoradiation therapy utilising concurrent irinotecan and capecitabine. This 
project aimed to identify mutations of the MRE11, RAD50, NBS1 and CtIP genes and 
determine any correlation between the presence of mutations and the response to treatment, 
and to investigate the impact of specific mutations on camptothecin sensitivity. This project 
also aimed to identify novel genetic markers in S. pombe that confer hypersensitivity to 5-FU, 
that may suggest potential genetic markers for 5-FU sensitivity in human orthologues. 
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2 Materials and Methods 
2.1 Media and Strains 
2.1.1 Media 
For 4L LB (Luria Broth) medium, the following was added to a 5 L beaker: 
 3 L dH2O 
 40 g tryptone 
 20 g yeast extract 
 20 g NaCl 
 
For 4 L YE (Yeast extract) medium, the following were added to a 5 L beaker: 
 3 L dH2O  
 20 g yeast extract 
 120 g glucose 
 400 mg each of adenine (ade), uracil (ura), histidine (his), leucine (leu) and arginine 
(arg)For 4 L EMM (Edinburgh Minimal Media), the following were added to a 5 L 
beaker: 
 3 L dH2O 
 109.2 g Formedium EMM powder 
 15 g glutamate 
 
All media were dissolved using a magnetic stirrer, then additional H2O was added to bring 
the total volume to 4 L. The medium was then distributed over 10 x 500 ml bottles (400 ml in 
each). If solid LB (LBA), YE (YEA) or EMM were required, then 8 g agar was added to each 
bottle. If EMM + ade/leu/ura is required, then the 400 mg of the required additive is added 
per 400 ml bottle. If the addition of ampicillin (+ Amp) is required, ampicillin is added to a 
final concentration 100 µg/ml) 
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2.1.2 Preparation of electrocompetent E. coli cells 
Electrocompetent DH5α E.coli cells were used for transformation by electroporation. To 
prepare these cells, DH5α cells were first streaked onto LBA plates and incubated overnight 
at 37°C. The next day, a colony was inoculated into 100 ml LBL in a sterile flask and 
incubated at 37°C. This pre-culture was then used to inoculate 400 ml of LBL and incubated 
at 37°C, the optical density was measured at regular intervals until the OD600 was between 
0.5-0.7. During this time, 10% glycerol solution, 2 x 50 ml centrifuge tubes and 2 x 250 ml 
centrifuge tubes were cooled on ice. After the cells had reached the desired optical density, 
the cells were chilled on ice for 30 minutes. 
The culture was then divided into two 250 ml centrifuge tubes and centrifuged at 4000 x g for 
15 minutes at 4°C. The supernatant was removed and the cell pellets were resuspended in 200 
ml 10% glycerol, the tubes were centrifuged at 4000 x g for 15 minutes at 4°C.  
The supernatant was removed and the cell pellets resuspended in 100 ml 10% glycerol, the 
tubes were centrifuged at 4000 x g for 15 minutes at 4°C. 
The supernatant was removed and the cell pellets resuspended in 10 ml 10% glycerol, the 
suspensions were transferred to the 10 ml tubes and centrifuged at 4000 x g for 15 minutes at 
4°C. 
50 μl of the cultures were then transferred to chilled labelled microcentrifuge tubes which 
were frozen using liquid nitrogen. The cells were stored at -80°.  
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2.1.3 E. coli strains 
E. coli strains used in this investigation are shown in the Table 5. 
Table 5: Table of E. coli strains used in this investigation 
Strain Plasmid Source 
DH5α  Hartsuiker collection 
TE2 pAW8-mre11-W210X This investigation 
TE5 pAW8-Δ5-7mre11 This investigation 
TE11 pAW8-ctp1-MSI This investigation 
TE12 pAW8-nbs1-MSI This investigation 
TE13 pAW8-rad50-MSI This investigation 
TE14 pAW8-mre11-R572X This investigation 
Table 5: Table showing the E. coli strains used in this investigation, showing the strain name, 
plasmid and the source of the strain. Strains TE2-TE14 were created during this project by 
transformation of DH5α. 
 
2.1.4 S. pombe strains 
S. pombe strains used in this investigation are shown in the Table 6, which continues to the 
next page. 
Table 6: Table of S. pombe strains used in this investigation 
Strain Genotype Description Source 
EH00065 h
-
 smt0 rad50::Kan, ura4-D18 ura4
- 
rad50Δ Hartsuiker collection 
EH00068 h
-
 smt0 ura4-D18 ura4
- 
wild type Hartsuiker collection 
EH00176 h
-
 smt0 rad50::Kan rad50Δ Hartsuiker collection 
EH00338 h- smt0 Wild type h
-
 Hartsuiker collection 
EH00722 h
+
 WT Wild type Hartsuiker collection 
EH00805 h
-
smt0 mre11-D65N ura4-D18 ura4
- 
mre11 
nuclease dead  
Hartsuiker collection 
EH00921 h
-
smt0 mre11-D65N mre11   
nuclease dead 
Hartsuiker collection 
EH01030 h
+ 
ade6-704 leu1-32 ctp1::loxP-
ura4-loxM3 ura4-D18 
ctp1 base 
strain 
Hartsuiker collection 
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EH01031 h
+ 
ade6-704 leu1-32 nbs1::loxP-
ura4
+
-loxM3 ura4-D18 
nbs1 base 
strain 
Hartsuiker collection 
EH01104 h
-
 smt0, leu1-32 mre11::loxP-
ura4
+
-loxM3, ura4-D18 
mre11 base 
strain 
Hartsuiker collection 
TJ1 h
- 
smt0, leu1-32, rad50::loxP-
ura4
+
-loxM3, ura4-D18 
rad50 base 
strain 
EH238 + Rad50bs 
TJ3 h
- 
smt0 ,leu1-32, mre11::loxP-
mre11-W210X-loxM3, ura4-D18 
mre11-W210X Transformation of 
EH01104 
TJ4 h
-
 smt0, leu1-32,mre11::loxP- 
mre11-484del88-loxM3, ura4-D18 
mre11-
484del88 
Transformation of 
EH01104 
TJ5 h
-
 smt0, leu1-32,mre11::loxP- 
mre11
+
-loxM3, ura4-D18 
lox-mre11-WT Transformation of 
EH01104 
TJ7 h
-
 smt0, leu1-32,rad50::loxP- 
rad50
+
-loxM3, ura4-D18 
lox-rad50-WT Transformation of TJ1 
TJ8 h
+
 ade6-704 leu1-32, nbs1::loxP- 
nbs1
+
-loxM3, ura4-D18 
lox-nbs1-WT Transformation of 
EH01031 
TJ9 h
+
 ade6-704 leu1-32,nbs1::loxP- 
nbs1-MSI-loxM3, ura4-D18 
nbs1-MSI 
(1651delA) 
Transformation of 
EH01031 
TJ12 h
+
 ade6-704 leu1-32, ctp1::loxP- 
ctp1
+
-loxM3, ura4-D18 
lox-ctp1-WT Transformation of 
EH01030 
TJ15 h
+
 ade6-704 leu1-32, ctp1::loxP- 
ctp1-MSI-loxM3, ura4-D18 
ctp1-MSI Transformation of 
EH01030 
TJ19 h
-
 smt0, leu1-32,mre11::loxP- Δ5-7 
mre11-loxM3, ura4-D18 
Δ5-7mre11 Transformation of 
EH01104 
TJ20 h
-
 smt0, leu1-32, mre11:loxP- 
mre11-R572X-loxM3, ura4-D18 
mre11-R572X Transformation of 
EH01104 
TJ21 h
-
 smt0, leu1-32, rad50::loxP- 
rad50-MSI2-loxM3, ura4-D18 
rad50-MSI Transformation of TJ1 
Table 6: Table showing the S. pombe strains used in this investigation, showing the strain 
name, genotype, the usage of the strain and the source of the strain. Strains TJ4-TJ21 were 
created during this project. 
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2.2 Creation of MRN Mutants in Schizosaccharomyces pombe 
2.2.1 Creation of mutant inserts by PCR 
Primers that could be used to create the MRN mutant inserts by the polymerase chain 
reaction (PCR) were designed. These primers incorporated loxP and loxM3 sites and any 
additional bases that may be present in the human mutants as a result of a frameshift. The lox 
sites are as follows: 
loxP: 5′-ATAACTTCGTATAGCATACATTATACGAAGTTAT-3′ 
loxM3: 5′-ATAACTTCGTATATGGTATTATATACGAAGTTAT-3′ 
The primers used for the creation of the mutant inserts are shown in Table 7. 
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Table 7: Primers used to create mutant mre11, rad50, nbs1 and ctp1 inserts 
Number Primer Name Sequence 
1 lox-mre11-F 5′-ggggataacttcgtatagcatacattatacgaagttat 
atgccaaatgacccctcagatatgaataat-3′ 
2 mre11-W210X –R 5′-ggggataacttcgtatataataccatatacgaagttat 
tcattcatcccgatatagatcaggacgtaa-3′ 
3 Δ5-7 mre11-R1 5′-aggtaaatagctcgttggtgtatgggcaga 
agccgtatccccagtggttaaggatgtgtc-3′ 
4 Δ5-7 mre11-F2 5′-gacacatccttaaccactggggatacggct 
tctgcccatacaccaacgagctatttacct-3′ 
5 Δ5-7 mre11-R2 5′-ggggataacttcgtatataataccatatacgaagttat 
tcaatcatctaaaatttcgtcatcctcgtt-3′ 
6 mre11- R572X-R 5′-ggggataacttcgtatataataccatatacgaagttat 
tcacaaaagtgctggagaaggtgttgcttc-3′ 
7 lox-rad50-F 5′-ggggataacttcgtatagcatacattatacgaagttat 
atgtcgtgcattgacagaatgtccatcatg-3′ 
8 rad50-MSI-R 5′-ggggataacttcgtatataataccatatacgaagttat 
ttatttagtagcttgaattttttt atctgcttctaatttttcatactctgactc-3′ 
9 Lox-nbs1-F 5′-ggggataacttcgtatagcatacattatacgaagttat 
atgtggataattgaggctgagggtgacatt-3′ 
10 nbs1-1651delA-R 5′-ggggataacttcgtatataataccatatacgaagttat 
ttaaggccacatcatccatttacc 
tggtttgaacggagaagaatttcctttatc-3′ 
11 lox-ctp1-F 5′-gggg ataacttcgtatagcatacattatacgaagttat 
atgaatgaggaggaacacaataagtcggtc-3′ 
12 ctp1-MSI-R 5′-gggg ataacttcgtatataataccatatacgaagttatttaaatgtttttt 
tttcacgttacccaatggcacagaaattgg-3′ 
 Table 7: This table shows the primers that were used to construct the mutant mre11, rad50, 
nbs1 and ctp1 genes. Each primer is numbered and the sequence is given. The lox sites are 
underlined. 
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The components added to a 0.2 ml PCR tube for the PCR reactions to create the mutant 
inserts were: 
 35.5 μl dH2O 
 1 μl S. pombe wild-type (WT) genomic DNA (100 ng/μl) 
 1 μl Forward primer (10 pmol/μl) 
 1 μl Reverse primer (10 pmol/μl) 
 1 μl dNTP solution (10 mM each) 
 0.5 μl Phusion DNA polymerase 
 10 μl high fidelity (HF) buffer (F-518 5x Phusion HF Reaction Buffer 7.5 mM MgCl2) 
The reagents were mixed by pipetting and the tubes were briefly spun to ensure that the 
reagents were at the bottom of the tubes.  
A 2-step PCR reaction was carried out to create the inserts due to reduce secondary structures 
as a result of hairpin formation. The reaction used was: 
 Initial denaturation of 98°C for 30 seconds 
 30 cycles of: 
o Denaturation of 98°C for 10 seconds 
o Extension of 72°C for 30 seconds per kb of product 
 Final extension of 72°C for 5 minutes 
 
 
2.2.2 Agarose gel electrophoresis 
The PCR was then checked by electrophoresis using a gel consisting of 0.8% agarose in 10% 
Tris/Borate/ EDTA (TBE) buffer. This was created by adding 0.4 g agarose (or 1.2 g for a 
150 ml gel) to 50 ml TBE buffer in a conical flask. The gel solution was heated in a 
microwave at 630 w for 2 minutes (or 3 minutes for a 150 ml gel). The flask was then cooled 
with cold running water, before adding 2 μl of ethidium bromide solution (6 μl for a 150 ml 
gel). The gel was poured into a casting tray and a wide-toothed comb was added to create the 
wells. Once the gel had set, the gel was transferred to an electrophoresis tank containing TBE 
buffer into which the gel was submerged.  
The samples were prepared by adding 1 μl 6x loading dye to 5μl PCR product. The samples 
were loaded into the wells following 6 µl 1 kb marker loaded into the first well. The gel tank 
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lid was placed onto the tank and connected to a power supply. The electrophoresis was run at 
400 mA and 90 V (or 120 V for a 150 ml gel) for 45 minutes. 
Following the electrophoresis the gel was imaged using a gel doc system, utilising ultraviolet 
light to visualise the bands of ethidium bromide stained DNA in the gel.  
 
2.2.3 DNA purification from agarose gels 
If the sample loaded into the gel requires purification, then an agarose gel containing SyBr 
green should be used. This gel was created as described previously but with SyBr green dye 
added instead of ethidium bromide. During the stage at which the comb is added, two or more 
teeth may be taped together to create large wells to accommodate a larger volume of sample. 
When the gel is loaded the entire PCR product may be used and prepared with 6 x loading 
dye.  
The gel was viewed using a blue light transilluminator and the bands were excised, using a 
scalpel blade, then placed into a sterile microcentrifuge tube. The DNA was then purified 
using the Machery Nagel DNA extract II kit as per manufacturer’s instructions. 
 
2.2.4 DNA quantification using the Invitrogen Qubit 
DNA was quantified using the Invitrogen Qubit. For this, Pico-green dye diluted 2,000 x in 
TE buffer was used. Two standard samples were created, the first consisting 100 μl 
Tris/EDTA (TE) buffer, 100 μl diluted pico-green solution; and the second standard 
consisting of 100 μl bacteriophage λ DNA solution (1 mg/μl), and 100 μl diluted pico-green 
solution. 
The samples were prepared by adding 1 μl of DNA sample to 99 μl TE buffer and 100 μl 
diluted pico-green solution. The standards and the samples were vortexed thoroughly and 
incubated at room temperature for two minutes. The Qubit was set to “dsDNA HS” and 
calibrated. The samples were read by the machine and the DNA concentration was recorded. 
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2.2.5 Fusion PCR 
In order to create the Δ5-7mre11(MRE1), in which a region inside the gene corresponding to 
exons 5-7 in the human MRE11 gene required deletion, fusion PCR was used. Firstly, two 
parts of the mutant gene were created by PCR (as described in section 2.2.1), the first part 
(Δ5-7mre11 A) consisting of the LoxP site and the region of the mre11 gene corresponding to 
exons 1-4 in human MRE11 (requiring primers 1 and 3 shown in Table 7), and the second 
part (Δ5-7mre11 B) consisting of the mre11 region corresponding to human MRE11 exons 8-
20 (requiring primers 4 and 5 shown in Table 7). An overlap of the sequences of the two 
constituent parts was required to allow for fusion of both parts by a subsequent PCR. The 
products were then checked by electrophoresis, purified and quantified (as described in 
sections 2.2.2 - 2.2.4 respectively). 
PCR was then carried out (as described in section 2.2.1) using 0.5 μl of Δ5-7mre11 A (10 
ng/μl) and 0.5 μl Δ5-7mre11 B (10 ng/μl) in one reaction as the template DNA using the 
external primers. The PCR products were checked by electrophoresis, purified from agarose 
gel, as described in section 2.2.3. The purified product was quantified. A diagram showing 
the stages of the creation of the mutant inserts, including fusion PCR, is shown in Figure 14, 
page 83. 
 
2.2.6 In vitro Cre recombination 
In order to carry out the in vitro cre recombination required to insert the mutant gene insert 
into the plasmid vector, the required mass of vector needs to be determined. The mass of 
insert required for a 1:1 ratio can be calculated using the equation below: 
                              
                
                
                
As an insert to vector ratio of 1:4 is required, the calculated mass of insert should be 
multiplied by 4. The required masses of insert and vector are then scaled so that the total 
mass of DNA in the reaction is approximately 250 ng. All inserts were diluted to 50 ng/μl and 
the pAW8ccdb plasmid was at a concentration of 100 ng/μl, the volumes of the plasmid and 
insert solutions required could then be calculated. 
53 
 
In addition to the reactions containing the insert, positive and negative controls were also 
used, all of which were carried out in 0.2 ml PCR tubes. The reagents that were added to each 
tube are shown in Table 8. 
Table 8: Required reagents for the in vitro Cre-lox reaction 
 Reaction 
Reagent Insert Reaction Positive Control Negative Control 
10x Cre Buffer 1 µl 1 µl 1 µl 
Linear pAW8ccdb 
(100 ng/µl) 
Calculated N/A N/A 
Insert (50 ng/µl) Calculated volume  N/A N/A 
2LoxP Control N/A 2 µl N/A 
PEG-8000 25% 2 µl N/A N/A 
dH2O Make up to 10 µl 6 µl 7 µl 
Cre Recombinase 1 µl 1 µl 1 µl 
Table 8: The above table shows the volumes of each reagent required for each in vitro cre 
recombinase reaction. The reagents required for the reaction to insert the desired mutant gene 
into the pAW8-ccdb plasmid vector, the positive control and the negative control, are shown. 
The reaction tubes were then placed into a thermocycler and run at 37°C for 30 minutes 
followed by 70°C for 10 minutes. 
The products were immediately transformed into electrocompetent DH5α E. coli cells. 
 
2.2.7 Transformation of Escherichia coli cells by electroporation 
2 mm cuvettes and micro centrifuge tubes (one of each for each reaction) were cooled on ice 
for approximately 20 minutes. Frozen electrocompetent E. coli cells were thawed on ice. 25 
μl of electrocompetent cell suspension was added to each of the empty microcentrifuge tubes, 
1 μl of the reaction product was then added to the tubes and mixed be pipetting. The contents 
of the microcentrifuge tube were then transferred to a cuvette. The cuvettes were then gently 
tapped on the bench to ensure the contents were at the bottom and that no bubbles were 
present as this can lead to arcing.  
The cuvettes were placed into a BioRad electropulser set for use with E. coli in 2 mm 
cuvettes. The cuvettes were pulsed, immediately followed by 975 μl of SOC medium 
carefully pipetted into the cuvette. The contents were gently mixed and transferred into the 
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original microcentrifuge tube. This process was repeated for all required reactions. Samples 
were incubated for 2 hours at 30°C in a shaking incubator. Following this incubation period, 
100 μl of the cell suspension was spread onto LBA + Amp plates, which were subsequently 
incubated for 2 days at 30°C. 
If following incubation, the positive control plate has a very low number or absence of 
colonies, or if the negative control plate has colonies present then the in vitro Cre 
recombination and electroporation need repeating.  
 
2.2.8 Screening of colonies for the uptake of the pAW8 plasmid containing the 
insert 
E. coli colonies were taken and inoculated into 3 ml LB + Amp medium and grown for 1-2 
days at 30°C. 1 ml of the cultures were then taken and used with the Machery Nagel plasmid 
mini-prep kit to extract the plasmids. This kit was used as per manufacturer’s instructions.  
The extracted plasmids can then be checked by electrophoresis and quantified to check for a 
successful extraction. 
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The plasmids were then checked for the correct integration of the mutant insert using PCR 
with Taq polymerase. For this a 2x master mix was created using the following volumes of 
each reagent per reaction: 
 5 μl 10x Taq buffer 
 3 μl 25mM MgCl2 
 1 μl dNTPs (10 mM each) 
 15.75 μl dH2O 
 0.25 μl Taq polymerase 
25 μl of this master mix was added to: 
 1 μl plasmid solution (10-100 ng/μl) 
 1 μl forward primer (10 pmol/μl) 
 1 μl reverse primer (10 pmol/μl) 
 22 μl dH2O 
The primers used are shown in Table 9. 
Table 9: Primers used to check for the correct integration of the mutant cassette 
Number Name  Sequence 
13 loxEx2-F 5′-gaccatgattacgccaagc-3′ 
14 loxEx2-R 5′-taaaacgacggccagtgaat-3′ 
Table 9: This table shows the name, designated number and sequence for the primers used to 
screen for the correct integration of the mutant insert into the pAW8-ccdb plasmid. 
The following PCR cycle was then used: 
 Initial denaturation of 95°C for 30 seconds 
 30 cycles of: 
o Denaturation of 95°C for 30 seconds 
o Annealing of 55° for 30 seconds 
o Extension of 72°C for 1 minute per kb of product (1 minute used for products 
under 1 kb) 
 Final extension of 68°C for 5 minutes 
The PCR products were checked by electrophoresis, if a band was seen at the desired length 
then this is indicative of a successful in vitro cre recombinase reaction and transformation. 
The products were then purified and quantified.  
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2.2.9 Sequencing 
For products under 1kb in length, 75 ng of DNA was added to a microcentrifuge tube bearing 
a barcode label, whereas for products over 1 kb, 150 ng was used. 1 μl of primer (10 ng/μl) 
was then added to the tube. The total volume was then made up to 15 μl with dH2O.  
To check for the presence of the mutant gene insert in the plasmid, the primers 13 and 14 
(shown in Table 9) were used. Additionally, primers which bind to regions inside genes were 
also used if required (shown in Table 10). One sequencing section was carried out per primer. 
The tubes were then sent to Eurofins MWG/Operon for sequencing. The sequences were 
analysed for the successful integration of the mutant gene cassette and to confirm the absence 
of undesired mutations.  
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Table 10: mre11, rad50, nbs1 and ctp1 internal primers used for sequencing 
Number Name Sequence 
15 mre11 int-F 5′-ggtacgaagctcaaggaacc-3′ 
16 mre11 int-R 5′-cggaagtatataggccgtcg-3′ 
17 rad50 int-F1 5′-ccgctcagcttgggtgtgag-3′ 
18 rad50 int-F2 5′-gcgctcacgctttgaaat cc-3′ 
19 rad50 int-R1 5′-tagacgatgctgtcttagcc-3′ 
20 rad50 int-R2 5′-gcgaaggtcccactataaga-3′ 
21 nbs1 int-F 5′-ggacctcgatacgaagttg-3′ 
22 nbs1 int-R 5′-ggtaaactatctacctccgc-3′ 
23 ctp1 int-F 5′-cgaagaagacactcctgaag-3′ 
24 ctp1 int-R 5′-gctaatcgcaagtgatgggg-3′ 
Table 10. Table shows the primers which bind internally to the target gene for use with 
sequencing to ensure that the entire length of the gene is sequenced. 
 
2.2.10 Archiving of E. coli strains 
After a strain of E. coli has been identified to contain the plasmid with the desired insert 
successfully integrated, the strain is then frozen and stored for future use. Firstly the strain 
was inoculated into 3 ml LBL + Amp and was grown for 2 days at 30°C in a shaker 
incubator. 500 μl of the culture was transferred to a cryogenic vial labelled with the strain’s 
designated number. An equal volume of 30% glycerol solution was added and mixed 
thoroughly by vortexing. The strains were stored at -80°C. 
When required, the strains can be woken by streaking a small amount of the frozen stock onto 
an LB + Amp plate, followed by incubation at 37ºC. 
 
2.2.11 Plasmid extraction from E. coli cells by Midi-prep 
In order to obtain larger quantities of the desired plasmid, a midi-prep plasmid extraction 
method was used. For this, the Machery-Nagel Midi-prep kit was used as per the 
manufacturer’s instructions for the extraction of low-copy number plasmids from E. coli 
cells.  
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Following the Midi-prep the purified plasmid solution is then checked by electrophoresis and 
quantified using the Invitrogen Qubit as described in section 2.2.4. 
 
2.2.12 Transformation of S. pombe cells 
Transformation was carried out to transform the plasmids into S. pombe in order to introduce 
the desired mutant genes into the cells. The S. pombe base strains for the desired genes were 
chosen for transformation.  
For this, a single colony of the chosen base strain was inoculated into 10 ml of YEL medium 
and incubated in a shaker incubator at 30°C for 1-2 days. 1ml of the culture was transferred 
into a sterile 250 ml conical flask containing 100 ml YEL medium. This was incubated for a 
further 1-2 days at 30°C until the culture was at a concentration of 5x10
6
 – 107 cells/ml. The 
concentration was determined by placing 10 μl of the culture onto a haemocytometer which 
was examined microscopically and the cells inside the gridded area were counted and 
multiplied by 10
4
 to give the number of cells per ml. 
50 ml of the culture was taken and transferred to a centrifuge tube and spun at 1,000 x g for 5 
minutes. The supernatant was removed and the cells were then washed in 50 ml dH2O. The 
cells were then resuspended in 1 ml LiAC/TE (0.1M lithium acetate, 10mM Tris pH 7.5, 1 
mM EDTA) and transferred to a microcentrifuge tube, and then spun for 30 seconds at 
11,000 x g the supernatant was subsequently discarded.  
The cell suspension was then resuspended in LiAc/TE to a concentration of 2x10
9
 cells/ml. 
100 μl of this suspension was then taken and placed into a microcentrifuge tube. 2 μl of 
salmon sperm DNA was added along with 10μl of the plasmid DNA extracted by midi-prep. 
This was then incubated at room temperature for 10 minutes. 260 μl 40% PEG/LiAC/TE was 
added and incubated for 1 hour at 30°C in a water bath.  
43 μl DMSO was added to the mixture, which was transferred to a second water bath at 42°C 
for and incubated for five minutes to heat shock the cells. 
The suspension was spun at 11,000 x g, for 30 seconds, the supernatant was removed, and the 
cells were resuspended in 1 ml dH2O. This was spun for 30 seconds at 11,000 x g, the 
supernatant discarded and the cells resuspended in 500 μl dH2O and then plated onto 5 EMM 
plates containing thiamine at 15 μM (+ Ade if necessary). and incubated for up to 5 days at 
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30°C. The lack of leucine in the medium is used to screen for transformants as the base 
strains are of the leu1-32 genotype and therefore require leucine in the medium for growth, a 
wild-type S. cerevisiae LEU2 gene present in the pAW8 plasmid and therefore provides 
transformants with leucine. The addition of thiamine in the medium reduces the expression of 
Cre via the nmt1 promotor. 
 
2.2.13 In vivo cre recombination in S. pombe and selection of transformants 
Transformants were inoculated into 10 ml of YEL medium and incubated for 2-3 days at 
30°C. The lack of thiamine in the medium allows for the expression of Cre, leading to 
cassette exchange. The plasmid was also lost from cells during this time. Serial dilutions of 
the culture were made to 10
-5
 times, 100 μl of each dilution were then plated onto YEA + 5-
fluroorotic acid (5-FOA) at 0.1% (w/v). The plates were incubated for 3-5 days at 30°C. The 
transformant colonies were then streaked onto YEA plates and incubated for a further 2-3 
days at 30°C. The plates were replica plated onto EMM + ura+ leu, EMM + ura and EMM 
+leu (adenine also added to all plates if required), the plates were incubated for 2 days at 
30°C. Colonies which grow on the EMM + ura +leu but not on the other two are indicative of 
successful cassette exchange (loss of ura4
+
) and plasmid loss (loss of LEU2
+
). 
 
2.2.14 Extraction of genomic DNA from S. pombe 
To confirm if the transformants have correctly integrated the mutant gene, the genomic DNA 
was extracted from the transformant cells so that the region of interest could be amplified by 
PCR, screened by electrophoresis, purified and sequenced. 
The transformant cells were inoculated into 10 ml YEL and incubated at 30°C until 
saturation. The cultures were spun at 3,000 x g for 5 minutes and the supernatant was 
removed. The cells were resuspended in 1 ml TE and transferred to a screw-cap 
microcentrifuge tube and centrifuged for 3,000 x g for 5 minutes. The supernatant was 
discarded and the cells were then resuspended in 250 μl TE buffer. 300 μl phenol chloroform 
and 0.3 g zircon beads were added. 
The tubes were ribolysed for 3 x 30 seconds at speed 6.5. The aqueous phase was collected 
and placed into a microcentrifuge tube. 2 μl RNAse (50 mg/ml) was added followed by a 30 
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minute incubation at 37 °C. 2μl 10% SDS (Sodium docecyl sulphate) and 2μl proteinase K (5 
mg/ml) were added, the tubes were subsequently incubated for 1 hour at 55°C. 
Equal volumes of phenol chloroform were added, vortexed and then spun for 5 minutes at 
11,000 x g. The aqueous phase was taken and placed into a clean microcentrifuge tube. This 
phenol chloroform extraction stage was then repeated.  
20 μl 3M NaAc and 440 μl isopropanol were added to precipitate the DNA. The tubes were 
vortexed and centrifuged at 11,000 x g for 15 minutes at room temperature. The supernatant 
was discarded and 1 ml 70% ethanol was added followed by a centrifugation at 11,000 x g for 
10 minutes. The supernatant was removed and the pellet was air dried for approximately 5 
minutes. The DNA pellet was then resuspended in 100 μl TE. 
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2.2.15 Screening of S. pombe genomic DNA 
The regions of interest were screened for the correct integration of the cassette by PCR of the 
desired region using the primers given in Table 11 and the method described in section 2.2.8.  
The PCR products were checked by electrophoresis. If the product formed a band at the 
correct length, then PCR product was purified and sequenced as described in section 2.2.9 
Table 11: Primers used to check for the correct integration of the mutant mre11, rad50, 
nbs1 and ctp1 genes in S. pombe 
Number Name Sequence 
25 mre11 check-F 5′- cgtgagatttctttcgccagc-3′ 
26 mre11 check-R 5′-gtacaggtgtgtgctcagc -3′ 
27 rad50 check-F 5′- ggcagtcaaactggtcatcg-3′ 
28 rad50 check-R 5′- gcgagagaatattttggatcacc-3′ 
29 nbs1 check-F 5′-gcaaggctaggacagagaac-3′ 
30 nbs1 check-R 5′-ggtcgtacattgctacgcag-3′ 
31 ctp1 check-F 5′-ctaatcgcaagtgatgggg-3′ 
32 ctp1 check-R 5′-cgaagaagacactcctgaag-3′ 
Table 11. The names and nucleotide sequences of the primers used to check for the correct 
integration of the mutant mre11, rad50, nbs1 and ctp1 genes in S. pombe by PCR and 
subsequent sequencing. 
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2.2.16 Archiving of S. pombe strains 
S. pombe strains which were found to have correctly integrated the cassette were designated 
numbers, frozen and stored. This was done by inoculating a single colony of the strain into 10 
ml YEL and incubating for at 30°C until saturation. 500 µl cell culture and 500 µl 50% 
glycerol were added to a cryogenic vial and vortexed. The strains were then stored at -80°C. 
When required, the strains can be woken by streaking a small amount of the frozen stock onto 
a YEA plate and incubated at 30ºC. 
 
2.2.17 Testing for the sensitivity of mre11, rad50, nbs1 and ctp1 mutants to 
camptothecin and methyl-methanesulphonate  
YEA plates containing camptothecin (CPT) at 0.5 μM, 1 μM, 5 μM and 10 μM; and Methyl-
Methanesulphonate (MMS) at 0.001%, 0.002%, 0.005% and 0.01% were made. YEA plates 
without drugs were used as a control. 
Strains were grown for 2 days in YEL at 30°C. The cellular concentration of each culture was 
determined as described in section 2.2.12 (page 58). The cultures were diluted to 
concentrations of 10
7
 cells/ml. Serial dilutions of 10
6
, 10
5
, 10
4
 and 10
3
 cells/ml were made.  
10 μl of each dilution for each strain were spotted onto a plate for each concentration of both 
drugs and the control plate. Plates were incubated for 3-5 days at 30°C. Following incubation 
images of the plates were created by scanning. 
For strains showing a very high sensitivity to the drugs, this test may be repeated using lower 
concentrations of the drugs in order to identify any differences in the sensitivity of the strains 
to the drugs in comparison to the base strains related to the mutant. CPT concentrations of 0.1 
μM – 0.5 μM, and MMS concentrations of 0.0001%, 0.0002%, 0.0005% and 0.001% were 
used. 
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2.3 Sequencing of MRE11, RAD50, NBS1 and CtIP in Patient Tumour 
Samples from the NWCOG-2 (RICE) Trial 
2.3.1 Evaluation of tumour samples 
The tumour biopsy samples acquired from patients participating in the NWCOG-2 (RICE) 
trial were evaluated for their quality and potential use in this investigation. The haematoxylin 
and eosin stained microscope slides of the samples were analysed microscopically along with 
Professor Geraint Williams of Cardiff University. The number of fragments, number of 
cancerous fragments, percentage of tumour nuclei in cancerous fragments, number of 
dysplastic fragments, percentage of dysplastic nuclei in fragments, number of non-tumours 
fragments and overall tumour nuclei were analysed for each sample and recorded. Any other 
relevant observations, such as high levels of immune infiltration, grade of dysplasia and type 
of cancer were also noted. 
The paraffin tissue blocks were also evaluated to assess their usability based upon their 
thickness, quantity of sample in block and quantity of tumorous regions in the blocks.  
 
2.3.2 Microtomy of tumour samples 
The tumour sample blocks, both those taken from the RICE trial and normal-tissue control 
blocks, were placed face down on ice. A clean unused microtome blade was inserted onto the 
microtome; the microtome was set to cut sections 10 μM thick. A cool block was then placed 
into the microtome and the blade holder was adjusted as to cut a full face of the block to 
minimise waste. This initial section was discarded to prevent the acquisition of contaminant 
DNA. Subsequent sections were cut from the block and a short ribbon of sections was cut 
from each sample, using forceps to lift the ribbon from the microtome. The ribbon was then 
removed from the microtome and then placed onto a water bath. Forceps were then used to 
separate the sections which were collected onto glass slides. Up to 8 sections were taken, 
when possible, from each block. The slides were left to dry. 
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2.3.3 Extraction of DNA from tumour samples 
The areas of the slide containing tissue were outlined on the reverse of the slide with a 
marker pen. The tissue was then scraped off the slide with a clean scalpel blade and placed 
into a microcentrifuge tube. 
The DNA was then extracted from the samples using the QIAgen QIAmp DNA FFPE Tissue 
kit used as per manufacturer’s instructions. 
 
2.3.4 Quantification of DNA using NanoDrop 
Following the extraction of DNA, the concentration of DNA in the sample was measured 
using a Thermo Scientific NanoDrop. This was carried out by washing the reader with 2 μl 
H2O. The NanoDrop software was opened and 2 μl H2O was added for the initialisation step 
when prompted, and then wiped off afterwards. A blank sample was then read using 2 μl of 
the DNA elution buffer into which the DNA sample was suspended. The first sample was 
then loaded and read. The reader was cleaned between each sample. This was repeated for all 
samples. The nucleic acid concentrations and the specificity readings were recorded. 
 
2.3.5 Primers used for PCR and sequencing of NWCOG-2 patient tumour samples 
The primers that were used to amplify the coding regions of MRE11, CtIP, NBS1 and RAD50 
were designed with the aid of Primer3 software. The primers were all designed to have a 
melting temperature (Tm) of approximately 60ºC. The primer sequences are shown, in 5′to 3′ 
direction in tables 12-15. Generally, 1 PCR reaction was used per exon, however for larger 
exons multiple reactions were required due to difficulties associated with the amplification of 
larger fragments with DNA extracted from FFPE tissue). 
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Table 12: Primers used for PCR and sequencing of the coding regions of MRE11 
Exon Forward Reverse 
Product 
Size 
2 TGCAGCGTAAATCATGTTGG CATAAACAGGTTCCTTATTTACTGC 314 bp 
3 CAGATTTTCAGATGAACTCTAAGGC TTCAAGCAGGCAAGGTAAGC 396 bp 
4 ACCAGATTGAAAGTCCCTTTGA GGAAGGCAAAACAGTTGTGTG 409 bp 
5 TGCAGTTTGCCTATGATTGC AAGGCATGCTTTCCACAGAC 262 bp 
6 CAGGTGATACGATATTCATGCAG GTCACCAATAAAGAATAAGGTTTGC 336 bp 
7 TTGAGAAGGACATAATTTAGAAGCAA CAAAATGAAATCACACAAAGCAAATC 359 bp 
8 CCAATCCTGTGCACACTTTC GTTAGCGGTAACCTTAACATAGGC 423 bp 
9 GAAAGCTTTCGTTTGCACATCA GTCCTTACAGGCTTCATGAGAA 371 bp 
10 CCTGTGGTAATAAGCTGCTATTCAG GAGCACTCTCCTCACTACTTTTCA 257 bp 
11 GCATAAACACTGTGAATACTGAAGG TCCCACTGTCAATTTGTTTAAGA 355 bp 
12 CCTTCTCCACTGACAACTTGC TTGTCACCCTACTTACTTCATAGAAA 318 bp 
13 AGTAGGCTTAACTACAGCTGTTCACT GAGAGGTTAAATAGTGATTTACCAGAA 400 bp 
14 GCATTTCTTAATTGTAGCCCCTTG TCCCCTAGACCTATGGACTGA 247 bp 
15 CAGCCTCCTTTATGTTTTTATAGTATG TTCAACTCTGACAAGATCTAATTCTG 416 bp 
16 TGGTCAGACTCTAGATGTTTGTTC GGGCTACCAATGGTGATTACC 314 bp 
17 GGCATCATTCAGTTTTGCAG CCTTCCAGCTTTAATGTTCCA 297 bp 
18 TGGTTATGGCTTTCTGTCTCC GCCCTTGGTCTGTTTTCATT 356 bp 
19 GCCGCTAATGTAGATTTTAAGGGA CACGCAATTCCCATGTAACAAA 373 bp 
20 CCCATGTGAAATGACTCTCACT TGGAGTTATGCTCAGGAAACAA 273 bp 
Table 12: The forward and reverse primers used in the PCR and sequencing of MRE11 in the 
NWCOG-2 patient tumour samples. This table shows the base sequences (in a 5′-3′ direction) 
and the size of the PCR product created using primer pair. 
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Table 13: Primers used for PCR and sequencing of the coding regions of CtIP 
Exon Forward Reverse 
Product 
Size 
3 TTTGACCTGTCCAAAGACGACT ACTGTCATACAAAGGTATACAAAGCC 280 bp 
4 TTTAGAGGCCAGACTGATGTGA GGTCAAATTGGACATCAGTATCAAC 238 bp 
5 AAACACGGTGGAGCTCTTAGAA AAGGTGAGAGAAGGCTGTGG 296 bp 
6 CAGTATTTGCCAAGTCAGTTCCT GTGGACAGTATTTGCACAACCT 430 bp 
7 TGGCACGGTGTGAGATGTAG CTGCAACTCTTACAGTTATCTTCATGG 343 bp 
8 CTCCATGCCATGTAGTAAATGTTTT GGATACCAGAATAGTGACTATCTTCTT 361 bp 
9 GCTTTGTTTCTTAGTGAAATTAAAGGAG ACTGTGGGTCACTGTTACCCA 369 bp 
10 GTGTGAGCCTTTTCCTTCATCT GTTTCAGGCCTTTACCCAAGA 323 bp 
11 ACATTATGTGGCCTTTGTCTGG TGTTGAAGGAGAGAAATGGCTTAA 344 bp 
12a GGTTAATCATTTGCTTCTAAGAGGTAG ACAAGTGTTGCTAAAAGGGAGTG 265 bp 
12b ACCTACTCGAGTGTCATCTCCTG GGGGCTCCAAATGTTTATCAGTG 347 bp 
12c TTCACACATCACAGTCTTGGGT CCTTGGCTTTTCTCTTGACGC 371 bp 
12d GTGAACATGAAGTAAGCTGCCC TTCAAGGGCTGAAGGATGAT 334 bp 
12e GACCATTCCAAAGGGCTTTTCC GGCTCATGAGAACCAGCACT 336 bp 
13 AAGGTTTGTGTTAAATGTTCAAGGAT CAGACACCTGAAGGAAGAAATAAGT 333 bp 
14 AGTCCTTTACCAGACATATGATTTGC GTGAGTCACGAGAGGAGGTTG 288 bp 
15 CCTAAATCCTTACCTGTTCGTAAAG CCTGCTTTATGGTGAAGAGGTC 387 bp 
16 GGACTGCATTCTGTTATTGTGTGG GTCATCAAGCCTTTGTTAATTAGCTTG 335 bp 
17 GGAAGTTTGAGTGCGTGTCATT GCAGTGAGCTGAGTTTACGC 312 bp 
18 AGCACTTAATAAGTATTTGACGAAGC CTGTTACGCCTGGCTCAAAT 364 bp 
19 AGACTGCTGAATATCTTAGTAAATGGC CAAAGTGTTGGGATTATAGGCGT 344 bp 
20 ATCAATCATCAGCATCACACAGC GGTGCAAAAGCAAAATATCACAAAC 400 bp 
Table 13: The forward and reverse primers used in the PCR and sequencing of CtIP in the 
NWCOG-2 patient tumour samples. This table shows the base sequences (in a 5′-3′ direction) 
and the size of the PCR product created using primer pair. Exon 12 was split into 5 smaller 
products due to the length of the exon (892 bp). 
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Table 14: Primers used for PCR and sequencing of the coding regions of NBS1 
Exon Forward Reverse 
Product 
Size 
1 CACTCCCGCCTCATCCAAG GCTTGCCATACAGCGTACTCG 336 bp 
2 CTTACATGTATGTGTGTGTTCGTG ACTGGTACCACTGCCACAATATAA 386 bp 
3 GGTTAGCCACCTGCCTATTGT CCATGGCACAGAGTCCAATACT 390 bp 
4 ACTAAAAATTGCCATCTCTGCAAC GTATACAAAGGGATGGAGTGGGTA 371 bp 
5 GGATGTAAACAGCCTCTTTGTAGT CCTGAAACAAGCATTAAAGAGGGA 294 bp 
6 GTGTCAGATAGTCACTCCGTTTAC CATGATCACTGGGCAGGTCT 362 bp 
7 CTCAAGAAGTAGCACCAAGTCTTC CTTTTACATTGTTAGGTGAAAAGCAAC 401 bp 
8 GAGGTTGCTTTATCTTGACATTATCTG TGAATATGGTCACCCCTAGCAAG 283 bp 
9 TCCCCTCAGCATGGTATAGTCT CCCATTCTTCCATGCTTTCTCTC 346 bp 
10a GGAGTTGCTTTCTTGGGATGG GATGGAGTTGGTCTGCTGCT 402 bp 
10b TCACAAGATGCACCCACTGT GACATTTCTGAGAGGGAAAGCG 356 bp 
11a GTGAACTAAATGGAGGGAGTGATG TGTCCACAGGCTCATTCTCA 249 bp 
11b GCAAATCAGCAAGAATAGAAACGTC GTTTCTATATCCATCCTTGGCCTT 364 bp 
11c CTGCCAGTAAATCTCATGCTGC GACATTAATGGATGCTCATACTGTCA 341 bp 
12 ATTCAAAAGGCCAAGAAGTGATAGA GATCAATCCATTTCAAGGCACAATC 291 bp 
13 TCTATAGATTCCCAAATGACAAGTGAC GCTTTTATCTTTGTTTAGCATCACTGG 318 bp 
14 CACTTATGCATGATTTACCATCTTTGC GGAATGCTCCTGAATGAATGACTT 345 bp 
15 CAGGATGTGGAAATCTCTAAGATGAC GGACTAGGTGTCTATGAGGACAG 265 bp 
16 CCCATCCTATTTGCCAAAGTGTG CATATAACCTTGTTGGCCTGAAGTAG 209 bp 
Table 14: The forward and reverse primers used in the PCR and sequencing of NBS1 in the 
NWCOG-2 patient tumour samples. This table shows the base sequences (in a 5′-3′ direction) 
and the size of the PCR product created using primer pair. Exons 10 and 11 were split into 
smaller products due to the lengths of the exons (273 bp and 478 bp respectively). 
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Table 15: Primers used for PCR and sequencing of the coding regions of RAD50 
Exon Forward Reverse 
Product 
Size 
1 CTTGCTTCGGCCTCAGTTAAG TAGGGACGCTTCTGCTCCTA 296 bp 
2 AGCATTTCTGTGAACTTACAGCA AGTTTTCCAGTGCCAAGTTTTCT 347 bp 
3 CCCTCATTTTGGGTAAGATTGCT GAAAACAACCATCAACTTACAGACC 321 bp 
4 CTAACGGGATAGGTGAAGGGC GAAGCATCCAAATTGCAAACACAG 381 bp 
5 GTGACAGCATAATATCCCACTGTATG GCCAGTCCACGATGTATACTTATATC 371 bp 
6 CTAAATGCCTGGACCTGGAGTATC CCAATGTGGATGGCAAAATGGAT 312 bp 
7 TCCATTTTGCCATCCACATTGG CACTCAGCATAAGTCCTTGGAGA 425 bp 
8 CGTGAATCTGCAGCTATCTCAAC GCCAAAATGGAGTCCAACCAA 357 bp 
9A CTGAGCAACACACGACTGTAC GCTCCTGGTCCAGTTCAAGAAT 317 bp 
9B CTGGACTGGGAAGAATAATTGAGTT GTTGTAGAACCAAAGAGTCAGAAGATC 318 bp 
10 CAGTAATATTTGGAACATTCTGAGGAG GACTTATGAGTGCAAGGTAGGC 366 bp 
11 GCTTAGAACTTTAGTCAGTCTAGAATT CTGAAGTCTCCTTGTATGTAAGAACT 391 bp 
12 CTCTTGTCATGATTTGTTGGCAGA ATTCCCCATCCTTAACAGTTACCT 364 bp 
13 AGATACAACCGTATTCAGAATACTGT CCCAGGCATGAGATGGGTAC 383 bp 
14 CAATGTCACTTCTGTGGTATTCTTCC ACTCTCACACTTCAAATTCAAGCC 357 bp 
15 AGTCAGCTTCCTTTTGTTTACATCA GACTGTAAAAGGCATGTGCTCG 395 bp 
16 GCATTTGTGGATTCCATAGACCG GGGTGACAGAACGAGACTGT 383 bp 
17 AGACTGTGAAGTCTGACCCCT CCGACGTGGTGCTATGAACA 253 bp 
18 GTTCATAACTTCCCAGCCAGTG TCTCGCATTCACTTAGTTGAGCT 310 bp 
19 AGATGGGAAAGACGACTATAAGAAGG TGTGAGCCACCACGCTT 336 bp 
20 GTCACCAGTTGCCTGTTACAGA CAAAGGATACCAGGCTGAGGC 314 bp 
21 CTATGACTTTTCCACTTCAGGTTGT CCAGCCTGGGAAACAAGAGT 430 bp 
22 GCCAAGCAGCAAAGTTTTGC GAGAGGTCATAAGGGGAAGAGC 347 bp 
23 CCTCATCTGTTGTTCCTAGGCTT GTGCTTCCACTGCACTGATG 319 bp 
24 TCAGGACTGCTTGCCTGC TGAAGAACTATCACAACCTGTCCC 276 bp 
25 CTGACAAGGTTTGCGGTGAC TCCTAGACACAATGTTCCTTTGAAAG 396 bp 
Table 15: The forward and reverse primers used in the PCR and sequencing of RAD50 in the 
NWCOG-2 patient tumour samples. This table shows the base sequences (in a 5′-3′ direction) 
and the size of the PCR product created using primer pair. Exon 9 was split into 2 smaller 
products due to the length of the exon (207 bp) and G/C poor regions which flank the exon, 
requiring primers that bind further from the exon. 
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2.3.6 Multiplex PCR  
Due to the generally low quality and concentration of patient sample DNA, a primary 
multiplex PCR reaction was carried out using all primers for a single gene for each patient in 
a single reaction to amplify the amount of template available. For this, the following were 
added to each reaction for a total reaction volume of 50 µl. 
 Multiplex primer mix containing each primer at a concentration of 20 pmol/µl. (1 µl 
for each primer pair 
 1 µl patient sample DNA 
 25 µl Bioline MyTaq HS Red Mix 
 Make up to 50 µl with PCR grade H2O 
The following reaction programme was used 
 Initial denaturation of 95°C for 3 minutes 
 25 cycles of: 
o Denaturation of 95°C for 30 seconds 
o Annealing and  synthesis at 56.8°C for 4 minutes 
 Final extension of 72°C for 5 minutes 
  
70 
 
2.3.7 PCR of patient tumour sample DNA 
The exons of the genes of interest in the patient sample DNA were amplified by PCR. 
Negative controls were also used for each primer pair to check for PCR contamination. The 
following were added to each reaction for a total reaction volume of 10 μl: 
 2 μl PCR grade dH2O (3 μl for negative control reactions in which multiplex products 
are not used) 
 1 μl patient sample DNA/patient sample multiplex PCR product/negative control 
multiplex PCR product 
 1 μl Forward primer (5 pmol/μl) 
 1 μl Reverse primer (5 pmol/μl) 
 5 μl Bioline MyTaq HS Red Mix 
The following reaction programme was used: 
 Initial Denaturation of 95°C for 3 minutes 
 33 cycles of: 
o Denaturation of 95°C for 15 seconds 
o Annealing for 15 seconds at the optimal temperature defined by gradient 
PCR 
o Extension of 72°C for 15 seconds 
 Final extension of 72°C for 5 minutes 
 
2.3.8 PCR optimisation 
2.3.8.1 Annealing Temperature 
The optimal annealing temperature for each primer pair was determined by gradient PCR 
using the conditions defined in section 2.3.7. A gradient for the annealing stage ranging from 
51.8°C – 62.2°C was used. The reactions were set-up in 96-well plates DNA acquired from a 
control sample was used in each reaction optimisation reaction. The full range of annealing 
temperatures was tested for each primer pair. 
The PCR products were checked by electrophoresis. The annealing temperature which gives 
a single specific band showing the correct length is chosen as the optimal temperature for use 
for the PCR reactions of the trial DNA for that specific primer pair. 
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2.3.8.2 Cycle Number 
To reduce the concentration of potential contaminating DNA PCR products in the PCR 
reactions whilst maintaining the highest possible yield of PCR product, the PCR cycle 
number was optimised. For this, PCR reactions were carried out as described 2.3.7 using 
wild-type DNA and a no-template control, with varying cycle numbers from 30-35. The 
primers for MRE11 exon 2 were used. The PCR products were checked by electrophoresis. 
The cycle number for which the highest yield of PCR product was observed in the wild-type 
DNA reaction with little to no PCR product in the no-template control reaction, was chosen. 
 
2.3.9 PCR screening using the QIAxcel system 
PCR products were screened by QIAxcel using QIAgen QIAxcel DNA screening kit with the 
15 bp – 1 Kb alignment marker and the 50-800 bp v2.0 size marker. The QIAxcel was run as 
per the manufacturer’s instructions using AM320 method. 
 
2.3.10 Purification of PCR product using the ExoSAP method 
0.5 µl of Exonuclease I (ExoI) (20 U/µl) and 2 µl of shrimp alkaline phosphatase (SAP) (1 
U/µl) were added to the PCR products and then incubated in a thermocycler for 15 minutes at 
37°C and then 85°C for a further 15 minutes.  
The purified products can then be checked and quantified as described in sections 2.2.2 and 
2.2.3.  
 
2.3.11 Plate Sequencing 
Sequencing was carried out using the Eurofins plate sequencing service for purified DNA. 
Approximately 75 ng of PCR products were added to the wells of the sequencing plate and 
then made up to 15 µl using dH2O. 2 µl of the corresponding primer (10 µM) were then 
added to samples. The plates were then sent to Eurofins MWG Operon for sequencing. 
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2.3.12 SmartSeq sequencing 
Sequencing of individual samples was also carried out using the Eurofins SmartSeq service in 
which approximately 75 ng PCR product, made up to 15 µl with dH2O, and 2 µl of the 
corresponding primer (10 µM) were added to a Eurofins SmartSeq barcoded tube. These 
samples were then sent to Eurofins MWG Operon for sequencing. 
 
2.3.13 Identification of mutations 
Sequencing data was aligned to the wild-type sequences ( accession numbers NG_007261.1, 
NG_021151.1, NG_008860.1 and NG_012121.1 for MRE11, RAD50, NBS1 and CtIP 
respectively) for the corresponding exons for each gene using Clustal Omega (ClustalO) 
alignment software to identify any bases in the patient tumour DNA that do not match that of 
the wild-type.  
Chromatograms were also checked by eye to identify and mutations that may be present that 
were not called by the base calling software. 
Sequencing of the opposite DNA strand was carried out for all exons in which a mutation was 
found to be present in order to confirm the presence of the mutation. 
 
2.3.14 Estimation of the pathogenic effect of mutations 
The potential damaging effect of the mutations was estimated using the Polyphen2 and Align 
GVGD mutation analysis software. 
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2.4 Resequencing of NWCOG-2 Patient Tumour Samples 
2.4.1 Resequencing of NWCOG-2 samples  
PCR and sequencing was carried out, as described in section 2.3.7, on exons in which 
mutations were identified, using primers that bind external to those used in the initial PCR 
and sequencing reactions. The primers are shown in tables 16-19. 
Table 16: Primers used for PCR and resequencing of MRE11 
Exon Forward Reverse 
Product 
Size 
3X CTGTATTGAACTAGTGGTTAGG GCTCCTACTTGAATTTAAGACAC 516 bp 
8X GGTCAGGAGTTAGCATTGATG CATATAAATGACAATACTGCCAG 478 bp 
11X GCTCCATCATGATCTACTGTAG CGTTGTGCACATGTACCCTAG 491 bp 
13X CGTGTCCTGTACTCCTCCC GCAAGACTCTGTTCTAGGC 553 bp 
19X CCTCGGCCCCAGAGTCC GGGATCTGTACCAAACCTCAGC 438 bp 
Table 16: The forward and reverse primers used in the PCR and sequencing of MRE11 exons 
which required resequencing in the NWCOG-2 patient tumour samples. This table shows the 
base sequences (in a 5′-3′ direction) and the size of the PCR product created using primer 
pair. The “X” next to the exon number denotes that these primers are external to the original. 
 
Table 17: Primers used for PCR and resequencing of CtIP 
Exon Forward Reverse 
Product 
Size 
11X GCTTTCTGTCCCTAGAGATTTACC GGTCAGAAACTAGGGAGACAATTT 462 
12AX GCCAAAAGCTGTACCTTGTCTT GTGTGAAAAGGGCACTATCTTCAG 349 
16X CACAGTTACTAAGCTCAGTACCCA GGTTGGGTCAAAGGTACAGGAG 533 
20X GAGGAAACTGATGCTAAATAGTGAGAT GAGTGCAAAATGAAAGCGCC 458 
Table 17: The forward and reverse primers used in the PCR and sequencing of CtIP exons 
which required resequencing in the NWCOG-2 patient tumour samples. This table shows the 
base sequences (in a 5′-3′ direction) and the size of the PCR product created using primer 
pair. The “X” next to the exon number denotes that these primers are external to the original. 
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Table 18: Primers used for PCR and resequencing of NBS1 
Exon Forward Reverse 
Product 
Size 
4X GGTTACAAAGCTTAATGATGAGGAAC GGTTATATGAAAAGCCACTCAAGCC 510 
Table 18: The forward and reverse primers used in the PCR and sequencing of NBS1 exons 
which required resequencing in the NWCOG-2 patient tumour samples. This table shows the 
base sequences (in a 5′-3′ direction) and the size of the PCR product created using primer 
pair. The “X” next to the exon number denotes that these primers are external to the original. 
 
Table 19: Primers used PCR and resequencing of RAD50 
Exon Forward Reverse 
Product 
Size 
1X CCTGACCCTGAGATTCGCG CCTACACCTGTGGAGCCC 354 
3X CATACCTGATCTCCTAATGATGCTG GCTCCCCTAAACTTATAGTAGAAAACA 477 
10X CCTTAGAGCATATATAGTGCCTTATGT GAGTACTAAGCTCACTTAGCCTCT 479 
11X GACCATCCCCACTTGAAGACT GAACTTGATGGAGCTTATGTTGAGA 542 
13X GCTCTTTGGAAGCGAATATCGG CCTTACTGAGTAACTACCATCTGCC 503 
16X TTGTTGCAGTGGGTGGGG TGCTACTGCACTCCAGCC 432 
19X CATGGCTATATGAAAGACATTGAG TGTGAGCCACCACGCTT 371 
21X CTGATTGCTAAGGAGAATGATACTTAACC GCTGAGATCGTGCCATTGC 494 
23X CCAGCCATTGTTTTCCTCTGG CAGGTGTAGCCTTGGGTGC 364 
24X CGTTTCCCACTTTTCCCTGC GGGAACACAGCTAGAGAACGT 355 
25X CCTGACACACAGCACAAGTTC GAACCTCTCAACATCCAAAATCCT 443 
Table 19: The forward and reverse primers used in the PCR and sequencing of RAD50 exons 
which required resequencing in the NWCOG-2 patient tumour samples. This table shows the 
base sequences (in a 5′-3′ direction) and the size of the PCR product created using primer 
pair. The “X” next to the exon number denotes that these primers are external to the original. 
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2.4.2 Resequencing on new sections cut from NWCOG-2 patient samples 
Sections were cut from the tumour sample bocks for patients in which MRN/CtIP mutations 
were found. Microtomy was carried out as described in section 2.3.2. DNA was then 
extracted as described in section 2.3.3. PCR was carried out as described in section 2.3.7 
using newly ordered primers (with the same sequences as the primers listed in tables 12-15), 
fresh PCR grade H2O and fresh MyTaq HS Red Mix. To prevent contamination in the DNA 
extraction and PCR stages, protective coveralls and facemasks were worn and the procedures 
were carried out in a laboratory in which no work on human DNA or PCR has previously 
been carried out. This laboratory was also cleaned thoroughly with bleach and DNA-Zap. 
The PCR products were checked by QIAxcel (as described in section 2.3.9), purified by 
ExoSAP method (described in section 2.3.10) and sequenced by SmartSeq (as described in 
section 2.3.12). The sequencing results were analysed by alignment using ClustalO, and the 
chromatograms were checked by eye (as described in section 2.3.13). 
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2.5 Analysis of Mutations in the Microsatellite Regions of MRE11 and CtIP 
2.5.1 Fluorescent fragment analysis 
FAM (6-Fluorescein amidite) labelled primers were designed to amplify the region of MRE11 
containing the poly(T)11 repeat and the region of CtIP containing the poly(A)9 repeat. These 
primers are shown below in Table 20. 
Table 20: Primers used for fluorescent fragment analysis of MRE11 and CtIP 
Gene Forward Reverse 
Product 
Size 
MRE11 FAM-
GAGGAGAATCTTAGGGAAAACAGC 
 GTTTCT-
GGAATTGAAATGTTGAGGTTGCC 
119 bp 
CtIP FAM- 
GGAGCTACCTCTAGTATCAAAAGTGG 
GTTTCT- 
GGGCACTATCTTCAGATTTTGATCTAG
  
163 bp 
Table 20: The forward and reverse primers used to amplify the regions of MRE11 and CtIP 
which required analysis by fluorescent fragment analysis in the NWCOG-2 patient tumour 
samples. This table shows the base sequences (in a 5′-3′ direction) and the size of the PCR 
product created using primer pair. FAM- denotes the fluorescent FAM label added to the 
forward primer to create a fluorescently labelled PCR product. The GTTCT tails were added 
to the 5′ ends of the reverse primers to promote the completion of the reaction by which Taq 
polymerase adds additional non-templated A bases to the fragment. This reduces the 
prevalence of stutter peaks [186] [187]. 
 
PCR was carried out as described in section 2.3.7 on patient sample DNA using the FAM 
labelled primers. The PCR products were then checked using the QIAxcel as described in 
section 2.3.9 
The products were treated with T4 DNA polymerase, as this is done to remove additional A 
bases added by the Taq polymerase to further reduce stutter peaks and inaccurate allele 
calling [188] [189]. 0.1 U of T4 polymerase was added to the samples. The samples were 
then heated for 37ºC for 10 minutes and then heat at 72ºC for 20 minutes to inactivate the 
enzyme. 
1 µl of 1/50 x dilution PCR product, 0.3 µl GeneScan 350 ROX size standard and 9 µl 
formamide were added to the wells of a 96 well optical plate and mixed well by pipetting. 
Samples were then run on an ABI 3130xl genetic analyser. The peaks were analysed using 
ABI GeneMapper software. 
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2.6 Screen for S. pombe Mutants Which Show an Increased Sensitivity to    
5-Fluorouracil 
2.6.1 Testing for sensitivity of mre11Δ, rad50Δ, nbs1Δ and ctp1Δ mutants to the 
drug 5-Flurouracil 
YEA plates containing 5-fluorouracil (5-FU) at concentrations of 0, 1, 10, 100, 150 and 500 
μM were made. The strains used were mre11Δ, rad50Δ, nbs1Δ and ctp1Δ (EH01104, TJ1, 
EH1031 and EH1030 respectively). Strains of these aforementioned genotypes with the ura4-
D18 mutation were also used. Sensitivity tests were then carried out as described in section 
2.2.17. 
 
2.6.2 5-FU pre-screen 
Wells of a 96-well culture plate were filled with 50 μl YEL. ura4-D18 EH00068 strain was 
inoculated into the wells. The plate was then tightly covered, placed into a humidity chamber 
to prevent evaporation, and incubated at 30°C for 4 days. 
YEA plates were made containing 5-FU at concentrations of 0 μM, 100-500μM in increments 
of 50 μM and 600-800 μM in increments of 100μM. 
A 48 pin replicator was sterilised by IMS and flaming. After the replicator cooled, the pins 
were inserted into the wells of the 96 well plate containing the cultures, and replicated onto 
the plates. The replicator was sterilised between each replication. 
The plates were scanned into a computer and then incubated at 30°C, being scanned every 12 
hours for 5 days. 
ImageJ software was then used to stack the images and measure the intensity of the spots on 
each plate at each time-point. These values were then used to construct growth curves for the 
WT strain for each concentration of 5-FU. This was then analysed to determine the 
concentration of 5-FU to be used in the plates for the library screen. 
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2.6.3 Waking of the S. pombe library 
34 96-well culture plates were filled with 50 μl YEL into each well and numbered. The 
Bioneer Library version 2.0 was thawed. Each plate was placed onto a plate vortex to 
resuspend the cells. A 96-pin replicator was then used to replicate the cells from the library 
into the fresh 96-well plate of the same number and at the correct rotation. This was then 
repeated for all plates.  
The plates were placed into a humidity chamber and incubated at 30°C for 4 days. 
 
2.6.4 Transfer of S. pombe deletion library to 384 solid agar format 
The library was transferred from 96 well liquid medium format onto 384 solid medium 
format to reduce the number of plates to be used. This was done using the Singer ROTOR 
robot. The protocols were set using 96 liquid format as the source plates, and 384 solid 
format as the target plates. 96-long-pin pads were used to replicate the library from liquid to 
solid. Following replication, the library, on solid media, was incubated for 3 days at 30ºC 
 
2.6.5 Library screen for mutants showing an increased sensitivity to 5-FU 
10 YEA control plates, 10 YEA + 200 µM 5-FU and 10 YEA + 400 μM 5-FU plates were 
made and numbered. The antibiotic G418 was added to a concentration of 1 µg/ml, to prevent 
contamination by bacteria and non-library yeast cells (the library strains are all G418 
resistant). The plates were dried under a microbial culture hood to prevent condensation. 
Using the ROTOR robot the library was replicated from the plates made in section 2.6.4 onto 
the plates described above. The settings were chosen for 384 solid medium as a source plate 
and for 3 x 384 solid medium target plates. 384-short-pin pads were used. Following the 
replication of the library, the plates were placed (colony-side down) onto a set of scanners (1 
set of plates per scanner) inside an incubator, to be incubated at 30 ºC for 72 hours. 
A script was run on a computer connected to the scanners in the incubator so that they would 
scan the library plates every 2 hours for 72 hours (starting at 0 hours). 
This was repeated a total of 8 times. 
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2.6.6 Analysis of the library screen using Colonyzer and QFA 
The scanned images were cropped using ImageMagick, so that there was an individual image 
of each plate, at each 5-FU concentration, at each time point, for each 8 repeats. The 
Colonyzer software was then used to measure the size and density of each colony throughout 
the time course. The statistics package R, was installed with the QFA package, and run to 
analyse the measurements obtained from Colonyzer. QFA then constructed growth curves, 
calculated the fitness for each strain and conducted fitness plots. QFA epistasis then 
calculates the significance of 5-FU sensitivity and resistance for each strain and identifies a 
list of strains that are sensitive to 5-FU at each concentration. 
 
2.6.7 Ontological Analysis 
Ontological analysis was carried out on the list of genes identified to be significantly 
sensitive to 5-FU when deleted using Cytoscape software with the BiNGO plugin. The list of 
genes were entered into the BiNGO interface on Cytoscape and the analysis was run with S. 
pombe selected as the organism and a custom reference list consisting of the genes deleted in 
the Bioneer deletion library. This generated a table showing the list of processes that were 
found to be significant in maintaining resistance to 5-FU in S. pombe, as well as a network 
image to visualise the relationships between the significant processes.  
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3 Creation of Known Patient MRE11, RAD50, NBS1 and CtIP Mutations 
in Schizosaccharomyces pombe 
3.1 Introduction 
3.1.1 Roles of Mre11, Rad50, Nbs1 and CtIP in DSB repair and topoisomerase 
removal 
Several studies in a range of model organisms have suggested roles of the MRN complex in 
the repair of DNA DSBs and the removal of covalently bound topoisomerases from DNA. As 
discussed in the introduction to this thesis, the Mre11, Rad50, Nbs1 and CtIP proteins are 
involved in the detection and repair of DNA DSBs. The Mre11 protein dimers detect DSBs 
and bind to each broken chromosome end [190]. A Rad50 protein binds to each Mre11 dimer, 
and then to one another via the zinc hook domain [191]. Nbs1 binds to Mre11 and then 
recruits and interacts with ATM leading to the activation of ATM via autophosphorylation 
[192] [11]. ATM then interacts and activates a range of substrates involved in cell cycle 
arrest, apoptosis and DNA repair [5] [11] [12]. One such protein is CtIP, which was shown in 
human cells to bind the fork-head associated (FHA) domain of Nbs1 following activation by 
ATM [193], and then function in the DNA DSB repair pathway of HR [194]. CtIP has also 
been shown to function in the repair of etoposide-induced DSBs by NHEJ in human cells 
[195]. In S. pombe the CtIP homologue Ctp1 functions in NHEJ by promoting the 
dissociation of the Ku heterodimer from DNA [28]. In human cells, CtIP promotes HR by 
regulating the initial DSB end resection [196]. 
Also, as described in the introduction to this thesis the S. pombe Mre11 and Ctp1 proteins 
have been shown to be involved in the removal of covalently bound topoisomerases from 
DNA and thus contribute to resistance to topoisomerase inhibitors [94]. The human Mre11 
protein is also known to have involvement in the removal of topoisomerase II from DNA 
[197].  
 
3.1.2 Aims 
Due to the known involvement of the MRN complex and CtIP in the resistance to 
topoisomerase inhibitors, and the knowledge that mutations within the encoding genes confer 
increased sensitivity to topoisomerase inhibitors, it was hypothesised that some specific 
patient mutations of these genes found in colorectal cancers may confer a specific 
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hypersensitivity to camptothecin. The aim of this investigation was to identify if known 
mutations in MRE11, RAD50, NBS1 and CtIP; which have previously been identified in 
cancer and associated syndromes (AT-LD, NBS-LD, NBS, Seckel syndrome and Jawad 
syndrome), confer an increased sensitivity to camptothecin. This investigation aimed to 
identify if any of these patient mutations cause separation of function mutants which 
specifically sensitise to camptothecin, without sensitising to other DNA damaging agents. 
Separation of function mutants which sensitise to camptothecin be of great relevance to the 
treatment of tumours with irinotecan, as irinotecan is a camptothecin derivative, and therefore 
these mutations, when present in cancers, may be indicative of a greater response to 
irinotecan but not to other treatments. 
A separation of function phenotype is observed for the S. pombe mre11-D65N mutant, in 
which camptothecin sensitivity is heightened and methyl-methanesulphonate (MMS) 
sensitivity remains unchanged in comparison to that of the wild-type (see Figure 20, page 
95). The mutant mre11-D65N is known to be a separation of function mutant as it is defective 
in Top1 and Top2 removal, for which Mre11 nuclease activity is required, yet retain 
proficiency in downstream DNA repair functions which do not require Mre11 nuclease 
activity [94]. The human MSI related Δ5-7Mre11 mutant is an example of a known separation 
of function mutant found in colorectal cancers that retains affinity for Rad50 and ssDNA, yet 
abolishes Nbs1 binding activity and 3′-5′ exonuclease activity, due to the loss of part of the 
nuclease and Nbs1 binding domains. This mutant was found to confer hypersensitivity to 
camptothecin, thymidine and higher doses of ionising radiation (IR), but remains resistant to 
IR at lower doses [107]. 
In this investigation the known mutations have been recreated into the orthologues of the 
aforementioned genes in the model eukaryotic organism S. pombe (mre11, rad50, nbs1 and 
ctp1 respectively), and tested for their sensitivity against camptothecin and MMS. 
 
3.1.3 Creation and testing of mutants in S. pombe 
To create the mutants in S. pombe, alignments of the human and S. pombe homologues of 
each gene were made (shown in the introductory section to this thesis) so that the homology 
of the amino acid sequences could be assessed. The mutations were constructed in S. pombe 
at locations that aligned to the location of the mutation in the human sequence. Any aberrant 
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C-terminal amino acids that occur due to frameshifts in the human mutants were incorporated 
into the corresponding S. pombe mutants. 
The mutant strains were created using the Cre-lox system (as shown in Figure 14 and Figure 
15) and then tested for sensitivity to camptothecin (CPT) and methyl-methanesulphonate 
(MMS), and compared to the sensitivity of the wild-type strain and corresponding knockout 
strain to gauge the sensitivity to both agents as a result of the mutation. A corresponding 
floxed wild-type strain (harbours the wild-type gene flanked by loxP and loxM3 sites) was 
also tested in order to identify if the presence of the lox sites affects the function of the 
corresponding gene. 
The mutants were tested for sensitivity to MMS in addition to CPT in order to identify if any 
degree of increased sensitivity is specific to CPT, and thus specifically impairs the ability of 
the cell to remove topoisomerases from DNA. MMS damages DNA through a different 
mechanism to that of CPT. MMS methylates DNA causing lethal lesions that inhibit DNA 
synthesis. These lesions are known to be repaired by recombination repair and base excision 
repair (BER) [198]. A small portion of lesions are repaired by the MMR pathway [199]. 
Studies in S. cerevisiae have also shown that disruptions in HR increase sensitivity to MMS 
[200] [201], as it is thought that MMS can induce DSBs. These DSBs are thought to arise 
during BER, when a SSB encounters a replication fork [201]. DSBs can also arise from two 
SSBs that form on opposite DNA strands in close proximity [202]. 
The nuclease dead mre11-D65N mutant was also tested alongside the mre11 mutants. This 
mutant is known to retain its proficiency for MRN complex formation [104] and downstream 
recombination repair. This mutant is however, defective in the removal of Top1 and Top2 
from DNA, as this process requires nuclease activity. These attributes result in a separation of 
function mutant that has a greater sensitivity to camptothecin, as resistance to this drug 
requires nuclease activity (see introduction) of which this mutant lacks; than to MMS, which 
does not. A previous study shows this to be the case [94]. 
The workflow for the creation and selection of the mutants is shown in figures 14 and 15.  
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Figure 14. In vitro Cre-lox recombination.  Diagram to show the first parts of the procedure used to create 
the mre11, rad50, nbs1 and ctp1 mutants in pAW8-ccdb. This diagram shows the creation of the mutant 
insert, consisting of the mutant gene flanked by the loxP and loxM3, the PCR product is then inserted into 
the pAW8-ccdb plasmid using cre recombinase. The plasmid is then transformed and cloned into E. coli.  
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Figure 15.Creation of mutant S. pombe strains using Cre-lox recombination. Diagram to show the latter 
stages of the procedure used to create the mre11, rad50, nbs1 and ctp1 mutants in S. pombe. This diagram 
shows the mutant plasmid being inserted into the S. pombe base-strain for the corresponding gene. Cre 
recombinase then functions to exchange the mutant gene insert with the ura4 gene in place of the 
corresponding gene in the base strain. Selection procedures select strains which have recombined to 
incorporate the mutant gene and have lost the ura4 marker and the plasmid. 
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3.1.4 Known MRE11, RAD50, NBS1 and CtIP patient mutations 
3.1.4.1 MRE11-W210X 
The MRE11-W210X (X refers to a stop codon) mutation has been identified heterozygously in 
a colorectal cancer with chromosomal instability [175]. This mutation causes a truncation, 
resulting in an Mre11 protein consisting of only 209 out of 708 amino acids. This truncation 
occurs partway through the nuclease domain resulting in a mutant protein which consists only 
of the first three phosphodiesterase domains, the first Mre11 binding domain and the Nbs1 
binding domain. When recreated into S. pombe in this study, this mutation consists of the first 
241 residues (W215X), however it is referred here as mre11-W210X to match that of the 
human homologue. In S. pombe, this mutant protein also only consists of part of the nuclease 
domain, including the first Mre11 dimer interface and the nbs1-binding domain. 
 
3.1.4.2 Δ5-7 MRE11 
In tumours, Δ5-7 MRE11 mutation is known to arise as a result of 1-2 base pair 
insertion/deletion in the poly(T)11 tract of intron IV caused by MSI. This mutant is known to 
function in a dominant negative manner [107], and has been found as both homo- and 
heterozygous in MSI tumours [165]. This mutant results in a mutant transcript that encodes a 
593 amino acid protein that lacks the 3
rd
 and 4
th
 highly conserved phosphodiesterase domains 
of the nuclease domain, which are required for 3ʹ-5 exonuclease activity [107]. This protein 
also lacks 14 amino acids of the Nbs1 binding domain. 
This mutant protein is known to have a reduced affinity for Rad50 and very little affinity at 
all for Nbs1 in comparison to the wild-type, whilst exhibiting a greater affinity for ssDNA 
[107]. This mutant is known to confer an increase in sensitivity to camptothecin, thymidine 
[107] and PARP-1 inhibitors in human cells1 [166]. 
When recreated into S. pombe in this study, this mutation is referred to as mre11-Δ5-7. In S. 
pombe this mutant protein also lacks the third and fourth phosphodiesterase domains and part 
of the Nbs1 binding domain. 
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3.1.4.3 MRE11-R572X 
The MRE11-R572X mutation results in a 571/708 amino acids long Mre11 protein. This 
mutant has been observed in cases of AT-LD [145] [203] [204]. This mutant protein lacks 
parts of the MLH1 binding domain and GAR motif in addition to a complete deletion of the 
second DNA binding domain. When recreated into S. pombe this mutant is referred to as 
mre11-R572X. It is unknown if the MLH1 and second DNA binding domain are present in S. 
pombe Mre11 and homology of these regions between human and S. pombe is poor. The 
GAR motif is not present in S. pombe Mre11. 
Diagrams of the wild-type Mre11 protein and the mutants described above are shown in 
Figure 16. 
  
87 
 
  
 
 
 
 
 
 
  
Figure 16. Diagram of the human Mre11 wild-type and patient mutant proteins (not to scale). The 
location of each domain in Mre11 is labelled on the wild-type diagram with the corresponding amino acid 
residue numbers. The schematic for the Mre11-W210X mutant shows that this protein is truncated in the 
nuclease domain before the fourth and fifth phosphodiesterase domains. This mutant also lacks both DNA 
binding domains, an Mre11 dimerization domain, the MLH1 binding domain and the glycine-arginine rich 
(GAR) motif. The Schematic for the Δ5-7Mre11 mutant shows that a region of the nuclease domain 
containing the third and fourth nuclease domains, and the last 14 residues of the Nbs1 binding domain, are 
missing. The third mutant, Mre11-R572X, is shown to be truncated partway through the MLH1-binding and 
GAR domains and therefore completely lacks the second DNA binding domain. The nuclease and Rad50 
binding domains and the first Mre11 dimer interface are known to be conserved in S. pombe. There is strong 
homology in the amino acid sequences of the human Mre11 Nbs-binding domain and the corresponding 
region of S. pombe  Mre11, this suggest that this domain is also conserved in S. pombe. It is unknown if the 
DNA binding or MLH1 binding domains exist in the S. pombe Mre11, there is poor homology between the 
human and S. pombe Mre11 proteins at these areas. The GAR motif is not present in S. pombe Mre11. 
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3.1.4.4 RAD50-MSI 
The human RAD50 gene is known to be subject to mutations as a result of MSI in two 
separate mononucleotide repeat sequences. The first occurs at the poly(A)9 repeat in exon 13 
[70] [168] [169], and the second occurs in the poly(A)8 tract of exon 17 [169] [171]. Both 
mutations cause frameshifts that result in truncations and have only been found 
heterozygously in patients [169]. For this investigation, the latter was chosen initially for 
creation in S. pombe as it results in a longer protein, 938 out of 1312 amino acids as opposed 
to the 726-734 amino acid length protein (length dependent on whether the mutation is a 1 bp 
insertion, 1 bp deletion or 2 bp deletion, as discussed in thesis introduction) that can arise 
from the former. If the longer mutant produces a null phenotype, then there will be no need to 
construct a shorter mutant. 
For this investigation, this mutant is referred to as RAD50-MSI, for the human mutant, and 
rad50-MSI for the S. pombe mutant. 
This truncation occurs partway through the second coiled-coil domain (residues 787-1116 
[191]) and deletes the C-terminal ABC ATPase (residues 1195-1297 [205]), the second and 
third Mre11 binding domains (residues 1140-1154 and 1192-1205 [206]), the second 
nucleotide binding domain (residues 1232-1270 [45]) and the Walker B motif (residues 1227-
1232 [45]). These domains appear to be conserved in S. pombe (see Figure 9), and are 
therefore absent in the S. pombe rad50-MSI mutant. Due to the frameshift, the final 5 amino 
acids (IQATK) are aberrant and not present in the wild-type protein. These aberrant amino 
acids have been incorporated into the S. pombe mutant.  
Due to the observed null phenotype of this mutant, as shown in section 3.3.2 (page 97), the 
poly(A)9 MSI mutant was not created and tested as it was assumed this would also result in a 
null phenotype due to a loss of an even greater portion of the protein. 
A diagram of the wild-type Rad50 protein, and the mutant described above are shown in 
Figure 17. 
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Figure 17. Diagram of the human Rad50 wild-type and MSI related patient mutant protein (not to 
scale). The location of each domain in Rad50 is labelled on the wild-type diagram with the corresponding 
amino residue numbers. The schematic for the Rad50-MSI mutant shows that this protein is truncated in the 
second coiled-coil domain and thus lacks the second ATPase domain, the second nucleotide binding domain, 
the Walker-B motif and the second and third Mre11 binding domains. Due to the frameshift that gives rise to 
this truncation, a short sequence of aberrant amino acids is present at the C-terminal of the protein (IQATK). 
The Zinc hook domain is known to be conserved in S. pombe Rad50. Strong homology between human and S. 
pombe Rad50 at the ABC-ATPase, DNA binding and Mre11 binding domains along with the Walker A and 
Walker B motifs suggests that these domains are conserved in S. pombe. 
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3.1.4.5 NBS1-MSI 
The poly(A)7 repeat in exon 7 of the human NBS1 gene is known to be subject to mutation in 
tumours exhibiting MSI. This mutation, a 1 bp deletion also known as NBS1-1651delA, 
causes a frameshift resulting in a mutant transcript that encodes a truncated Nbs1 protein, 577 
out of 754 amino acids in length [172]. In this investigation, this mutant is referred to as 
NBS1-MSI (human) and nbs1-MSI (S. pombe). The final 7 amino acids are aberrant and arise 
due to the frameshift. These aberrant amino acids have been incorporated into the S. pombe 
mutant. 
As a result of this truncation, in humans the C-terminal Mre11 and ATM binding domains are 
absent (amino acid residues 640-691 and 734-754 respectively [205]). This mutant protein 
retains the N-terminal region consisting of the FHA domain, BRCT1 domain, BRCT2 
domain and the Nbs1 dimer interface. These domains are conserved in S. pombe, so that 
when this mutant was created in the S. pombe nbs1 gene the N-terminal Mre11 and Tel1
ATM
 
binding domains in the Nbs1 protein were absent [207] [208]. 
A diagram showing the human wild-type and mutant Nbs1 proteins are shown in Figure 18. 
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Figure 18. Diagram of the human Nbs1 wild-type and MSI related patient mutant protein (not to 
scale). The location of each domain in Nbs1 is labelled on the wild-type schematic with the corresponding 
amino residue numbers. The diagram for the Nbs1-MSI mutant shows that this mutant lacks the Mre11 and 
ATM binding domains due to the truncation. These domains are conserved in S. pombe. Due to the 
frameshift that gives rise to this truncation, a short sequence of aberrant amino acids is present at the C-
terminal of the protein (GKWMMWP). 
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3.1.4.6 CtIP-MSI 
In the human CtIP gene, the poly(A)9 tract can also be subject to mutation in MSI+ tumours. 
A single base pair deletion, which occurs in around 22.9% of MSI+ colorectal cancers, causes 
a frameshift that causes a premature stop codon resulting in a truncated CtIP protein 
consisting of only 358 out of 897 amino acids [174].  
The resultant truncated protein retains the first MRN binding domain, the CtIP dimerizing 
coiled-coil domain, CxxC motif I and the Rb binding site, which are all located between 
residues 22-167 [209] [210]. The CtBP binding site, Proliferating cell nuclear antigen 
(PCNA) binding domain, DNA binding domain, second MRN binding domain and CxxC 
motif II are all absent in this mutant protein. Of three known important phosphoserine 
residues, two are omitted (both ATM binding residues) leaving only one (the first 
CDK/BRCA1 binding residue). The phosphothreonine residue, which is involved in CDK 
binding is also absent. The frameshift that causes this truncation also encodes 2 aberrant 
amino acids at the C-terminus prior to the stop codon. These amino acids were included in 
the S. pombe mutant protein. 
In the S. pombe Ctp1 protein, a MRN binding site is located between residues 74-94 [211]. It 
is not known if a second MRN binding domain exists; however the whole Ctp1 protein is 
known to have homology with the C-terminal region of CtIP, which comprises the second 
MRN binding domain of CtIP [212]. The C-terminal region of S. pombe Ctp1 (residues 200-
294) comprise the RHR domain, which has been found to be required for the efficient repair 
of DSBs [211]. 
In this study, this mutation is referred to as CtIP-MSI in humans and ctp1-MSI for this 
mutation created in S. pombe. 
A diagram showing the locations of the functional domains of the human wild-type and 
mutant CtIP proteins is shown in Figure 19. 
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Figure 19. Diagram of the human CtIP wild-type and MSI related patient mutant protein (not to 
scale). The location of each domain in CtIP is labelled on the wild-type schematic with the corresponding 
amino residue numbers. The schematic for the CtIP-MSI mutant shows that this mutant lacks the CtBp, 
PCNA and second MRN binding domains. This mutant also lacks two phosphoserine residues that function 
in ATM and one phosphothreonine residue that functions in CDK binding. This mutant protein also lacks 
the second CxxC motif.  Due to the frameshift that gives rise to this truncation, a short sequence of aberrant 
amino acids is present at the C-terminal of the protein (NI). There is little homology between the human 
CtIP and S. pombe Ctp1 proteins. The S. pombe Ctp1 protein is known to be somewhat homologous to the 
C-terminal region of the human CtIP protein (a region often referred to as the Sae2/Ctp1-like region). The 
phosphoesterase and phosphothreonine residues are not conserved. The C-terminal CxxC motif is 
conserved. 
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3.2 Results 
3.2.1 Creation and verification of mutants 
Mutants were created using the Cre-lox system as described in the Materials and Methods 
section 2.2 (Pages 48-62). Candidate strains were grown in medium containing leucine and 
uracil, to cause the plasmid to be lost from the cells. Candidate strains were then grown on 
medium containing 5-FOA to select for cells which have lost the ura4 marker. The locus of 
interest for the candidate strains was then fully sequenced in both directions to check that the 
mutant gene has been integrated into the correct part of the genome, is intact and has not 
gained any additional spontaneous mutations. All mutant strains used in this investigation 
have been sequenced. The integration of the mutant gene into the correct locus, with no 
additional undesired changes, has been confirmed for all mutant strains used in this 
investigation. 
 
3.2.2 Sensitivity to camptothecin and MMS for mre11 mutant strains 
Sensitivity to camptothecin and MMS for the mutant mre11 strains was tested and compared 
to the sensitivity of the wild-type, mre11Δ and the nuclease-dead mre11-D65N strain. 
Sensitivity of the floxed wild-type mre11 gene was also tested to determine if the lox sites 
affect the function of Mre11. The results are shown in Figure 20. 
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Figure 20. Sensitivity of mre11 mutants to CPT and MMS. Sensitivity of the WT, mre11Δ strain and the 
mre11::loxP-mre11
+
-loxM3 strain compared to the hMRE11 mutant equivalents (MRE11-W210X, Δ5-
7MRE11 and MRE11-R572X) recreated in S. pombe  (mre11-W210X, mre11-Δ5-7and mre11-R572X 
respectively) to Camptothecin (A) and MMS (B). The tests shown are representative of three repeats. 
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Figure 20 shows that that the nuclease dead mre11-D65N mutant shows sensitivity to 
camptothecin and MMS greater than that of the wild-type but not as severe as the mre11Δ 
strain. This figure also shows that the floxed mre11 wild-type shows no increase in sensitivity 
compared to the wild-type indicating that the lox sites do not affect the function of Mre11. 
The mutants, mre11-W210X and mre11-Δ5-7 are both severely sensitive to camptothecin and 
MMS, similar to that of the base-strain, indicating a null phenotype. The mre11-R572X 
mutant however, shows slightly increased sensitivity to camptothecin only at high 
concentrations and an increase in sensitivity to MMS only at high concentrations, in 
comparison to the wild-type, showing that this mutation confers only a slight increase in 
sensitivity to these drugs.  
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3.2.3 Sensitivity to camptothecin and MMS for the mutant rad50 strains  
Sensitivity to camptothecin and MMS for the mutant rad50 strains was tested and compared 
to the sensitivity of the wild-type and rad50Δ strain. Sensitivity of the floxed wild-type rad50 
gene was also tested to determine if the lox sites affect the function of Rad50. The results are 
shown below in Figure 21. 
 
 
 
 
 
Figure 21 shows that the floxed rad50 strain shows a level of sensitivity to camptothecin 
similar to that of the wild-type, and an increased sensitivity to MMS at high concentrations, 
thus suggesting that the lox sites have a slight effect on the function of Rad50. The rad50-
MSI mutant shows a severe sensitivity to both drugs, similar to that of the base strain, 
suggesting a null phenotype. 
  
Figure 21. Sensitivity of rad50 mutants to CPT and MMS. Sensitivity of the WT, rad50Δ and 
rad50::loxP-rad50
+
-loxM3 strains and  the equivalent of the hRAD50 related MSI mutant recreated in S. 
pombe (rad50-MSI) to Camptothecin (A) and MMS (B). The tests shown are representative of three repeats. 
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3.2.4 Sensitivity to camptothecin and MMS for the mutant nbs1 strains 
Sensitivity to camptothecin and MMS for the mutant nbs1 strains was tested and compared to 
the sensitivity of the wild-type and nbs1 base strain. Sensitivity of the floxed wild-type nbs1 
gene was also tested to determine if the lox sites affect the function of Nbs1. The results are 
shown below in Figure 22. 
 
 
  
Figure 22. Sensitivity of nbs1 mutants to CPT and MMS. Sensitivity of the WT, nbs1Δ and the 
nbs1::loxP-nbs1
+
-loxM3strains and  the equivalent of the hNBS1 related MSI mutant recreated in S. pombe 
(nbs1-MSI) to Camptothecin (A) and MMS (B). The tests shown are representative of three repeats. 
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The results shown in Figure 22 suggest that the lox sites affect the function of Nbs1 as the 
floxed nbs1 strain shows an increase in sensitivity to both camptothecin and MMS compared 
to wild type. Due to this, the sensitivity of the nbs1-MSI mutant was compared to the floxed 
wild-type nbs1 strain and not the wild-type strain. The nbs1-MSI mutant shows a slight 
increase in sensitivity to camptothecin compared to the floxed wild-type, however there was a 
greater increase in sensitivity of the nbs1-MSI mutant to MMS in comparison to the floxed 
wild-type, this suggests that this mutant is a possible separation of function mutant thus 
having a greater effect on the role of Nbs1 in the resistance to MMS than to camptothecin. 
Due to the observed effect of the lox sites on the function of Nbs1, this mutant should be 
recreated into a strain which lacks the lox sites in order to further study the effects of this 
mutation without any additional effects of the lox sites. 
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3.2.5 Sensitivity to camptothecin and MMS for the mutant ctp1 strains 
Sensitivity to camptothecin and MMS for the mutant ctp1 strains was tested and compared to 
the sensitivity of the wild-type and ctp1Δ. Sensitivity of the floxed wild-type ctp1 gene was 
also tested to determine if the lox sites affect the function of Ctp1. The results are shown 
below in Figure 23. 
 
 
 
 
Figure 23 shows that the floxed ctp1 strain shows a level of sensitivity to camptothecin and 
MMS similar to that of the wild-type, suggesting that the lox sites have no effect on the 
function of Ctp1. The ctp1-MSI mutant shows a severe sensitivity to both drugs, similar to 
that of the base strain, suggesting a null phenotype. 
Figure 23. Sensitivity of cpt1 mutants to CPT and MMS. Sensitivity of the WT, ctp1Δ and the 
ctp1Δ::loxP-mre11+-loxM3 strains and  the equivalents of the  CtIP related MSI mutant recreated in S. 
pombe (ctp1-MSI) to Camptothecin (A) and MMS (B). The tests shown are representative of two repeats. 
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3.3 Discussion 
3.3.1 Sensitivity of mre11 mutants 
3.3.1.1 mre11-Δ5-7 
In human cells, this mutant is known to act in a dominant negative manner [107]. In human 
cells the, Δ5-7Mre11 mutant protein was shown to exhibit weak interactions with the Rad50 
protein, whereas this mutant abrogates affinity with Nbs1 [107], this may be due to the partial 
deletion (the last 14 amino acids) of the Nbs1 binding domain of Mre11, located between 
residues 86-119 [213] (see Figure 16), whereas the Rad50 binding domain, located between 
residues 446-484 [206], remains intact (see Figure 16).  
This mutant protein also retained affinity for binding to ssDNA (including 3′-overhangs and 
ssDNA regions at fork-like structures) [14] which may be due to the fact that both DNA 
binding domains, located between residues 407-421 and 643-692 [213] [214] [215], remain 
intact.  
One study showed that this mutation confers sensitivity to PolyADP ribose polymerase-1 
(PARP-1) inhibitors [166]. PARP-1 functions in the detection and repair of SSBs [216]. 
PARP-1 inhibition allows for SSBs to persist, which then, upon DNA replication, become 
DSBs [217]. The sensitivity of this mutant to PARP-1 inhibition would suggest that this 
mutant is defective in DSB repair. 
This mutant was also found to be defective in the formation of Mre11 foci, ATM 
autophosphorylation and thymidine induced homologous-recombination [107]. The lack of 
Mre11 nuclease activity alone does not abrogate the formation of Mre11 foci, and the 
activation of ATM [218]. Studies have suggested that Nbs1 may be involved in the formation 
of Mre11 foci, as NBS cells (harbouring mutations in Nbs1) were deficient in formation of 
Mre11 foci [219] [220], cells harbouring a deletion of the Forkhead-associated domain of 
NBS1 also showed a decrease in Mre11 foci formation [221]. Nbs1 is also required for the 
recruitment, autophosphorylation and activation of ATM [208], therefore failure of Mre11 to 
recruit Nbs1 at a site of a DSB would result in the failure to recruit and activate ATM and 
thus failure to activate DSB repair pathways such as NHEJ and HR. The inability of Δ5-7 
MRE11 cells to form Mre11 foci, autophosphorylate ATM and carryout HR may be due to 
the partial deletion of Nbs1 binding site, leading to a lack of affinity for Nbs1 and thus 
inability to recruit Nbs1 to the MRN complex. 
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In this investigation the S. pombe Δ5-7Mre11 equivalent, mre11-Δ5-7, was shown to have a 
severe sensitivity to both camptothecin and MMS, similar to that of the mre11Δ strain, thus 
suggesting a null phenotype (see Figure 20). This mutant was shown to be more sensitive to 
both agents than the nuclease dead mre11-D65N mutant (see Figure 20). This suggests that 
this mutation affects more functions of this protein than just nuclease activity. 
This phenotype may be due to this mutant’s combined deficiencies in nuclease activity and 
Nbs1 binding. It is unknown exactly if the Nbs1 binding domain described in human Mre11 
is conserved in S. pombe Mre11, however there is a strong level of homology in the amino 
acid sequences for the human Nbs1 binding domain and the corresponding S. pombe Mre11 
region (see Figure 11), suggesting that this domain may be conserved. The lack of nuclease 
activity, due to the deletion of the fourth and fifth highly-conserved phosphodiesterase motifs 
in the nuclease domain, could result in defective topoisomerase removal as Mre11 nuclease 
activity is required for topoisomerase removal from DNA [94]. Defective topoisomerase 
removal would then confer an increase in camptothecin sensitivity. Sensitivity to MMS, and 
further sensitivity to camptothecin, could possibly be explained by the inability to bind to 
Nbs1. Inability to recruit Nbs1, which would in turn recruit and activate ATM, would result 
in the failure to activate downstream pathways involved in DNA repair thus allowing for the 
persistence of DSBs. 
The 1-2 bp insertion/deletion in the poly(T)11 tract of MRE11 intron IV which results in the 
Δ5-7 MRE11 mutant transcript is found in approximately 80% of all human MSI+ colorectal 
tumours [163]. One study has shown that MSI+ tumours exhibit an increased sensitivity to 
the camptothecin derived drug irinotecan [105]. These results coincide with the increased 
sensitivity to camptothecin in yeast for the mre11-Δ5-7 mutant found in this investigation. 
 
3.3.1.2 mre11-W210X 
The mre11-W210X mutant also showed a null phenotype with severe sensitivity to 
camptothecin and MMS, similar to that of the base strain. This mutant is without the 
phosphodiesterase domains IV and V of the nuclease domain, which likely renders this 
mutant unable to remove topoisomerases from DNA as Mre11 nuclease activity is required 
for this process [94]. The deletion of the second Mre11 dimer interface (residues 430-530 
[222]) could prevent Mre11 dimerization, which is required for Mre11 to efficiently bind to 
DNA [215] [223] and presumed to aid the stability of the MRN complex [224]. The absence 
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of both DNA binding domains would abolish DNA binding activity for this protein. It is 
unknown if these DNA binding domains and the C-terminal Mre11 dimer interface are 
conserved in S. pombe, homology of these domains with the S. pombe Mre11 protein is poor 
(See Figure 7). The absence of the Rad50 binding domain (residues 446-484 [206]) would 
prevent Mre11 from binding to Rad50 and therefore prevent MRN complex formation and 
the repair of DSBs. The Rad50 binding domain is conserved in S. pombe Mre11 (residues 
452-490) [206]. These factors would all contribute to the observed phenotype of this mutant. 
 
3.3.1.3 mre11-R572X 
The mre11-R572X mutant shows a slightly increased sensitivity to camptothecin and MMS at 
higher concentrations, compared to that of the wild-type. If the S. pombe Mre11-R572X 
protein lacks the second DNA binding domain (residues 643-692 [213] [214] [215]) as the 
human Mre11-R562X protein does, then this would suggest that only a single DNA binding 
domain may be sufficient for Mre11 to bind to DNA and form the MRN complex. It is 
unknown if this domain is present in S. pombe, and homology of this region between the 
human and S. pombe Mre11 protein is low (see Figure 7). In humans, this mutant is also 
missing part of the GAR motif, which functions to recruit and activate ATR and Chk1 and 
also to recruit RPA and Rad51 [225]; however this motif is not present in the S. pombe 
Mre11 protein (See section 3.1.4 ).  
In the mutant human protein, part of the MLH1 binding domain (residues 452-634 [226]) is 
absent in this mutant. As described in the introduction, MLH1 functions in the mismatch 
repair pathway, only 0.3% of lesions caused by MMS are repaired by MMR, these lesions are 
O
6
-Methylguanine (O6MG) [199]. Human Mre11 has been shown to interact with MLH1 
during the MMR pathway in the repair of O6MG lesions [227]. Should this be the case with 
the S. pombe Mre11 protein, the partial deletion in the S. pombe Mre11-R572X mutant and 
corresponding MMR defect, may only confer an increased sensitivity to MMS at high 
concentrations, (as was observed in this study and shown in Figure 20) due to the very small 
portion of lesions that require MMR for repair. 
Even though in S. pombe this mutant only shows a mild phenotype, the human equivalent of 
this mutant, which is a recessive allele and found as compound heterozygous AT-LD patients 
[203] [204], is degraded by non-sense mediated decay [145].  
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Further work is required for these mutants. These mutants should be recreated in a human cell 
line using the CRISPR/Cas9 system to study the effects of these mutations in human. A 
nuclease activity assay could be performed for each mutant to asses any impairment to 
nuclease activity caused by the mutants. Also, binding activity to Rad50 and Nbs1, and MRN 
complex formation could be assessed to identify if these mutants cause impairments to these 
interactions, which may account for the increased sensitivity to the drugs. DNA binding 
activity of the mutants should be assessed as a lack of Mre11 DNA binding activity would 
abolish DNA DSB repair. Lastly, the effects that these mutant proteins have on 
topoisomerase removal should be assessed to study if these mutants impair topoisomerase 
removal, which would contribute to an increased sensitivity to camptothecin. 
 
3.3.2 Sensitivity of rad50 mutants 
3.3.2.1 rad50-MSI 
The rad50-MSI mutant was recreated from the MSI related mutation that occurs within the 
poly(A)8 tract of the human RAD50, which has been identified in the cell lines RKO, HCT-
116 and LoVo [228]. This mutation causes a truncation of the Rad50 protein, partway 
through the second coiled-coil domain (residues 787-1116 [191]). This mutant appears to be 
severely sensitive to camptothecin to a level similar to that of the rad50Δ strain, and only 
possibly slightly less sensitive than the rad50Δ to MMS, showing a null phenotype (see 
Figure 21).  
This phenotype is probably due to the lack of several functional domains of Rad50, which 
share a strong homology between human and S. pombe (See Figure 9). This mutant is without 
the C-terminal ABC ATPase (human residues 1195-1297 [205]), which is involved in the 
dimerization of Rad50 [229] and the modulation of Mre11 nuclease activity through the 
binding and hydrolysis of ATP [230]. This may affect this mutant’s ability to remove 
topoisomerases from DNA, as this requires Mre11 nuclease activity [94], and therefore may 
result in hypersensitivity to camptothecin. 
The second and third Mre11 binding domains (human residues 1140-1154 and 1192-1205 
[206]) have been lost as a result of this truncation and therefore, in combination with the lack 
of the second ABC-ATPase domain and second DNA binding domain (human residues 1232-
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1270 [45]), would affect the MRN complex to form, bind to DSBs and remove 
topoisomerases from DNA, thus contributing to the observed phenotype. 
Further work is required to study how this mutant confers sensitivity camptothecin. These 
mutants should be recreated in a human cell line using the CRISPR/Cas9 system to study the 
effects of these mutations in human. This would include studies into the affinity of this 
mutant for DNA and Mre11, as well as studies into MRN complex formation. 
 
3.3.3 Sensitivity of nbs1 mutants 
3.3.3.1 nbs1-MSI 
The nbs1-MSI mutant is recreated from the nbs1 poly(A)7 tract that is frequently mutated in 
MSI+ tumours [26]. In humans, this mutation causes a truncation that results in a Nbs1 
protein without the Mre11 binding domains (residues 640-662 and 681-691) and the ATM 
binding domain (residues 734-754) [205] (see Figure 18). 
The lack of the ATM/Tel1 binding domain (S. pombe residues 604-616 [208]), and thus the 
inability of MRN to recruit ATM, may affect topoisomerase removal or repair functions 
downstream of removal. In humans, ATM is involved in the pathway of Top1-cleavage 
complex resolution and ATM deficiency can result in the accumulation of these complexes 
[231]. If the ability of the MRN complex to recruit Tel1
ATM
 is impaired by this mutation, then 
that may explain the observed increase in sensitivity of this mutant in S. pombe compared to 
the wild-type. However, this increase in sensitivity is only slight, suggesting that the binding 
of Nbs1 to Tel1
ATM
 may not be essential for the removal of topoisomerase inhibitors from 
DNA, or the downstream repair of topoisomerase induced DNA lesions, in S. pombe. 
One study showed that a deficiency of ATM did not cause a reduction in the frequency of HR 
in the repair of a DSB or affect MRE11 focus formation. It was also shown that the deletion 
of the ATM binding site of Nbs1 caused only a slight reduction in the frequency of HR. The 
ATM binding domain is however crucial for the intra-S checkpoint [232].  
Although homology of amino acid sequence is limited between human and S. pombe Nbs1 
(see figure 11), the S. pombe Mre11 binding domains are located at residues 470-500 and 
517-27 [207]. These domains are absent in this mutant and could therefore have impact on 
the ability of Nbs1 to bind Mre11.The lack of camptothecin sensitivity in this mutant would 
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suggest that the Nbs1-Mre11 interaction may not be essential for the removal of 
topoisomerase inhibitors from DNA, or the downstream repair of topoisomerase induced 
DNA lesions, in S. pombe. 
This mutant does however retain the FHA (human residues 1-110) and BRCT (human 
residues 111-206 and 227-334) domains [205] and the dimer interface (human residues 126-
138). In S. pombe Ctp1 binds to the FHA domain of Nbs1, mutations in this domain disrupt 
interactions between Nbs1 and Ctp1 and result in a greatly increased sensitivity to 
camptothecin [233]. The retention of the FHA domain may then account for the observed 
lack of sensitivity to camptothecin observed in this mutant. 
The increased sensitivity to camptothecin as a result of FHA domain mutations contrasts the 
results for the deletion of Tel1 and Mre11 binding domains in which only a very slight 
increase in sensitivity was observed (see Figure 22). This suggests that the FHA domain 
plays a greater role in the removal of covalently bound topoisomerases, or downstream repair 
functions, and the resistance to camptothecin than the C-terminal domains. This also suggests 
that ATM activation, and the Mre11-Nbs1 binding may not be essential for camptothecin 
resistance in S. pombe. The lack of ATM and Mre11 binding activity may contribute to the 
increased sensitivity to MMS as ATM activation and Mre11 binding are essential for HR 
[232], and in S. cerevisiae, disruptions of the HR pathway leads to an increase in sensitivity 
to MMS [200] [201]. 
The retention of the FHA domain in this mutant may prevent hypersensitivity to 
camptothecin as this domain binds to Ctp1, a protein known to have involvement in 
topoisomerase removal [12]. nbs1Δ cells show no enrichment of Ctp1 at DSBs even though 
the abundance of Ctp1 remains unchanged. nbs1-FHAΔ cells also exhibit vast impairment of 
Ctp1 enrichment at DSBs. Also, cells harbouring mutants in the Nbs1-binding SXT motifs of 
Ctp1 show a great reduction in Ctp1 enrichment at DSBs with no change to Ctp1 abundance 
or nuclear localisation. These cells also exhibited great sensitivity to camptothecin, showing 
that interaction between Nbs1 and Ctp1 is essential for camptothecin resistance [233].  
In humans certain mutations in the FHA and BRCT domains can be detrimental to MDC1 
interaction leading to defective MRN accumulation at damaged sites of DNA [234]. MDC1 is 
a protein that functions in the localisation of repair factors at DSB sites [235]. An orthologue 
of MDC1 was not known to exist in S. pombe and it was been speculated that the Nbs1 FHA 
domain may mediate interactions with other DSB repair proteins in a phosphorylation-
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dependent FHA-only interaction [233]. Recently the Mdb1 protein was identified as an 
orthologue of MDC1 in S. pombe [236]. 
In conclusion, the slightly increased sensitivity to MMS may be as a result of defective HR 
due to inability of this mutant to bind Mre11 and Tel1
ATM
. The lack of camptothecin 
hypersensitivity for this mutant cannot be currently fully explained, but may be as a result of 
the ability to bind CtIP, or possible alternative interactions between other domains of Nbs1 
and Mre11 or other proteins involved in DNA repair and/or topoisomerase removal; or that 
Nbs1/Ctp1 may possibly be able to function separately from Mre11/Rad50 in the removal of 
topoisomerases from DNA. 
Further analysis of this mutant is required. This mutant in future should be created into a 
strain lacking the lox sites, to study if this mutant confers similar changes in sensitivity to 
camptothecin and MMS if the lox sites are not present. This will be especially important for 
this mutant as the lox sites were found to interfere with wild-type Nbs1 function. Further 
studies should be undertaken to identify if this protein maintains any affinity at all for Mre11 
and Tel1 and if MRN complex formation still occurs. Further work should also examine any 
reduction in affinity for Ctp1. 
 
3.3.4 Sensitivity of ctp1 mutant 
3.3.4.1 ctp1-MSI 
The ctp1-MSI mutant was recreated from a CtIP mutation that occurs frequently in MSI 
tumours, resulting in truncation that removes the CtBp binding site (residues 490-494), DNA 
binding domain (residues 509-557), PCNA binding site (residues 515-537), the MRN binding 
domain (residues 650-897), the second CxxC motif (residues 813-816) and two 
phosphoserine residues involved in ATM binding and the phosphothreonine residue involved 
in CDK binding [210] (see Figure 19). The CDK binding site does not exist in S. pombe Ctp1 
however [212]. 
This mutant showed to be severely sensitive to both camptothecin and MMS, to a level 
similar to that of the ctp1Δ strain (see Figure 23). This mutant lacks the C-terminal region 
involved with MRN binding, although a smaller N-terminal MRN binding domain is known 
to exist in human CtIP (residues 22-45) [212] [194] and S. pombe Ctp1 (residues 78-89) 
[237].  
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In humans, CtIP is required to bind to the MRN complex, at Nbs1, so that CtIP can be 
recruited to sites of DSBs. CtIP then acts to repair DSBs, as it aids the transition from DSB 
sensing to processing thus promoting resection of DNA, checkpoint activation and HR [238]. 
CtIP is required for HR as it functions to promotes the coating of ssDNA with RPA near 
DSBs, aids the MRN complex in 5′-3′ resection and recruits ATR to the DSB [35] functions 
that are also provided by S. pombe Ctp1 [239].  
CtIP requires dimerization for recruitment to sites of DSBs. Mutants unable to dimerize CtIP 
exhibit strong defects in HR, end resection and activation of ATM [240]. The CxxC motifs of 
CtIP may function to bring the two termini of the protein together and may facilitate 
dimerization [241]. The loss of this second CxxC motif could therefore confer defects in CtIP 
dimerization and thus HR. 
The loss of the aforementioned domains of Ctp1 could contribute to the hypersensitivity of 
this mutant to MMS, as disruptions of HR pathway increase MMS sensitivity [200] [201]. 
In S. pombe it is known that Ctp1, along with the MRN complex, is required for the removal 
of topoisomerase like protein Rec12 from DNA [104] [242]. It is also known that Ctp1 is 
involved in the removal of Top2 from DNA yet inhibits the removal of Top1 [94]. CtIP has 
also been shown to be involved in topoisomerase II removal [243]. The inhibiting role of 
Ctp1 on Top1 removal contrasts the increased sensitivity to camptothecin observed in the 
mutant, as camptothecin inhibits Top1 [244] [245], and therefore removal of this inhibitory 
activity of Ctp1 would increase resistance to camptothecin, this suggests that there may be 
another possible way in which Ctp1 deficiency can sensitise cell to camptothecin other than 
lack of direct role in Top1 removal. Even if ctp1Δ cells are proficient in Top1 removal, they 
may still be defective in downstream repair. 
The hypersensitivity of this mutant to camptothecin may be due to detrimental effects on 
MRN nuclease activity that could occur as a result of an inability of Ctp1 to bind to MRN due 
to loss of the C-terminal MRN binding region. CtIP is known to modulate the nuclease 
activity of MRN though it’s conserved C-terminal region [246]. Binding of CtIP stimulates 
the nuclease activity of MRN [35] [247] [248]. MRN nuclease activity is required for the 
removal of topoisomerases from DNA [94]. If MRN nuclease activity is not stimulated by 
Ctp1 binding in this mutant, then this could account for inability to remove topoisomerases 
and camptothecin sensitivity. 
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The deletion of the PCNA binding domain in human CtIP is known to result in excess DNA 
DSBs [246], this region is absent in the human CtIP-MSI mutant. If this domain is conserved 
in S. pombe Ctp1, and absent in Ctp1-MSI, then this could potentially increase sensitivity to 
both agents. 
Further work is required to study the interactions between this mutant and the MRN complex 
and Tel1 to identify if all MRN and Tel1 binding functions are abolished due to the omission 
of the second MRN binding domain and tel1 interaction phosphoserine residues. Also, studies 
should also be carried out to assess the DNA binding capability of this protein due to the lack 
of the DNA binding domain in the human homologue. Interactions with Nbs1 should also be 
assessed to identify if a possible lack of Nbs1 binding affinity may account for the increased 
sensitivity to the two drugs. Further experiments should also be carried out to identify if this 
protein retains any ability to remove topoisomerases. 
 
3.3.5 Conclusion 
It can be concluded that certain mutations in mre11, rad50, nbs1 and ctp1 can confer 
increased sensitivity to the topoisomerase inhibitor camptothecin as they may have 
detrimental effects on the ability of the cells to remove DNA-bound topoisomerases or 
downstream repair functions. However not all mutations confer an increase in topoisomerase 
inhibitor sensitivity, suggesting that certain domains of the studied proteins are not required 
for topoisomerase removal or are not conserved in the S. pombe homologues. Mutations may 
also increase sensitivity to other DNA damaging agents, such MMS, without increasing 
sensitivity to camptothecin. This suggests that certain domains of these proteins are not 
required for topoisomerase removal but are involved in the repair of other DNA lesions. 
The main aim of this project was to identify separation of function mutants in mre11, rad50, 
nbs1 and ctp1, that confer sensitivity to CPT without sensitising to MMS, but none were 
found. There was one separation of function mutant, nbs-MSI, which showed hypersensitivity 
to MMS but not to CPT. This mutant encoded for a Nbs1 protein that lacks the C-terminal 
Mre11 and Tel1
ATM
 binding domains, indicating that the binding of Nbs1 to Mre11 and Tel1 
may not be required for the removal of topoisomerases from DNA, but is required for the 
repair of MMS induced damage. 
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The human homologues of these mutations may have similar effects on the ability of affected 
cells to remove topoisomerases from DNA and may also confer hypersensitivity to 
camptothecin. This therefore may suggest that tumours harbouring these mutations would be 
sensitive to camptothecin, and that patients with tumours harbouring these mutations may 
benefit from camptothecin treatment. 
Additional work is required to study these mutations further. Such work would include assays 
of MRN complex formation and interaction between individual MRN proteins and CtIP; 
DNA binding, and topoisomerase interaction. Also due to possible effects of the lox-sites, 
certain mutants should be created into strains which lack the lox sites to identify if the 
observed sensitivity is purely due to the mutation and not partly due to the presence of the lox 
sites. 
Additional studies of these mutations in human cell lines would identify if the sensitivities 
conferred by these mutants in S. pombe also lead to hypersensitivity in human cells. These 
mutants could be created using the CRISPR (clustered regularly interspaced short 
palindromic repeat) system, for an easier and more efficient method of genome editing [249]. 
This would provide evidence that could further suggest that, in tumours, these mutations 
sensitise the cells to camptothecin. These results could therefore be indicative of the use of 
camptothecins, such as irinotecan, in patients whose tumours harbour the described mutation. 
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4 Sequencing of NWCOG-2 Patients to Identify the Presence of MRE11, 
RAD50, NBS1 and CtIP Mutations to Correlate with Patient Outcome 
4.1 Introduction 
4.1.1 The NWCOG-2 (RICE) trial 
The North West/ North Wales Clinical Oncology Group (NWCOG) -2 clinical trial involved 
a total of 110 patients with confirmed rectal adenocarcinoma. This trial aimed to study the 
effectiveness of preoperative downstaging of colorectal carcinomas utilising chemoradiation 
with irinotecan and capecitabine. This trial is also known as the RICE trial due to the 
methods of treatment involved (radiotherapy, irinotecan, capecitabine and excision) [110] 
[100]. 
The patients of this trial were selected to be candidates for preoperative downstaging as they 
had tumours with TNM stages of T3/4 (in which the tumour invades through the muscularis 
propria (T3) or through to other nearby organs and tissues (T4)), N0-2 (any number of 
lymph-node involvement) and M0 (no distant metastasis). Tumours of T3/T4 stage may carry 
a high risk of postoperative local recurrence unless downstaging is carried out on the tumour 
prior to surgery in order to achieve a better overall long-term outcome [110]. TNM staging is 
shown in Figure 24. 
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(Fauci et al 2012) [250] 
 
 
 
A previous study into preoperative downstaging using concurrent 5-FU with capecitabine, 
radiotherapy and excision, showed that for the 65% of patients, for whom downstaging was 
achieved, a better prognosis was achieved [251]. Orally administered capecitabine, a prodrug 
that is metabolised to 5-FU [252], was used instead of intravenous 5-FU in the NWCOG-2 
trial [110].The drug 5-FU acts as a thymidylate synthase inhibitor, which blocks the 
production of thymidine, a nucleoside essential for DNA replication, leading to death of 
rapidly proliferating cancer cells due to depleted thymidine pools [253].  
Due to a need to improve downstaging methods, a second chemotherapeutic drug was added. 
The drug that was chosen was the camptothecin derivative irinotecan. This was chosen due to 
its radio sensitising properties [110]. 
Figure 24. Diagram showing the progression of colorectal carcinomas through the TNM system. The T 
stages grade the invasion through the submucosa, muscularis propria and other layers of the colon. The N 
stages assess the involvement of nearby lymph nodes. M stages the presence of distant metastasis. Sourced 
from McGraw-Hill’s Access Medicine [250]. 
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The NWCOG-2 regimen showed to be an effective method of downstaging, with 67% of 
patients showing downstaging in their T-stage and 80% had their N-stage downstaged. 22% 
of patients showed a pathologic complete response (pCR) [100], which is defined as no 
residual invasive tumour or lymph node metastasis [99]. The three-year local recurrence free 
survival, metastasis-free survival, disease-free survival and overall survival were 96.9%, 
71.1%, 63.5% and 88.2% respectively [100].  
Another study into preoperative downstaging using 5-FU and irinotecan showed that 22% of 
patients achieved a pCR, corresponding with that found in the NWCOG-2 trial. An additional 
28% of patients achieved a near-pCR [98]. It is currently unknown what genetic factors 
influence the response to these regimens and only around 15-30% of all cancers are found to 
be hypersensitive to camptothecins, such as irinotecan [102] [103]. 
The use of preoperative chemoradiotherapy to downstage colorectal carcinomas is now 
standard practice in the UK in the treatment of advanced colorectal cancer [254] [255]. 
 
4.1.2 Roles of Mre11, Rad50, Nbs1 and CtIP in irinotecan resistance 
Irinotecan is a topoisomerase I inhibitor and as discussed in the introduction of this thesis 
(Page 13) functions to increase the half-life of DNA-topoisomerase cleavage complexes, 
allowing for the persistence of the associated SSB which sequentially leads to cell death.  
Also as previously discussed (section 1.3.3, page 14), the fission yeast orthologues of Mre11 
and CtIP function in the removal of covalently bound topoisomerase I [94]. The human 
Mre11 protein has also been shown to function in the removal of topoisomerase II from DNA 
[197]. The Rad50 and Nbs1 proteins form the MRN complex with Mre11. These proteins 
may also function in topoisomerase removal, as Rad50 modulates Mre11 nuclease activity 
[26], which is essential for topoisomerase removal in S. pombe [94]. The Nbs1 protein is 
required to recruit CtIP at sites of DSBs [233] and may recruit CtIP to topoisomerase 
cleavage complexes. A deletion of the Ctp1 binding FHA domain of S. pombe Nbs1 causes 
affected cells to become hypersensitive to camptothecin [233] [256]. 
In S. pombe it has been shown that a deletion of any MRN gene or ctp1 causes a severe 
sensitivity to camptothecin (see Chapter 3 results). In humans the Δ5-7MRE11 mutant, which 
lacks parts of the nuclease and Nbs1 binding domains, confers hypersensitivity to 
camptothecin when transfected into a camptothecin resistant cell line [107]. 
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MRE11, RAD50, NBS1 and CtIP are known to be subject to mutations in short mononucleotide 
repeat sequences in tumours exhibiting MSI [163] [169] [172] [173], a characteristic caused by 
MMR deficiency that is found in approximately 15-20% of all sporadic colorectal cancers [82] 
[83]. MSI related MRE11, RAD50 and CtIP mutations occur at high frequencies in colorectal 
cancers exhibiting a high level of MSI (MSI-H) [165] [170] [174], whilst NBS1 mutations are 
much less frequent [172]. Studies of MSI colorectal cancer cell lines showed an increased 
sensitivity to camptothecin and etoposide (a topoisomerase II inhibitor), compared to MMR 
proficient cells [257] [258]. One clinical trial showed that MSI colon cancers showed a more 
favourable outcome to a chemotherapeutic regimen consisting of irinotecan, 5-FU and leucovorin 
compared to the regimen of just 5-FU and leucovorin [67]. MSI-H colorectal cancers do not 
appear to predict a benefit from 5-FU based drugs [259] [260], although unpublished data suggest 
that MRE11 mutants are hypersensitive to nucleoside analogues such as gemcitabine 
[Unpublished, Hartsuiker Lab]. Mutations in MRE11 and RAD50 may account for the increased 
sensitivity to topoisomerase inhibitors as they are frequently mutated in MSI tumours [163] [169] 
and studies have shown that cells deficient in these genes are sensitive to camptothecin [105]. 
These observations, along with those obtained in chapter 1 suggest that Mre11, Rad50, Nbs1 
and CtIP may be factors that contribute to camptothecin resistance and that mutations within 
encoding genes may confer hypersensitivity to camptothecin. 
4.1.3 Hypothesis and aims 
Due to the observations discussed in the previous section and chapter 1, it is hypothesised 
that mutations within the MRN and CtIP genes could confer an increased sensitivity to 
camptothecin. It is also hypothesised that patients harbouring these mutations would have a 
more favourable outcome in a treatment regimen that utilises topoisomerase inhibitors, such 
as the regimen used by the NWCOG-2 trial. This investigation aims to identify if the 
presence of these mutations correlates to a better response to this regimen in comparison to 
tumours without such mutations. 
This investigation aimed to first identify any mutations of MRE11, RAD50, NBS1 and CtIP 
present in the tumours of patients from the NWCOG-2 trial. Formalin-fixed paraffin 
embedded (FFPE) tumour pre-treatment biopsy sample blocks were available for patients of 
the NWCOG-2 trial. DNA was extracted from sections cut from these blocks, amplified by 
PCR and then sequenced (see Materials and Methods section 2.3, pages 63-72). The 
sequencing data was then analysed in conjunction with the patient response information to 
detect any correlations between the presence of mutations and response to treatment.  
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4.2 Results 
4.2.1 Selection of patient samples 
Haematoxylin and Eosin (H&E) stained sections of NWCOG-2 patient tumour samples, were 
available and were previously prepared by various centres partaking in the NWCOG-2 trial, 
and were examined microscopically and assessed for their usability in this investigation. The 
samples were assessed by Professor Geraint Williams of Cardiff University Medical School, 
whilst I recorded the observations. The criteria for which they were assessed were: the 
number of tissue fragments in the section; the number of fragments that contained dysplasia; 
the number of fragments that contained cancer; the percentage of tumour nuclei in the 
dysplastic fragments; the percentage of tumour nuclei in cancerous fragments; the number of 
fragments without tumour and the overall percentage of tumour nuclei in the section. The 
amount of tissue available in the block was also assessed as an adequate amount of tissue 
would be required to successfully take sections and extract DNA. Other observations were 
also made on any distinctive morphological features that are characteristic of certain types of 
colorectal cancer, for example if the cancer was mucinous or if there was marked 
inflammation. 
FFPE tissue blocks were available for a total of 132 patients, of which prepared H&E stained 
biopsy slides were available for 113. Two blocks no longer contained any tissue and a further 
40 blocks contained only very small amounts of tissue. This left a total of 90 blocks for which 
H&E stained slides were available for 77. For two of these samples, no tumour was present in 
the biopsies. Another 6 biopsies showed presence of adenoma but no invasive carcinoma. 
This left 69 potentially usable cases. 
For this investigation, samples from the 69 potentially usable cases were selected for analysis 
based on a high percentage of tumour nuclei (≥60%) observed on the biopsy slide. Samples 
with a high percentage of tumour nuclei were chosen for initial analysis as these were easier 
to process for analysis as no microdisection was required. By these criteria, a total of 26 cases 
were selected, however patient consent was not available for one case leaving a total of 25 
cases for analysis. Information on these patient samples are shown in Table 21. Information 
for all patient samples is available in Table 45 in Appendix I: NWCOG-2 Patient Biopsy 
Information. 
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Table 21: Biopsy information for the 25 NWCOG-2 patient samples selected for initial analysis                                                                                                                        
Table 21. Table showing the information for each of the 25 patient biopsy samples selected for analysis. This table shows the patient number and biopsy number for each 
sample along with information on the approximate percentage of dysplastic and cancerous nuclei in the samples, and an overall tumour nuclei percentage for the samples. 
Additional comments onto the quality of the block/sample and descriptions of specific types and grading of cancer and dysplasia are also shown in the table.
P
a
ti
en
t 
(R
IC
E
) 
N
u
m
b
er
 
B
io
p
sy
 N
u
m
b
er
 
N
u
m
b
er
 o
f 
ti
ss
u
e 
fr
a
g
m
en
ts
 i
n
 
b
io
p
sy
 
N
u
m
b
er
 o
f 
ti
ss
u
e 
fr
a
g
m
en
ts
 w
it
h
 
ca
n
ce
r
 
A
v
er
a
g
e 
%
 o
f 
tu
m
o
u
r 
n
u
cl
ei
 i
n
 
ca
n
ce
r
o
u
s 
fr
a
g
m
en
ts
 
N
u
m
b
er
 o
f 
ti
ss
u
e 
fr
a
g
m
en
ts
 w
it
h
 
d
y
sp
la
si
a
 
A
v
er
a
g
e 
%
 o
f 
tu
m
o
u
r 
n
u
cl
ei
 i
n
 
d
y
sp
la
st
ic
 
fr
a
g
m
en
ts
 
N
u
m
b
er
 o
f 
ti
ss
u
e 
fr
a
g
m
en
ts
 
w
it
h
o
u
t 
tu
m
o
u
r
 
A
v
er
a
g
e 
%
 o
f 
o
v
er
a
ll
 t
u
m
o
u
r 
n
u
cl
ei
 
A
m
o
u
n
t 
o
f 
ti
ss
u
e 
a
v
a
il
a
b
le
 i
n
 
b
lo
ck
 
C
o
m
m
en
ts
 
R7 9656/03 5 5 65 0 0 0 65 Good Small fragments 
R11 1337/04 2 2 80 0 0 0 80 Good  
R12 16/04 4 4 60 0 0 0 60 Good  
R13 711/04 5 2 75 3 85 0 80 Good High grade dysplasia 
R18 4590/04 2 2 80 0 0 0 80 Good  
R24 14223/04 5 4 85 0 0 2 70 Poor Thin block, small fragments 
R38 672/05 5 5 65 0 0 0 65 Good  
R48 3539/05 7 5 70 0 0 2 60 Good  
R50 10391/05 A 6 6 75 0 0 0 75 Good Mucinous Cancer 
R51 3073/05 B 2 0 0 2 80 0 80 Good Low grade dysplasia 
R60 7192/05 7 6 75 0 0 1 70 Good  
R61 7366/05 4 2 70 0 0 1 65 Good  
R69 25344/05 4 4 65 0 0 0 65 Poor Small biopsies 
R72 12975/05 5 5 65 0 0 0 65 Good Marked Inflammation 
R74 10104/05 B 3 3 75 0 0 0 75 Good  
R84 15814/05 D1 3 3 60 0 0 0 60 Good  Thin Block 
R93 1477/06 6 6 60 0 0 0 60 Poor  
R103 4254/06 5 5 60 0 0 0 60 Good  
R104 3273/06 7 7 70 0 0 0 70 Good Marked inflammation 
R115 8025/06 7 6 70 1 70 0 60 Good Low grade dysplasia, serrated dysplasia 
R119 4984/06 7 7 60 0 0 0 60 Poor  
R133 8159/06 2 2 75 0 0 0 75 Good  
R135 10627/06 2 2 65 0 50 0 65 Good  
R139 10628/06 3 3 70 0 0 0 70 Good Mucinous Cancer 
R145 15760/06 3 3 70 0 0 0 70 Good  
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4.2.2 Microtomy and DNA extraction of patient tumour material 
Up to eight 10 µm thick sections were cut from each of the initial 25 NWCOG-2 sample 
blocks for each DNA extraction. DNA was then extracted from these sections as described on 
page 64. The DNA was then quantified using the NanoDrop. The concentration for each 
DNA sample is given in Table 22 on the next page. The DNA extraction concentrations 
varied from as low as 2.7 ng/µl, to as high as 539.6 ng/µl. 
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Table 22: Nucleic acid concentration for each NWCOG-2 patient DNA sample 
Patient 
Number 
Extraction 
Number 
Nucleic Acid 
Concentration 
(ng/µl) 
Patient 
Number 
Preparation 
Number 
Nucleic Acid 
Concentration 
(ng/µl) 
R7 
1 2.7 
R69 
1 25.8 
2 8.7 2 29.8 
R11 
1 9.5 3 34.6 
2 8.4 R72 1 160.6 
3 73.8 R74 1 176.8 
4 220.7 
R84 
1 5.0 
R12 
1 8.2 2 27.7 
2 29.1 
R93 
1 6.9 
R13 
1 56.6 2 37.6 
2 238.8 
R103 
1 5.1 
3 165.7 2 44.2 
R18 1 210.6 
R104 
1 78.2 
R24 
1 8.2 2 206.2 
2 29.1 3 191 
R38 
1 76.6 
R115 
1 37.4 
2 72.2 2 108.1 
3 39.8 3 376.6 
R48 
1 13.0 
R119 
1 45.8 
2 20.5 2 230.1 
3 56.9 
R133 
1 74.1 
R50 
1 97.8 2 281.6 
2 320.1 3 32.7 
3 168.8 
R135 
1 54.9 
R51 
1 6.0 2 506.7 
2 2.9 3 539.6 
R60 
1 119.9 
R139 
1 13.7 
2 169.7 2 9.9 
3 141.0 3 79.6 
R61 
1 22.7 4 89.0 
2 74.2 
R145 
1 8.5 
3 153.9 2 60.9 
Table 22: Table showing the DNA concentrations of the NWCOG-2 patient samples for each DNA extraction. 
Each extraction had a total volume of 23 µl after quantification.  
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4.2.3 Optimisation of PCR for individual exons 
The PCR procedure was optimised in order to achieve highly specific PCR reactions which 
yield a high concentration of the desired product. For this, PCR was carried out on wild-type 
control DNA (extracted from a normal colon tissue sample) for each exon for each gene in 
which a gradient of 10ºC for the annealing stage was used over 12 PCR tubes for each exon. 
The PCR products were checked and quantified using the QIAgen QIAxcel capillary 
electrophoresis system. The annealing temperature that generated the highest yield of the 
desired PCR product with very low or preferably no undesired non-specific PCR product for 
the most exons was chosen as the annealing temperature to be used on the PCR products of 
patient samples. This optimisation procedure was carried out for all required PCRs. The 
temperature of 56.8ºC was selected as the optimum annealing temperature, as this was the 
annealing temperature which gave the highest yield of PCR product for the majority of PCRs. 
An example of a QIAxcel image of the optimisation is shown on the next page as Figure 25. 
Figure 25 suggests that annealing temperature makes little difference to the PCR product 
yield. 
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Temperature 
(ºC) 
53.8 54.3 55.1 56.1 56.8 57.6 58.2 59.6 60.2 61.3 62.2 62.2 
DNA 
Concentration 
(ng/µl) 
64.25 64.27 44.21 53.64 94.56 67.4 62.74 87.13 83.18 57.58 58.11 78.01 
 
  
Figure 25. An example of a QIAxcel electrophoresis image for the optimisation of PCR using a 
temperature gradient for the annealing stage of the PCR reaction. This image here shows the optimisation of 
the PCR of CtIP exon 5(shown by the dark band in each column at a length of 296 bp). This image shows 
the presence of nonspecific PCR products at annealing temperatures from 53.8ºC-56.1ºC. The 
accompanying table show the concentration of the 296 bp band at each different annealing temperature as 
measured by the QIAxcel, this shows that an annealing temperature of 56.8ºC yields the highest 
concentration of PCR product.  
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In order to reduce the concentration of potential contaminating PCR products in the reactions 
whilst attaining the highest possible yield of desired PCR product, the number of PCR cycles 
was optimised. Two PCR reactions were carried out using 10 ng wild-type control DNA 
template and a no template control for different PCR cycles varying in cycle number from 
30-35. The products were checked by electrophoresis. The highest cycle number in which 
very little to no product was observed in the no template control, yet show a high yield of 
product in the sample in which template DNA was added, was selected as the cycle number 
to use for the PCR of the patient samples. 33 cycles was chosen as the optimum cycle 
number. This is shown below in Figure 26. 
 
 
 
 
 
 
 
 
 
 
Figure 26. Gel electrophoresis image of the PCR products for the optimisation of PCR cycle number, 
from the reactions using DNA template (+) and no DNA template (-) at varying cycle numbers from 30-35 
cycles. This image shows a band present for each reaction in which DNA template was used, with increasing 
intensity as cycle number increases from 30 to 33 cycles, indicating an increase in the concentration of PCR 
product. This band shows the PCR product for MRE11 exon 2, and is 314 bp in length. For the reactions in 
which no DNA template was used, contaminant can be seen faintly at 34 cycles. 
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Multiplex PCR using primers for every exon of a single gene was used as a preliminary PCR 
stage to amplify the amount of DNA available for two reasons. Firstly due to the generally 
low quantities of patient DNA available, as little as 2.7 ng/µl for one patient (see Table 22). 
Secondly, because of large number of PCR reactions required for each patient sample 
(usually one per coding exon, with some large exons requiring multiple PCR reactions).  
PCR for each individual exon was then carried out using the multiplex PCR product as a 
template. Negative controls, which contained no patient DNA, were amplified by multiplex 
and then for each individual exon using the negative control multiplex PCR product as a 
template, along with the patient samples to assess the level of contamination when checked 
by QIAxcel. In most cases, no contamination was detected. If substantial contamination (a 
DNA concentration in the negative control greater than 5% of DNA concentration measured 
in the patient sample) was detected, the corresponding samples were discarded and the PCR 
was repeated. 
 
4.2.4 Sequencing of each exon of MRE11, RAD50, NBS1 and CtIP for each patient 
sample 
Each exon for each gene for each patient was amplified by PCR and then sequenced to 
identify any mutations. Some exons of some patients were unable to be sequenced due to low 
PCR yields and unsuccessful PCR reactions. Successful PCR amplification and sequencing in 
all patients was achieved for 100% of exons in MRE11, 98.5% of all exons in RAD50, 97.7% 
of all exons in NBS1 and 99.6% of all CtIP exons. 98.9% of all exons for all genes for all 
patients were successfully amplified and sequenced. 
The sequences were aligned to the wild-type consensus sequences using ClustalO software to 
identify mutations. The reference sequences used were obtained from NCBI, the accession 
numbers for MRE11, RAD50, NBS1 and CtIP were NG_007261.1, NG_021151.1, 
NG_008860.1 and NG_012121.1 respectively. The chromatograms were then also analysed 
by eye, to identify any heterozygous/mix of mutant and wild type bases in which the mutant 
base was not called over the wild-type base. A heterozygous/mix mutant is defined as mutant 
that both the wild-type and mutant bases are detected at the same position. This can be due to 
heterozygosity of the mutation or as a result of a mix of the sequences of wild-type and 
mutant cells present in the sample. 
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For any mutations that were detected, a second sequencing reaction to sequence the opposite 
strand was carried out to confirm the presence of the mutation. If the mutation was 
confirmed, then sequencing was carried out on patient blood DNA to identify if said mutation 
was present in the germline or was of somatic origin. Patient blood was not available for 
patients R13, R24, R50, R51 and R104. 
Examples of chromatogram for the mutations are shown in figures 27-30. These figures show 
the chromatograms for forward and reverse sequencing reactions for the patient tumour DNA 
and the forward sequencing reaction for the patient blood DNA. Figure 27 shows an example 
of a homozygous/hemizygous somatic mutation as only the mutant base is present in the 
tumour sample sequence. A hemizygous mutation occurs if only one copy of the gene is 
present in a cell, which can occur as a result of a loss of heterozygosity a frequent feature of 
cancers. Figure 28 shows an example of a heterozygous/mix mutant and a wild-type somatic 
mutation, as both the wild-type and mutant bases were present in the tumour sample 
sequences. Figure 29 shows an example of a frameshift caused by a single base-pair deletion. 
Figure 30 shows an example of a germline variant. Chromatograms for all other mutations 
are available in Appendix II, (chapter 10). 
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Figure 27. Example Chromatograms for the MRE11-L341P mutation in patient R119 from three 
separate sequencing reactions (forward and reverse sequences from the same PCR product). This shows the 
T>C base change in the forward strand and the corresponding A>G base change in the reverse strand (as 
indicated by the arrows). The forward and reverse traces show no trace of the wild-type base suggesting that 
this mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the same 
region in the same patient from normal DNA extracted from the patient’s blood. This shows an absence of 
this mutation, indicating that this mutation has occurred somatically. 
T>C 
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Figure 28. Example chromatograms for the MRE11-E257X mutation in patient R11 from three separate 
sequencing reactions (forward and reverse sequences from independent PCR products). This shows the G>T 
base change in the forward strand and the corresponding C>A base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequences also show a trace of the wild-type base suggesting that 
either this trace may include sequence from nearby normal tissue, or that this mutation may be heterozygous. 
This figure also shows the chromatogram for the same region in the same patient from normal DNA 
extracted from the patient’s blood. This shows an absence of this mutation, indicating that this mutation has 
occurred somatically. 
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Figure 29. Example chromatograms for the CtIP-1073delA mutation in patient R48 from three separate 
sequencing reactions (forward and reverse sequences from independent PCR products from the same initial 
multiplex PCR). The forward and reverse sequences show a single base pair deletion in the poly(A)9 
(poly(T)9 for reverse) tract in exon 12 of CtIP. The forward and reverse sequence chromatograms show a 
trace of the wild-type base suggesting that either this trace may include sequence from nearby normal tissue, 
or that this mutation may be heterozygous. This figure also shows the chromatogram for the same region in 
the same patient from normal DNA extracted from the patient’s blood. This shows an absence of this 
mutation, indicating that this mutation has occurred somatically. 
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Figure 30. Example chromatograms for the NBS-P672P silent variant in patient R18 from three 
separate sequencing reactions (forward and reverse sequences from the same PCR product). This shows the 
A>G base change in the forward strand and the corresponding T>C base change in the reverse strand (as 
indicated by the arrows). The forward and reverse traces show no trace of the wild-type base suggesting that 
this mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the same 
region in the same patient from normal DNA extracted from the patient’s blood. This shows the presence of 
this variant, showing that this mutation is germline. This variant was also found in patients R7, R24, R84, 
R93, R103 and R115. This variant was found to also be homozygous in patients R7, R18, R24 and R103, 
and was found to be heterozygous in patients R84, R93, and R115. This variant was found to be germline in 
all patients were blood DNA was available (no blood DNA available for patient R24), and is a known SNP     
(rs ID: rs1061302). 
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For MRE11 a total of 8 different mutations were identified, all of which were somatic. 1 
mutation was a silent mutation, 6 were missense mutations and 1 was a nonsense mutation. 
Mutations in MRE11 were only found in patients R11 and R119. Information on these 
mutations is shown in Table 23. 
 
Table 23: Table of MRE11 mutants identified in the NWCOG-2 patient samples 
Gene Mutation Patient(s) Homozygous* 
/Mix** 
(Tumour) 
Somatic/ 
Germline 
MRE11 
E51V R11 Homozygous* Somatic 
E257X R11 Mix** Somatic 
L314P R119 Homozygous* Somatic 
S382N R11 Homozygous* Somatic 
L446P R11 Mix** Somatic 
G569P R119 Homozygous* Somatic 
K682K R11 Homozygous* Somatic 
V684A R11 Homozygous* Somatic 
*May be hemizygous   
**Mixture of wild-type and mutant traces. May be heterozygous and/or represent a mixture of 
wild-type and mutant cells 
Table 23. Table showing information on the MRE11 mutations identified in the NWCOG-2 patients. This shows 
a total of 8 different somatic mutations found in a total of 2 patients. 6 of these mutations were 
homozygous/hemizygous whilst two showed traces of the wild-type and mutant base in the chromatograms. 
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For CtIP a total of 7 different mutations/variants were identified, 5 of which were somatic 
and 2 were germline. 3 of these mutations/variants were silent, of these silent 
mutations/variants 1 was somatic and the other two were germline. Three of the mutations 
were missense mutations, all of which were somatic. A frameshift mutation caused by a 
single base pair deletion was also identified, this was somatic. These mutations were found in 
6 different patients. Information on these mutations is shown in Table 24. 
 
Table 24: Table of CtIP mutants identified in the NWCOG-2 patient samples 
Gene Mutation Patient(s) Homozygous* 
/Mix** 
(Tumour) 
Somatic/ 
Germline 
CtIP 
L286L R11 Homozygous* Somatic 
Q293R R119 Mix** Somatic 
Poly(A)9 
1bp del 
R48 Mix** Somatic 
D548D R11 Mix** Germline 
S641F R119 Homozygous* Somatic 
K704K 
R72 Homozygous* Germline 
R135 Mix** Germline 
R139 Mix** Germline 
L740S R11 Mix** Somatic 
*May be hemizygous 
**Mixture of wild-type and mutant traces. May be heterozygous and/or represent a mixture of 
wild-type and mutant cells 
Table 24. Table showing information on the CtIP mutations identified in the NWCOG-2 patients. This shows a 
total of 5 different somatic mutations found in a total of 3 patients and 2 germline mutations found in 4 patients. 
Most of these mutations showed traces wild-type and mutant base in the chromatograms.  
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For NBS1 a total of 6 different mutations/variants were identified, 2 of which were somatic 
and the other 4 were germline. Of the 4 germline mutations/variants 3 were silent and 1 was 
missense. The two somatic mutants/variants were both missense. These mutations were found 
in 12 different patients. Information on these mutations is shown in Table 25. 
Table 25: Table of NBS1 mutants identified in the NWCOG-2 patient samples 
Gene Mutation Patient(s) Homozygous* 
/Mix** 
(Tumour) 
Somatic/ 
Germline 
NBS1 
L34L 
R7 Mix** Germline 
R18 Homozygous* Germline 
R24 Homozygous* Unknown 
R60 Homozygous* Germline 
R84 Mix** Germline 
R93 Mix** Germline 
R103 Homozygous* Germline 
R115 Mix** Germline 
R139 Mix** Germline 
H149D R119 Homozygous* Somatic 
V155E R11 Mix** Somatic 
E185Q 
R7, R84, R93, R115, R133, R139 Mix** Germline  
R18, R103 Homozygous* Germline 
R24                Homozygous* Unknown               
D399D 
R13 Mix** Unknown 
R18 Homozygous* Germline 
R24 Homozygous* Unknown 
P672P 
R7 Homozygous* Germline 
R18 Homozygous* Germline 
R24 Homozygous* Unknown 
R84 Mix** Germline 
R103 Homozygous* Germline 
R115 Mix** Germline 
*May be hemizygous 
**Mixture of wild-type and mutant traces. May be heterozygous and/or represent a mixture of 
wild-type and mutant cells 
 
Table 25. Table showing information on the NBS1 mutations identified in the NWCOG-2 patients. This shows a 
total of 7 different somatic mutations found in a total of 2 patients and 2 germline mutations found in 10 patients 
(although this could not be confirmed for patients R13 and R24 as no blood DNA was available for these 
patients). 
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For RAD50 a total of 17 different mutations/variants were identified. 4 of these 
mutations/variants were silent, 1 was a frameshift, 1 was a nonsense mutation and the 
remaining 11 were all missense mutations/variants. None of the mutations were found to be 
germline. The somatic/germline status could not be confirmed for 5 of these mutations, as no 
blood DNA was available for these patients. RAD50 mutations were found in 9 different 
patients. Information on these mutations is shown in Table 26. 
 
Table 26: Table of RAD50 mutants identified in the NWCOG-2 patient samples 
Gene Mutation Patient(s) Homozygous* 
/Mix** 
(Tumour) 
Somatic/ 
Germline 
RAD50 
G36E R50 Homozygous* Unknown 
G39G R93 Mix** Somatic 
R78R R93 Mix** Somatic 
Q524Q R12 Mix** Somatic 
1703delG R50 Mix** Unknown 
C680S R60 Mix** Somatic 
V733M R60 Mix** Somatic 
T896I R133 Homozygous* Somatic 
M1001K R93 Mix** Somatic 
Q1006R R60 Homozygous* Somatic 
Q1011H R93 Homozygous* Somatic 
E1084G R104 Mix** Unknown 
L1092F R72 Homozygous* Somatic 
R1093X R50 Mix** Unknown 
V1250I R61 Mix** Somatic 
E1275E R12 Mix** Somatic 
S1280F R51 Mix** Unknown 
*May be hemizygous 
**Mixture of wild-type and mutant traces. May be heterozygous and/or represent a mixture of 
wild-type and mutant cells 
 
Table 26. Table showing information on the RAD50 mutations identified in the NWCOG-2 patients. This shows 
a total of 12 different confirmed somatic mutations found in a total of 6 patients and 5 unknown 
germline/somatic mutations found in 3 patients. 
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The numbers of identified somatic mutations, germline mutations/natural variants and 
mutations/variants for which the somatic/germline could not be confirmed for each patient 
are shown in Table 27. 
 
Table 27: Numbers of mutations identified in NWCOG-2 patient samples 
Patient Number of Somatic 
mutations 
Number of germline 
mutations/variants 
Number of mutations/variants with 
unknown somatic/germline status 
R7 0 3 0 
R11 9 1 0 
R12 3 0 0 
R13 0 0 1 
R18 0 4 0 
R24 0 0 4 
R38 0 0 0 
R48 1 0 0 
R50 0 0 2 
R51 0 0 1 
R60 3 1 0 
R61 1 0 0 
R69 0 0 0 
R72 2 1 0 
R84 0 3 0 
R93 4 2 0 
R103 0 3 0 
R104 0 0 1 
R115 0 3 0 
R119 5 0 0 
R133 1 1 0 
R135 0 1 0 
R139 0 3 0 
R145 0 0 0 
 
Table 27. This table shows the numbers of somatic mutations, germline mutations/natural variants and 
mutations/variants for which the somatic/germline could not be confirmed for each NWCOG-2 trial patient. 
This table shows that no mutations/variants were identified in patients R38, R69 and R145. This also shows that 
a high number of somatic mutations were found in patient R11 with 9 mutations identified. Patients R12, R60, 
R72, R93 and R119 were also found to harbour multiple somatic mutations. A single somatic mutation was 
found in patients R48, R61 and R133. 
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4.3 Discussion 
4.3.1 Predicted pathogenicity of missense mutations in MRE11, CtIP, NBS1 and 
RAD50 identified by sequencing of NWCOG-2 patient tumour samples 
Missense mutations can vary in the degree of impact they have on the affected protein which 
can in turn lead to pathogenicity. The most common way in which missense mutations may 
pathogenically affect protein function is by affecting the structural stability of the protein, 
most prominently by disruptions of the hydrophobic core [261] [262]. This accounts for 
around 80% of disease associated missense mutations [261] [263]. A missense mutation can 
also affect protein function if it occurs in binding interfaces and can thus affect interaction 
with DNA or other proteins due to geometric or energetic changes [263]. Missense mutations 
can also effect protein expression and subcellular localisation [263]. 
In order to estimate the pathogenicity of the mutations identified in this study, the programs 
Polyphen-2 and Align GVGD were used to predict the severity of impact the mutations 
would have on the protein. Polyphen-2 estimates the effect of the mutation based on 
structural parameters and structural effects of an amino acid change; analysis and alignment 
with homologous proteins; and analysis of specific protein sites, such as active sites and 
coiled-coil regions [262]. Polyphen-2 also calculates the Naïve Bayes posterior probability of 
a mutation being damaging and grades the mutation as either benign, possibly damaging or 
probably damaging [264]. The Naïve Bayes posterior probability is a statistical classification 
method using the Bayesian classification algorithm that assumes all features are independent 
(naïve) and assigns the probability of the feature (in this case, the probability of the mutation 
being damaging) to the category of maximum probability [265].  
Align GVGD estimates the effect of the mutation by combining the differences in biophysical 
characteristics between the exchanged amino acids with multiple sequence alignment analysis 
of the protein with homologues of other species [266]. Alignment and comparison of amino 
acid sequences between homologous proteins of different species is useful as highly 
conserved residues are generally of great importance in protein stability, function and 
interaction [263]. 
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This analysis was carried out in order to predict which mutations may have detrimental 
effects on the function of the associated protein, which may impair topoisomerase removal or 
repair following removal, and thus confer increased sensitivity to irinotecan. 
Information and predicted pathogenicity for each missense mutation are shown in Table 28.1 
(for MRE11, CtIP and NBS1) and Table 28.2 (for RAD50). 
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Table 28: Predictions of pathogenicity for MRE11, CtIP and NBS1 missense mutations identified in the 
NWCOG-2 patient samples 
Gene Mutation Patient(s) 
Homozygous* 
/Mix** 
(Tumour) 
Polyphen 
Prediction 
Align 
GVGD 
Prediction 
(1) 
Align 
GVGD 
Prediction 
(2) 
Somatic/ 
Germline 
MRE11 
E51V R11 Homozygous* 
Benign 
 
C15 C35 Somatic 
L314P R119 Homozygous* 
Probably 
damaging 
C0 C65 Somatic 
S382N R11 Homozygous* 
Possibly 
damaging 
C0 C45 Somatic 
L446P R11 Mix** 
Possibly 
damaging 
C45 C65 Somatic 
G569P R119 Homozygous* 
Possibly 
damaging 
C0 C0 Somatic 
V684A R11 Homozygous* 
Benign 
 
C0 C65 Somatic 
CtIP 
Q293R R119 Mix** 
Benign 
 
C0 C0 Somatic 
S641F R119 Homozygous* 
Possibly 
damaging 
C0 C0 Somatic 
L740S R11 Mix** 
Possibly 
damaging 
C0 C65 Somatic 
NBS1 
H149D R119 Homozygous* 
Probably 
damaging 
C65 C65 Somatic 
V155E R11 Mix** 
Probably 
damaging 
C35 C65 Somatic 
E185Q 
R7, R84, 
R93, 
R115, 
R133, 
R139 
Mix** Benign C0 C0 
Germline 
Mix 
R18, R103 Homozygous* Benign C0 C0 
Germline 
Homozygous 
R24                  Homozygous* 
Benign 
 
C0 C0 Unknown               
Table 28.1 *May be hemizygous.                                                                                                                                    
** Mixture of wild-type and mutant traces. May be heterozygous and/or represent a mixture of 
wild-type and mutant cells 
Table 28: Predictions of pathogenicity for MRE11, CtIP, NBS1 and RAD50 missense mutations 
identified in the NWCOG-2 patient samples 
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Table 28.2: Predictions of pathogenicity for RAD50 mutants identified in the NWCOG-2 patient samples 
Gene Mutation Patient(s) 
Homozygous* 
/Mix** 
(Tumour) 
Polyphen 
Prediction 
Align 
GVGD 
Prediction 
(1) 
Align 
GVGD 
Prediction 
(2) 
Somatic/ 
Germline 
RAD50 
G36E R50 Homozygous* 
Probably 
damaging 
C65 C65 Unknown 
C680S R60 Mix** 
Possibly 
damaging 
C0 C65 Somatic 
V733M R60 Mix** 
Benign 
 
C0 C0 Somatic 
T896I R133 Homozygous* 
Possibly 
damaging 
C0 C65 Somatic 
M1001K R93 Mix** 
Possibly 
damaging 
C0 C65 Somatic 
Q1006R R60 Homozygous* 
Benign 
  
C0 C35 Somatic 
Q1011H R93 Homozygous* 
Benign 
 
C0 C15 Somatic 
E1084G R104 Mix** Benign C0 C65 
Unknown 
 
L1092F R72 Homozygous* 
Probably 
damaging 
C0 C15 Somatic 
V1250I R61 Mix** 
Possibly 
damaging 
C0 C25 Somatic 
S1280F R51 Mix** 
Possibly 
damaging  
C15 C65 Unknown 
Table 28.2  *May be hemizygous                                                                                                                                                 
** Mixture of wild-type and mutant traces. May be heterozygous and/or represent a mixture of 
wild-type and mutant cells 
Table 28.1 and 28.2: Missense mutations identified in MRE11, CtIP, NBS1 and RAD50 by sequencing these 
genes from DNA extracted from NWCOG-2 trial patient tumour samples. Bold text indicates that the the 
mutation has been confirmed by sequencing in the opposite direction, for the mutation not denoted by bold text, 
sequencing in the other direction was not possible due to the low quantity and quality of the patient DNA 
available. The predicted pathogenicity of these mutations is shown as predicted by Polyphen2 and Align GVGD. 
The Align GVGD predictions range from C0 to C65, the least likely and most likely to be damaging 
respectively. The Align GVGD (1) is based on alignments of the proteins from human to sea urchin (MRE11, 
NBS1), Coelacanth (CtIP) or zebra fish (RAD50). The Align GVGD (2) column is based on alignments from 
human to platypus (MRE11, RAD50) or chicken (NBS1, CtIP). This table shows if the mutations found in the 
tumour samples are somatic or germline; this was done by sequencing patient blood DNA. “Unknown” in the 
somatic/germline section denotes a lack of blood DNA available (the case for R50, R51 and R104). Underlined 
text denotes an independent PCR product was used for confirmatory sequencing using the same multiplex 
product as template. Double underlined text denotes the PCR product for confirmation was amplified directly 
from the template.  
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According to the Polyphen-2 analysis a total of 10 mutations are predicted to be benign and 
carry no associated pathogenicity or detrimental effects on protein function. 10 mutations 
were predicted to be possibly damaging and may affect protein function. The remaining 5 
mutations were predicted to be probably damaging and are thus most likely to affect protein 
function. Of these 5 mutations 4 were also given the highest value of predicted pathogenicity 
(C65) by Align GVGD (prediction 2). This would suggest that these mutations would very 
likely disrupt protein function and therefore may impair topoisomerase removal and confer 
hypersensitivity to the topoisomerase inhibitor irinotecan. 
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4.3.2 Nonsense and frameshift mutations identified in NWCOG-2 patient tumour 
samples 
Nonsense and frameshift mutations which result in premature stop codons are generally the 
most detrimental form of mutation which produce truncated proteins that are often non-
functional [263]. The transcribing mRNA for such non-functional proteins are often degraded 
by the process of nonsense-mediated decay [267]. 
Two nonsense mutations and two frameshift mutations, which lead to a truncation, have been 
identified in the NWCOG-2 patient tumour samples. Information on these mutations is shown 
below in Table 29. 
Table 29: Information on nonsense and frameshift mutations identified in NWCOG-2 patient samples 
Gene Mutation Patient Homozygous*/Mix** Somatic/Germline 
MRE11 E257X R11 Mix** Somatic 
CtIP 
Poly(A)9 1bp 
deletion 
(1073delA) 
R48 Mix** Somatic 
RAD50 
1703delG R50 Mix** Unknown 
R1093X R72 Homozygous* Somatic 
*May be hemizygous                                                                                                                                               
** Mixture of wild-type and mutant traces. May be heterozygous and/or represent a mixture of wild-type and 
mutant cells 
Table 29: Table showing the nonsense and frameshift mutations of MRE11, CtIP, NBS1 and RAD50. All 
mutations have been confirmed by sequencing of the opposite strand. This table also shows whether the 
mutations found in the tumour samples are somatic or germline, this was done by sequencing of patient blood 
DNA. The “unknown” in the somatic/germline section denotes a lack of blood DNA available for this patient 
(R50). Underlined text denotes that a new PCR product, from the same multiplex was used for confirmatory 
sequencing. 
 
The MRE11-E257X mutation would result in an Mre11 protein consisting only of the N-
terminal nuclease domain, the first Mre11 dimer interface and the Nbs1 binding domain. This 
would likely result in a non-functional protein due to a lack of both DNA binding domains, 
the second Mre11 dimer interface and the Rad50 binding domain (see Figure 16, page 87).  
The CtIP Poly(A)9 1 bp deletion is a known mutation that is associated with MSI. This 
mutation results in a truncated protein only 357 amino acids in length [173]. This mutation is 
found in around 22.9% of MSI+ colorectal tumours. The frequency is also known to differ by 
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tumour grade, with frequencies of 16%, 52%, 28% and 4% at grades I, II, III and IV 
respectively [174]. This mutation was created in S. pombe in chapter 3 and conferred a null 
phenotype and severe sensitivity to camptothecin (see page 100). A diagram of this mutant 
protein in comparison to the wild-type is shown in chapter 3 (Figure 19, page 93). This shows 
that certain important functional domains, including the DNA binding and MRN binding 
domains, are absent in this mutant, and therefore may contribute to a severe phenotype. The 
transcript of this mutant is not degraded by nonsense-mediated decay [268]. 
The RAD50-1703delG frameshift mutation would cause a truncation in the first coiled-coil 
domain. This protein would lack multiple important functional domains including the Zinc 
hook domain, second coiled-coil domain, second and third Mre11 binding domains, the 
second nucleotide binding domain and the ABC ATPase C domain. Therefore this protein 
would likely be non-functional and the mutation is likely to cause irinotecan sensitivity if 
present heterozygously as a single functional copy of RAD50 has been reported to be 
haploinsufficient [269]. This mutation is unlikely to occur homozygously as functional Rad50 
is essential for life in mammalian cells [270]. 
The RAD50-R1093X mutant protein would lack the important C-terminal domains involved 
in Mre11 binding and nucleotide binding and the ABC ATPase C domain. This truncation 
would therefore likely have a great impact on the function of the protein and likely render it 
non-functional. This mutant has been identified in a patient with an NBS-like disorder (NBS-
LD) as a compound heterozygous with RAD50-YextX*66 [161]. This mutation was found to 
produce low levels of unstable protein [161]. In the NBS-LD patient, this mutation was 
germline, whereas it was found to occur somatically in the NWCOG-2 patient. 
 
4.3.3 Silent mutations and natural variants identified in NWCOG-2 patient tumour 
samples 
A total of 12 different silent mutations/variants were identified in the NWCOG-2 patient 
tumour samples. Of these 5 were found to be germline and also occur in the Patient blood 
DNA. The other 7 were somatic. Information on these mutations and variants are shown in 
Table 30 on the next page. 
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Gene Mutation Patient(s) Homozygous*/Mix 
**(Tumour) 
Homozygous*/Mix**/Wild-
type (Blood) 
Somatic/Germline 
MRE11 K682K R11 Homozygous* Wild-type Somatic 
CtIP 
L286L R11 Homozygous* Wild-type Somatic 
D548D R11 Mix** Mix** Germline 
K704K 
R72 Homozygous* Mix** Germline 
R135 Mix** Mix** Germline 
R139 Mix** Mix** Germline 
NBS1 
L34L 
R7 Mix** Mix** Germline 
R18 Homozygous* Homozygous* Germline 
R24 Homozygous* Unknown Unknown 
R60 Homozygous* Mix** Germline 
R84 Mix** Mix** Germline 
R93 Mix** Mix** Germline 
R103 Homozygous* Homozygous* Germline 
R115 Mix** Mix** Germline 
R139 Mix** Mix** Germline 
D399D 
R13 Mix** Unknown Unknown 
R18 Homozygous* Homozygous* Germline 
R24 Homozygous* Unknown Unknown 
P672P 
R7 Homozygous* Mix** Germline 
R18 Homozygous* Homozygous* Germline 
R24 Homozygous* Unknown Unknown 
R84 Mix** Mix** Germline 
R103 Homozygous* Homozygous* Germline 
R115 Mix** Mix** Germline 
RAD50 
G39G R93 Mix** Wild-type Somatic 
R78R R93 Mix** Wild-type Somatic 
Q524Q R12 Mix** Wild-type Somatic 
V1187V R12 Mix** Wild-type Somatic 
E1275E R12 Mix** Wild-type Somatic 
*May be hemizygous                                                                                                                                               
** Mixture of wild-type and mutant traces. May be heterozygous and/or represent a mixture of wild-type and 
mutant cells 
Table 30: Table showing all the silent mutations found in the MRE11, CtIP, NBS1 and RAD50 genes in the 
patients in the NWCOG-2 (RICE) trial. Bold text indicates mutations which have been confirmed by sequencing 
of the opposite strand. This table also shows whether the mutations found in the tumour samples are somatic or 
germline; this was done by sequencing of patient blood DNA. The “unknown” in the somatic/germline section 
denotes that blood DNA is currently unavailable for that patient. Underlined text denotes that the product from 
an independent PCR from the original multiplex was used for confirmatory sequencing. 
Table 30: Information on silent mutations/variants identified in NWCOG-2 patient samples 
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Table 30 shows that generally most germline mutations/variants that showed traces of both 
mutant and wild-type base in the patient blood DNA also showed the same in the patient 
tumour DNA. However for some, CtIP-K704K in patient R72, NBS1-L34L in patient R60 and 
NBS1-P672P in patient R7, appeared to be homozygous/hemizygous only showing the 
mutant trace in the tumour DNA despite the mixture of traces in the blood DNA. This 
suggests that a loss of heterozygosity may have occurred in these patients at loci 
encompassing the region containing the mutation. 
 
4.3.4 Natural variants found in the NWCOG-2 trial 
The mutations/variants found in the NWCOG-2 trial patient tumour samples were searched 
for in the SNP databases dbSNP [271] [272] and EVS/ESP [273]. 6 of the NWCOG-2 
mutations/variations were found in these databases. A table of these mutations and data on 
their respective frequencies and heterozygosity rates are shown in Table 31 on the next page. 
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Gene Mutation/ 
Variation 
rs ID MAF* 
(dbSNP) 
MAF* 
(EVS/ESP) 
Heterozygosity 
(dbSNP) 
Heterozygosity 
(EVS/ESP) 
Homozygosity 
(EVS/ESP) 
Patient(s) Pathogenicity 
CtIP D548D rs534780140 0.73% 
1.1863%(EU) 
0.8382% (All) 
1.5% 
2.37(EU) 
1.68 (All) 
0 (EU) 
0 (All) 
R11 
Unknown 
(Silent) 
NBS1 
L34L rs1063045 34.99% 
31.47% (EU) 
31.2% (All) 
45.5% 
43.58% (EU) 
42.95% (All) 
9.67% (EU) 
9.84% (All) 
R7, R18, R24, R84, 
R93, R103, R115, 
R139 
Unknown 
(Silent) 
E185Q rs1805794 33.29% 
31.63% (EU) 
28.66% (All) 
44.4% 
43.51% (EU) 
40.77% (All) 
9.60% (EU) 
8.27% (All) 
R7, R18, R24, R84, 
R93, R103, R115, 
R133, R139 
Unknown 
D399D rs709816 42.38% 
35.59% (EU) 
49.03% (All) 
48.8% 
46.11% (EU) 
43.25% (EU) 
12.53% (EU) 
27.4% (All) 
R13, R18, R24 
Unknown 
(Silent) 
P672P rs1061302 32.78% 
31.32% (EU) 
28.42 %(All) 
41% 
43.56% (EU) 
40.5% (All) 
9.54% (EU) 
8.17% (All) 
R7, R18, R24, R84, 
R103, R115 
Unknown 
(Silent) 
RAD50 R1093X rs121912628 N/A N/A N/A N/A N/A R72 
Damaging, 
found in a case 
of NBS-like 
disorder 
*MAF: Minor Allele Frequency 
Table 31: Table showing mutations/variations of MRE11, CtIP, NBS1 and RAD50 found in the patients of the NWCOG-2 (RICE) trial that have also been previously 
identified and are included in the dbSNP and ESP databases. This table shows the rare variants CtIP-D548D, RAD50-V315L, R1093X and T1114I, in addition to the more 
common variants of NBS1. No mutations/variants of MRE11 found in NWCOG-2 were found in dbSNP or ESP databases. (EU) denotes European ethnicity; (ALL) denotes 
all ethnicities combined.
Table 31: Information on known CtIP, NBS1 and RAD50 variants identified in the NWCOG-2 patient samples 
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The mean allele frequency (MAF) for the CtIP-D548D variant in the dbSNP and EVS/ESP 
databases is 0.73% - 1.19%. The European MAF is 1.9%. In this study, this variant was found 
to be mix/heterozygous in one patient, thus the MAF is approximately 2%. This is similar to 
that found in the databases. 
The NBS1 variants L34L, E185Q and P672P in the databases are 31.2-34.99%, 28.66-33.29% 
and 28.42-32.78% respectively. For the NWCOG-2 patients the respective MAFs for these 
variants are 24%, 30% and 18% which are not too dissimilar to those of the databases. The 
homozygosity rates for these three variants in the NWCOG-2 patients were 12%, similar to 
the 9.67-9.84%, 8.27-9.60% and 8.17-9.54% stated by the EVS/ESP database. The MAFs for 
these variants was found to be slightly higher in Europeans than all ethnicities combined. 
The MAF of the NBS1-D399D variant was much lower in the NWCOG-2 patients, at only 
10%, in comparison to the 35.59-49.03% MAFs stated by the databases. The homozygosity 
of this variant was also lower than the homozygosity rate stated by the EVS/ESP database at 
8% compared to 12.53-27.4%. The relatively small sample size of this study may account for 
differences in MAF and homozygosity found in this study compared to the dbSNP and 
EVS/ESP databases. Unlike the other NBS1 variants, the MAF of this variant is much lower 
in Europeans compared to the global population. 
The rare RAD50-R1093X variant was found in case of NBS-LD as a compound heterozygous 
with another RAD50 variant [161]. This was found in a single NWCOG-2 patient, however it 
was found to have occurred somatically in that patient. 
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4.3.5 Mutation rates in NWCOG-2 patient tumours 
The somatic mutation rates for each patient were calculated by dividing the total number of 
the patient’s somatic mutations by the total combined length of the coding regions of MRE11, 
RAD50, NBS1 and CtIP (a total of 11,025 bp). Mutations for which the somatic/germline 
status could not be confirmed were not included. Separate mutation rates were calculated for 
silent and non-silent mutations in addition to a combined mutation rate. The silent, non-silent 
and combined mutation rates for the whole study were also calculated. The MSI status for 
each patient was obtained. The MSI status was graded based on the Negri and Braun criteria. 
A table showing the somatic mutation rates and MSI status for each patient is shown on the 
next page in Table 32.  
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Table 32: Mutation rates for the NWCOG-2 patient tumour samples 
Patient 
Silent 
Mutations 
Non-Silent 
Mutations 
Total 
Mutations 
Silent 
Mutation 
Rate*  
Non Silent 
Mutation 
Rate*  
Total 
Mutation 
Rate*  
MSI 
Status 
R7 0 0 0 0 0 0 MSS 
R11 2 7 9 181.4 634.92 816.32 MSS 
R12 3 0 3 272.11 0 272.11 MSS 
R13 0 0 0 0 0 0 MSS 
R18 0 0 0 0 0 0 MSS 
R24 0 0 0 0 0 0 MSI 
R38 0 0 0 0 0 0 MSS 
R48 0 1 1 0 90.7 90.7 MSS 
R50 0 0 0 0 0 0 MSI 
R51 0 0 0 0 0 0 MSS 
R60 0 3 3 0 272.11 272.11 MSS 
R61 0 1 1 0 90.7 90.7 MSS 
R69 0 0 0 0 0 0 MSI 
R72 0 2 2 0 181.4 181.4 MSS 
R74 0 0 0 0 0 0 MSS 
R84 0 0 0 0 0 0 MSS 
R93 2 3 5 181.4 272.11 453.51 MSI 
R103 0 0 0 0 0 0 MSS 
R104 0 0 0  90.7 90.7 MSS 
R115 0 0 0 0 0 0 MSI 
R119 0 5 5 0 453.51 453.51 MSS 
R133 0 1 1 90.7 90.7 181.4 MSS 
R135 0 0 0 0 0 90.7 Unknown 
R139 0 0 0 0 0 0 MSS 
R145 0 0 0 0 0 0 MSS 
Total 7 23 30 25.4 83.45 108.84  
*Mutation rate = Mutations/Mb. Common natural variants and germline mutations not included. 
Table 32: Table showing the mutations of MRN/CtIP found in colorectal tumours for patients of the NWCOG-2 
(RICE) trial. Common natural variants have been excluded. Microsatellite instability (MSI) status is also given. 
The level of MSI is based on showing an altered mismatch repair (MMR) status by Negri and Braun criteria. 
None of these 25 patients were found to show alterations by Braun criteria. Mutations for which it is unknown 
whether they are somatic or germline, have been excluded. In the entire NWCOG-2 study, two patients of the 
124 tested showed alterations in both Negri and Braun criteria. 
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The MSI status of each patient shows that most patients (19/25) are MSS and only 5 show a 
level of MSI based on Negri criteria. No patients were found to be MSI based on Braun 
criteria. Of the entire NWCOG-2 study, MSI status was assessed for 124 patient tumours, of 
which 23 (16.94%) were MSI. Of the initial 25 patients, MSI status was tested in 24 patients, 
for which 5 (20.83%) were MSI. The percentage of MSI tumours in this study is lower than 
the 37.6% reported in a previous study [274]. There does not appear to be any correlation 
between MSI status and mutation rate. Interestingly, patient R48 was MSS, despite 
harbouring the CtIP poly(A)9 1 bp deletion mutation, which has only before been identified 
in MSI tumours [174]. 
The mutation rates were calculated and compared to the mutation rates of two other studies in 
order to estimate the likelihood that the non-silent mutations are driver mutations, 
contributing to the phenotype, and not just passenger mutations or artefacts which arose as 
result of formalin fixation. If these mutations were passenger mutations or due to formalin 
fixation then it would be expected that there would be a higher silent mutation rate and a 
lower non-silent to silent mutation ratio, as these mutations would occur at random. 
Passenger mutations are the mutations which arrive during tumourigenesis that are neutral to 
the phenotype, providing no selective advantage for affected cells [275]. DNA extracted from 
FFPE tissues are known to frequently generate sequencing artefacts appearing as mutations, 
most commonly as G>A/C>T, due to the deamination of cytosine [276]. The MRE11 
mutations E51V, S382N and G569P; the CtIP mutations L286L and S641F; and the RAD50 
mutations G36E, G39G, Q524Q, V733M, T896I, L1092F, R1093X, V1187V, V1250I, E1275E 
and S1280F are all G>A/C>T mutations. 
As silent mutations do not generally contribute to tumourigenesis, the ratio of non-silent to 
silent mutations can be used to estimate the likelihood that the mutations are driver mutations 
and not passenger mutations. A high number of driver mutations would also suggest that the 
mutations are real and not artefacts caused by tissue processing. 
The silent mutation rate of MRN/CtIP for the NWCOG-2 patients is 25.4 mutations per Mb. 
The non-silent mutation rate of MRN/CtIP for NWCOG-2 patients is 83.45 per Mb. The total 
mutation rate of MRN/CtIP for NWCOG-2 is 108.84 mutations per Mb. 
The silent, non-silent and combined mutation rates along with the non-silent: silent mutation 
rate ratio for the NWCOG-2 samples, were compared with those found in colorectal cancers 
by The Cancer Genome Atlas (TCGA) and the Catalogue of Somatic Mutations in Cancer 
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(COSMIC) studies. In TCGA, whole genome analysis was carried out over 276 samples 
[277]. COSMIC collects data from the Cancer Genome Project (CGP) and TCGA [278]. 
These studies use fresh frozen samples as opposed to FFPE tissue. A table showing the 
mutation rate information is shown in Table 33 below. 
 
Table 33: Mutation rates of NWCOG-2, TCGA and COSMIC 
Patient Set 
Silent mutation 
rate (mutations 
per Mb) 
Non-silent mutation 
rate (mutations per 
Mb 
Total Mutation 
rate (mutations 
per Mb) 
Non-silent: silent 
mutation ratio 
(approximate) 
NWCOG-2 35.4 83.45 108.84 2.5:1 
TCGA 0.81 12.15 12.96 15:1 
COSMIC 2.38 12.47 14.85 5:1 
 
Table 33: Table showing silent, non-silent and total mutation rates for MRN/CtIP for the NWCOG-2, TCGA 
and COSMIC patients. This shows far greater mutation rates for NWCOG-2 compared to TCGA and COSMIC. 
This table also shows that the non-silent: silent mutation ratio is greater in TCGA than COSMIC and NWCOG-
2, and that the non-silent: silent mutation ratio for NWCOG-2 is less than that of COSMIC. Mutations for which 
it is unknown whether they are somatic or germline, have been excluded. 
In comparison to the two other studies, the NWCOG-2 patients have a far greater silent 
mutation rate and a far greater non-silent and total mutation rates. Also, the non-silent: silent 
mutation ratio for the NWCOG-2 patients is far less than that of TCGA and half-that of 
COSMIC. The small sample size of the 25 NWCOG-2 patients may have distorted the 
mutation rates as a the presence of a single mutation in a single patient would increase the 
NWCOG-2 mutation rate by 3.6, therefore a single silent mutation would cause a higher 
silent mutation rate in NWCOG-2 than TCGA or COSMIC. The increased mutation rates 
may also be due to the fact that these tumour samples were not randomly selected and do not 
represent a broad spectrum of cancers. All tumours of the NWCOG trial were T grade T3/4 
and all 25 that were selected for this analysis consisted of at least 60% tumour nuclei in the 
biopsy samples. These tumours may be more prone to hypermutation than colorectal cancers 
in general and may have been unintendedly selected for. The TCGA and COSMIC studies 
may have underestimated the total number of mutations due to the mutation detection and 
validation procedures that are performed. For example, any variant found fewer than five 
times were removed [277]. 
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4.3.6 NWCOG-2 mutation spectra 
To further study the mutation rates and assess the likelihood that the mutations are real and 
not just sequencing artefacts, the mutation spectra were analysed to assess the spread of 
different base changes. Studies have shown that such sequencing artefacts are most 
commonly G:C>A:T, accounting for 70-91.5% [279], or even up to 94% [280] or 96% [276] 
of FFPE related sequencing artefacts, thought to possibly arise as a result of cytosine 
deamination [280] although there may be other mechanism [281]. The mutation spectra by 
patient and by gene are shown on the next page in Table 34 and Table 35 respectively.  
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Table 34: Mutation spectra of NWCOG-2 patient samples by patient 
 Transversions Transitions 
Patient A:T>C:G A:T>T:A C:G>A:T C:G>G:C Total A:T>G:C G:C>A:T Total 
R11 0 2 1 0 3 4 2 6 
R12 0 0 0 0 0 0 3 3 
R48 0 0 0 0 0 0 0 0 
R60 0 1 0 0 1 1 1 2 
R61 0 0 0 0 0 0 1 1 
R72 0 0 0 0 0 0 2 2 
R93 0 1 1 0 2 1 1 2 
R119 0 0 0 1 1 2 2 4 
R133 0 0 0 0 0 0 1 1 
Total 0 
4  
(14.3) 
2 
 (7.1) 
1  
(3.6) 
7  
(25) 
8 
 (28.6) 
13  
(46.4) 
21 
(75) 
 
Table 34: Mutation spectrum for somatic mutations of MRE11, CtIP, NBS1 and RAD50 for the NWCOG-2 
patients. This table shows the types of mutation and the numbers of each type for each patient. Only Patients 
with somatic mutations are shown. Mutations for which it is unknown whether they are somatic or germline 
have been excluded. Numbers in parentheses indicate percentage of total mutations. 
 
Table 35: Mutation spectra of NWCOG-2 patient samples by gene 
 Transversions Transitions 
Gene A:T>C:G A:T>T:A C:G>A:T C:G>G:C Total A:T>G:C G:C>A:T Total 
MRE11 0 1 1 0 2 4 2 6 
CtIP 0 0 0 0 0 2 3 6 
NBS1 0 1 0 1 2 0 0 0 
RAD50 0 2 1 0 3 2 8 10 
Total 0 
4  
(14.3) 
2  
(7.1) 
1  
(3.6) 
7 
(25) 
8 
 (28.6) 
13  
(46.4) 
21 
(75) 
 
Table 35: Mutation spectrum for somatic mutations for the NWCOG-2 patients for each gene. This table shows 
the types of each mutation and the numbers of each type for MRE11, CtIP, NBS1 and RAD50. Numbers in 
parentheses indicate the percentage of total mutations. 
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Table 34 and Table 35 show that G:C>A:T was the most common type of mutation overall, 
accounting for 46.4% of all mutations. This however is not as high as the 70-96% of total 
mutations for this type that is reported to arise due to FFPE related sequencing artefacts [276] 
[279] [280]. This suggests that many of the observed mutations may not be FFPE related 
sequencing artefacts. 
The mutation spectra of NWCOG-2 patients was compared to the mutation spectra of TCGA 
and COSMIC. This is shown below in Table 36. 
 
Table 36: Mutation spectra of NWCOG-2, TCGA and COSMIC 
 Transversions Transitions 
Study A:T>C:G A:T>T:A C:G>A:T C:G>G:C Total A:T>G:C G:C>A:T Total 
NWCOG-2 0 
4 
(14.3) 
2 
(7.1) 
1 
(3.6) 
7 
(25) 
8 
(28.6) 
13 
(46.4) 
21 
(75) 
TCGA 
3 
(12) 
0 
7 
(28) 
0 
10 
(40) 
5 
(20) 
10 
(40) 
15 
(60) 
COSMIC 
2 
(2.6) 
1 
(1.3) 
24 
(31.2) 
0 
27 
(35.1) 
25 
(32.5) 
25 
(32.5) 
50 
(65) 
 
Table 36: Mutation spectra for somatic mutations in MRE11, CtIP, NBS1 and RAD50 in the NWCOG-2, TCGA 
and COSMIC studies. The percentages of each mutation for the studies are shown in parentheses. This shows 
similar spectra across all studies. 
The total percentage of transitions of the NWCOG-2 (75%) trial is not vastly greater than that 
of TCGA (60%) or COSMIC (65%), which are taken from frozen samples as opposed to 
FFPE tissue samples. The total percentage of G:C>A:T mutations of NWCOG-2 (46.7%) was 
slightly higher than those observed in TCGA (40%) and COSMIC (32.5%). This similarity in 
mutation spectra would suggest that the observed apparent NWCOG-2 mutations are not 
largely artefactual. 
Interestingly, the A:T>T:A transversion was the most common transversion, occurring 4 
times and accounting for 14.3% of total mutations. This type of mutation was much rarer in 
TCGA and COSMIC, observed only once in COSMIC (1.3% of mutations) and not at all in 
TCGA, despite the vastly larger sample sizes of both studies and the greater number of 
mutations found in total. 
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Some mutations were confirmed by sequencing of the reverse strand in independent PCR 
products. This suggests that these mutations are not artefactual as it would be unlikely for the 
same artefact to appear at the same location in two separate independent PCR reactions, and 
not occur in any other samples. 
 
4.3.7 NWCOG-2 patient response and the presence of MRE11, RAD50, NBS1 and CtIP 
mutations 
The NWCOG-2 mutation data was analysed with respect to the patient response data in order 
to identify if there is any correlation between the presence of MRN/CtIP mutations and 
response to treatment with concurrent irinotecan. A table showing the patient mutation and 
response data is shown on the next page in Table 37. 
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Table 37: Mutation and response information for NWCOG-2 patients as of March 2013 
Patient Silent 
Mutations 
Non-silent 
Mutations  
Total 
Mutations 
Recurrent Local 
Recurrence 
Distant 
Metastases 
Alive  
R7** 0 0 0 No No No Yes 
R11 2 7 9 No No No Yes 
R12** 3 0 3 No No No Yes 
R13 0 0 0 Yes No No No 
R18 0 0 0 No No No Yes 
R24 0 0 0 Yes No No No 
R38** 0 0 0 Yes No Yes No 
R48** 0 1 1 No No No Yes 
R50 0 0 0 No No No Yes 
R51 0 0 0 Yes No No No 
R60* 0 3 3 No No No Yes 
R61* 0 1 1 No No No Yes 
R69* 0 0 0 No No No Yes 
R72 0 2 2 Yes Yes Yes Yes 
R74 0 0 0 No No No Yes 
R84** 0 0 0 Yes Yes No Yes 
R93** 2 2 4 No No No Yes 
R103 0 0 0 Yes No Yes Yes 
R104 0 0 0 Yes No Yes No 
R115 0 0 0 Yes No Yes Yes 
R119 0 5 5 No No No Yes 
R133 0 1 1 No No No Yes 
R135 0 0 0 No No No Yes 
R139 0 0 0 No No No Yes 
R145** 0 0 0 No No No Yes 
* pCR: No residual invasive tumour or lymph node metastasis in post resection sample                                            
**Near pCR: Only microfoci present in in post resection sample 
Table 37: Table showing the numbers of mutations for the patients in addition to the disease recurrence and 
survival data as of March 2013, mutations for which it is unknown whether they are somatic or germline have 
been excluded. This table shows that all patients with mutations survived and that only 1 patient out of 8 
(12.5%) showed a recurrence of disease. Bold text denotes patients with somatic, non-synonymous MRN/CtIP 
mutations.  
  
153 
 
All patients for whom MRN/CtIP mutations were found were alive as of March 2013, 
whereas 5 (29.4%) patients with wild-type MRN/CtIP had died. Distant metastases were only 
seen in a single (11%) MRN/CtIP mutated patient as opposed to the 4 (23.2%) wild-type 
MRN/CtIP patients. Local recurrence only occurred in one (12.5%) MRN/CtIP mutated 
patient and one (5.9%) MRN/CtIP wild-type patient. Recurrence was only observed in a 
single MRN/CtIP mutated patient (12.5%), but observed in 8 (47.06%) MRN/CtIP wild-type 
patients. The survival and recurrence rates for MRN/CtIP wild-type and mutated patients are 
shown below in Table 38. 
 
Table 38: Survival and recurrence information for wild-type and mutated MRN/CtIP NWCOG-2 Patients 
Genotype Survival Recurrence 
MRN/CtIP Wild Type* 70.59% (12/17) 47.06% (8/17) 
MRN/CtIP Mutated** 100% (8/8) 12.5% (1/8) 
* Also includes patient R12, which only harboured silent mutations 
**At least one non-synonymous mutation in one of the MRN/CtIP genes 
 
Table 38: This table shows the percentages of wild type and muted MRN/CtIP patients that survived and the 
percentages of MRN/CtIP wild type patients that showed recurrence of disease. This table shows a higher 
survival and lower recurrence rates in patients with mutated MRE11, CtIP, NBS1 and RAD50 genes. 
 
The MRN/CtIP mutated patients show higher survival rates and lower recurrence rates than in 
wild-type patients, suggesting that these patients have responded better to treatment, due to a 
possible sensitising effect to irinotecan, 5-FU or radiation that the MRN/CtIP mutations have 
on the tumours. This would support the hypothesis that the presence of MRN/CtIP mutations 
confers an increased response to treatment using topoisomerase inhibitors. Chi-squared 
analyses were carried out on this data for the effect of mutations on survival and recurrent-
free survival; the respective p values were 0.082 and 0.062, which do not show statistical 
significance. The small sample size may be responsible for this lack of statistical 
significance; therefore future work should involve the sequencing of the remaining usable 
NWCOG-2 tumour samples, which then may give a clearer picture of any correlation 
between the presence of mutation and response to treatment.  
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4.3.8 Conclusion 
In this investigation a total of 30 somatic MRN/CtIP mutations, 25 of which were non-
synonymous, were identified in 9 of 25 NWCOG-2 patient samples. 5 of these were missense 
mutations that were predicted to be probably damaging by Polyphen-2, with a further 10 
missense predicted to be possibly damaging. Two nonsense mutations and two frameshift 
mutations, including the CtIP poly(A)9 1 bp deletion (CtIP-1073delA), were found. This is 
the first time that the CtIP-1073delA mutation has been reported in a microsatellite stable 
cancer. 
 This patient set appeared to have higher non-silent, silent and total mutation rates in 
comparison to the TCGA and COSMIC studies, but without a vastly different mutation 
spectrum. The percentage of mutations that are of the G:C>A:T is 46.4%, much lower than 
the 70-96% that has been reported to occur as a result of FFPE sequencing artefacts [276] 
[279] [280], this suggest that the mutations found in this investigation are not purely 
artefactual arising from FFPE tissue processing. Further work was required to test for 
whether these mutations are genuine or artefactual; this work forms the next chapter. 
The survival data appears to show a more favourable response in those who harboured 
MRN/CtIP mutations with a 100% survival rate, and an 87.5% recurrence free survival. This 
survival data supports the hypothesis that the presence of MRN/CtIP mutations in colorectal 
cancer confers a more favourable response to treatment utilising irinotecan, capecitabine and 
radiation than those that do not. The correlation between survival/recurrence-free survival 
and presence of mutations was not found to be statistically significant, which may be due to 
the small sample size of this study, therefore this study should in future be expanded to 
encompass more NWCOG-2 patients to better study and understand any possible correlation 
between the presence of mutations and the response to treatment. 
I was confident that these mutations were not artefactual due to several factors. Firstly, the 
presence of these mutations was confirmed by sequencing of the opposite strand, which in 2 
cases was carried out on totally independent PCR products. It would be unlikely for a PCR or 
sequencing artefact to occur at the same location in one patient in two independent PCR 
reactions but not occur in any other samples. Secondly, the mutation spectra of this study 
showed that only 46.4% of the NWCOG-2 mutations were of the G:C>A:T variety, much 
lower that 70-96% that is reported to occur due to FFPE related artefacts. This rate of 
G:C>A:T is similar to that found in the TCGA and COSMIC studies (40% and 32.5% 
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respectively). Lastly, the response data showed more positive response for those with at least 
one mutation in MRN/CtIP in comparison to those with wild-type MRN/CtIP, and thus 
supporting the hypothesis that MRN/CtIP mutations would confer an increased sensitivity to 
this treatment regimen.  
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5 Resequencing of NWCOG-2 Mutants and Fluorescent Fragment 
Analysis 
5.1 Introduction 
5.1.1 Resequencing of NWCOG-2 mutations 
The previous chapter discussed mutations that were identified in the NWCOG-2 patient 
tumour samples. Out of the 25 patient samples analysed, a total of 30 somatic mutations were 
identified, of which 23 were non-synonymous. An additional 3 non-synonymous mutations 
were found for which the somatic/germline status could not be confirmed. 
The silent, non-silent and total mutations rates for the NWCOG-2 patients were far greater 
than those of the TCGA and COSMIC studies. The non-silent: silent mutation ratio is less for 
the NWCOG-2 patients than for TCGA and COSMIC. It is currently unknown why this is. 
All mutations were confirmed by sequencing of the reverse DNA strand. In 21 cases the same 
PCR product was resequenced, for 5 cases a new final PCR product was amplified from the 
same multiplex PCR product and resequenced. For 2 cases a fresh PCR product, amplified 
from a fresh multiplex PCR product, was used for resequencing. The presences of the 
mutations were confirmed for these 29 of these somatic mutations. Due to the low quantity 
and quality of DNA available for patient R133, the RAD50-T869I mutation was not 
confirmed with resequencing. 
Due to the observed high mutation rates, we were advised by Professor Jeremy Cheadle of 
Cardiff University to resequence with new primers on DNA from fresh sections to check that 
the observed mutations are real and not FFPE related artefacts, PCR errors, or from 
contaminant DNA. The mutation spectra (as discussed in the previous chapter) are similar to 
that of TCGA and COSMIC, and do not suggest that there is a problem with contamination. 
Also, if the observed mutations were due to contamination, it would be expected that the 
same mutation would arise in multiple samples. 
For the first round of resequencing, each mutation containing exon was amplified by PCR 
using primers that bind external to the previous PCR primers to prevent amplification of 
previous PCR product that could cause contamination. 
For the second round of resequencing, DNA was extracted from freshly cut sections of 
tumour and extra precautions were put into place to minimize the risk of contamination of 
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patient DNA with wild-type DNA or DNA from another patient. The precautions included 
using newly ordered external PCR primers, PCR grade H2O and polymerase mix. DNA 
extraction and PCR was carried out in a laboratory in which no work on human DNA or PCR 
has previously been carried out. This laboratory was cleaned with bleach and DNA-Zap. 
Coveralls and facemask were worn to prevent contamination with human DNA.  
For the work in the previous chapter, similar precautions were implemented in the PCR 
procedure, however no coveralls or face mask were worn. Due to the repeated use of the 
same primer stocks, template DNA, and the area in which the procedures were carried out, 
contamination could have occurred through these factors.  
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5.1.2 Analysis of mononucleotide repeats 
As discussed in previous chapters, each of the four genes of interest include mononucleotide 
repeat sequences that have been found to be subject to single or double base pair insertions 
and deletions (see section 1.5.2, page 21). Therefore the determination of the length of said 
mononucleotide repeats is essential to identify whether such mutations are or are not present 
in the patient tumour samples. It is known that the sequencing of mononucleotide repeats can 
be problematic [282]. For the NWCOG-2 patient samples, sequencing of the MRE11 
poly(T)11 repeat was particularly problematic, and thus an alternative method was required 
to measure the length of the mononucleotide sequence. The sequencing of the MRE11 
poly(T)11 tract suggested that mutations may be present in this repeat for all patients. Figure 
31 shows an example of the problematic sequencing of the MRE11 poly(T)11 repeat. 
 
 
 
 
 
MRE11 Poly(T)11 Repeat 
P 
Figure 31. Example chromatograms for the attempted sequencing of the MRE11 Poly(T)11 tract. This 
shows that the sequences become unclear through the poly(T)11 tract in both the forward and reverse 
sequencing. There appears to be a frameshift in the reverse sequence, however this was seen in a high 
number of samples and could likely be due to polymerase slippage during PCR or sequencing. Due to this 
another method is required to determine if any mutations are present in this tract. 
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Fluorescent fragment analysis is a method that can be used to determine the length of 
mononucleotide sequences to a resolution of a single base pair. This technique involves the 
PCR amplification of a fragment of the patient DNA that contains the mononucleotide repeat 
using a fluorescently labelled primer. The lengths of the fluorescently labelled PCR products 
are then measured by a capillary electrophoresis platform on a genetic analyser [187]. The 
intensity of each peak was recorded. The patient sample peaks were compared to the wild-
type control peak to determine if any peaks exist at a different length, and thus show the 
presence of a mutation. This method was chosen to analyse these repeats as it may reduce the 
effects of polymerase slippage. For sample sequencing polymerase slippage can occur at the 
PCR and sequencing stages, whereas in fluorescent fragment analysis, polymerase is only 
utilised in the PCR stage. 
 
5.2 Results 
5.2.1 Resequencing of mutations identified in NWCOG-2 patient tumour samples 
To confirm that the mutations described in the previous chapter are real and not artefactual, 
PCR was carried out for the regions in which mutations were found, using the primers 
external to the primers used in previous sequencing; these PCR products were then 
sequenced. The same patient genomic DNA samples analysed in the previous chapter were 
used as template DNA for a new multiplex reaction, from which secondary PCR reactions 
were carried out to be sent for resequencing. All somatic mutations, except for the CtIP-
Poly(A)9 1 bp deletion, were not detectable after resequencing; instead the wild-type base 
was present. 
 To then check if the observed loss of mutation could have been the product of 
contamination, the PCR was repeated using fresh tumour sections. After DNA from fresh 
sections of NWCOG-2 patient tumour material was obtained, PCR was carried out to amplify 
the regions of DNA for which somatic mutations have been identified. Fresh ordered primers 
with the same sequence as those used in the PCR and sequencing round in the previous 
chapter (sequences shown on pages 65-68), were used for this PCR. These procedures were 
carried out in conditions to minimise contamination risk (described in materials and method 
page 75). These sequencing products also showed wild-type sequence, with exception of the 
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CtIP-Poly(A)9 1bp deletion. Of the 29 identified somatic mutations, 20 were resequenced 
using this method, the remaining 9 were not resequenced due to failed PCR. Figure 32 shows 
an example of the chromatograms of one mutation, showing the blood, initial sequencing, 
sequencing of product from PCR with external primers and fresh section sequencing product 
chromatograms. Figure 33 shows chromatograms for the same products but for the CtIP-
Poly(A)9 1 bp deletion mutation. These figures are shown over the next 2 pages. 
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Figure 32. Example chromatograms for the MRE11-S382N mutation in patient R11, from four separate 
sequencing reactions from independent PCR products. A is the chromatogram for the base in question 
sequenced from patient blood DNA, this chromatogram shows the wild-type G base (as indicated by the 
arrow). B is the chromatogram for the forward sequencing of this mutation, showing the mutant A base. C is 
the chromatogram from the sequence of the exon, from a longer PCR product (amplified with primers 
external to that of the original), this chromatogram shows an absence of the mutation and the presence of the 
wild-type G base. D is the chromatogram of the sequence for this region from DNA extracted from a new 
tissue section, this chromatogram also shows the wild-type base. 
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Figure 33. Chromatograms for the CtIP-1073delA mutation in patient R48, from four separate 
sequencing reactions from independent PCR products. A is the chromatogram for the base in question 
sequenced from patient blood DNA, this chromatogram shows the wild-type A9 tract. B is the 
chromatogram for the forward sequencing of this mutation, showing a mix of the mutant A8 and the wild-
type A9 tracts (reverse sequencing of this mutation shown in Figure 29). C is the chromatogram from the 
sequence of the exon, from a longer PCR product (amplified with primers external to that of the original), 
this chromatogram also shows a mixture of the wild-type A9 tract and the mutant A8 tract. D is the 
chromatogram of the sequence for this region from DNA extracted from a new section of tissue, this 
chromatogram only shows the presence of the mutant A8 tract. This indicates presence of a single base-pair 
mutation in the microsatellite that may be homozygous and/or not present in all cells in the sample. 
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The sequencing of CtIP-Poly(A)9 1 bp deletion showed a mixture of the wild-type A9 tract 
and the mutant A8 tract for the initial sequence and sequence of longer PCR product. For the 
sequence of a new section only the mutant A8 tract was found to be present (see Figure 33). 
Despite the fact that the vast majority of mutants identified in chapter 2, were not found when 
sequencing from a longer product or from the new section, 2 new mutations did arise that 
were not found in the original sequencing reaction. These mutations also appeared when 
sequencing the reverse strand. An example of one such mutation is shown in Figure 34 on the 
next page. A total of 2625 bp were resequenced in new section samples, therefore the 
observed mutation rate for the resequencing was approximately 762 mutations per Mb, much 
higher than that observed for TCGA and COSMIC (see page 147), although this was a very 
small sample size. 
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Figure 34. Example chromatograms for a new MRE11 mutation which only arose from sequencing of 
DNA from a new section of tissue, in patient R11, from four separate sequencing reactions each from 
independent PCR products. A is the chromatogram for the base in question sequenced from patient blood 
DNA, this chromatogram shows the wild-type C base (as indicated by the arrow). B is the chromatogram for 
the forward sequencing of this base from the initial sequencing of this exon, showing the wild-type C base. 
C is the chromatogram from the forward sequencing of the exon, from  DNA extracted from a fresh section 
of the tumour, this chromatogram shows the presence of a C>T mutation that was not present in the initial 
sequencing. D is the chromatogram of the reverse sequence from a fresh sample, also showing the presence 
of this mutation.  
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5.2.2 Fluorescent fragment analysis of the MRE11-poly(T)11 and CtIP-poly(A)9 tracts 
Due to the difficulty in sequencing through the mononucleotide repeat sequences of MRE11 
and CtIP, that can occur as a result of polymerase slippage in either the PCR or sequencing 
reaction, fluorescent fragment analysis was carried out to determine the size of the PCR 
product, and thus the length of the mononucleotide tract, to a single base-pair to identify any 
insertions or deletions within the tract. The FAM labelled PCR products for the MRE11 
poly(T)11 tract were determined. The electropherograms for the wild-type control and patient 
R12 are shown in Figure 35. Electropherograms for all patients are available in Apendix III 
(chapter 11). 
 
 
 
 
 
Figure 35. Example electropherograms for the fluorescence fragment analysis of the region of MRE11 
that contains the poly(T)11 tract, which is subject to mutation in MSI+ cancers. A is from normal tissue. 
This shows the presence of only a single strong peak at 119 base-pairs, showing the wild-type length of this 
region. The peaks either side of the wild-type peak are likely due to polymerase slippage, or the addition of 
A bases by the polymerase during the PCR reaction. B shows the chromatogram for the same region in 
patient R12, this shows a stronger peak at 118bp, suggesting that this patient sample may harbour a 1 bp 
deletion in the MRE11 poly(T)11 tract . 
 
R12 MRE11 
A 
B 
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Peak Intensity: 4598 
118 bp                  
Peak Intensity: 1397 
 
119 bp                  
Peak Intensity: 1337 
118 bp                  
Peak Intensity: 796 
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The sizes of the primary (WT) and secondary (mutant) peaks for all patients and the wild-
type control were measured and compared. Table 39 shows the intensities of each peak and 
the WT: mutant peak intensity ratio. 
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Table 39: Average wild-type and mutant peak intensities of the MRE11 Poly(T)11 repeat in the NWCOG-
2 patient samples 
Patient WT peak Mutant Peak WT/Mutant 
WT 2963 937 3.16 
R11 2146 787 2.73 
R12 1262 705 1.79 
R13 932 335 2.78 
R18 1180 438 2.69 
R24 1097 429 2.56 
R38 1500 547 2.74 
R48 1820 763 2.38 
R50 3550 1167 3.04 
R60 4869 1624 3.00 
R61 3534 1243 2.84 
R69 6773 2122 3.19 
R72* 7658 2637 2.90 
R74* 6028 2905 2.08 
R93 2042 682 3.00 
R103 4990 142 2.71 
R104 6501 2427 2.68 
R115 5039 1760 2.86 
R119 893 339 2.63 
R133 4963 1735 2.86 
R135* 5556 2487 2.23 
R139 2886 1056 2.73 
R145 4399 1485 2.96 
*Saturated peak in at least one repeat 
WT/Mutant Mean for all samples: 2.72  
WT/Mutant Standard Deviation for all samples: 0.34 
 
Table 39: Table showing the intensities of the wild-type and 1 bp deletion mutant peaks for the Wild-type 
control and each NWCOG-2 patient sample. The measurements are shown as averages from two repeats, which 
were both from independent PCR products taken from independent preliminary multiplex reactions. The wild-
type peaks for patient samples R72, R74 and R135 were saturated. There is little variance between the wild-
type/mutant ratios of the control and patient samples. Only one patient sample showed a wild-type/mutant ratio 
greater than 2 standard deviations above the mean, R12, which was a total of 2.76 standard deviations from the 
mean. This suggests that this patient may harbour a 1bp deletion in the poly(T)11 tract of MRE11. 
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The length of the wild-type fragment is 119 bp, all patient samples, except for patient R12, 
appeared to show one main peak, similar that which is shown in Figure 35, this indicates that 
none of these NWCOG-2 patient tumours tested harbour insertion or deletion mutations in 
the MRE11-poly(T)11 tract. No patients showed a mutant peak higher than that of the wild-
type. The wild-type/mutant peak intensity ratios of the NWCOG-2 patient samples did not 
appear to deviate greatly from that of control. It is likely that the smaller peaks either side of 
the primary peak do not represent a mutation but a variation in PCR product that occurs due 
to the random addition of 3′ A bases by the Taq polymerase used in PCR, known as stutter 
peaks [283]. Only one patient sample wild-type/mutant peak intensity ratio was greater than 2 
standard deviations away from the mean (within the 5% confidence interval), Patient R12, 
this suggests that this patient sample may harbour a 1bp deletion in the poly(T)11 tract of 
MRE11. 
The chromatogram for the poly(T)11 repeat of patient R12 is shown in Figure 36. 
 
 
 
 
 
 
MRE11 Poly(T)11 Repeat 
Patient: R12 
Figure 36. Chromatogram for the reverse MRE11-poly(T)11 repeat in patient R12. This shows a 
sequence of 11 A bases in the repeat, indicating that this patient has the wild-type poly(T)11 tract (A bases 
are shown as this is the reverse sequence). An apparent frameshift can be seen indicated by the arrow. This 
suggests that this patient sample may possess a 1 bp deletion in the poly(T)11 tract of MRE11. 
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The chromatogram of the poly(T)11 tract of patient R12 shows a frameshift in the poly(T)11 
tract. This indicates that this patient sample may harbour both the wild-type T11 allele and 
the mutant T10 allele. This therefore shows that this sample may harbour a 1 bp deletion in 
this tract heterozygously, or the sample may be a mixture of wild-type and mutant cells. 
Wild-type control and patient sample DNA FAM-labelled PCR products of the CtIP-
poly(A)9 tract were also checked by fluorescent fragment analysis. The electropherograms 
for the wild-type and patients R48 and R51 are shown in Figure 37. Electropherograms for all 
patients are available in Apendix III (chapter 11). 
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Figure 37. Example electropherograms for the fluorescence fragment analysis of the region of CtIP 
that contains the poly(A)9 tract, which is subject to mutation in MSI+ cancers. A shows the 
elctropherogram for normal tissue, this only shows a single strong peak at 164 bp, showing that it is the 
wild-type length. This is similar to how the electropherograms appeared for all patients, except R48 and 
R51, showing that none of those patients harboured a insertion or deletion in this region. B and C show the 
chromatograms for patients R48 and R51 respectively. These both show a higher signal at 163 bp in 
comparison to the WT, suggesting the presence of a single base deletion in the microsatellite, that may be 
heterozygous and/or not present in all cells in the sample. 
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The electropherograms for the CtIP-poly(A)9 tract show the wild-type fragment length at 
approximately 164 bp, the only peak present for the wild-type sample, and for most of the 
NWCOG-2 patient tumour samples. However for patient R48 a peak with a high intensity (an 
intensity of 1883, compared to the wild-type peak at 3364) was also seen at the 163 bp 
position suggesting the presence of fragments containing a 1 bp deletion in the CtIP-poly(A)9 
tract. Due to the large wild-type peak in this patient sample, this suggests that the mutation is 
present as a heterozygous mutation and/or due to a mixture of mutated and normal cells. This 
coincides with the sequencing data for this patient at this region (see page 162). For patient 
R51 a smaller, yet still prominent, 163 bp peak was seen in the fragment. This suggests that 
this patient may also harbour a single base-pair deletion in the CtIP-poly(A)9 tract, and that 
the fragments represent a smaller number of mutated cells mixed with a larger population of 
non-mutated cells. For patient R51, the single base-pair deletion in the CtIP-poly(A)9 tract 
was not as prominent in the sequencing chromatogram as it was in patient R48. This 
sequence is shown in Figure 38. 
 
 
 
 
 
The sizes of the primary (WT) and secondary (mutant) peaks for all patients and the wild-
type control were measured and compared. Table 40 shows the intensities of each peak and 
the WT: mutant peak intensity ratio.  
Figure 38. Chromatogram for the CtIP-poly(A)9 repeat in patient R51. This shows a sequence of 9 A 
bases in the repeat, indicating that this patient has the wild-type poly(A)9 tract. An apparrant frameshift 
can be seen to be present at very low levels, this is likely due to polymerase slippage during PCR or 
sequencing that can occur at mononucleotide repeat sequences. 
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Table 40: Wild-type and mutant peak intensities of the CtIP Poly(A)9 repeat in the NWCOG-2 patient 
samples 
Patient WT peak Mutant Peak WT/Mutant 
WT 2911 432 6.74 
R7 843 211 4.00 
R11 2394 296 8.09 
R12 3413 689 4.95 
R13 8649 2076 4.17 
R18 2200 325 6.77 
R24 2436 331 7.36 
R38 4715 690 6.83 
R48 3364 1883 1.79 
R50 3496 506 6.91 
R51 1539 554 2.78 
R60 7606 950 8.01 
R61 3419 487 7.02 
R69 8814 2326 3.79 
R72 443 58 7.64 
R74 586 173 3.39 
R84 1161 297 3.91 
R93 2746 327 8.40 
R103 905 123 7.36 
R104 2519 332 7.59 
R115 1670 220 7.59 
R119 979 284 3.45 
R133 1928 456 4.23 
R135 1089 149 7.31 
R139 985 143 6.89 
R145 3512 402 8.74 
R48b 169 84 2.01 
R48c 596 322 1.85 
R48d 1167 582 2.01 
R48e 590 305 1.93 
R51b 2977 1013 2.94 
WT/Mutant Mean: 5.95 (does not include additional repeats for R48 and R51) 
WT/Mutant Standard Deviation: 2.05 (does not include additional repeats for R48 and R51) 
 
Table 40: Table showing the intensities of the wild-type and mutant peaks for the Wild-type control and each 
NWCOG-2 patient sample. Repeats for patient R48 are shown as R48b-e and the repeat of R51 is shown as 
R51b. Samples for patients R48 and R51 are highlighted in bold as they have strong mutant peaks. 
173 
 
 
The data shown in Table 40 was used to plot a graph of the mutant peak intensity against the 
wild-type peak intensity. This is shown below in Figure 39. 
 
 
 
 
 
 
 
Table 40 shows that patient samples R48 and R51 both have relatively low WT/Mutant peak 
ratios compared to that of the other patient samples and the wild-type control. The average 
WT/mutant ratio for R48 is 1.92, which is approximately 2 standard deviations away from the 
mean (5.95), and thus puts this patient sample within the 5% confidence interval, suggesting 
that the height of the secondary peak is due to the presence of a mutant fragment. The 
WT/mutant ratio for patient sample R51 is 2.86, which is 1.5 standard deviations below the 
mean. The graph (Figure 39) shows that the points representing R48 samples lie above the 
trend line. The points for R51 also lie above the trend line albeit to a lesser extent. 
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Figure 39. Intensity of WT and mutant peaks for the fluorescent fragment analysis of CtIP. Plot of the 
intensity (height of peak) of the mutant (1 bp deletion) peak against the intensity of the wild-type peak of the 
region of CtIP containing the poly(A)9 region for all patients. A linear trend line has been drawn for all 
patients. This graph shows that the two data points  for patient R51 lie above the trend line showing a greater 
mutant to wild-type peak intensity ratio compared to all patients. The four plots for R48 lie further from the 
trend line showing a greater mutant to wild-type peak intensity for this patient in comparison to all patients. 
This indicates the possible presence of a single base deletion in the microsatellite that may be heterozygous 
and/or not present in all cells in the sample. 
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5.3 Discussion 
5.3.1 Loss of NWCOG-2 mutations 
Out of all the somatic mutations identified in the NWCOG-2 patients, only the CtIP-poly(A)9 
1 bp deletion was found present in both rounds of resequencing. Also, two new mutations 
were found in the resequencing that were not found in the initial sequencing. There are a few 
possible reasons as to why this apparent loss of mutations may have occurred.   
One potential explanation for this lack of reproducibility is these mutations may have been 
artefacts caused by FFPE processing of tissue. This process is known to cause the 
deamination of cytosine residues which leads to a high number of apparent C:G>T:A 
mutations, accounting for 70-96% of FFPE related sequencing artefacts  [276] [279] [280]. 
However in the NWCOG-2 patient mutations, only 46.4% of mutations were of this type, 
much lower than what is commonly reported. This suggests that cytosine deamination is not 
the sole cause of apparent NWCOG-2 mutations. 
Another possible explanation is that the observed mutations were actually errors incorporated 
into the DNA by the polymerase. However, many of the observed mutations showed a clear 
mutant trace with no wild-type trace. This would require the error to be incorporated during 
the first PCR cycle without subsequent amplification of the original wild-type strand. This is 
also unlikely as each initial reaction contained 10 ng of DNA, which contains around 2786 
copies of the human genome (using 3.59 pg as the mass of the human genome, based on a 
genome length of 3,300 Mb [284]) and thus around 2786 copies of each gene per sample. 
This would require the PCR to only amplify erroneous copies without the amplification of the 
wild-type. Also, 2 mutations were confirmed in the initial section with new PCR products 
amplified directly from the patient DNA, which also showed the mutations, it is unlikely that 
the same polymerase error would appear in two separate samples. There is also a possibility 
that in those samples only 1 of the 2786 copies of each gene was amplifiable. This 
amplification may have been facilitated by the long elongation time of the multiplex PCR. 
This copy harbouring this mutation may have then provided the template for all subsequent 
PCR reactions, and thus the PCR products would incorporate this mutation. 
Another potential explanation is that the DNA samples became contaminated with wild-type 
DNA following the confirmatory reverse sequencing. This contaminant DNA then may have 
been preferentially amplified over the patient DNA thus showing wild-type traces, especially 
if the contaminant DNA is of a higher quality than that of the FFPE extracted patient DNA. 
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Tumour heterogeneity may have also contributed to this. The PCR amplified from the new 
sections may have had a greater percentage of non-cancerous cells than the original sections 
or may have had a smaller population of cancerous cells that do not harbour the original 
mutations, which may harbour mutations not found in the original section, such as the two 
new mutations that were found. Also, this may account for change in zygosity observed with 
the CtIP-poly(A)9 mutation of patient R48, as the second sections may have contained a high 
population of homozygous/hemizygous cells as oppose to the population of heterozygous 
cells or mutant/wild-type mixture of the original sections. This could be due to a loss of 
heterozygosity, as loss of heterozygosity at loci 5q and 18q have been reported as frequent 
intratumoural heterogeneous events in colorectal cancer [285], the CtIP gene is located at 
18q11.2 [286]. The heterozygosity of RAD50 may also subject to such heterogeneity in 
tumours as it is located at 5q31 [287]. 
If the CtIP-poly(A)9 mutation produces a null phenotype as it does in S. pombe (see page 
100), then it would not be able to be present homozygously as total depletion of CtIP is lethal 
in mammalian cells [243]. Although, two C-terminal truncation mutants are known to occur 
homozygously in patients with Seckel syndrome or Jawad syndrome, showing that C-
terminal truncation of CtIP does not necessarily lead to a null phenotype [162]. 
 
5.3.2 Mutations in mononucleotide repeat sequences 
Fluorescent fragment analysis of the region of MRE11 containing the poly(T)11 repeat for the 
NWCOG-2 patients showed little differences in the wild-type/mutant peak intensity ratios of 
the wild-type control compared to the NWCOG-2 patient samples. Only one patient, patient 
R12, showed a wild-type/mutant peak intensity ratio that was more than 2 standard deviations 
lower the mean, which would indicate that this lies within the 5% confidence interval of 
being a genuine mutation. This would suggest that a single base-pair deletion mutation may 
be present in the MRE11 poly(T)11 tract for this patient. 
For CtIP however, two patients, R48 and R51, showed secondary peaks of relatively high 
intensity at the 1 bp deletion position, suggesting that a single base-pair deletion mutation 
may be present at the CtIP poly(A)9 region for these patients.  
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All fluorescent fragment analyses performed on the poly(A)9 region of CtIP in patient R48 
indicate the presence of a single base-pair deletion (See Figure 37. This further supports that 
this mutation is present in this patient sample and is not artefactual. In the resequencing of 
DNA from a new section of R48 patient tumour material, this mutation appeared as 
hemizygous/homozygous, whereas it had appeared as a mixture of wild-type and mutation in 
prior sequencing reactions. This may have occurred as a result of the PCR initially only 
amplifying a single strand, although this is unlikely. This could have also occurred due to 
tumour heterogeneity, and the initial section may have contained a mixture of mutant and 
wild-type or heterozygous cells, whereas the new section may have consisted mostly of 
homozygous/hemizygous mutant cells. For patient R51, the mutation was not as prominent in 
sequencing reactions.  
This mutant has been described in the literature [167] [173] [174], in which it was only found 
in MSI patients. The patient R48 tumour is microsatellite stable (See Table 32, page 145). 
The MSI status was determined by immunohistochemistry of MMR proteins, which is 
considered a simple method for the diagnosis of MSI in colorectal cancer patients [288], 
however one study showed that only as little as 23% of MSI-H colorectal cancers show 
immunohistochemical evidence for a loss of an MMR protein [289]. If patient R48 genuinely 
is microsatellite stable, then this would be the first time in which this mutation has been 
identified in a microsatellite stable tumour. This shows that this mutation can occur 
independently of MSI, but less frequently. 
 
5.3.3 MRE11-Poly(T)11 mutant 
A single base pair deletion within the MRE11-poly(T)11 tract is known to give rise to two 
mutant transcripts. One of which is the Δ5-7MRE11 mutation, caused by a splicing defect that 
removes exons 5-7, resulting in a loss of the third and fourth highly conserved 
phosphodiesterase motifs of the nuclease domain [107], and part of the Nbs1 binding domain 
(see Figure 16). The other mutant transcript is the MRE11-484del88 mutation which results in 
the loss of the 5
th
 exon from the mRNA due to a splicing defect, resulting in a frameshift and 
truncation, resulting in a protein 105 amino acids (out of 708) in length [163]. The MRE11-
484del88 mutation is known to be associated with a reduction in the expression of RAD50 
and NBS1 [165]. A 1 or 2 bp deletion in this tract has been found to occur in up to 100% of 
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all lower-grade MMR deficient tumours, and 68.8% of higher grade MMR deficient tumours 
[165]. 
The Δ5-7MRE11 mutation was studied in the third chapter (see section 3.1.4.2). In humans, 
this mutant results in a protein which lacks the 3
rd
 and 4
th
 phosphodiesterase domains of the 
nuclease domain, which are required for 3′-5′ exonuclease activity [107]. This mutation is 
known to act in a dominant negative manner [107]. This could lead to an increase in 
sensitivity to topoisomerase inhibitors, as Mre11 nuclease activity is thought to be required 
for topoisomerase removal, also in S. pombe. [94]. A previous study has shown that this 
mutant transcript sensitises cells to camptothecin when transfected into a camptothecin 
resistant cell line [107]. The results in chapter 3 show that when this mutant is recreated into 
S. pombe, it results in an apparent null phenotype, severely sensitive to camptothecin and 
MMS, showing that this mutant is defective in topoisomerase removal and/or downstream 
DNA repair functions (See page 95). Studies have also shown that in human cell lines, this 
mutant transcript also sensitises cells to thymidine [107] and PARP-1 inhibitors [166] [167]. 
The Δ5-7Mre11 mutant protein is known to have a decreased infinity for Rad50, and very little 
binding affinity for Nbs1 [107], which may be due to a lack of part of the Nbs1 binding 
domain (see Figure 16, page 87). This could therefore severely affect the ability of this 
mutant to activate ATM, and result in a failure to activate the downstream repair pathways 
required to repair DNA DSBs. 
The positive response to treatment using concurrent irinotecan observed in this patient (R12) 
may be due to the presence of this mutation as this mutation may sensitise cells to 
topoisomerase inhibitors. Table 37 in section 4.3.7 (page 152) showed that this patient did 
respond well to treatment of radiotherapy, irinotecan and capecitabine, with no recurrence or 
metastasis and only microfoci present in the resection sample. 
 
5.3.4 CtIP-Poly(A)9 mutant 
 If this mutant is present heterozygously, it is known to lead to a two-fold decrease in the 
expression of functional CtIP and a defective HR response [167]. This mutant was found to 
occur in 22.9% [173] to 36% [167] of MSI tumours. In one study, this mutation was found to 
sensitise cells to PARP inhibition [167]. 
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This mutation was one of the mutations studied in the third chapter, Figure 19 (page 93) 
shows that this mutant CtIP protein lacks the CtBp binding site, the DNA binding domain, 
the PCNA binding site, the second MRN binding domain, the CxxC motif, the two ATM 
binding phosphoserine residues and the CDK binding phosphothreonine residue. The deletion 
of the second MRN binding domain could prevent this protein from binding to MRN and 
being recruited to the sites of DSBs, where it is required for DSB resection [35]. Binding of 
CtIP to MRN is required for efficient HR, a lack of an MRN binding domain may be a 
possible explanation for the HR defects [35]. This could also hinder topoisomerase removal, 
as CtIP is required for topoisomerase removal along with the MRN complex, therefore if this 
mutant is unable to bind the MRN complex then it may not lead to defective topoisomerase 
removal. The lack of the DNA binding domain could also contribute to the defective HR as 
this domain functions to promote DNA resection at sites of DSBs, which leads to checkpoint 
activation and HR [290]. As this mutation is heterozygous, a wild-type copy is still present. 
This may be insufficient as studies have shown that CtIP is haploinsufficient in mice 
resulting in tumourigenesis [291].  
The lack of the C-terminal CDK binding phosphothreonine residue could also lead to defects 
in HR, as the activation of CtIP in HR requires phosphorylation of this residue [196]. This 
residue is also required for the activation, via phosphorylation by Plk3, in G1 phase to 
function in the NHEJ pathway [292]. The activation of CtIP in HR also requires the 
phosphorylation of the phosphoserine residues S664 and S745, by ATM [193]. Mutations in 
these residues have shown to result in HR defects [193], and therefore, a lack of these 
residues would also confer HR defects. 
In chapter 3, it was shown that this mutation, when created into S. pombe ctp1, leads to an 
increase in sensitivity to camptothecin and MMS (see page 100). If this mutation has a 
similar effect in humans then it would lead to a greater sensitivity to camptothecin, and 
possibly a better response to treatment with irinotecan. In the NWCOG-2 trial this patient 
responded positively with near pCR (only microfoci present post-resection) and no 
recurrence or distant metastases. This mutation may have contributed to this positive 
response through its sensitising effect to topoisomerase inhibitors. 
Further work should be conducted to analyse the effects of this mutation on sensitivity to 
topoisomerase inhibitors. This mutation should be created in human cell line and then tested 
for sensitivity to camptothecin in comparison to the wild-type. 
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5.3.5 Conclusion 
Despite the number of mutations identified in the previous chapter, all but one could not be 
reproduced in subsequent PCR using different primers and new sections of patient tumour 
material. One mutation however, the CtIP-poly(A)9 1 bp deletion mutation of patient R48 
was confirmed in all subsequent sequencing reactions, albeit with altered zygosity in the new 
section. This mutation was also confirmed by fluorescent fragment analysis, also showing 
that this mutation may be present in patient R51 also. This mutant has only before been 
described in MSI tumours, were here was found in an apparent microsatellite stable tumour. 
If this tumour is genuinely microsatellite stable, then this marks the first time in which this 
mutation has been found in a non-MSI tumour, showing that this mutation is not purely 
specific to MSI cancers. Further work is required to confirm that this tumour is microsatellite 
stable, for example sequencing of the MMR gene MSH2 [289]. 
Patient R48 showed a positive response with a near pCR and no recurrent disease, however it 
cannot be confirmed that this positive response was due to the mutation. Further study of this 
mutation is required to assess its role in sensitising cells to topoisomerase inhibitors. This 
mutation should be created into a human cell line and then tested for sensitivity to 
camptothecin.  
A 1 bp deletion mutation was also identified in the MRE11-poly(T)11 tract of patient R12, 
which was not identified initially by sequencing due to difficulties in sequencing through this 
tract (as described on page 158). This patient also showed a near pCR and no recurrent 
disease or distant metastasis. It also could not be confirmed that this response was due to this 
mutation. This mutation has also only been previously identified in MSI tumours [163], 
whereas the tumour for patient R12 was MSS. Further work is required to asses that this 
tumour is MSS. If this tumour is confirmed to be MSS, this would mark the first time in 
which this mutation has been identified in a MSS tumour, showing that this mutation is not 
specific to MSI cancers. 
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6 Identification of S. pombe Mutants That Confer Hypersensitivity to 5-
FU 
6.1 Introduction 
6.1.1 Use of 5-FU in cancer treatment 
The NWCOG-2 trial, as described in section 4.1.1, utilises the drug Capecitabine 
concurrently with Irinotecan. This trial showed a pathologic complete response in 22% of all 
patients. It is currently unknown what genetic factors influence response to this treatment 
regimen. 
Capecitabine is a prodrug for 5-FU, that is administered orally. Capecitabine is first 
metabolised by carboxylesterase (CES) to 5′-deoxy-5-fluorocytidine (5′-DFCR). 5′-DFCR is 
then metabolised to 5′-deoxy-5-fluorouridine (5′-DFUR) by cytidine deaminase. Thymidine 
phosphorylase then converts 5′-DFUR to 5-FU [111]. The administration of capecitabine is 
advantageous over 5-FU administration, as capecitabine can be administered orally, whereas 
5-FU can only be administered intravenously, offering greater convenience [293]. A previous 
clinical trial also showed that oral capecitabine administration has a greater relapse free 
survival rate and a lower rate of adverse side-effects than intravenous 5-FU [294]. 
 
6.1.2 5-FU mechanism of action 
Once inside the body, 80% of 5-FU is degraded by dihydropyrimidine dehydrogenase (DPD) 
[295] into dihydrofluorouracil (DHFU) [296]. The remaining 5-FU can then be converted 
through a series of reactions into the three different main active metabolites, 
fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and 
Fluorouridine triphosphate (FUTP) [297] (See Figure 40). 
5-FU is known to cause cytotoxicity in three different ways. One such way is through the 
inhibition of thymidylate synthase (TS) [298]. Thymidylate synthase is an enzyme essential 
for the de novo synthesis of 2′deoxythymidine-5′monophosphate (dTMP). For this reaction 
the substrate, 2′deoxyuridine-5′monophosphate (dUMP) is methylated by TS using 5, 10-
methylene-tetrahydrofolate as the methyl donor [299]. The 5-FU active metabolite FdUMP 
inhibits TS [299]. Inhibition of TS prevents the synthesis of dTMP, and thus the synthesis of 
deoxythymdine triphosphate (dTTP) leading to depletion of cellular thymidine pools and 
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thymidineless death. TS inhibition has also been found to increase the cellular concentration 
of deoxyuridine triphosphate (dUTP). In the absence of thymidine, dUTP is misincorporated 
into DNA and subsequently excised, leading to DNA strand breakage [133].  
The other ways in which 5-FU can cause cytotoxicity is by incorporation of the active 
metabolites FdUTP and FUTP into DNA [300] and RNA [301] respectively. A study in 2004 
showed that there was no correlation between the efficacy of 5-FU and the incorporation of 
5-FU metabolites into DNA and RNA [302]. However later studies then found that DNA and, 
to a greater extent, RNA incorporation are important contributing factors to 5-FU cytotoxicity 
[303] [304]. Excision of FdUTP from DNA can reduce cytotoxicity from FdUTP DNA 
incorporation. Two previous studies showed that Smug1, and not uracil-DNA glycosylase 
(UNG) excised incorporated FdUTP [303] [305]; however another study showed UNG to be 
more important in FdUTP excision [304].  
DNA and RNA incorporation can lead to apoptosis through a number of mechanisms [125]. 
Incorporation into DNA can lead to cytotoxicity by causing mutations and miscoding during 
transcription, leading to aberrant protein synthesis [126] [125]. Incorporation of FUTP into 
RNA causes cytotoxicity in a number of ways. mRNA can be affected by polyadenylation, 
splicing defects and miscoding [125] [127]. tRNA post-transcriptional modification can be 
inhibited [125] [128]. rRNA can be affected through the inhibition of pre-rRNA processing 
[125] [129].  
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(Longley, Harkin & Johnston 2003) [297] 
 
  
Figure 40. The pathways of 5-FU metabolism. This figure shows pathways, enzymes and intermediates 
involved in the metabolism of 5-FU into the three active metabolites, fluorodeoxyuridine monophosphate 
(FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP), which cause 
cytotoxicity by TS inhibition, DNA incorporation and RNA incorporation respectively. This also shows the 
pathways which cause 5-FU to be metabolised into the inert product dihydrofluorouracil DHFU. The 
skeletal formula of 5-FU is shown in the bottom left corner. 
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6.1.3 Known genes, proteins and pathways involved in 5-FU resistance and sensitivity 
in human cancers 
6.1.3.1 Thymidylate synthase (TS) 
As described in section 6.1.2, thymidylate synthase is an important enzyme required for the 
synthesis of dTMP, which is required for DNA synthesis. TS is inhibited by the 5-FU 
metabolite FdUMP leading to dTMP depletion, dUTP accumulation, DNA damage and 
thymidineless death.  
It was found that a reduced protein and gene expression of TS correlate to an improved 
response to treatment with 5-FU in gastric and colorectal tumours [306]. Another study 
showed that in colorectal cancer cell lines, amplification of the TS gene can increase 
resistance to 5-FU, and that a constant exposure to 5-FU can result in TS amplification and 
overexpression leading to 5-FU resistance [307]. Multiple studies have shown that TS 
polymorphisms confer hypersensitivity to 5-FU [298] [308] [309].  
The S. pombe TS homologue is hal3 (SPAC15E1.04) [310]. A genome-wide screen by 
Mojardín et al found that deletion of hal3 in S. pombe is known to sensitise to 5-FU [311]. 
 
6.1.3.2 Dihydropyrimidine Dehydrogenase (DPD) 
As discussed in section 6.1.1, the DPD enzyme degrades approximately 80% of 5-FU into a 
DHFU, which is then expelled from the body. A previous study has shown that elevated 
levels of DPD correlated directly to decreased 5-FU sensitivity [312]. An increase in the 
levels of DPD would cause an increase in the portion of 5-FU that is metabolised into the 
non-cytotoxic DHFU, and thus a decrease in the percentage of 5-FU that is ultimately 
converted into the three cytotoxic metabolites. It is unknown if there is a DPD homologue in 
S. pombe. 
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6.1.3.3 Orotate Phosphoribosyltransferase (OPRT) 
Orotate phosphoribosyltransferase (OPRT) is the enzyme which catalyses the conversion of 
5-FU into Fluorouridine monophosphate (FUMP), a precursor of FUTP, which causes 
cytotoxicity via RNA incorporation. Subsequent reactions can also lead to the conversion of 
FUMP to FdUTP and FdUMP, which cause cytotoxicity by DNA incorporation and TS 
inhibition [297]. Studies have shown that an increase in OPRT activity leads to heightened 
sensitivity to 5-FU [313] [314]. This may be due to an increase in the percentage of 5-FU that 
is ultimately converted into the cytotoxic active metabolites as opposed to DHFU. The S. 
pombe OPRT enzyme is encoded by the ura5 gene [315]. 
 
6.1.3.4 MMR 
As discussed in sections 1.2.1 and 1.4.2.1, the MMR pathway functions in the removal of 
misincorporated DNA bases, lesions which can be caused by the misincorporation of FdUTP 
or dUTP into DNA. The fluouracil and uracil bases are known to form mismatches with 
guanine [316]. A proficient MMR pathway is required for cytotoxicity [317] as the repair of 
these mismatches by MMR creates a nick in the DNA 250-1000 bp from the mismatch, the 
DNA from these points is degraded. The synthesis of DNA to repair this gap then increases 
the chances of further incorporation of FdUTP or dUTP into DNA [120]. Defects in the 
MMR pathway result in increased resistance to 5-FU due to a decrease in the 
misincorporation of 5-FU metabolites into DNA during the MMR process [318]. A clinical 
trial has showed that for the treatment of colon cancer MMR deficiency provides a predictive 
marker for a lack of benefit when treated with 5-FU based therapies [319]. A direct 
correlation exists between 5-FU cytotoxicity and the binding activity of hMutSα and hMutSβ 
[320].  
 
6.1.3.5 ATM, CHK1, CHK2 & H2AX 
The ATM, CHK1, CHK2 proteins and H2AX levels are elevated following induction of 
DNA damage by 5-FU,suggesting that these proteins function in the repair of 5-FU induced 
damage and 5-FU resistance, therefore defects in functions of these proteins may sensitise 
cells to 5-FU [321]. As these proteins are involved in the signalling and repair of DNA DSBs, 
it suggests that other DSB signalling and repair proteins, such as the MRN complex and CtIP, 
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may also function in the repair of 5-FU induced DNA damage, and 5-FU resistance. The S. 
pombe homologues of ATM, CHK1, CHK2 are Tel1, Chk1, Cds1 [322] respectively. 
6.1.3.6 p53 & p53R2 
Defective p53 is known to increase sensitivity of cancer cells to 5-FU [323], and is thought to 
be a major determinant of 5-FU sensitivity [324]. The p53R2 gene, which encodes for subunit 
2 of the ribonucleotide reductase (RNR) homolog, is induced by DNA damage. Increased 
expression of p53R2 increases resistance to 5-FU, and silencing of this gene was found to 
sensitise cancer cells to 5-FU [325]. 
 
6.1.3.7 Bcl2 & Bax 
Bcl-2 represses apoptosis by binding to proapoptoic proteins [326]. Apoptosis is promoted by 
heterodimerisation of Bcl2 with Bax, binding with Bax prevents Bcl2 from binding to 
proapoptotic proteins, therefore allowing for the progression of apoptosis. The ratio of Bcl2 
to Bax determines whether apoptosis is repressed or promoted [327]. The induction of Bax 
and the Bcl2 to Bax protein ratio was found to correlate with 5-FU sensitivity in cancer cells 
[328]. Low levels of Bax have been found to correlate with a greater resistance to 5-FU 
whereas high levels of Bax, coupled with low Bcl levels, have been found to correlate with an 
increase in sensitivity to 5-FU [329]. 
 
6.1.3.8 Methylenetetrahydrofolate reductase (MTHFR) 
The methylenetetrahydrofolate reductase (MTHFR) protein functions in the conversion of 5, 
10-methylenetetrahydrofolate into 5-methylenetetrahydrofolate, a step required for the 
conversion of homocysteine to methionine. 5, 10-methylenetetrahydrofolate is required for 
the inhibition of TS, as 5,10-methylenetetrahydrofolate forms a ternary complex with 
FdUMP and TS, preventing the methylation of dUMP to dTMP, leading to thymidineless 
death [330] [331]. Defective MTHFR would cause an accumulation of 5, 10-
methylenetetrahydrofolate, and thus an increase in TS inhibition. Polymorphisms in the 
MTHFR gene have been found to increase sensitivity of cancer cells to 5-FU [309] [331] 
[332]. The S. pombe orthologues of MTHFR are met9 and met11 [333]. 
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6.1.3.9 c-Myc 
The c-Myc transcription factor, which functions in the expression of a wide range of genes 
involved in a variety of cellular processes including cellular proliferation, cell growth and 
apoptosis; has been found to be involved in 5-FU sensitivity. A previous study has shown that 
elevated levels of the c-Myc protein increase 5-FU sensitivity in human colorectal cancers 
[334]. 
 
6.1.3.10 Base Excision Repair 
The base excision repair (BER) system functions in the removal of damaged DNA bases, and 
also in the removal of misincorporated uracil [335]. As 5-FU can cause cytotoxicity through 
DNA incorporation, the BER pathway may be an important mechanism functioning in the 
resistance of 5-FU. In S. cerevisiae the mutations of the BER genes ntg1, ntg2, apn1 and 
apn2 have been found to confer hypersensitivity to 5-FU [125]. A study of 5-FU sensitivity in 
an ung1Δ S. cerevisiae strain showed an increased resistance to 5-FU and a vast increase in 
the amounts of incorporated uracil bases in the genome [336]. 
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6.1.4 Possible implications of the MRN complex and CtIP in 5-FU resistance 
Mre11, Rad50 and ATM, which is activated by Nbs1, have been found to have involvement 
in the resistance to nucleoside analogues. These proteins have been found to respond to the 
stalled replication forks that are caused by incorporation of nucleoside analogues such as 
gemcitabine, troxacitabine and cytarabine into DNA, and are required for the survival of such 
damage. Nbs1 and H2AX, however were found to not greatly affect response to such stalled 
replication forks [134]. 
As previously discussed (see section 6.1.3.5, page 184), levels of the ATM protein, which 
functions in the DSB repair pathway along with the MRN complex, have been found to be 
elevated following exposure to 5-FU suggesting a possible role of ATM in the response to 5-
FU [321]. As ATM may function in 5-FU response, the associated MRN and CtIP proteins 
may therefore also be involved in 5-FU response. 
Also as discussed (section 6.1.2) 5-FU can cause DNA damage through strand breakage as a 
result of TS inhibition and subsequent incorporation and excision of dUTP in DNA [133]. 
The MRN complex and CtIP proteins function in the repair of DNA DSBs (see section 1.1.1), 
therefore MRN and CtIP may provide resistance to 5-FU through the repair of DSBs. 
These observations suggest that the MRN complex, and the associated CtIP protein may be 
involved in resistance to 5-FU through responding to the stalled replication forks that occur 
as a result of the incorporation of the 5-FU metabolite FdUTP or by the repair of DSBs that 
occur as a result of SSBs following the incorporation and excision of dUTP. 
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6.1.5 Aims and hypotheses 
This investigation aims to identify if the S. pombe MRN and Ctp1 function in the resistance 
to 5-FU, this was studied by testing the sensitivity of mre11Δ, rad50Δ, nbs1Δ and ctp1Δ cells 
to 5-FU. This investigation also aims to identify a number of genes in S. pombe that function 
in the resistance to 5-FU, by screening of the Bioneer genome-wide deletion library to 5-FU. 
The roles of any specific pathways will then be assessed through the ontological analyses of 
the genes identified to function in 5-FU resistance. 
The hypothesis of this investigation is that the mre11Δ, rad50Δ, nbs1Δ and ctp1Δ strains will 
be hypersensitive to 5-FU due to defects in the repair of stalled replication forks and defects 
in DSB repair. It is also hypothesised that strains lacking the genes involved in the base 
excision repair pathway will also sensitise to 5-FU as this pathway is required for 5-FU 
resistance in S. cerevisiae.  
 
6.1.6 Screening and analysis of the Bioneer deletion mutant library  
It is estimated that the S. pombe genome contains around 4941 protein coding genes [337], of 
which 17.5% are thought to be essential [338]. The Bioneer deletion mutant library consists 
of 3345 different mutant strains, each one lacking a different gene. The deletion mutants in 
this library represent approximately 68% of all non-essential S. pombe genes. This library 
was screened against 5-FU, at concentrations of 200 µM and 400 µM, in order to identify 
mutants that confer increased sensitivity, or resistance, to 5-FU. This procedure was carried 
out as described in the Materials and Methods section (section 2.6.5) for 8 repeats for each 
different 5-FU concentration. 
The growths of the strains were quantified using Colonyzer, which assesses the growth of 
colonies based on their size and optical intensity. Colonyzer provides an accurate and reliable 
method of detecting even small differences in the densities of microbial colonies [339].  
QFA (Quantitative fitness analysis) software is used to estimate the effects of drugs and 
genetic mutations on the growth of microbes and can be used in experiments using thousands 
of colonies in parallel [340]. Colonyzer data are fitted to a generalised logistic population 
growth model [341]. The software offers a choice of fitness parameters, some of which are 
making use of the fitted model, some using the curve passing through the experimental points 
(experimental curve). For this analysis, we used the maximum slope of the experimental 
189 
 
curve (“maxslp” parameter, C. Lawless, personal communication), as this parameter was 
shown to discriminate well between reference genotypes (data not shown). The biological 
interpretation of this parameter is not trivial. However, it was decided not to make use of 
maximum growth rate estimators, as these rely heavily on early data points, for which the 
signal/noise ratio can lead to significant error. The QFA analyses identifies colonies which 
show an increase in sensitivity or resistance to 5-FU by calculating the genetic interaction 
score (GIS), which calculates the deviation of the fitness for each point against the regression 
line (as shown in Figure 44 and Figure 45). The expected fitness of the strain is subtracted 
from the observed fitness of the strain. A negative GIS indicates a strain with an increased 
sensitivity to 5-FU, a positive GIS indicates a strain with an increased resistance to 5-FU. A 
Wilcoxon test is then carried out to calculate the statistical significance of the sensitivity or 
resistance of the deletion mutants to 5-FU.
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6.2 Results 
6.2.1 Testing of mre11, rad50, nbs1 and ctp1 mutants for sensitivity to 5-FU 
The mre11Δ, rad50Δ, nbs1Δ and ctp1Δ strains, along with wild-type S. pombe were tested for 
their sensitivity to 5-FU at concentrations varying from 0 to 400 µM. This is shown below in 
Figure 41. 
 
 
 
 
The mre11Δ, rad50Δ, nbs1Δ and ctp1Δ S. pombe strains appeared to show sensitivity to 5-FU 
similar to that of the wild-type. This suggests that the Mre11, Rad50, Nbs1 and Ctp1 do not 
function in 5-FU resistance and mutations within these genes do not confer sensitivity to 5-
FU. Due to this other mutants of these genes, like those tested in chapter 3 (see sections 3.2.2 
- 3.2.5), were not tested for their sensitivity to 5-FU. A slight hyper-resistance of the mre11Δ 
and rad50Δ strains can be seen in Figure 41; however this was not apparent in repeats. 
Figure 41. Sensitivity of the WT, mre11Δ, rad50Δ, ctp1Δ and nbs1Δ strains to 5-FU. This figure shows 
that the mre11Δ and rad50Δ strains show no increase in sensitivity to 5-FU in comparison to the wild-type. 
This suggests that mutations in these genes will not confer an increase in sensitivity to 5-FU. A slight hyper-
resistance of the mre11Δ and rad50Δ strains can be seen, however this was not apparent in repeats. This spot 
test is indicative of 3 repeats. 
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6.2.2 Optimisation of screen 
The pre-screen was carried out, as described in the Materials and Methods section (see page 
77) in order to determine the concentration of 5-FU for which the library screen should be 
carried out at. The colony density for each time point and each 5-FU concentration were 
measured using ImageJ software and were plotted onto a graph. This graph is shown below in 
Figure 42.  
 
 
 
 
 
The graph in Figure 42 shows that the growth of the wild-type S. pombe decreases at around 
200 µM and then another marked decrease in growth at around 400 µM. From this it was 
decided that the screen should be carried out at both 200 µM and 400 µM. 
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Figure 42. Growth curves for wild-type S. pombe grown on media with varying concentrations of 5-FU 
varying from 0 µM to 800 µM, with samples taken every 12 hours for 120 hours. This shows that the growth 
of the wild-type S. pombe decreases at around 200 µM, with another large decrease in growth at 400 µM. 
Therefore it was decided that the screen of the Bioneer library to 5-FU would be carried out at 200 µM and 
400 µM. 
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6.2.3 Deletion mutants identified to have an increased sensitivity or an increased 
resistance to 5-FU 
The analyses for the growth of the deletion mutants of the Bioneer library screen were carried 
out as described (page 79). The QFA analyses generated growth curves for each strain at each 
concentration of 5-FU. An example of such growth curves is shown in Figure 43. 
Figure 43 shows the growth curves for the wild-type (Positive Strain), the dus3 mutant and 
the pub1 mutant. The dus3 mutant is shown as it was found to be significantly hypersensitive 
to 5-FU. The pub1 mutant is shown as this strain was found to be significantly resistant to 5-
FU. The growth curve of the wild-type (WT) shows slight decreases in growth from the no 
drug control to the 200 µM plate and again to the 400 µM plate. The growth curves for the 
dus3 mutant show that this strain is greatly hindered by that of the 5-FU exposure, whereas 
the growth of the pub1 mutant is unaffected by the presence of 5-FU at 200 µM and 400 µM 
respectively. The genotype of the wild-type strain is h
+
 ade6-M210, leu1-32, ura4-D18. 
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Figure 43. Example growth curves for mutant strains in the Bioneer library screen. The dus3 deletion 
mutant was found to be significantly sensitive to 5-FU at 200 µM and 400 µM, as seen by the sharp decrease 
in growth between the control and 5-FU growth curves in comparison to the WT. dus3 is predicted to 
encode for the tRNA diuridine synthase Dus3. Pub1 (encodes an ubiquitin protein ligase) deletion mutant 
was found to be resistant to 5-FU and maintains a high level of growth at 200 µM and 400 µM 5-FU in 
comparison to the WT. This is indicative of 8 repeats. 
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The screen of the library was carried out as described in the Materials and Methods section 
(page 78). 8 repeats of the screen for the control, 200 µM 5-FU and 400 µM 5-FU were 
carried out. Images for each plate were acquired every 2 hours for a total of 72 hours. 
Colonyzer software measured the growth of each strain. The fitness, GIS and significance 
was calculated using QFA (as described in section 6.1.6). A negative GIS indicates sensitivity 
to 5-FU and a positive GIS indicates resistance to 5-FU.  
The QFA analysis generated fitness plots of the deletion library strains. The fitness plots for 
the screens at 200 µM and 400 µM generated by the QFA analyses are shown in Figure 44 
and Figure 45. Resistant strains are plotted above the trend line and have positive GIS value. 
Sensitive strains have a negative GIS value and are plotted below the trend line. 
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Figure 44. Fitness plot for the screen of the Bioneer genome wide deletion library screen at a 5-FU 
concentration of 200 µM. This graph shows a distinct cloud of strains (highlighted by black text and green 
markers) which have been found to be significantly sensitive to 5-FU at a concentration of 200 µM. This also 
shows a distinct cloud of mutants that have been found to be significantly resistant to 5-FU (highlighted by 
red markers and black text) at a concentration of 400 µM. 
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For both screens, distinct clouds of strains that are sensitive to 5-FU (highlighted by green 
markers) can be seen. Also, distinct clouds of strains for which 5-FU resistance was enhanced 
can be seen (as indicated by red markers). The lists of strains sensitive and resistant to 5-FU 
at 200µM and 400µM are similar, but with more strains identified at 400 µM. Due to this the 
results for the screen at 400 µM 5-FU were used for analysis. Full lists of strains identified as 
significantly sensitive or resistant at 400 µM 5-FU are shown in Table 41 and Table 42. 
Figure 45. Fitness plot for the Bioneer genome wide deletion library screen at a 5-FU concentration of 
400 µM. This graph shows a distinct cloud of strains (highlighted by black text and green markers) which 
have been found to be significantly sensitive to 5-FU at a concentration of 400 µM. This also shows a 
distinct cloud of mutants that have been found to be significantly resistant to 5-FU (highlighted by red 
markers and black text) at a concentration of 400 µM. 
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Table 41: Genes identified to sensitise to 5-FU when deleted in S. pombe (p<0.05) 
ORF Gene Product Human homolog P GIS 
SPCPB16A4.04C trm8 
tRNA (guanine-N7-)-methyltransferase 
catalytic subunit Trm8 
METTL1 0.0104 -0.0260 
SPAC17G6.04C cpp1 
Protein farnesyltransferase beta subunit 
Cpp1  
FNTB/         
CHURC1-FNTB 
0.0002 -0.0225 
SPAC16.04 dus3 tRNA Dihydrouridine Synthase Dus3 DUS3L 0.0104 -0.0209 
SPCC18.13 SPCC18.13 
tRNA (guanine-N7-)-methyltransferase 
subunit Trm82 (predicted)  
WDR4 0.0104 -0.0197 
SPCC4G3.11 mug154 Conserved Fungal Protein Unknown 0.0003 -0.0185 
SPAC18G6.13 SPAC18G6.13 Schizosaccharomyces specific protein  Unknown 0.0104 -0.0172 
SPAC57A10.10C sla1 La protein homolog  SSB 0.0104 -0.0165 
SPBC428.08C clr4 Histone H3 lysine methyltransferase Clr4 SUV39H1/SUV39H1 0.0404 -0.0164 
SPAC18G6.10 lem2 LEM domain protein Heh1/Lem2  LEMD2 0.0019 -0.0163 
SPAC17H9.10C ddb1 Damaged DNA binding protein Ddb1 DDB1 0.0070 -0.0159 
SPCC70.06 SPCC70.06 Nuclear export factor (predicted)  SAC3D1/MC3AP 0.0002 -0.0159 
SPBC11B10.10C pht1 Histone H2A variant H2A.Z, Pht1  H2AFV/H2AFZ 0.0104 -0.0159 
SPCC188.08C ubp22 Ubiquitin C-terminal hydrolase Ubp5  USP7 0.0002 -0.0158 
SPBC2D10.16 mhf1 
CENP-S ortholog, FANCM-MHF complex 
subunit Mhf1 
APITD 0.0002 -0.0155 
SPCC970.07C raf2 Rik1-associated factor Raf2  DNMT1 0.0003 -0.0146 
SPAC23H3.05C swd1 Set1C complex subunit Swd1  RBBP5 0.0379 -0.0145 
SPAC25A8.01C fft3 
SMARCAD1 family ATP-dependent DNA 
helicase Fft3  
SMARCAD1 0.0002 -0.0144 
SPCC1682.16 rpt4 
19S proteasome regulatory subunit Rpt4 
(predicted)  
PSMC6 0.0379 -0.0144 
SPAC1610.02C mrpl1 
Mitochondrial ribosomal protein subunit L1 
(predicted)  
MRPL1 0.0104 -0.0142 
SPBC337.13C gtr1 Gtr1/RagA G protein Gtr1 (predicted RRAGA/RRAGB 0.0104 -0.0142 
SPBC29A10.02 spo5 Meiotic RNA-binding  protein 1  
RBMS1/RBMS2/ 
RBMS3 
0.0002 -0.0140 
SPBC31F10.09C nut2 Mediator complex subunit Med10  MED10 0.0009 -0.0137 
SPAC31A2.14 bun107 
WD repeat protein, human WDR48 family 
Bun107  
WDR48 0.0104 -0.0136 
SPCC576.12C mhf2 
CENP-X homolog, FANCM-MHF complex 
subunit Mhf2  
STRA13 0.0104 -0.0134 
SPAC23D3.09 arp42 SWI/SNF and RSC complex subunit Arp42 ACTL6A/ATCL6B 0.0104 -0.0131 
SPCC1919.10C myo52 Myosin type V 
MYO5A/MYO5B/ 
MYO5C 
0.0104 -0.0123 
SPCC306.04C set1 Histone lysine methyltransferase Set1  SET1A/SET1B 0.0207 -0.0123 
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SPBC36B7.08C SPBC36B7.08c Nucleosome assembly protein (predicted)   SET 0.0019 -0.0122 
SPAC6B12.09 trm10 tRNA m(1)G methyltransferase Trm10 TRMT10A 0.0002 -0.0120 
SPBC119.12 rud3 Golgi matrix protein Rud3 (predicted) Unknown 0.0003 -0.0117 
SPBC21C3.20C git1 C2 domain protein Git1 Unknown 0.0104 -0.0116 
SPAC1F5.05C mso1 Endocytic docking protein Mso1 Unknown 0.0379 -0.0113 
SPAC57A10.08C SPAC57A10.08c 
Carboxylic ester hydrolase activity 
(predicted 
Unknown 0.0104 -0.0113 
SPAC12G12.13C cid14 Poly(A) polymerase Cid14  PAPD5/PAPD7 0.0104 -0.0113 
SPBC1198.11C reb1 
RNA polymerase I transcription termination 
factor/ RNA polymerase II transcription 
factor Reb1 
DMTF1 0.0002 -0.0110 
SPAC4G9.10 arg3 Ornithine carbamoyltransferase Arg3 OTC 0.0104 -0.0109 
SPCC550.14 vgl1 Vigilin (predicted) HDLBP 0.0070 -0.0107 
SPAC4C5.02C ryh1 GTPase Ryh1  
RAB6A/RAB6B/ 
RAB6C 
0.0148 -0.0107 
SPBC3B8.03 SPBC3B8.03 Saccharopine dehydrogenase (predicted)  AASS 0.0207 -0.0107 
SPBP8B7.23 rnf10 
Ubiquitin-protein ligase E3 implicated in 
transcription (predicted)  
RNF10 0.0070 -0.0106 
SPBC577.06C srt4 
1-phosphatidylinositol 4-kinase Stt4 
(predicted)  
PI4KA 0.0074 -0.0105 
SPAC3H5.11 SPAC3H5.11 NAD/NADH kinase (predicted) NADK 0.0002 -0.0104 
SPBC16A3.19 eaf7 
Histone acetyltransferase complex subunit 
Eaf7  
MRGBP 0.0148 -0.0102 
SPAC824.04 swd22 WD repeat protein (predicted)  WDR82 0.0006 -0.0101 
SPAC6C3.08 nas8 
Proteasome regulatory particle, gankyrin 
(predicted)  
PSMD10 0.0047 -0.0101 
SPBC21C3.02C dep1 Sds3-like family protein Dep1  
BRMS1/BRMS1L/ 
SUDS3 
0.0011 -0.0100 
SPBC14F5.10C SPBC14F5.10c Ubiquitin-protein ligase E3 (predicted)  
LONRF1/LONRF2/ 
LONRF3 
0.0030 -0.0100 
SPBC530.14C dsk1 SR protein-specific kinase Dsk1  
SPRK1/SPRK2/ 
SPRK3 
0.0070 -0.0100 
SPBC1709.14 SPBC1709.14 Peptide N-glycanase (predicted)  NGLY1 0.0011 -0.0098 
SPAC23H3.13C gpa2 
Heterotrimeric G protein alpha-2 subunit 
Gpa2  
Unknown 0.0003 -0.0098 
SPBC23E6.08 sat1 
Golgi membrane exchange factor subunit 
Sat1 (predicted)  
RGP1 0.0104 -0.0097 
SPAC11E3.01C swr1 
SNF2 family ATP-dependent DNA helicase 
Swr1  
EP400 0.0002 -0.0097 
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SPBC725.10 SPBC725.10 
Mitochondrial transport protein, tspO 
homolog (predicted)  
TSPO/TSPO2 0.0003 -0.0097 
SPBC3B8.10C nem1 
Nem1-Spo7 phosphatase complex catalytic 
subunit Nem1 (predicted) 
CTDNEP1 0.0104 -0.0095 
SPAC144.06 apl5 
AP-3 adaptor complex subunit Apl5 
(predicted)  
AP3D1 0.0104 -0.0094 
SPAC3G9.04 ssu72 Phosphoric ester hydrolase Ssu72 (predicted)  SSU72 0.0003 -0.0092 
SPBC3H7.12 rav2 RAVE complex subunit Rav2  ROGDI 0.0499 -0.0091 
SPCC23B6.03C tel1 ATM checkpoint kinase ATM 0.0006 -0.0091 
SPBC16G5.15C fkh2 Forkhead transcription factor Fkh2 Unknown 0.0006 -0.0090 
SPAC343.11C msc1 Multi-copy suppressor of Chk1 
KDMC5A/KDMC5B/
KDMC5C/KDMC5D 
0.0003 -0.0090 
SPAC12G12.12 gms2 
UDP-galactose transmembrane transporter 
Gms2 (predicted)  
SLC35F6 0.0030 -0.0090 
SPCC188.02 par1 Protein phosphatase regulatory subunit Par1 
PPP2R5A/PPP2R5B/ 
PPP2R5C/PPP2R5D/ 
PPPPR5E 
0.0002 -0.0089 
SPBC16C6.05 SPBC16C6.05 
Mitochondrial translation initiation factor 
(predicted)  
DENR 0.0006 -0.0088 
SPBC106.10 pka1 
cAMP-dependent protein kinase catalytic 
subunit Pka1  
PRKACA/PRKACB/ 
PRKACG/PRKX 
0.0002 -0.0087 
SPBC23G7.08C rga7 Rho-type GTPase activating protein Rga7  CHN1/CHN2 0.0047 -0.0087 
SPAC6G9.14 SPAC6G9.14 RNA-binding protein (predicted)  Unknown 0.0070 -0.0086 
SPAC4G9.14 sym1 
Mitochondrial Mpv17/PMP22 family protein 
2 (predicted)  
PXMP2 0.0011 -0.0086 
SPBC16H5.13 SPBC16H5.13 WD repeat protein, human WDR7 ortholog WDR7/WDR72 0.0207 -0.0085 
SPAC13A11.06 SPAC13A11.06 Pyruvate decarboxylase (predicted)  Unknown 0.0006 -0.0084 
SPBP4H10.17C SPBP4H10.17c Carboxyl methyl esterase (predicted)  PPME1 0.0281 -0.0084 
SPAC30D11.05 aps3 
AP-3 adaptor complex subunit Aps3 
(predicted)  
AP3S1/AP3S1 0.0281 -0.0083 
SPCC794.03 SPCC794.03 Amino acid permease (predicted) Unknown 0.0002 -0.0083 
SPBC18H10.15 ppk23 Serine/threonine protein kinase cdk11  CDK11B 0.0002 -0.0083 
SPBC16G5.02C rbk1 Ribokinase Rbk1 (predicted)  RBKS 0.0006 -0.0082 
SPAC13G7.07 arb2 Agonaute binding protein 2  
FAM172A/ 
FAM172BP 
0.0002 -0.0081 
SPAC4F10.20 grx1 Glutaredoxin Grx1 GLRX/GLRX2 0.0011 -0.0081 
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SPBC30B4.03C adn1 Adhesion defective protein  LDB1 0.0030 -0.0081 
SPBPB2B2.10C gal7 
Galactose-1-phosphate uridylyltransferase 
Gal7  
GALT 0.0104 -0.0079 
SPAC1296.02 cox4 Cytochrome c oxidase subunit IV (predicted)  COX5B 0.0047 -0.0079 
SPAC30D11.14C SPAC30D11.14c RNA-binding protein (predicted)  KIAA0907 0.0281 -0.0078 
SPBC106.07C SPBC106.07c 
N alpha-acetylation related protein Nat2 
(predicted)  
FAM210A/FAM210B 0.0104 -0.0078 
SPAC6G10.08 idp1 Isocitrate dehydrogenase Idp1 (predicted)  IDH1/IDH2 0.0104 -0.0077 
SPAC922.03 SPAC922.03 
1-aminocyclopropane-1-carboxylate 
deaminase (predicted)  
Unknown 0.0499 -0.0076 
SPAC26A3.09C rga2 Rho-type GTPase activating protein Rga2  CHN1/CHN2 0.0379 -0.0075 
SPBC577.11 SPBC577.11  DUF3074 family protein  Unknown 0.0019 -0.0075 
SPAC513.03 mfm2  M-factor precursor Mfm2 Unknown 0.0104 -0.0075 
SPAC57A10.12C ura3 Dihydroorotate dehydrogenase Ura3 DHODH 0.0148 -0.0074 
SPCC297.05 SPCC297.05 Diacylglycerol binding protein (predicted) Unknown 0.0104 -0.0073 
SPAC4G9.06C chz1 Histone chaperone Chz1 (predicted)  
CDY1/CDY2A/ 
CDYL2 
0.0070 -0.0073 
SPBC1778.09 SPBC1778.09 GTPase activating protein (predicted)  USP6NL 0.0104 -0.0073 
SPAC1486.04C alm1 Medial ring protein Alm1  Unknown 0.0104 -0.0072 
SPAC27D7.14C tpr1 
 RNA polymerase II associated Paf1 
complex subunit Tpr1  
CTR9 0.0009 -0.0071 
SPCC1223.11 ptc2 Protein phosphatase 2C Ptc2 PPM1G 0.0030 -0.0071 
SPCC162.01C SPCC162.01c 
U4/U6 x U5 tri-snRNP complex subunit 
(predicted)  
SNRNP27 0.0047 -0.0070 
SPBC2A9.11C iss9 Conserved eukaryotic protein  LENG8 0.0104 -0.0069 
SPBC31F10.12 tma20 RNA-binding protein Tma20 (predicted) MCTS1 0.0070 -0.0068 
SPBC1604.02C ppr1 Mitochondrial PPR repeat protein Ppr1  Unknown 0.0379 -0.0067 
SPCC126.08C SPCC126.08c 
Lectin family glycoprotein receptor 
(predicted)  
LMAN/LMAN2 0.0006 -0.0067 
SPAC694.02 SPAC694.02 DEAD/DEAH box helicase DDX60/DDX60L 0.0047 -0.0067 
SPBC776.15C kgd2 
Dihydrolipoamide S-succinyltransferase, e2 
component of oxoglutarate dehydrogenase 
complex Kdg2 (predicted)  
DLST2 0.0207 -0.0066 
SPBC21B10.13C yox1 MBF complex corepressor Yox1 Unknown 0.0047 -0.0066 
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SPBC1861.07 SPBC1861.07 elongin C (predicted)  TCEB1 0.0281 -0.0066 
SPAC4G8.05 ppk14 
Serine/threonine protein kinase Ppk14 
(predicted)  
Unknown 0.0019 -0.0065 
SPAC1296.04 mug65 
Spore wall assembly protein Mug65 
(predicted)  
Unknown 0.0006 -0.0064 
SPAC1782.09C clp1 
Cdc14-related protein phosphatase 
Clp1/Flp1 
CDC14A/CDC14B 0.0030 -0.0064 
SPAPB17E12.04
C 
csn2 COP9/signalosome complex subunit Csn2  COPS2 0.0070 -0.0064 
SPAC890.07C rmt1 
Type I protein arginine N-methyltransferase 
Rmt1  
PRMT1/PRMT8 0.0148 -0.0064 
SPAC26F1.05 mug106 
Schizosaccharomyces pombe specific protein 
Mug106  
UNknown 0.0030 -0.0063 
SPAC19G12.08 scs7 Sphingosine hydroxylase Scs7  FA2H 0.0104 -0.0063 
SPAC9.02C SPAC9.02c Polyamine N-acetyltransferase (predicted)   AANAT 0.0104 -0.0063 
SPAC31G5.18C sde2 Silencing defective protein Sde2  SDE2 0.0379 -0.0063 
SPCC736.08 cbf11 
CBF1/Su(H)/LAG-1 family transport factor 
Cbf11  
RBPJ/RBPJL 0.0499 -0.0063 
SPAC7D4.13C SPAC7D4.13c Schizosaccharomyces specific protein  Unknown 0.0499 -0.0063 
SPAC2F7.03C pom1 DYRK family protein kinase Pom1  
DYRK2/RYRK3/ 
DYRK4 
0.0281 -0.0062 
SPCC1393.10 ctr4 
Vacuolar copper transmembrane transporter 
Ctr6 
SLC31AC/SLC31A2 0.0499 -0.0061 
SPBC1105.10 rav1 RAVE complex subunit Rav1  DMXL1/DMXL2 0.0281 -0.0060 
SPBC1105.08 SPBC1105.08 EMP70 family  TM9SF2/TM9SF4 0.0047 -0.0059 
SPAC22H10.09 SPAC22H10.09 Schizosaccharomyces specific protein  Unknown 0.0379 -0.0059 
SPAC1142.08 fhl1 Forkhead transcription factor Fhl1  Unknown 0.0011 -0.0058 
SPCC1840.05C SPCC1840.05c Phosphoglucomutase (predicted)  PGM2/PGM2L1 0.0104 -0.0058 
SPBC29A10.16C SPBC29A10.16c Cytochrome b5 (predicted)  CYB5A/CYB5B 0.0499 -0.0057 
SPAC6C3.07 mug68 
Schizosaccharomyces specific protein 
Mug68  
Unknown 0.0499 -0.0057 
SPCC18B5.03 wee1 M phase inhibitor protein kinase Wee1 WEE1/WEE2 0.0207 -0.0057 
SPBC3H7.13 far10 
SIP/FAR complex FHA domain subunit 
Far10/Csc1  
SLMAP 0.0207 -0.0057 
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SPCC663.12 cid12 Poly(A) polymerase Cid12  Unknown 0.0207 -0.0056 
SPAC26A3.16 dph1 UBA domain protein Dph1 UBQLN1-4 0.0148 -0.0056 
SPAC23C4.08 rho3 Rho family GTPase Rho3  RHOA/RHOB/RHOC 0.0281 -0.0056 
SPAP27G11.10C nup184 Nucleoporin Nup184 NUP188 0.0379 -0.0056 
SPBC336.13C SPBC336.13c 
Mitochondrial inner membrane peptidase 
complex catalytic subunit 2 (predicted)  
IMMP2L 0.0148 -0.0055 
SPAC140.03 arb1 Argonaute inhibitor protein 1 Unknown 0.0499 -0.0054 
SPBC6B1.06C ubp14 Ubiquitin C-terminal hydrolase Ubp14  USP5 0.0379 -0.0054 
SPCC1223.15C spc19 DASH complex subunit Spc19 Unknown 0.0006 -0.0054 
SPCC1259.11C gyp2 GTPase activating protein Gyp2 (predicted)  
TBC1D8B/TBC1D9/ 
TBC1D9B 
0.0499 -0.0053 
SPBC651.09C prf1 
RNA polymerase II associated Paf1 complex 
(predicted)  
RTF1 0.0499 -0.0053 
SPBC2G2.06C apl1 
AP-2 adaptor complex subunit Apl1 
(predicted)  
AP1B1/AP2B1 0.0070 -0.0052 
SPAC56E4.07 SPAC56E4.07 N-acetyltransferase (predicted)  Unknown 0.0281 -0.0052 
SPAC20H4.07 rhp57 RecA family ATPase Rad57/Rhp57  XRCC3 0.0047 -0.0052 
SPCC1739.07 cti1 
Cut3 interacting protein Cti1, predicted 
exosome subunit  
C1D 0.0207 -0.0051 
SPCC594.06C vsl1 Vacuolar SNARE Vsl1/Vam7 STX8 0.0281 -0.0051 
SPCC553.08C ria1 GTPase Ria1 (predicted)  EFTUD1 0.0281 -0.0050 
SPAC17C9.02C lys7 
Alpha-aminoadipate reductase 
phosphopantetheinyl transferase Lys7  
AASDHPPT 0.0207 -0.0050 
SPAC2C4.05 cor1 Cornichon family protein (predicted)  
CNIH1/CNIH2/ 
CNIH3/CNIH4 
0.0003 -0.0050 
SPAP7G5.04C lys1 Aminoadipate-semialdehyde dehydrogenase   AASDH 0.0499 -0.0050 
SPAC18B11.04 ncs1 
Neuronal calcium sensor related protein 
Ncs1  
NCS1 0.0379 -0.0049 
SPBC1734.06 rhp18 
Rad18 homolog ubiquitin protein ligase E3, 
Rhp18  
RAD18 0.0104 -0.0048 
SPAC22H10.11C SPAC22H10.11c 
TOR signaling pathway transcriptional 
corepressor Crf1 (predicted)  
Unknown 0.0379 -0.0047 
SPBC23G7.16 ctr6 
Vacuolar copper transmembrane transporter 
Ctr6  
SLC31A1/SLC31A2 0.0281 -0.0047 
SPAPB17E12.08 eos1 N-glycosylation protein Eos1 (predicted) Unknown 0.0104 -0.0047 
SPAC1F7.09C SPAC1F7.09c Allantoicase (predicted)  ALLC 0.0379 -0.0047 
SPBC887.15C sur2 Sphingosine hydroxylase Sur2  Unknown 0.0030 -0.0046 
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SPAC13A11.04C ubp8 
SAGA complex ubiquitin C-terminal 
hydrolase Ubp8  
USP51 0.0207 -0.0046 
SPAC8C9.19 SPAC8C9.19 conserved fungal protein Unknown 0.0379 -0.0045 
SPBC21B10.08C SPBC21B10.08c 
Antibiotic biosynthesis monooxygenase-like 
domain (predicted)  
Unknown 0.0281 -0.0044 
SPAC24B11.10C chr3 
Chitin synthase regulatory factor-like Cfh1 
(predicted)  
Unknown 0.0499 -0.0044 
SPAC4A8.10 rog1 
Vacuolar membrane alkaline phosphatase 
(predicted)  
Unknown 0.0281 -0.0044 
SPAC56E4.06C ggt2 Gamma-glutamyltranspeptidase Ggt2  
GGT1/GGT2/GGT3P/
GGT5/GGTLC1-3 
0.0011 -0.0043 
SPAC6F6.01 cch1 Calcium channel Cch1  NALCN 0.0499 -0.0042 
SPAC22G7.06C ura1 
Carbamoyl-phosphate synthase (glutamine 
hydrolyzing), aspartate carbamoyltransferase 
Ura1  
CAD 0.0499 -0.0041 
SPBC29A3.05 vps71 Swr1 complex subunit Vps71 ZNHIT1 0.0070 -0.0041 
SPAC1783.05 hrp1 ATP-dependent DNA helicase Hrp1  CHD1/CHD2 0.0379 -0.0040 
SPCC11E10.08 rik1 Silencing protein Rik1  DDB1 0.0104 -0.0040 
SPCC1620.07C SPCC1620.07c Lunapark homolog Lnp1 KIAA1715 0.0104 -0.0039 
SPBC16C6.08C qcr6 
Ubiquinol-cytochrome-c reductase complex 
subunit 8, hinge protein (predicted)  
UQCRH 0.0148 -0.0039 
SPAC3H1.12C snt2 Lid2 complex subunit Snt2  Unknown 0.0207 -0.0039 
SPCC1259.09C pdx1 
Pyruvate dehydrogenase protein x 
component, Pdx1 (predicted)  
PDXP 0.0379 -0.0038 
SPBC32F12.07C SPBC32F12.07c 
Ubiquitin-protein ligase E3, MARCH family 
(predicted) 
MARCHH9 0.0499 -0.0037 
SPAC19A8.04 erg5 C-22 sterol desaturase Erg5 
CYP26A1/CYP26B1/
CYP26C1 
0.0030 -0.0037 
SPBC1734.12C alg12 
Dolichyl pyrophosphate Man7GlcNAc2 
alpha-1,6-mannosyltransferase Alg12 
(predicted)  
ALG12 0.0281 -0.0037 
SPAC1851.02 slc1 
1-acylglycerol-3-phosphate O-
acyltransferase Slc1 (predicted)  
AGPAT1/AGPAT2 0.0379 -0.0034 
SPAC227.11C yos9 
Sensor for misfolded ER glycoproteins Yos9 
(predicted) 
OS9/ERLEC1 0.0499 -0.0033 
SPAC110.02 pds5 Mitotic cohesin-associated protein Pds5  PDS5B 0.0207 -0.0033 
SPCC550.15C SPCC550.15c Ribosome biogenesis protein (predicted)  ZNF622 0.0104 -0.0032 
SPBC725.06C ppk31 
Serine/threonine protein kinase Ppk31 
(predicted)  
STK38/STK38L 0.0148 -0.0031 
SPCC576.01C xan1 
Alpha ketoglutarate dependent xanthine 
dioxygenase Xan1  
Unknown 0.0499 -0.0029 
SPAPB17E12.02 yip12 SMN family protein Yip12  GEMIN2 0.0281 -0.0029 
SPAC1783.01 SPAC1783.01 Methionine synthase reductase (predicted)  MTRR 0.0499 -0.0029 
SPAC17G8.05 med20 Mediator complex subunit Med20 MED20 0.0180 -0.0028 
SPAC8E11.07C alp31 
Tubulin specific chaperone cofactor A, 
Alp31 
TBCA 0.0006 -0.0013 
SPAC688.11 end4 Huntingtin-interacting protein homolog HIP1/HIP1R 0.0046 -0.0007 
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SPCC31H12.03C tho1 RNA binding protein (predicted) SARNP 0.0249 -0.0005 
SPAC16A10.05c dad1 DASH complex subunit Dad1 Unknown 0.0128 -0.0003 
 
Table 41: Genes identified by the screen of the S. pombe genome wide deletion library to 
sensitise to 5-FU when deleted (p<0.05). These tables shows the open reading frames 
(ORFs), gene, the product encoded by the gene and the name of any known human homologs. 
The tables are sorted by GIS (in ascending order), then by p value (in ascending order).   
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Table 42: Genes found to confer resistance to 5-FU when deleted in S. pombe cells 
ORF Gene Product Human Homologue P GIS 
SPAC29B12.04 snz1 Pyridoxine biosynthesis protein  SNZ1/SNZ2/SNZ3 0.0002 0.0154 
SPBC4F6.08C mrpl39 
Mitochondrial ribosomal protein subunit L39 
(predicted)  
MRPL33 0.0002 0.0146 
SPAC1B3.01C SPAC1B3.01c Uracil phosphoribosyltransferase (predicted)  UCK1/UCK2/UCKL1 0.0002 0.0141 
SPAC11G7.02 pub1 HECT-type ubiquitin-protein ligase E3 Pub1  NEDD4/NEDD4L 0.0002 0.0139 
SPCC162.11C SPCC162.11c 
Uridine kinase/uracil 
phosphoribosyltransferase (predicted)  
UCKL1 0.0011 0.0127 
SPAC3F10.17 SPAC3F10.17 
 Ribosome biogenesis protein Ltv1 
(predicted)  
LTV1 0.0002 0.0121 
SPAC2F3.11 SPAC2F3.11 Exopolyphosphatase (predicted)  PRUNE/PRUNE2 0.0002 0.0115 
SPBC36.07 iki3 Elongator subunit Elp1 (predicted) IKBKAP 0.0002 0.0113 
SPBC3H7.10 elp6 Elongator complex subunit Elp6 (predicted)  ELP6 0.0047 0.0111 
SPCC584.01C SPCC584.01c 
Sulfite reductase NADPH flavoprotein 
subunit (predicted)  
Unknown 0.0002 0.0110 
SPCC1235.13 ght6 Hexose transmembrane transporter Ght6 Unknown 0.0030 0.0108 
SPAC1250.03 ubc14 
Ubiquitin conjugating enzyme E2 Ubc14 
(predicted)  
Unknown 0.0002 0.0105 
SPBC776.04 sec2302 
COPII cargo receptor subunit Sec23b 
(predicted)  
SEC23A/SEC23B 0.0030 0.0105 
SPBP22H7.06 SPBP22H7.06 Nicotinamide riboside kinase (predicted) NMRK1/NMRK2 0.0003 0.0101 
SPAC6G10.06 SPAC6G10.06 
FAD-dependent amino acid oxidase 
involved in late endosome to Golgi transport 
(predicted)  
Unknown 0.0011 0.0099 
SPBC30D10.03C SPBC30D10.03c IMP 5'-nucleotidase (predicted) Unknown 0.0019 0.0099 
SPBC106.04 ada1 Adenosine deaminase Ada1 AMPD1-3 0.0003 0.0099 
SPAC23G3.04 ies2 Ino80 complex subunit Ies4  Unknown 0.0019 0.0093 
SPAC11D3.13 hsp3104 Thij domain protein Unknown 0.0379 0.0093 
SPAC1687.10 mcp1 Microtubule binding protein Mcp1  PRC1 0.0002 0.0090 
SPBC16H5.09C omh2 
Alpha-1,2-mannosyltransferase Omh2 
(predicted) 
Unknown 0.0006 0.0089 
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SPAC222.08C sno1 
Glutamine aminotransferase subunit Sno1 
(predicted)  
Unknown 0.0003 0.0089 
SPBC3B9.09 vps36 ESCRT II complex subunit Vps36  VPS36 0.0207 0.0086 
SPAC25G10.09C pan1 
Actin cortical patch component, with EF 
hand and WH2 motif Panl (predicted)  
ITSN1/ITSN2 0.0030 0.0085 
SPAC5D6.10C mug116 
Schizosaccharomyces pombe specific protein 
Mug116  
Unknown 0.0379 0.0085 
SPCC736.07C uri1 
Unconventional prefoldin chaperone 
involved protein complex assembly Uri1 
(predicted)  
URI1 0.0011 0.0085 
SPAC11D3.04C SPAC11D3.04c Polyketide cyclase snoal-like domain protein  Unknown 0.0281 0.0084 
SPCC1672.09 SPCC1672.09 
Triglyceride lipase-cholesterol esterase 
(predicted)  
LIPA/LIPF/LIPJ/ 
LIPK/LIPM 
0.0104 0.0083 
SPBC685.02 exo5 
Mitochondrial single stranded DNA specific 
5'-3' exodeoxyribonuclease Exo5 (predicted)  
EXO5 0.0281 0.0083 
SPAC57A10.09C nhp6 
High-mobility group non-histone chromatin 
protein (predicted)  
SSRP1 0.0030 0.0082 
SPAC1834.07 klp3 Kinesin-like protein Klp3 KIF5B 0.0011 0.0081 
SPAC4D7.06C met8 Siroheme synthase Met8 (predicted) Unknown 0.0002 0.0080 
SPAC1805.05 cki1 Serine/threonine protein kinase Cki3  
CSNK1G1/CSNK1G2
/CSNK1G3 
0.0104 0.0080 
SPBC119.08 pmk1 MAP kinase Pmk1  MAPK7 0.0002 0.0080 
SPAC15A10.15 sgo2 Inner centromere protein, shugoshin Sgo2  SGOL1 0.0047 0.0080 
SPBC725.04 SPBC725.04 Oxalyl-coa coA decarboxylase (predicted)  ILVBL 0.0011 0.0079 
SPBC11C11.10 SPBC11C11.10 tRNA pseudouridine synthase (predicted)  TRUB1 0.0379 0.0079 
SPAP7G5.03 prm1  Conjugation protein Prm1  Unknown 0.0148 0.0078 
SPAC4H3.05 srs2 
ATP-dependent DNA helicase, uvrd 
subfamily 
Unknown 0.0030 0.0078 
SPBC26H8.01 thi2 Thiazole biosynthetic enzyme THI4 0.0070 0.0077 
SPAC8E11.06 SPAC8E11.06 Schizosaccharomyces pombe specific protein  Unknown 0.0207 0.0076 
SPCC16C4.11 pef1 
Pho85/phoa-like cyclin-dependent kinase 
Pef1 
CDK5 0.0030 0.0076 
SPAC1250.04C atl1 Alkyltransferase-like protein Atl1  MGMT 0.0030 0.0076 
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SPBC27.06C mgr2 
Mitochondrial membrane protein Mgr2 
(predicted)  
ROMO1 0.0002 0.0076 
SPBC21B10.06C inp2 
Myosin binding vezatin family protein 
involved in peroxisome inheritance Inp2 
(predicted)  
VEZT 0.0030 0.0076 
SPAP27G11.12 SPAP27G11.12 Human HID1 ortholog 1  HID1 0.0070 0.0075 
SPBC19G7.17 SPBC19G7.17 
Translocon subunit Sec61 homolog 
(predicted)  
SEC61A1/SEC61A2 0.0047 0.0074 
SPAC29E6.07 SPAC29E6.07 Schizosaccharomyces pombe specific protein  Unknown 0.0070 0.0074 
SPBPB2B2.07C SPBPB2B2.07c S. pombe specific duf999 protein family 7  Unknown 0.0047 0.0074 
SPAC694.05C rps2502 40S ribosomal protein S25 (predicted) RPS25 0.0070 0.0074 
SPAC4A8.14 prs1 
Ribose-phosphate pyrophosphokinase 
(predicted)  
PRPSAP1/PRPSAP2 0.0030 0.0074 
SPCC285.10C SPCC285.10c SPRY domain protein  Unknown 0.0002 0.0073 
SPAPB1A10.08 SPAPB1A10.08 Schizosaccharomyces specific protein  Unknown 0.0207 0.0073 
SPAC23H4.09 cdb4 
Curved DNA-binding protein Cdb4, 
peptidase family  
PA2G4 0.0281 0.0073 
SPBP23A10.05 ssr4 SWI/SNF and RSC complex subunit Ssr4  Unknown 0.0003 0.0073 
SPBC651.06 mug166 
Schizosaccharomyces specific protein 
Mug166  
Unknown 0.0281 0.0072 
SPAC2H10.02C nas3 
26S proteasome regulatory particle assembly 
protein Nas2 (predicted)  
PSMD9 0.0207 0.0072 
SPAC22G7.02 kap111 Karyopherin Kap111 (predicted) IPO13 0.0006 0.0072 
SPCC1494.01 SPCC1494.01 Iron/ascorbate oxidoreductase family  Unknown 0.0047 0.0071 
SPBC21H7.06C opi10 Hikeshi protein, Opi10  C11orf73 0.0148 0.0071 
SPBC215.14C vps20 ESCRT III complex subunit Vps20  CHMP6 0.0070 0.0071 
SPBC27B12.11C pho7 Transcription factor Pho7  Unknown 0.0148 0.0071 
SPCC417.11C SPCC417.11c 
Glutamate-1-semialdehyde 2,1-aminomutase 
(predicted)  
Unknown 0.0207 0.0070 
SPAC11D3.01C SPAC11D3.01c Conserved fungal protein  Unknown 0.0047 0.0070 
SPAC1071.12C stp1 Protein tyrosine phosphatase Stp1 ACP1 0.0281 0.0070 
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SPAC1B3.03C wis2 
Cyclophilin family peptidyl-prolyl cis-trans 
isomerase Wis2  
PPID 0.0011 0.0070 
SPAC22A12.04C rps2201 40S ribosomal protein S15a (predicted)  RPS15A 0.0148 0.0069 
SPAC2E1P3.05C SPAC2E1P3.05c Fungal cellulose binding domain protein Unknown 0.0104 0.0069 
SPAC26H5.03 pcf2 
CAF assembly factor (CAF-1) complex 
subunit B, Pcf2  
CHAF1B 0.0011 0.0068 
SPBC25B2.03 SPBC25B2.03 Zf-C3HC4 type zinc finger  Unknown 0.0148 0.0068 
SPBC23G7.14 SPBC23G7.14 Schizosaccharomyces specific protein Unknown 0.0379 0.0068 
SPBC14C8.03 fma2 
Methionine aminopeptidase Fma2 
(predicted) 
METAP2 0.0379 0.0068 
SPBC530.04 mod5 Tea1 anchoring protein Mod5  Unknown 0.0003 0.0068 
SPCC1442.11C SPCC1442.11c 
Schizosaccharomyces pombe specific 
protein  
Unknown 0.0002 0.0067 
SPBC8E4.05C SPBC8E4.05c Fumarate lyase superfamily  Unknown 0.0104 0.0067 
SPBC17D11.08 SPBC17D11.08 
WD repeat protein, DDB1 and CUL4-
associated factor 7 (predicted) 
DCAF7 0.0047 0.0067 
SPAC6G9.16C xrc4 
XRCC4 nonhomologous end joining factor 
Xrc4 
XRCC4 0.0148 0.0067 
SPAC3H5.09C SPAC3H5.09c 
Conserved eukaryotic mitochondrial protein 
(predicted)  
KIAA0100 0.0207 0.0066 
SPAC1556.04C cdd1 Cytidine deaminase Ccd1 (predicted)  CDA 0.0104 0.0066 
SPCC1393.13 SPCC1393.13 DUF89 family protein  C6orf211 0.0047 0.0066 
SPAC2G11.10C uba42 
Thiosulfate sulfurtransferase, URM1 
activating enzyme E1-type Uba42 
(predicted)  
MOCS3 0.0011 0.0066 
SPAC5D6.06C alg14 
UDP-glcnac transferase associated protein 
Alg14 (predicted)  
ALG15 0.0070 0.0066 
SPAC31G5.12C maf1 Repressor of RNA polymerase III Maf1 MAF1 0.0104 0.0066 
SPCC1620.03 mug163 Conserved eukaryotic protein, mitochondrial  C6orf136 0.0148 0.0066 
SPBC18E5.07 SPBC18E5.07 DUF3210 family protein  Unknown 0.0379 0.0065 
SPAC1F5.03C SPAC1F5.03c 
FAD-dependent oxidoreductase involved in 
late endosome to Golgi transport (predicted)  
Unknown 0.0019 0.0065 
SPAC144.14 klp8 Kinesin-like protein Klp8 
KIF1A/KIF1C/ 
KIF13A/KIF13B/ 
KIF14/ KIF16B 
0.0281 0.0064 
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SPAC11H11.01 sst6 ESCRT I complex subunit Vps23  TSG101 0.0499 0.0064 
SPAC3F10.18C rpl4102 60S ribosomal protein L41 (predicted)  RPL41A/RPL41B 0.0281 0.0063 
SPCC1183.06 ung1 Uracil DNA N-glycosylase Ung1  UNG 0.0379 0.0063 
SPCC16A11.07 coq10 
Mitochondrial ubiquinone binding protein 
Coq10  
COQ10A/COQ10B 0.0207 0.0063 
SPAC17G6.05C bro1 BRO1 domain protein Bro1 (predicted)  
RHPN1/RHPN2/ 
PTPN23/PDCD6IP 
0.0104 0.0063 
SPAC8F11.05C mug130 Schizosaccharomyces specific protein  Unknown 0.0047 0.0062 
SPAC26F1.12C ghg1 Conserved eukaryotic protein Hgh1 HGH1 0.0148 0.0062 
SPBC19C7.10 bqt4 Bouquet formation protein Bqt4  Unknown 0.0104 0.0062 
SPBC16E9.06C uvi31 Bola domain UV induced protein Uvi31 BOLA1 0.0499 0.0061 
SPBC27.08C sua1 Sulfate adenylyltransferase  PAPSS1/PAPSS2 0.0207 0.0061 
SPAC10F6.08C nht10 
Ino80 complex HMG box subunit Nhp10 
(predicted)  
NHP10 0.0011 0.0061 
SPAC4H3.01 SPAC4H3.01 
DNAJ domain protein Caj1/Djp1 type 
(predicted)  
Unknown 0.0207 0.0061 
SPAC23H3.04 SPAC23H3.04 Conserved fungal protein  Unknown 0.0104 0.0061 
SPAC1F7.06 hsp3105 Thij domain protein  Unknown 0.0148 0.0061 
SPBC2G2.10C mug110 
Schizosaccharomyces specific protein 
Mug110  
Unknown 0.0281 0.0061 
SPBC3B8.08 SPBC3B8.08 
Sjögren's syndrome/scleroderma autoantigen 
1 family (predicted)  
SSSCA1 0.0379 0.0061 
SPAC17G8.06C SPAC17G8.06c Dihydroxy-acid dehydratase (predicted)  Unknown 0.0047 0.0061 
SPBP8B7.27 mug30 
HECT-type ubiquitin-protein ligase E3 
(predicted)  
HECTD2 0.0019 0.0060 
SPCC1259.01C rps1802 40S ribosomal protein S18 (predicted)  RPS18 0.0006 0.0060 
SPAC13F5.07C hpz1 Zf PARP type zinc finger protein Hpz2  Unknown 0.0281 0.0060 
SPBC25H2.05 egd2 
Nascent polypeptide-associated complex 
alpha subunit Egd2  
NACA 0.0011 0.0059 
SPAC3A11.14C pkl1 Kinesin-like protein Pkl1  KIFC1 0.0207 0.0059 
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SPAC13C5.02 dre4 Splicing associated factor Dre4  PRPF40A/PRF40B 0.0207 0.0059 
SPBC27B12.14 SPBC27B12.14 
Mitochondrial membrane protein complex 
assembly protein (predicted)  
Unknown 0.0148 0.0059 
SPBC19F5.01C puc1 Cyclin Puc1  Unknown 0.0104 0.0059 
SPAC17H9.12C SPAC17H9.12c 
Mitochondrial cytochrome c-heme linkage 
protein Cyc2 (predicted)  
CYB5RL 0.0070 0.0059 
SPBC14C8.15 SPBC14C8.15 
Triglyceride lipase-cholesterol esterase 
(predicted)  
LIPA/LIPF/LIPJ/ 
LIPK/LIPM 
0.0104 0.0059 
SPAC2E1P5.02C mug109 
Rab GTPase binding protein upregulated in 
meiosis II (predicted)  
Unknown 0.0499 0.0058 
SPBC1347.09 SPBC1347.09 
Hexaprenyldihydroxybenzoate 
methyltransferase, Coq3 variant (predicted)  
COQ3 0.0499 0.0058 
SPBC1778.02 rap1 Telomere binding protein Rap1  TERF2IP 0.0104 0.0058 
SPAC4F8.01 did4 ESCRT III complex subunit Did4  CHMP2A 0.0499 0.0058 
SPBC25B2.08 SPBC25B2.08 
Schizosaccharomyces pombe specific 
protein  
Unknown 0.0207 0.0058 
SPAC8C9.07 SPAC8C9.07 rRNA processing protein Fyv7 (predicted)  CCDC59 0.0011 0.0058 
SPAC17G8.14C pck1 Protein kinase C (PKC)-like Pck1  
PRKCA/PRKCB/ 
PRKCD/PRKCDE/ 
PRKCH/PRKCQ 
0.0030 0.0058 
SPCC1322.16 phb2 Prohibitin Phb2 (predicted) PHB2 0.0379 0.0058 
SPAC6G10.11C ubi3 
Ribosomal-ubiquitin fusion protein Ubi3 
(predicted)  
RPS27A 0.0019 0.0057 
SPBC25H2.14 mug16 UNC-50 family protein  UNC50 0.0148 0.0057 
SPBC1105.04C cbp1 CENP-B homolog  
JRKL/CENPB /              
TIGD1-7 
0.0379 0.0057 
SPAC607.07C SPAC607.07c Schizosaccharomyces specific protein  Unknown 0.0148 0.0057 
SPBC106.13 SPBC106.13 
Ubiquitin ligase complex subunit, involved 
in proteasome-dependent catabolite 
inactivation of fbpase (predicted)  
MAEA 0.0281 0.0057 
SPAC12B10.10 nod1 
Medial cortical node Gef2-related protein 
protein Nod1  
Unknown 0.0379 0.0057 
SPCP31B10.06 mug190 C2 domain protein  
ESYT1/ESYT2/ 
ESYT3 
0.0104 0.0057 
SPAC4F10.06 bud22 
Ribosome small subunit biogenesis protein, 
BUD22 family (predicted)  
SRFBP1 0.0104 0.0056 
SPAC16C9.06C upf1 ATP-dependent RNA helicase Upf1  UPF1 0.0006 0.0056 
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SPBC11C11.09C rpl502 60S ribosomal protein L5  RPL5 0.0148 0.0056 
SPBC19C2.13C ctu2 Cytosolic thiouridylase subunit Ctu2 CTU1 0.0148 0.0056 
SPCC1739.05 set5 
Histone lysine methyltransferase Set5 
(predicted)  
Unknown 0.0070 0.0056 
SPBC839.03C SPBC839.03c Neddylation protein Dcn1 (predicted)  DCUN1D1 0.0207 0.0056 
SPAPB1A11.02 SPAPB1A11.02 Esterase/lipase (predicted)  
AADAC/AADACL2/
AADACL3/ 
AADACL4/NCEH1 
0.0207 0.0056 
SPBC1778.10C ppk21 Serine/threonine protein kinase Ppk21  PDPK1 0.0070 0.0056 
SPAC3G9.11C SPAC3G9.11c Pyruvate decarboxylase (predicted)  Unknown 0.0003 0.0055 
SPBPB10D8.05C SPBPB10D8.05c Transmembrane transporter (predicted) Unknown 0.0148 0.0055 
SPAC11E3.08C nse6 Smc5-6 complex non-SMC subunit Nse6  Unknown 0.0002 0.0055 
SPAC22E12.18 SPAC22E12.18 Conserved fungal protein  Unknown 0.0047 0.0055 
SPAC1A6.06C meu31 
Schizosaccharomyces specific protein 
Meu31  
Unknown 0.0281 0.0055 
SPAC4F10.17 SPAC4F10.17 Conserved fungal protein Unknown 0.0104 0.0055 
SPAC31G5.07 dni1 Tetraspan protein Dni1 Unknown 0.0379 0.0055 
SPCC794.02 wtf5 Wtf element Wtf5 Unknown 0.0207 0.0054 
SPBC685.03 SPBC685.03 Schizosaccharomyces specific protein  Unknown 0.0379 0.0054 
SPCC1742.01 gsf2 Galactose-specific flocculin Gsf2  Unknown 0.0379 0.0054 
SPAC27D7.05C apc14 
Anaphase-promoting complex subunit 
Apc14  
Unknown 0.0207 0.0053 
SPBC21B10.04C nrf1 GTPtpase regulator Nrf1  Unknown 0.0047 0.0053 
SPBC1709.04C cyp3 
Cyclophilin family peptidyl-prolyl cis- trans 
isomerase Cyp3  
PPIH 0.0006 0.0053 
SPCC970.05 rpl3601 60S ribosomal protein L36  RPL36 0.0006 0.0053 
SPBC428.07 meu6 
Meiotic chromosome segregation protein 
Meu6  
Unknown 0.0207 0.0053 
SPCC737.05 SPCC737.05 Peroxin Pex28/29 (predicted)  Unknown 0.0019 0.0053 
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SPBPJ4664.05 SPBPJ4664.05 Conserved fungal protein  Unknown 0.0379 0.0053 
SPAC1687.05 pli1 SUMO E3 ligase Pli1  PIAS1-4 0.0281 0.0053 
SPAC25G10.06 rps2801 40S ribosomal protein S28 (predicted)  RPS28 0.0281 0.0053 
SPBC800.10C SPBC800.10c 
EPS15 repeat family actin cortical patch 
component (predicted)  
EPS15/EPS15L1 0.0148 0.0053 
SPBC83.18C fic1 C2 domain protein Fic1  Unknown 0.0148 0.0052 
SPBC651.07 csa1 
Schizosaccharomyces specific protein 
Mug166  
Unknown 0.0499 0.0052 
SPCC1739.15 wtf21 Wtf element Wtf21  Unknown 0.0207 0.0052 
SPAC9E9.13 wos2 p23 homolog, predicted co-chaperone Wos2  PTGES3 0.0148 0.0052 
SPCC548.04 urm1 Ubiquitin family protein Urm1 (predicted URM1 0.0104 0.0052 
SPAC458.06 atg1803 
WD repeat protein involved in autophagy 
Atg18c 
WDR45/WDR45B 0.0281 0.0052 
SPAC23H4.16C SPAC23H4.16c Schizosaccharomyces specific protein  Unknown 0.0148 0.0052 
SPCC569.04 SPCC569.04 Schizosaccharomyces pombe specific protein  Unknown 0.0104 0.0052 
SPBC409.03 swi5 Swi5 protein  SWI5 0.0499 0.0051 
SPCC777.02 SPCC777.02 Transcription factor (predicted)  Unknown 0.0070 0.0051 
SPAC14C4.13 rad17 RFC related checkpoint protein Rad17  RAD17 0.0030 0.0051 
SPBC25B2.04C mtg1 
Mitochondrial GTPase involved in 
translation Mtg1 (predicted)  
MTG1 0.0030 0.0051 
SPCP1E11.03 mug170 
Arrestin family Schizosaccharomyces 
specific protein Mug170  
Unknown 0.0070 0.0051 
SPBPB10D8.02C SPBPB10D8.02c Arylsulfatase (predicted)  
ARSA/ARSB/ARSD/ 
ARSE/ARSF/ARSG/ 
ARSH/ARSI/ARSJ/ 
GALNS/STS 
0.0047 0.0051 
SPAC823.13C SPAC823.13c 
Mitochondrial inner membrane protein 
(predicted)  
Unknown 0.0047 0.0051 
SPBC29A10.05 exo1 Exonuclease I Exo1  EXO1 0.0148 0.0051 
SPAC27E2.07 pvg2 Galactose residue biosynthesis protein Pvg2  Unknown 0.0281 0.0050 
SPAC12G12.11C SPAC12G12.11c DUF544 family protein  FAM63A/FAM63B 0.0104 0.0050 
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SPAP8A3.04C hsp9 Heat shock protein Hsp9  Unknown 0.0148 0.0050 
SPAPB8E5.05 mfm1 M-factor precursor Mfm1  Unknown 0.0104 0.0050 
SPBC106.08C mug2 Mug2/mug135/meu2 family  Unknown 0.0499 0.0050 
SPAPJ695.01C SPAPJ695.01c S. pombe specific upf0321 family protein 3  Unknown 0.0148 0.0050 
SPAC9.06C SPAC9.06c 
5'-methylthioribulose-1-phosphate 
dehydratase, adducin (predicted)  
APIP 0.0148 0.0050 
SPAC57A7.08 pzh1 Serine/threonine protein phosphatase Pzh1  Unknown 0.0148 0.0050 
SPAC25G10.02 cce1 
Mitochondrial cruciform cutting 
endonuclease Cce1  
Unknown 0.0281 0.0050 
SPBC29A3.10C atp14 F1-ATPatpase subunit H (predicted) Unknown 0.0148 0.0050 
SPBP35G2.06C nup131 Nucleoporin Nup131  NUP133/NUP155 0.0070 0.0049 
SPCC70.02C SPCC70.02c Mitochondrial ATPase inhibitor (predicted)  ATPIF1 0.0207 0.0049 
SPAC15A10.08 ain1 Alpha-actinin  
ACTN1/ACTN2/ 
ACTN4 
0.0207 0.0049 
SPAC19B12.10 sst2 
Human AMSH/STAMBP protein homolog, 
ubiquitin specific-protease  
STAMBP 0.0047 0.0048 
SPBC25B2.01 SPBC25B2.01 
Elongation factor 1 alpha related protein 
(predicted)  
HBS1L 0.0281 0.0048 
SPCC622.19 jmj4 Jmj4 protein (predicted)  Unknown 0.0148 0.0048 
SPAC2G11.12 rqh1 RecQ type DNA helicase Rqh1  WRN/BLM 0.0011 0.0048 
SPAC1F7.12 yak3 Aldose reductase ARK13 family yakc  Unknown 0.0499 0.0048 
SPBC713.05 SPBC713.05 
WD repeat protein, human MAPK organizer 
1 (MORG1) family (predicted)  
WDR83 0.0207 0.0048 
SPAC24B11.08C SPAC24B11.08c 
 COPII-coated vesicle component Erv46 
(predicted)  
ERGIC3 0.0104 0.0047 
SPAC12B10.15C SPAC12B10.15c 
 Ribonuclease H2 complex subunit 
(predicted)  
RNASEH2C 0.0379 0.0047 
SPAC22E12.04 ccs1 
Superoxide dismutase copper chaperone 
Ccs1  
CCS 0.0499 0.0047 
SPBC19F8.02 nud3 Nuclear distribution protein NUDC homolog  NUDC 0.0047 0.0047 
SPBC12C2.05C bzz1 
 Diacylglycerol binding protein Bzz1 
(predicted)  
FNBP1/TRIP10/ 
FNBP1L 
0.0499 0.0047 
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SPBC15D4.12C mug98 
Schizosaccharomyces specific protein 
Mug98  
Unknown 0.0207 0.0047 
SPAC1952.03 otu2 
Ubiquitin specific cysteine protease, OTU 
family, Otu2  
OTUD6A/OTUD6B 0.0379 0.0046 
SPAC144.11 rps1102 40S ribosomal protein S11 (predicted)  RPS11 0.0148 0.0046 
SPAC26A3.11 SPAC26A3.11 Amidohydrolase (predicted) NIT2 0.0104 0.0046 
SPBC106.11C plg7 Phospholipase A2, PAF family homolog  PLA2G7/PAFAH2 0.0379 0.0046 
SPAC10F6.13C SPAC10F6.13c Aspartate aminotransferase (predicted) GOT1/GOTL1 0.0019 0.0045 
SPAC56F8.14C mug115 
Schizosaccharomyces pombe specific protein 
Mug115  
Unknown 0.0148 0.0045 
SPBC29A10.14 rec8 Meiotic cohesin complex subunit Rec8  REC8 0.0148 0.0045 
SPCC24B10.12 cgi121 
EKC/KEOPS complex subunit Cgi121 
(predicted)  
TPRKB 0.0281 0.0045 
SPBC776.11 rpl2801 60S ribosomal protein L27/L28  RPL27A 0.0379 0.0045 
SPBP35G2.07 ilv1 Acetolactate synthase catalytic subunit  Unknown 0.0006 0.0044 
SPBC1711.13 his2 Histidinol dehydrogenase His2 (predicted)  Unknown 0.0207 0.0044 
SPAC1687.14C SPAC1687.14c EF hand family protein, unknown role  
CETN1/CETN2/ 
CETN3 
0.0047 0.0044 
SPAC32A11.01 mug8 Conserved fungal protein  Unknown 0.0104 0.0044 
SPBC15D4.03 slm9 Hira protein Slm9  HIRA 0.0379 0.0044 
SPBC646.15C pex16 
Pex16 family peroxisome import protein 
Pex16 (predicted)  
PEX16 0.0499 0.0044 
SPAC23D3.03C SPAC23D3.03c GTPase activating protein (predicted) TBC1D12/TBC1D14 0.0104 0.0043 
SPAC11G7.04 ubi1 
Ribosomal-ubiquitin fusion protein Ubi1 
(predicted)  
UBA52 0.0047 0.0043 
SPAC328.06 ubp2 Ubiquitin C-terminal hydrolase Ubp2  Unknown 0.0207 0.0043 
SPAC26A3.06 bud23 
rRNA (guanine) methyltransferase Bud23 
(predicted)  
WBSCR22 0.0281 0.0043 
SPAC25B8.07C rcf1 
Cytochrome c oxidase assembly protein 
Rcf1  
HIGD1A/HIGD1B/ 
HIGD1C/HIGD2A/ 
HIGD2B 
0.0207 0.0043 
SPAC5H10.01 SPAC5H10.01 DUF1445 family protein  C14orf159 0.0104 0.0043 
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SPAC1250.02 mug95 
Schizosaccharomyces specific protein 
Mug95  
Unknown 0.0379 0.0043 
SPAC22F8.11 plc1 Phosphoinositide phospholipase C Plc1  
PLCB1/PLCB2/ 
PLCB3/PLCD1/ 
PLCD3/PLCD4/ 
PLCG1/PLCG2/ 
PLCH1/PLCH2/ 
PLCL1/PLCL2 
0.0499 0.0043 
SPAC3F10.06C rit1 
Initiator methionine tRNA 2'-O-ribosyl 
phosphate transferase (predicted)  
Unknown 0.0207 0.0043 
SPAC4F8.08 mug114 
Schizosaccharomyces pombe specific protein 
Mug114  
Unknown 0.0281 0.0043 
SPAC2G11.04 SPAC2G11.04 
RNA-binding protein, G-patch type, splicing 
factor 45 ortholog (predicted)  
RBM17 0.0030 0.0042 
SPBC3E7.10 fma1 
Methionine aminopeptidase Fma1 
(predicted)  
METAP1 0.0148 0.0042 
SPBC1711.11 SPBC1711.11 Autophagy associated protein (predicted)  SNX4/SNX7/SNX30 0.0379 0.0042 
SPBC28E12.06C lvs1 Beige protein homolog Lvs1 (predicted)  WDFY3/WDFY4 0.0499 0.0042 
SPAC25H1.02 jmj1 Histone demethylase Jmj1 (predicted)  JMJD4 0.0281 0.0042 
SPAC11E3.11C syt22 Guanyl-nucleotide exchange factor Syt22  
PSD/PSD2/PSD3/ 
PSD4 
0.0002 0.0042 
SPAC1952.07 rad1 Checkpoint clamp complex protein Rad1 RAD1 0.0499 0.0042 
SPAC664.12C SPAC664.12c 
Mitochondrial succinate dehydrogenase 
assembly factor 1 (predicted)  
SDHAF1 0.0207 0.0042 
SPAP8A3.14C sls1 
Mitochondrial inner membrane protein Sls1 
(predicted)  
Unknown 0.0207 0.0042 
SPCC584.11C SPCC584.11c Svf1 family protein Svf1  Unknown 0.0281 0.0042 
SPBC1289.15 pfl5 Cell surface glycoprotein (predicted)  Unknown 0.0207 0.0042 
SPCC320.07C mde7 RNA-binding protein Mde7  RBPMS 0.0379 0.0041 
SPAC1399.05C toe1 
Transcription factor, zf-fungal binuclear 
cluster type  
Unknown 0.0281 0.0041 
SPCC1281.08 wtf11 Wtf element Wtf11 Unknown 0.0499 0.0041 
SPAC19G12.13C poz1 Pot1 associated protein Poz1  Unknown 0.0104 0.0041 
SPAC3C7.04 SPAC3C7.04 Transcription factor (predicted)  Unknown 0.0003 0.0041 
SPCC777.08C bit61 TORC2 subunit Bit61  PRR5/PRR5L 0.0030 0.0041 
SPCC2H8.05C dbl1 
Schizosaccharomyces specific protein, 
double strand break localizing Dbl1  
Unknown 0.0499 0.0040 
216 
 
SPBC1861.02 abp2 ARS binding protein Abp2  Unknown 0.0019 0.0040 
SPAC11D3.16C SPAC11D3.16c Schizosaccharomyces specific protein  Unknown 0.0379 0.0040 
SPAC4G9.05 mpf1 Meiotic PUF family protein 1 (predicted)  Unknown 0.0379 0.0040 
SPCC132.02 hst2 Sir2 family histone deacetylase Hst2  SIRT2/SIRT3 0.0148 0.0039 
SPAC25B8.15C SPAC25B8.15c 
Wybutosine biosynthesis protein Tyw3 
(predicted)  
TYW3 0.0379 0.0039 
SPBC839.13C rpl1601 60S ribosomal protein L13/L16 (predicted)  
RPL13A/RPL16A/ 
RPL16B 
0.0104 0.0039 
SPAC8C9.11 fra2 
Transcriptional repressor protein bola 
domain (predicted)  
BOLA2/BOLA2B 0.0207 0.0039 
SPBC4B4.04 SPBC4B4.04 Translation initiation factor eif2a (predicted)  EIF2A 0.0148 0.0039 
SPAC2C4.15C ubx2 UBX domain protein Ubx2 UBXN7 0.0148 0.0038 
SPBC418.01C his4 
Imidazoleglycerol-phosphate synthase 
(predicted)  
Unknown 0.0499 0.0038 
SPCC162.06C SPCC162.06c Vacuolar sorting protein Vps60 (predicted) CHMP5 0.0104 0.0038 
SPCC191.06 SPCC191.06 Schizosaccharomyces pombe specific protein  Unknown 0.0499 0.0038 
SPCC576.14 dph5 Diphthine synthase Dph5 (predicted)  DPH5 0.0499 0.0038 
SPCC777.10C ubc12 NEDD8-conjugating enzyme Ubc1 UBE2M 0.0281 0.0038 
SPAC9.12C atp12 
Mitochondrial F1-ATPatpase chaperone 
Atp12 (predicted) 
ATPAF2 0.0207 0.0038 
SPAC22F8.07C rtf1 Replication termination factor Rtf1  DMTF1 0.0379 0.0037 
SPCC297.04C set7 
Histone lysine methyltransferase Set7 
(predicted)  
Unknown 0.0379 0.0037 
SPAC1039.08 SPAC1039.08 Serine acetyltransferase (predicted)  Unknown 0.0281 0.0036 
SPBC685.06 rps001 40S ribosomal protein S0A (p40)  RPSA 0.0047 0.0036 
SPAC8C9.08 rps5 40S ribosomal protein S5 (predicted) RPS5 0.0499 0.0036 
SPAC521.05 rps802 40S ribosomal protein S8 (predicted)  RPS8 0.0006 0.0036 
SPCC285.15C rps2802 40S ribosomal protein S28, Rps2802  RPS28 0.0104 0.0036 
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SPAC25G10.05C his1 ATP phosphoribosyltransferase  Unknown 0.0207 0.0036 
SPBPB2B2.11 SPBPB2B2.11 Nucleotide-sugar 4,6-dehydratase (predicted)  TGDS 0.0104 0.0035 
SPBC428.15 SPBC428.15 Obg-like ATPatpase (predicted)  OLA1 0.0499 0.0035 
SPBC14C8.16C bot1 Mitochondrial ribosomal protein subunit S35  Unknown 0.0104 0.0035 
SPBC14C8.09C dbl3 IMPACT domain protein, Dbl3  IMPACT 0.0379 0.0035 
SPBP35G2.10 mit1 
SHREC complex ATP-dependent DNA 
helicase subunit Mit1  
CHD3 0.0030 0.0034 
SPAC1A6.10 SPAC1A6.10 Small protein activating enzyme (predicted)  UBA5 0.0148 0.0034 
SPBC29A10.11C vps902 
Guanyl-nucleotide exchange factor Vps902 
(predicted)  
RABGEF1 0.0207 0.0034 
SPAC1687.06C rpl44 60S ribosomal protein L28/L44 (predicted)  RPL28 0.0207 0.0034 
SPBC28F2.03 ppi1 
Cyclophilin family peptidyl-prolyl cis-trans 
isomerase Cyp2  
PPIA/PPIE/PPIF 0.0379 0.0034 
SPBC2A9.07C hpz1 
Zf-PARP type zinc finger protein, G1-S 
transition regulator Hpz1  
Unknown 0.0281 0.0033 
SPAC1F8.01 ght3 Hexose transmembrane transporter Ght3 Unknown 0.0281 0.0033 
SPAC11E3.04C ubc13 Ubiquitin conjugating enzyme E2 Ubc13  UBE2N 0.0499 0.0033 
SPAC23C4.12 hhp2 Serine/threonine protein kinase Hhp2 CSNK1D/CSNK1E 0.0379 0.0033 
SPAC9G1.05 aip1 Actin cortical patch component Aip1  WDR1 0.0207 0.0032 
SPAP32A8.03C bop1 Ubiquitin-protein ligase E3 (predicted) RNF126 0.0499 0.0032 
SPCC613.03 SPCC613.03 Conserved fungal protein  Unknown 0.0499 0.0032 
SPAC23D3.01 pdp3 
PWWP domain protein, involved in 
chromatin remodeling (predicted)  
Unknown 0.0104 0.0032 
SPBC106.02C srx1 Sulfiredoxin SRXN1 0.0104 0.0032 
SPBC56F2.09C arg5 
Arginine specific carbamoyl-phosphate 
synthase subunit Arg5 (predicted)  
CPS1 0.0207 0.0032 
SPCC1020.13C SPCC1020.13c DDHD family phospholipase (predicted) 
SEC23IP/DDHD1/ 
DDHD2 
0.0207 0.0031 
SPBC106.03 SPBC106.03 DUF1776 family protein Unknown 0.0379 0.0031 
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SPBC660.12C egt2 Ergothioneine biosynthesis protein Egt2  Unknown 0.0281 0.0031 
SPAC22H10.04 ppa3 Protein phosphatase type 2A Ppa1 
PPP3CA/PPP3CB/ 
PPP3CC 
0.0499 0.0031 
SPAC20G4.01 caf16 
CCR4-Not complex subunit Caf16 
(predicted)  
Unknown 0.0379 0.0031 
SPBC800.05C tub1 Tubulin alpha 2 TUBA/B 0.0379 0.0030 
SPAC806.07 ndk1 Nucleoside diphosphate kinase Ndk1  
NME2/NME3/NME4/
NME2P1 
0.0281 0.0030 
SPCC737.09C hmt1 Vacuolar transmembrane transporter Hmt1  ABCB6 0.0379 0.0030 
SPBC27B12.05 SPBC27B12.05 
WD repeat protein involved in 
transcriptional regulation (predicted)  
Unknown 0.0499 0.0030 
SPAC14C4.03 mek1 
Cds1/Rad53/Chk2 family protein kinase 
Mek1 
Unknown 0.0148 0.0029 
SPBC16G5.16 SPBC16G5.16 
Transcription factor, zf-fungal binuclear 
cluster type (predicted)  
Unknown 0.0499 0.0029 
SPAC12G12.16C SPAC12G12.16c 
Fen1 family nuclease, XP-G family 
(predicted)  
FEN1 0.0499 0.0029 
SPAC23G3.05C SPAC23G3.05c 
Regulator of G-protein signaling (RGS) 
domain (predicted)  
Unknown 0.0379 0.0029 
SPBC3H7.14 mug176 BRCT domain protein Unknown 0.0047 0.0028 
SPCC1840.03 sal3 Karyopherin Sal3 IPO5/RANBP6 0.0379 0.0028 
SPBC21B10.05C pop3 WD repeat protein Pop3  MLST8 0.0104 0.0028 
SPAC824.02 bst1 GPI inositol deacylase Bst1 (predicted) PGAP1 0.0104 0.0027 
SPBC83.05 SPBC83.05 
Mitochondrial RNA-binding protein 
(predicted)  
Unknown 0.0281 0.0027 
SPAC824.08 gda1 Guanosine-diphosphatase Gda1  ENTPD5/ENTPD6 0.0379 0.0027 
SPAC20H4.11C rho5 Rho family GTPase Rho5  RHOA/RHOB/RHOC 0.0499 0.0025 
SPBC106.17C cys2 Homoserine O-acetyltransferase (predicted)  Unknown 0.0003 0.0024 
SPAC823.14 ptf1 
Mst2 histone acetytransferase 
acytyltransferase complex, predicted 
phosphoric monoester hydrolase Ptf1  
PSPH 0.0207 0.0024 
SPBC2G5.03 ctu1  Cytosolic thiouridylase subunit Ctu1 CTU1 0.0281 0.0024 
SPBC28E12.04 SPBC28E12.04  Schizosaccharomyces specific protein  Unknown 0.0499 0.0023 
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SPCC11E10.07C SPCC11E10.07c 
Translation initiation factor eif2b alpha 
subunit (predicted)  
EIF2B1 0.0281 0.0021 
SPAC23C11.10 mpn1 RNA processing protein (predicted)  USB1 0.0281 0.0020 
SPCC1450.07C dao1 D-amino acid oxidase  DAO 0.0499 0.0019 
SPCC1020.11C ecm6 
ER membrane protein complex subunit 6 
(predicted)  
EMC6 0.0298 0.0017 
SPCC777.13 vps35 Retromer complex subunit Vps35  VPS35 0.0298 0.0017 
SPAC23C4.11 atp18 F0-ATPatpase subunit J (predicted)  Unknown 0.0128 0.0002 
SPBC776.02C dis2 
Serine/threonine protein phosphatase PP1 
subfamily, Dis2  
PPP1CA/PPP1CB/ 
PPP1CC 
0.0325 0.0002 
SPCC191.11 inv1 External invertase, beta-fructofuranosidase Unknown 0.0325 0.0002 
 
Table 42: Genes identified by the screen of the S. pombe genome wide deletion library to 
increase resistance to 5-FU when deleted (p<0.05). This table shows the open reading frames 
(ORFs), gene, the product encoded by the gene and the name of any known human homologs. 
Table is ordered by GIS (in descending order), then by p value (in ascending order). 
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6.2.4 Ontologies for genes found confer increased sensitivity or resistance to 5-FU 
when deleted 
Ontological analysis, using Cytoscape and BiNGO software, was carried out on this list of 
genes to identify which cellular processes and pathways are over-represented in the list of 
genes, and thus identify cellular pathways which may lead to 5-FU hypersensitivity when 
impaired. The Cytoscape and BiNGO analysis generated a network showing the ontologies of 
the genes identified by the screen. This is shown as Figure 46. The processes and genes 
involved in said process, which confer sensitivity to 5-FU when deleted are shown in Table 
41. Ontological analysis was also carried out for genes that where identified by the screen to 
confer resistance to 5-FU when deleted, this is shown in Figure 47, the identified process and 
genes identified by the ontological analysis to confer resistance to 5-FU when deleted are 
shown in Table 43.
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Figure 46. Gene ontology network for the genes identified to confer hypersensitivity to 5-FU when deleted by QFA analysis of the S. pombe deletion mutant library. 
The relevant processes indicated by the terminal nodes of this network are sown in table 43. 
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Table 43: Table of relevant process identified by ontological analysis to confer increased 
sensitivity to 5-FU when deficient 
Process Genes 
Chromatin remodelling arp42, chz1, clr4, dep1, eaf7, fft3, hrp1, msc1, pht1, 
set1, snt2, swd1, swr1, ubp8, vps71 
Chromatin silencing at centromere arb1, arb2, cid12, clr4, hrp1, raf2, rik1 
Attachment of spindle microtubules to kinetochore 
involved in mitotic sister chromatid segregation 
cid12, clr4 
Kinetochore assembly mhf1, mhf2 
Sister chromatid biorientation cid12, clp1, dad1, spc19 
Negative regulation of histone modification hrp1, raf2, rik1 
Positive regulation of histone modification raf2, rik1, SPBC36B7.08C 
Histone Exchange msc1, pht1, swr1, vps71 
Gene silencing by RNA arb1, arb2, raf2, cid12 
RNA polyadenylation cid12, cid14, swd22 
Conversion of ds siRNA to ss siRNA involved in 
RNA interference 
arb1, arb2 
Donor selection clr4, rik1 
G2/M transition of mitotic cell cycle clp1, fkh2, wee1 
cAMP-mediated signalling  git1, gpa2, ncs1, pka1 
Regulation of Ras protein signal transduction clp1, clr4, fft3, gyp2,  par1, rga2, rga7, SPBC1778.09  
Transcription termination hrp1, reb1, sla1, ssu72 
Regulation of cytokinetic process cbf11, clp1, par1, pom1, rho3  
Regulation of ascospore formation chr3, sla1 
Regulation of cell shape end4, pka1, pom1, ppk14, ppk23, rho3, wee1  
Vacuolar proton-transporting V-type ATPase complex 
assembly 
rav1, rav2 
Macromolecule methylation clr4, prf1, set1, SPCC18.13, swd1, trm8, trm10, rmt1  
Protein modification process alg12, clp1, clr4, cpp1, csn2, ddb1, dep1, dsk1, eaf7, 
eos1, gal7, msc1, nem1, pka1, pom1, ppk14, ppk23, 
ppk31, prf1, ptc2, rhp18, rmt1, rnf10, set1, 
SPBC106.07C, SPBC14F5.10C, SPBC1709.14, 
SPBC1861.07, SPBC32F12.07C, swd1, tel1, ubp8, 
ubp14, wee1  
Regulation of catabolic process csn2, dph1, gyp2, pka1, rav2, rga2, rga7, 
SPBC1778.09  
Sulphur compound catabolic process ggt2, xan1 
Sphingolipid metabolic process arb1, arb2, clr4, scs7, sur2 
Response to zinc ion grx1, rav1 
 
Table 43. Table showing a list of processes and associated genes found to be required for the 
maintenance of 5-FU resistance in S. pombe, as identified by ontological analysis using 
Cytoscape software with the BiNGO plugin. These terms were selected by Cytoscape and the 
BiNGO plugin. 
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Figure 47. Gene ontology network for the genes identified to confer hyper-resistance to 5-FU 
when deleted by QFA analysis of the S. pombe deletion mutant library. Only one significant process, 
protein urmylation, was identified, as indicated by the single terminal node. The genes identified by 
this screen that are involved in this process are shown in table 44.
 
Table 44. 
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Table 44: Table of relevant process identified by ontological analysis to confer increased 
resistance to 5-FU when deficient 
Process Genes  
Protein urmylation ctu1, ctu2, uba42, urm1 
 
Table 44. Table showing the process (protein urmylation) and associated genes found to 
confer resistance to 5-FU when deficient in S. pombe identified by ontological analysis using 
Cytoscape software with the BiNGO plugin. This term was selected by Cytoscape and the 
BiNGO plugi
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6.3 Discussion 
6.3.1 S. pombe mre11, rad50, nbs1 and ctp1 mutants were not found to be 
hypersensitive to 5-FU 
The S. pombe mre11Δ, rad50Δ, nbs1Δ and ctp1Δ mutants did not show any increased 
sensitivity to 5-FU in comparison to the wild-type, this show that mre11, rad50, nbs1 and 
ctp1 mutants do not confer hypersensitivity to 5-FU and that these genes do not function in 5-
FU resistance in S. pombe. This contrasts to the hypothesis (discussed on page 188), despite 
the known roles of the MRN complex in the resistance to nucleoside analogues, such as 
gemcitabine.  
This insensitivity suggest that the MRN complex does not function in the resistance to 5-FU 
in S. pombe. In humans, the primary pathway leading to 5-FU cytotoxicity is through the 
inhibition of TS by the active 5-FU metabolite FdUMP, which leads to the misincorporation 
of dUTP, which is then excised leading to DNA strand breakage. FdUMP synthesis requires 
either the conversion of fluorodeoxyuridine (FUDR) by thymidine kinase (TK), or the 
conversion of fluorouridine diphosphate (FUDP) to fluorodeoxyuridine diphosphate 
(FdUDP), by the ribonucleotide reductase (RNR) protein. FdUDP is then subsequently 
converted by dephosphorylation to FdUMP [253]. FdUDP can also be phosphorylated to 
FdUDP, which can be incorporated into DNA, leading to cytotoxicity [253]. S. pombe is 
known to lack a thymidine kinase gene [342], but retains RNR homologues cdc22 and suc22, 
which encode for the large and small RNR subunits respectively [343]. The lack of TK in S. 
pombe may lead to a reduction in the proportion of 5-FU that is ultimately metabolised 
intracellularly to FdUMP in comparison to mammalian cells, and therefore thymidineless 
death. Integration of the active metabolites FdUTP and FUTP into DNA and RNA 
respectively may contribute more to 5-FU cytotoxicity in S. pombe than TS inhibition. 
The S. pombe mutants that were tested retain proficiency in BER, a pathway which functions 
in the removal of misincorporated uracil from DNA [335]. The BER pathway may therefore 
be sufficient in the removal of FdUTP and FUTP that has been misincorporated into DNA, 
and thus provide resistance to 5-FU in the absence of a functional DSB repair pathway. 
The lack of 5-FU hypersensitivity conferred by these mutants suggests that mutations in these 
genes may also not confer hypersensitivity to 5-FU in human carcinomas. Further work is 
required by testing mutants of MRE11, RAD50, NBS1 and CtIP in human cancer cells. If a 
similar lack of increased sensitivity is observed in human cells, this may suggest that in the 
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NWCOG-2 trial, an increased response to the treatment regimen of radiation, irinotecan and 
capecitabine, conferred by MRN/CtIP mutations may be a result of sensitisation to radiation 
or irinotecan and not capecitabine. 
The insensitivity to 5-FU observed in these S. pombe mutants may not necessarily be 
conferred in higher eukaryotes. Due to this further work is required in testing the sensitivity 
in mutants in homologous genes in a mammalian cell line.  
 
6.3.2 S. pombe deletion mutants identified to confer hypersensitivity to 5-FU 
The QFA analysis of the screen that was carried out on S. pombe deletion mutants identified a 
total of 181 genes for which deletion is significantly sensitive to 5-FU at 400 µM. The mre11, 
rad50, nbs1 and ctp1 deletion mutants were not found to have a greater sensitivity to 5-FU. 
A number of significant genes and processes that were found to confer hypersensitivity to 5-
FU when deficient are described in sections 6.3.2.1 - 6.3.2.5. 
 
6.3.2.1 Chromatin modelling, histone modification and centromere function 
As shown by Figure 46 and Table 43, one process that has been found to be important in 5-
FU resistance is chromatin silencing at centromeres. Chromatin silencing is required or 
normal chromosome segregation during mitosis. The genes clr4 and rik1, were to confer 
hypersensitivity to 5-FU in the screen, are known to function in the silencing of chromatin at 
centromeric regions. Deficiencies of clr4 and rik1 are known to cause a sharp reduction in 
centromeric chromatin silencing leading to elevated rates of chromosome loss [344] [345]. 
Centromeres were found to lag at anaphase spindles in mutants lacking clr4, rik1 or swi6 
[344] [345]. A recently published 5-FU S. pombe screen [311] has also determined that 
defects in chromatin silencing at centromeres correlate to increased 5-FU sensitivity and that 
5-FU impairs chromosome segregation. The study by Mojardín et al also identified swi6, 
clr4, rik1, arb1, arb2, cid12, pob3 and rdp1 as genes that function in this pathway for which 
deletions causes 5-FU hypersensitivity. The study by Mojardín et al further confirmed the 
role of centromeres in 5-FU resistance. This was shown by an increase in 5-FU sensitivity 
caused by the application of thiabendazole, an agent which destabilises microtubules [311].  
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The raf2 gene functions in chromatin silencing at centromeres. raf2 has not before been 
identified to confer 5-FU hypersensitivity upon knockout. Raf1 and Raf2 are known to form 
the histone H3K9 methyltransferase CLRC complex along with Clr4, Cul4 and Rik1. 
Formation of this complex requires RNAi. The CLRC complex is required for 
heterochromatin formation [346]. Raf2 contains a Replication Foci Targeting Sequence 
(RFTS) domain, which shares homology to the RFTS domain of human DNMT1, this RFTS 
domain is required for interaction with Cul4 and centromeric heterochromatin formation 
[347]. 
In human cells, the SWI/SNF complex functions in chromatin remodelling and transcription 
modulation and has been found to be frequently mutated in cancers [348]. A study has shown 
that knockdown of ING2, a protein that is known to associate with SWI/SNF, sensitises cells 
to 5-FU [349], this therefore may indicate a role of SWI/SNF in 5-FU resistance. The S. 
pombe arp42 gene, which was identified by the screen to confer hypersensitivity when 
deleted and identified by the gene ontology analysis to be involved in the process of 
chromatin remodelling, is an S. pombe homologue of a SWI/SNF subunit [350]. 
The cAMP-mediated signalling pathway was also identified by the screen to confer 
sensitivity to 5-FU when deficient. In S. cerevisiae this pathway has been found to function in 
the regulation of Ras and chromatin modelling [351]. In mammalian cells this pathway has 
been found to function in the regulation of the progression of the cell cycle through G1 phase 
through the histone 3 phosphorylation regulatory mechanisms of protein kinase A (PKA) and 
mitogen activated protein (MAP) kinases [352]. In this screen, deletion of the S. pombe 
homolog of PKA, pka1 was found to sensitise cells to 5-FU. Other genes which were 
identified by this screen to sensitise to 5-FU in deletion mutants include git1, gpa2 and ncs1 
(see Table 43). The genes git1 and gpa2 have not before been identified to confer 5-FU 
sensitivity upon deletion in S. pombe. The ncs1 gene has been previously identified to confer 
5-FU hypersensitivity when deleted in S. pombe [311]. 
Histone modification was identified to be another significant process which can sensitize to 
5-FU when defective. A study in colorectal cancer cells has shown that inhibition of histone 
deacetylase induces sensitivity to 5-FU [353]. In mammalian cells, phosphorylation of 
histone H3 occurs following activation of Ras or MAP kinase pathways. This modification is 
thought to function in chromatin remodelling and transcription initiation [354]. In S. pombe 
histone 3 phosphorylation at serine 10 (H3S10) suppresses swi6 expression. During mitotic 
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S-phase the heterochromatic transcripts accumulate. These transcripts are processed into 
siRNA following replication and function to promote swi6 expression when cohesin 
isrecruited [355]. 
The Ras signalling pathway, which is known to induce histone modification [354], has also 
been shown to induce 5-FU sensitivity if defective. In human cells, RAS mutants are known 
to sensitise to 5-FU [356]. The S. pombe RAS homologue (ras1) mutant was not tested in this 
screen as it did not grow on any plates, although a previous screen carried out by Mojardín et 
al showed an increased sensitivity of 5-FU for this mutant [311]. Other genes in this pathway 
identified by the screen to induce hypersensitivity to 5-FU when deleted include clp1, clr4, 
fft3, gyp2, par1, rga2, rga7 and SPBC1778.09. 
Novel chromatin remodelling genes, which increase sensitivity to 5-FU upon deletion, that 
were identified by this screen include chz1, dep1, msc1 and ubp8. The msc1 gene is known to 
encode a protein that interacts with Swi6 [357] and functions in chromosome function and 
stability of centromere through interaction with histone H2A.Z [358]. Other relevant 
chromatin remodelling genes identified in this screen, that were also identified in the screen 
recently published by Mojardín et al include ada2, arp42, bdc1, clr4, eaf7,  fft3, hrp1, pht1, 
pob3, set1, snt2, swd1, swr1 and vps71 [311]. 
The ontological analysis identified G2/M transition of the mitotic cycle as a relevant cellular 
process that can sensitise to 5-FU when deficient. One of the proteins involved in this process 
is Wee1. In human cells, Wee1 functions in the G2/M-phase checkpoint regulation by 
inactivating CDK1, via phosphorylation, in response to DNA damage. An inhibitor of Wee1, 
MK-1775, was found to increase cytotoxicity to 5-FU [359], this is in keeping with the 
observations of wee1 in the S. pombe 5-FU screen. wee1, along with mitotic regulator gene 
clp1 have not before been associated with 5-FU cytotoxicity in S. pombe. The fkh22 (which 
also functions in the G2/M transition of mitotic cell cycle) strain, was also identified to 
sensitise to 5-FU in this screen in addition to the recently published screen by Mojardín et al 
[311]. 
Gene silencing by RNA was also found to be associated with 5-FU response. This process 
also involves raf2, and gene silencing by RNAi is required for the formation of the CLCR 
complex, which includes Raf2, and is required for centromeric heterochromatin formation 
[347]. The RNAi component genes ago1, dcr1 and rdp1 are known to be required maintain 
the chromatin silencing, that is required for centromere formation, and Swi6 binding [360]. 
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Other genes involved in silencing by RNA identified in this screen, that were also identified 
in the screen recently published by Mojardín et al include arb1, arb2, and cid12 [311]. 
Some genes identified by the screen to confer 5-FU sensitivity when deleted are known to 
encode proteins which function in RNA processing, such as cid12 [361] and cid14 [362].In 
mammalian cells, pre-rRNA processing is known to be inhibited by the application of 5-FU 
[129]. In S. pombe cells, rRNA processing by polyadenylation requires cid14 function. cid14 
mutants are known to exhibit increased chromosomal missegregation and heightened 5-FU 
sensitivity [363]. Other RNA processing genes identified by this screen, which have not been 
previously linked to 5-FU sensitivity, include swd22 [364] and sla1 [365]. 
Transcription termination was also identified as a relevant process. A study has shown that 
dUTP DNA incorporation in S. cerevisiae is linked to transcription [366]. sla1 and ssu72 are 
novel 5-FU associated genes that function in transcription termination. The reb1 and hrp1 
(which also function in transcription termination) strains, were also identified to sensitise to 
5-FU in this screen in addition to the recently published screen by Mojardín et al [311]. 
 
6.3.2.2 tel1ATM 
As discussed in the introduction to this chapter (see page 184), it was suggested that ATM 
mutants may sensitise human cells to 5-FU [321]. This screen has identified that a deletion of 
the S. pombe ATM homologue tel1 confers sensitisation to 5-FU in S. pombe, tel1 has not 
before been identified to confer hypersensitivity to 5-FU in S. pombe when deleted. 
 
6.3.2.3 rhp18RAD18 
The S. pombe RAD18 homolog rhp18 deletion mutant was found to be hypersensitive to 5-
FU. In humans Rad18 functions in the promotion of homologous recombination via 
interactions with Rad51C [367], and also recruits pol-η to stalled replication forks via 
monoubiquitination and direct interaction with PCNA [368]. In S. cerevisiae Rad18 and Rad6 
(homologue of S. pombe rhp6) form a heterodimeric complex [369] with DNA binding, ATP 
hydrolytic and ubiquitin conjugating activities [370]. In S. pombe rhp18 mutants exhibit a 
longer DNA damage checkpoint arrest following irradiation [371]. rhp18 has not before been 
identified to confer hypersensitivity to 5-FU in S. pombe when deleted. 
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6.3.2.4 rhp57XRCC3 
The human homologue of rhp57, XRCC3, is required to mediate homologous recombination 
[372] and for the assembly of Rad51 complexes [373]. XRCC3 is also known to be required 
for chromosome stability [374] and correct chromosomal segregation in mammals [375]. A 
study has found that XRCC3 can provide a useful marker to predict the outcome of colorectal 
cancer treatment using 5-FU and oxaliplatin [376]. Rhp57 has not before been identified to 
confer hypersensitivity to 5-FU in S. pombe when deleted. 
 
6.3.2.5 trm8METTL1, trm10 and dus3 
The S. cerevisiae homologous proteins, Trm8, Trm10 and Dus3 function in the modification 
of tRNA. The Trm8 methyltransferase forms a complex with Trm82, and catalyses the 
formation of the m7G46 (methylation of guanidine at position 46), Trm8 possesses the 
catalytic activity [377]. Trm10 is an m
1
G9 methyltransferase (catalyses the methylation of 
guanidine at position 9) [378] and is known to be sufficient to catalyse all required m
1
G9 in S. 
cerevisiae [379]. The Dus3 tRNA dihydrouridine synthase is required for the formation of D 
U47 (dihydrouridine at position 47) [380]. These tRNA modifications are required to protect 
tRNA from rapid tRNA degradation (RTD) [381] [382]. S. cerevisiae deletion mutants of 
trm8, trm10 and dus3 were also found to be hypersensitive to 5-FU [383]. Knockdown of the 
trm8 human homolog METTL1 in HeLa cells has been shown to sensitise to 5-FU [384]. 
trm10 has not before been identified to confer hypersensitivity to 5-FU in S. pombe when 
deleted. 
 
6.3.3 Role of centromere function in 5-FU sensitivity 
Many of the genes identified by the screen function in the establishment and maintenance of 
centromeres directly through the silencing and remodelling of chromatin at centromeric 
regions, such as clr4, or indirectly through the RNAi mechanism, such as arb1 and arb2. This 
suggests an additional route in which 5-FU causes toxicity, through the disruption of 
centromeres during mitosis, leading to chromosome missegregation and subsequent cell 
death.  
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6.3.4 S. pombe deletion mutants identified to confer increased resistance to 5-FU 
The QFA analysis of the screen that was carried out on S. pombe deletion mutants identified a 
total of 316 genes for which deletion is significantly resistant to 5-FU at 400 µM. The mre11, 
rad50, nbs1 and ctp1 deletion mutants were not found to have a greater resistance to 5-FU. 
A number of significant genes and processes that were found to confer resistance to 5-FU 
when deficient are described in sections 6.3.4.1 - 6.3.4.4. 
 
6.3.4.1 ctu1, ctu2, uba42 and urm1 
The process identified by the screen and gene ontology analysis to confer increased 5-FU 
resistance when deficient was protein urmylation (see Figure 47 and   
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Table 44), of which four genes were associated. These genes are ctu1, ctu2, uba42 and urm1. 
Deletions of ctu1, ctu2, uba42 and urm1 have not before been identified to confer increased 
5-FU resistance in S. pombe. 
Ubiquitination is the process of the conjugation of the ubiquitin modifier protein to other 
proteins. Ubiquitination marks proteins for degradation, although there are other known 
regulatory roles for ubiquitination. The process of urmylation involves the conjugation of the 
ubiquitin related modifier Urm1 to proteins [385]. In S. cerevisiae Urm1 was found to be 
conjugated to the antioxidant Ahp1 in response to oxidative stress by a process involving 
Uba4 (the S. cerevisiae homologue of Uba42) [386].  
In addition to urmylation the Ctu1, Ctu2, Uba42 and Urm1 proteins also function in the 
thiolation of uridine in tRNA. In S. pombe the Ctu1 and Ctu2 proteins form a cytosolic 
thiouridylase complex which functions in the 2-thiolation of uridine in cytosolic tRNAs. 
Inactivation of this complex is known to result in a deficiency of tRNA thiolation leading to 
marked aneuploidy and aberrant development [387]. 
In S. cerevisiae the Urm1 and Uba4 protein function in the 2-thiolation step of the synthesis 
of 5-methoxycarbonylmethyl-2- thiouridine (mcm
5
s
2
U) in tRNA [388]. These proteins are 
known to carry out such modifications at position 34 (mcm
5
s
2
U34), close to the anticodon. 
The modification of tRNA nucleosides close to the anticodon are known to be important for 
translation, particularly at the uridine at the 34
th
 position (U34) in glutamate, glutamine and 
lysine tRNAs. The addition of the 5-methoxycarbonylmethyl side-chain is mediated by Elp3 
[387].  
The dual urmylation and thiolation functions of Uba42 and Urm1 are conserved from yeast to 
humans [389]. 
The genes iki3 and elp6 were also identified by the screen to confer resistance to 5-FU when 
deleted. The S. cerevisiae homologues proteins Elp1 and Elp6 also function in the 
modification of uridines in tRNA to form mcm
5
s
2
U, 5-carbamoylmethyluridine (ncm
5
U34), 
and 5-methoxycarbonylmethyluridine (mcm
5
U) [390].  
The mechanisms by which Ctu1, Ctu2, Urm1 and Uba42 contribute to 5-FU cytotoxicity is 
unknown. These four proteins all function in the modification of uridine in tRNA. 5-FU is 
known to cause cytotoxicity through the incorporation of FUTP into RNA. RNA 
incorporation is known to contribute significantly to 5-FU cytotoxicity in S. cerevisiae [391]. 
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These modifying proteins may then act to thiolate the incorporated fluourouridine bases 
which may possibly destabilise RNA or create a cytotoxic product. One study has shown that 
5-Fluoro-4′-thiouridine is toxic in leukaemia L1210 and Streptococcus faecium cells [392].  
 
6.3.4.2 exo1 and rqh1WRN/BLM  
The Exo1 protein is known to function in the processing of DSBs [393], a process which in S. 
cerevisiae also requires Sae2 (Ctp1) and Sgs1 (Rqh1). Exo1 is also known to function in the 
MMR pathway in S. pombe [394] and humans [395]. As discussed in section 6.1.3.4, MMR 
pathway is known to be required for 5-FU toxicity in mammalian cells [317] and deficient 
MMR is known to confer an increased resistance to 5-FU. No other MMR mutants were 
found in the screen, this suggests that this heightened resistance may be due to the loss of 
MMR independent functions of Exo1.Deletions of exo1 and rqh1 have not before been 
identified to confer increased 5-FU resistance in S. pombe. 
 
6.3.4.3 xrc4XRCC4 
In mammalian cells the Xrc4 homologue XRCC4 functions in NHEJ to link DNA end 
processing to DNA ligation in the final stages of NHEJ [396]. Studies have shown that NHEJ 
deficiency does not confer 5-FU sensitivity in S. cerevisiae [125] or hamster cell lines [397]. 
The results indicate that NHEJ may play a role in 5-FU cytotoxicity, however further 
investigation into a potential role for NHEJ in the cytotoxicity of 5-FU is required. Deletions 
of xrc4 have not before been identified to confer increased 5-FU resistance in S. pombe. 
6.3.4.4 rad1 and rad17 
The Rad1 protein, along with Rad9 and Hus1, form the 9-1-1 complex upon Hus1 
phosphorylation in response to DNA damage [398] and is loaded onto sites of damage by the 
Rad17-replication factor C (RFC) [399]. The 9-1-1 complex also exists in humans [400] and 
is also loaded by the Rad17-RFC complex [401]. In humans 9-1-1 recruits TopBP1, which 
subsequently activates the ATR-mediated Chk1 pathway by phosphorylation [402]. In S. 
cerevisiae TopBP1 activates ATR via the phosphoinositide 3-kinase related kinase (PIKK) 
domain of ATRIP [403]. 
The human Rad9 component of the 9-1-1 complex is known to interact with BCL-2 to 
promote apoptosis [404]. A lack of the Rad1 subunit is known to destabilise Rad9 and Hus1 
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[405]. This destabilisation of the 9-1-1 complex may abrogate Rad9-BCL-2 interaction, and 
therefore prevent apoptosis, which may contribute to the increased resistance of the rad1Δ 
mutant to 5-FU. As discussed in section 6.1.3.7, defects in BCL/Bax proapoptotic pathways 
increases resistance to 5-FU [328] [329]. These findings, along with the data obtained from 
the S. pombe deletion mutant library screen, may indicate at a potential role for 9-1-1 in 
maintaining 5-FU toxicity. Further work is required to determine if the 9-1-1 complex is 
involved in 5-FU sensitivity. Deletions of rad1 and rad17 have not before been identified to 
confer increased 5-FU resistance in S. pombe. 
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6.3.5 Future work 
In order to confirm the conferred effects of increased 5-FU sensitivity or resistance that result 
from any of the mutants identified, further tests should be carried out. These tests should be 
in the form of “spot-tests”, as shown on page 190, testing for the sensitivity of the mutants at 
varying concentrations of 5-FU, and varying cell densities, in comparison to the wild-type.  
Future work should be carried out to identify if 5-FU affects centromere function in higher 
eukaryotes as many genes found to sensitise to 5-FU upon deletion effect the centromeres in 
a direct or indirect manner. One such experiment in a mammalian cell line could involve the 
visualisation of centromeres, using a fluorescently labelled anti-CENPA antibody, and 
microtubules through mitosis following 5-FU exposure, compared to a no drug control. Other 
experiments could then be carried out to create the mutants identified in the screen in the 
mammalian homologues, and then test for sensitivity to 5-FU. Such mutants could be created 
using the CRISPR/Cas9 system. 
Future work should also be carried out to test if mutations in the genes encoding certain 
tRNA modifying lead to an increase in 5-FU sensitivity as seen in the screen. Mutants could 
be created using the CRISPR/Cas9 system and then tested for 5-FU sensitivity in comparison 
to a wild-type. 
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6.3.6 Conclusion 
The 5-FU sensitivity tests of the mre11Δ, rad50Δ, nbs1Δ and ctp1Δ were not found to 
increase sensitivity to 5-FU despite the known sensitising effects of these mutations to other 
nucleoside analogues. Thus showing that Mre11, Rad50, Nbs1 and Ctp1 do not function in 
the cellular resistance to the drug 5-FU. 
The S. pombe genome wide deletion mutant library screen identified a total of 181 strains that 
were found to be significantly sensitive to 5-FU. Gene ontology identified a number of 
processes in which the mutant genes functioned. Such processes involved chromatin 
modelling process, centromeric processes and cell cycle related process. Many genes which 
function in these processes, and for which the mutants were identified to confer 5-FU 
sensitivity, have not previously been identified to enhance 5-FU sensitivity when deficient, 
for example raf2, wee1 and cid14. Other genes for which deficiency is known to increase 5-
FU cytotoxicity, such as clr4 and rik1, were also identified by the screen. 
These results also suggest that 5-FU may cause cytotoxicity in S. pombe by interfering with 
centromeres, leading to chromosome missegregation and cell death following mitosis, as 
most of the identified genes and processes function, either directly or indirectly, in 
centromere formation, centromere maintenance and mitosis. 
The screen also identified a total of 316 novel genes that confer an increased resistance to 5-
FU. Some of the genes identified are involved in the processing of uridine in tRNA. This may 
suggest that the processing of incorporated fluorouridine in tRNA is a significant contributing 
factor of 5-FU cytotoxicity in S. pombe. A number of DNA repair genes, such as exo1, rqh1, 
xrc4, rad1 and rad17 also showed to increase 5-FU resistance when deleted, therefore DNA 
repair pathways may be required to integrate 5-FU metabolites into DNA. 
Further work is required to confirm that the novel mutants found to increase sensitivity or 
resistance to 5-FU actually confer increased sensitivity or resistance to 5-FU. Sensitivity tests 
should be carried out in these mutants at varying concentrations of 5-FU, and sensitivity 
should then be compared to a wild-type strain.  
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Further work should be then carried out in mammalian cells to identify if the mammalian 
homologs of the S. pombe genes that were found to increase 5-FU sensitivity or resistance, to 
determine if such mutants have a similar effect in higher eukaryotes. The mutants could be 
created using the CRISPR/Cas9 system.  
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7 Final Conclusions 
7.1 Conclusions of Research 
This project identified that certain mutations in S. pombe mre11, rad50, nbs1 and ctp1 confer 
hypersensitivity to the topoisomerase inhibitor camptothecin. The mre11Δ5-7, mre11-W210X, 
rad50-MSI and ctp1-MSI all showed null phenotypes, with severe sensitivity to camptothecin 
and MMS. This increase in cytotoxicity may be due to impairment of topoisomerase removal 
or defective downstream repair functions. One of the truncation mutants studied, mre11-
R572X, showed no increase in sensitivity to camptothecin, suggesting that the C-terminal 
region of S. pombe Mre11 are not required for removal of topoisomerase I from DNA. A 
mutant of nbs1, nbs1-MSI, which encodes a protein lacking the C-terminal Mre11 and ATM 
binding domains, showed a great increase in sensitivity to MMS, whilst only showing a very 
slight increase in sensitivity to camptothecin, this suggests that this mutant is a separation of 
function mutant and that the Mre11 and ATM binding domains of Nbs1 may not be required 
for topoisomerase removal but are still required for other forms of DNA repair. The MRE11-
R572X mutant showed only a very slight phenotype, indicating that the C-terminal region of 
S. pombe Mre11 may not be required for topoisomerase removal, downstream DNA repair or 
repair of MMS induced lesions. 
Similar mutations in the human homologues of the aforementioned genes may confer similar 
increases to camptothecin sensitivity via impairment of topoisomerase removal or 
downstream DNA repair mechanisms. These mutations, when present in cancers, may have 
sensitising effects to camptothecin, and thus patients with such tumours may benefit from 
camptothecin based treatment. 
The sequencing of MRE11, RAD50, NBS1 and CtIP in the 25 NWCOG-2 patient tumour 
samples initially revealed a total of 30 somatic mutations, of which 25 were non-
synonymous. 15 of these mutations were missense mutations that were predicted by 
Polyphen-2 analysis to be either possibly or probably damaging. An additional 2 nonsense 
and additional 2 frameshift mutations were identified. One such frameshift mutation was the 
CtIP-poly(A)9 1 bp deletion, which has previously only been described in cancers displaying 
MSI, this therefore marks the first occasion of this mutation being identified in an MSS 
tumour. 
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The patient set appeared to have higher mutation rate than that of the TCGA and COSMIC 
studies with a vastly different mutation spectrum. The percentage of mutations that were of 
the G:C>A:T type was much lower than that known occur as a result of FFPE sequencing 
artefacts.  
The patient survival data appeared to show an improved response to treatment in those of 
whom a mutation was identified over patients with wild-type MRN/CtIP tumours, thus 
supporting the hypothesis that MRN/CtIP mutations are indicative of improved treatment 
with camptothecin based therapies. 
We were advised to resequence the mutations using primers which bind external to those 
used in the original sequencing reactions. All but one mutation were irreproducible in this 
resequencing, despite the confirmatory sequencing that was previously carried out for all 
mutations. Again, when sequencing from newly cut patient tumour sections only the 
identification of the CtIP-poly(A)9 1 bp deletion mutant in patient R48 was found to be 
reproducible. The presence of this mutation was then confirmed using fluorescent fragment 
analysis, which also identified that this mutation may also be present in the patient R51 
tumour sample. As discussed previously, this mutation has only before been observed in 
cancers displaying MSI. If this tumour genuinely is MSS, confirmation of this mutant would 
mark the first occasion of this mutation being identified in an MSS tumour. Further work 
should be carried out on the patient R48 tumour sample to determine the MSI status. 
A 1 bp deletion mutation was also found in the MRE11-poly(T)11 tract in patient R12 using 
fluorescent fragment analysis. This mutation has also only previously been described in MSI 
cancers, whereas the cancer for patient R12 is MSS. If this tumour genuinely is MSS, 
confirmation of this mutant would therefore mark the first occasion of this mutation being 
identified in an MSS tumour. Further work should be carried out on the patient R12 tumour 
sample to determine the MSI status. 
The loss of the mutations upon resequencing may have been due FFPE related sequencing 
artefacts, however the mutation spectra showed a much lower level of C:G>T:A mutations 
than what is known to occur as a result of FFPE processing. These mutations may have been 
caused by errors incorporated by the polymerase, however with approximately 3000 copies of 
the genome per sample, it is unlikely for the same error to be incorporated in PCRs from all 
template copies. Another possibility is that due to the low quality of FFPE DNA, a low 
number, possibly even just a single copy, of the genome may be amplifiable by PCR which 
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may contain the mutation. This PCR may have been facilitated by the long elongation time of 
the initial multiplex PCR reactions. This copy may then have formed the template for all 
other subsequent reactions, and thus leading to the synthesis of PCR products harbouring the 
mutation. Another possible explanation is tumour heterogeneity, in which subsequent PCRs 
may have amplified from an area of tumour which does not contain cells harbouring the 
previously observed mutations. 
Tests for the sensitivity of 5-FU on S. pombe mre11, rad50, nbs1 and ctp1 deletion mutants 
did not reveal any increase in the sensitivity to 5-FU, despite the known sensitising effects of 
these mutations to nucleoside analogues. This shows that in S. pombe Mre11, Rad50, Nbs1 
and CtP1 are not required for cellar resistance to 5-FU.  
The S. pombe deletion mutant library screen identified at total of 181 mutations that were 
found to be significantly sensitive to 5-FU. Ontological analysis identified a number of 
cellular pathways that are over represented by the genes of the mutants identified by the 
screen. The processes identified included chromatin silencing, chromatin remodelling, 
negative regulation of mitotic cell cycle, gene silencing by RNA and RNA 3′-end processing. 
Some of these genes and processes have been recently described to contribute to 5-FU 
sensitivity when disrupted, such as chromatin remodelling and chromatin silencing at 
centromeres, and the genes clr4 and rik1. However, a number of genes have been identified 
as novel markers for 5-FU hypersensitivity including raf2, wee1, cid14 and many more.  
The results of the screen suggest that 5-FU may cause cytotoxicity in S. pombe through 
disruption of centromeric activities, leading to chromosome missegregation following 
mitosis, as many of the identified genes and processes which increase 5-FU sensitivity when 
deficient, function either directly or indirectly in centromere formation, maintenance and 
mitosis. 
The mutants of some DNA repair genes were found to sensitise to 5-FU, these mutants 
include tel1
ATM
, rhp18
RAD18
 and rhp57
XRCC3
. 
The screen also identified a total of 316 mutants which have an increased resistance to 5-FU. 
These mutants include ctu1, ctu2, uba42 and urm1, which function in the thiolation of uridine 
residues in tRNA. This may suggest that the thiolation of incorporated 5-FU, in the form of 
fluorothiouridine, in tRNA may be a contributing factor to 5-FU toxicity in S. pombe. 
241 
 
The screen also identified certain DNA repair genes which increase 5-FU resistance when 
deleted. These genes are exo1, rqh1
WRN/BLM
, xrc4
XRCC4
, rad1 and rad17. This suggests that 
these genes may also contribute to 5-FU toxicity, possibly aiding the incorporation of 5-FU 
metabolites into DNA. It is known that BER and MMR can lead to the incorporation of 
nucleoside analogues and 5-FU metabolites into DNA [119] [120].  
 
7.2 Potential Significance of Research on Cancer Therapy 
This work identified that when certain patient tumour mutations are created in S. pombe, the 
cells become sensitised to camptothecin, whereas some mutations confer little to no 
hypersensitivity to camptothecin. This suggests that certain domains, such as the Mre11 
nuclease domain, are important for camptothecin resistance, whereas other domains, such as 
the Nbs1, Mre11 and ATM binding domains, are not as essential. This suggests that these 
mutations may potentially confer a similar effect in human cancer cells, and that the presence 
of certain MRN/CtIP mutations may provide markers that are indicative of an improved 
response to topoisomerase inhibition. These genes therefore may be good candidates for 
personalised therapy using camptothecin based therapies in patients in which such mutations 
are identified. 
The genome wide deletion screen identified a number of candidate genes for 5-FU sensitivity 
in S. pombe, many of which function in the formation, maintenance and function of 
centromeres. This has therefore identified a number of potential genes, for which the human 
homologues, may contribute to 5-FU resistance in cancers. Therefore such genes may provide 
potential candidates for personalised cancer therapy using 5-FU when mutated. This also 
identified a potential role of the centromere function in 5-FU resistance, and therefore drugs 
which affect centromeric function, such as thiabenzadole [406] or Eribulin (E7398) [407], 
could potentially be administered concurrently with 5-FU to increase the efficacy of 5-FU 
[311]. The identification of mutations which increase sensitivity to 5-FU could also 
potentially contribute to personalised therapy as mutations in these genes may provide 
contraindicative markers for 5-FU based therapies. 
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7.3 Future Work 
Additional work to study the mutants created in S. pombe could include assays that assess 
MRN complex formation, interaction between individual MRN proteins and Ctp1, DNA 
binding and topoisomerase interaction. This would aim to identify the mechanisms in which 
these proteins are dysfunctional. Also, due to the possible effects of the lox-sites, these 
mutants should be created into strain lacking the lox sites, to confirm that the observed 
phenotype is a result of the mutation and not caused by the presence of the lox sites. This is 
especially important for nbs1 mutants as the lox-nbs1-WT strain exhibited a phenotype 
showing increased sensitivity to camptothecin and MMS. 
As the CtIP-poly(A)9 1 bp deletion and MRE11-poly(T)11 mutants have only been 
previously identified in MSS tumours, further work should be carried out to confirm that 
these tumours are microsatellite stable. Such work could include the sequencing of MMR 
genes such as MLH1. If all tests confirm that that these patients definitely are MSS, then this 
will mark the first time that these mutations have been identified in MSS tumours, showing 
that these particular mutations are not specific to MSI tumours. 
Future work should be carried out to evaluate the potential of the role of centromeres as a 
target for cancer therapy using 5-FU. Mutations of the candidate genes identified by the 
screen could be made using the CRISPR/Cas9 system in mammalian cells and then tested for 
sensitivity to 5-FU. Work could also be carried out to test the effects of centromere disruption 
on 5-FU efficacy in mammalian cells. An experiment using 5-FU resistant cells comparing 
the cytotoxicity of cells treated with 5-FU + thiabendazole/Eribulin versus 5-FU alone could 
be carried out to study these effects. 
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9 Appendix I: NWCOG-2 Patient Biopsy Information 
 
Table 45: Biopsy information for the NWCOG-2 patient samples 
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R1 6337/03 5 1 5 0 0 4 1 Good   
R2 6703/03        Poor Block only, not much tissue 
R3 7167/03        Good Block only, adequate tissue 
R4 9069/03 8 7 55 0 0 2 50 Good Small fragments 
R5 8897/03        Poor Block only, not much tissue 
R5 9520/03        Good Block only, adequate tissue 
R6 16866/03 2 2 35 0 0 0 35 Good Marked inflammation 
R7 9656/03 5 5 65 0 0 0 65 Good Small fragments 
R8 15306/03 6 0 0 6 70 0 70 Good High grade dysplasia 
R10 13121/03 8 6 40 0 0 2 35 Poor Only 5 fragments in block, three contain cancer 
R11 1337/04 2 2 80 0 0 0 80 Good  
R12 16/04 4 4 60 0 0 0 60 Good  
R13 711/04 5 2 75 3 85 0 80 Good High grade dysplasia 
R14 2861/04 4 4 40 0 0 0 40 Good Small fragments, marked inflammation 
R15 2775/04 5 4 40 1 15 0 30 Poor 4 fragments in block, 3 contain cancer 
R17 5985/04 5 2 70 1 10 2 30 Good High grade dysplasia 
R18 4590/04 2 2 80 0 0 0 80 Good  
R19 2404/04 3 1 15 1 40 1 30 Poor Thin block, low grade dysplasia 
R21 8229/04 6 6 45 0 0 0 45 Good Marked inflammation 
R22 9038/04 5 4 45 1 10 0 35 Poor Low grade dysplasia, marked inflamation, some thin 
fragments 
R23 2404/04 3 1 15 1 40 1 30 Poor Thin block, low grade dysplasia 
R24 14223/04 5 4 85 0 0 2 70 Poor Thin block, small fragments 
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R25 7919/04 5 4 35 0 0 1 30 Good  
R26 7910/04 2 2 25 0 0 0 25 Good  
R27 08475/04 2 2 70 0 0 0 70 Good  
R28 15678/04         No block 
R29 9459/04        Good Block only 
R30 9798/04 6 5 60 0 0 1 55 Good  
R31 10093/04 9 8 60 0 0 1 50 Good Marked area: 60% cancer 
R32 9768/04 4 2 20 0 0 2 10 Poor Thin Block 
R34 9928/04 5 2 40 0 0 3 20 Good  
R35 13125/04 5 5 50 0 0 0 50 Good Marked inflammation 
R37 9420/04        Good Block only 
R38 672/05 5 5 65 0 0 0 65 Good  
R39 512/05 4 3 60 0 0 1 40 Poor  
R40 11865/05 4 3 20 0 0 1 15 Poor Thin Block 
R41 6327/05 6 6 45 0 0 0 45 Poor Thin Block 
R42 8168/15 5 3 40 2 60 0 50 Good Most tumour is not cancer 
R43 2689/05 2 2 30 0 0 0 30 Poor Not much in block 
R44 6327/05 5 3 80 0 0 2 50 Good May be able to microdisect 
R45 6329/05 1 1 5 0 0 0 5 Good Small amount of tissue 
R46 3141/05 1       Poor Block only, small amount of tissue 
R47 3657/05        Poor Block only, small amount of tissue 
R48 3539/05 7 5 70 0 0 2 60 Good  
R49 6423/05 5 4 60 0 0 1 50 Good  
R50 10391/05 A 6 6 75 0 0 0 75 Good Mucinous Cancer 
R50 10391/05 B          
R51 3073/05 A        Good Mostly Normal 
R51 3073/05 B 2 0 0 2 80 0 80 Good Low grade dysplasia 
R52 5408/05 1 1 60 0 0 0 60 Good  
R54 8110/05 2 2 40 0 0 0 40 Good Smal fragments 
R55 16902/05 5 5 45 0 0 0 45 Good  
R56 19352/05 6 2 40 2 70 2 50 Poor Not much in block, low grade dysplasia 
R57 8662/05         No block 
R58 6571/05 3 1 45 2 55 0 45 Poor Low grade dysplasia. Much of the cancerous tissue is 
lost in the bloc 
R59 9535/05 4 3 45 0 0 1 40 Good  
R60 7192/05 7 6 75 0 0 1 70 Good  
R61 7366/05 4 2 70 0 0 1 65 Good  
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R63 8336/05 7 2 70 0 0 5 35 Poor Not much tissue 
R64 15809/05 7 5 25 0 0 2 15 Poor  
R65 6086/05         No block 
R66 8000/05 2       Poor Block only, thin block 
R67 10669/05 1       Unusable inadequate tissue 
R68 8178/05        Good Block only 
R69 25344/05 4 4 65 0 0 0 65 Poor Small biopsies 
R70 23046/05 5 5 50 0 0 0 50 Poor Not much tissue on block 
R71 8044/05 5 0 0 5 70 0 70 Good Low grade dysplasia 
R72 12975/05 5 5 65 0 0 0 65 Good Marked Inflammation 
R73 6907/05 5 5 50 0 0 0 55 Good Marked inflammation 
R74 10104/05 A          
R74 10104/05 B 3 3 75 0 0 0 75 Good  
R74 10104/05 X          
R75 12146/05 3 3 45 0 0 0 45 Good Most cancer in one fragment, 75% cancer in said 
fragment 
R76 19939/05 6 3 10 0 0 3 5 Poor Thin block, inflammation 
R77 9378/05        Good Block only 
R78 16912/05 5 4 50 0 0 1 30 Poor Only 2 fragments in block, 50% cancer in two 
fragments 
R79 9329/05        Poor Blok only 2 small fragments 
R80 14129/05 4 1 60 3 55 0 55 Good High grade dysplasia 
R82 19975/05 3 3 30 0 0 0 30 Good Marked inflammation 
R83 9952/05 5 5 40 0 0 0 40 Good 60% in marked areas 
R84 15814/05 A1 1 0 0 1 70 0 70 Good Low grade dysplasia 
R84 15814/05 B1 1 0 0 1 50 0 50 Good Low grade dysplasia 
R84 15814/05 C1 3 0 0 3 45 0 45 Good Low grade dysplasia 
R84 15814/05 D1 3 3 60 0 0 0 60 Good  Thin Block 
R85 10117/05 8 4 55 0 0 4 30 Good 65% cancer in marked area 
R86 11209/05        Good Block only 
R87 13513/05 4 1 60 3 80 0 70 Good Villous adenoma, low grade dysplasia, 
adenocarcinoma, most pieces that contain cancer are 
lost from block 
R88 668/06 5 2 20 3 50 0 35 Poor High grade dysplasia, cancerous fragment lost from 
block 
R89 2043/06 4 4 50 0 0 0 50 Poor Marked inflammation 
R90 344/06 4 1 30 0 0 3 10 Good 60% cancer in marked area 
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R91 138/06 1 0 0 1 30 0 30 Good Low grade adenoma 
R92 452/06         11 blocks, probable endoscopy series 
R93 1477/06 6 6 60 0 0 0 60 Poor  
R94 1958/06 1 0 0 1 70 0 70 Good High grade adenoma 
R95 1682/06 4 4 25 0 0 0 25 Good  
R96 2037/06 6 6 65 0 0 0 65 Poor  
R97 1221/06 6 3 45 0 0 3 25 Poor 70% cancer in marked areas 
R98 51552/06 5 4 35 0 0 1 25 Poor Small fragments, marked inflammation,70% cancer in 
marked area 
R100 1725/06 7 7 70 0 0 0 70 Poor Signet ring cell carcinoma 
R101 1214/06 5 5 10 0 0 0 10 Good Only 2 sections with 30 
R102 2355/06 4 2 40 0 0 2 20 Good 1 piece with 70% cancer 
R103 4254/06 5 5 60 0 0 0 60 Good  
R104 3273/06 7 7 70 0 0 0 70 Good Marked inflammation 
R105 4490/06 5 4 50 0 0 1 40 Good  
R106 2795/06 (1) 3         
R106 2795/06 (2) 3         
R106 2795/06 (3) 6 6 50 0 0 0 50 Good 65% cancer in marked area 
R108 4550/06 8 4 50 0 0 4 25 Good 55% cancer in marked area 
R109 4752/06 2 2 40 0 0 0 40 Good 60% cancer in marked area 
R110 2737/06 5 4 70 0 0 1 40 Poor Mucinous cancer 
R111 1732/06 1 0 0 1 75 0 75 Unusable Low grade dysplasia 
R112 3866/06        Poor Block only 
R113 13580/06 6 5 60 0 0 1 45 Good 65% cancer in marked area 
R115 8025/06 7 6 70 1 70 0 60 Good Low grade dysplasia, serrated dysplasia 
R116 637373 2 2 35 0 0 0 35 Good 45% cancer in marked area 
R117 3886/06 6 3 20 0 0 3 10 Good 20% cancer in marked area 
R118 7252/06 (1) 4 0 0 0 0 4 0 Good  
R118 7252/06 (2) 9 5 60 1 70 3 40 Good Low grade dysplasia, 70% cancer in marked area 
R119 4984/06 7 7 60 0 0 0 60 Poor  
R120 4724/06 3 2 20 0 0 1 10 Poor 40% cancer in marked area 
R122 7346/06 9 7 50 0 0 2 40 Good 60% cancer in marked area 
R123 15966/06 2 0 0 0 0 2 0 Unusable  
R124 6178/06        Good Block only 
R125 7255/06 3 0 0 3 40 0 40 Good Low grade dysplasia, 50% cancer in marked area 
R127 6785/06 A1        Poor Block only 
R127 6785/06 B1        Poor Block only 
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R128 9066/06 5 5 50 0 0 0 50 Good  
R129 10770/06 7 2 70 1 15 4 15 Good Low grade dysplasia 
R130 6870/06 7 6 60 0 0 1 50 Good 75% cancer in marked area 
R131 7501/06        Good Block only 
R132 4971/06 6 4 50 0 0 0 30 Good 75% cancer in marked area 
R133 8159/06 2 2 75 0 0 0 75 Good  
R135 10627/06 2 2 65 0 50 0 65 Good  
R136 21525/06 3 3 50 0 0 0 50 Good  
R137 7949/06 4 3 45 0 0 0 35 Good Cancer in marked areas 
R138 22385/06 6 3 70 0 0 0 35 Good  
R139 10628/06 3 3 70 0 0 0 70 Good Mucinous Cancer 
R140 10166/06 7 7 55 0 0 0 55 Good  
R141 11935/06 5 1 30 2 50 2 15 Poor High grade dysplasia 
R142 14375/06 5 1 45 0 0 0 15 Good  
R143 9245/06 6 3 65 3 45 0 50 Good Low grade dysplasia 
R144 13412/06 3 3 10 0 0 0 5 Poor  
R145 15760/06 3 3 70 0 0 0 70 Good  
R146 10189/06 2 2 50 0 0 0 50 Poor  
R147 11103/06 6 5 55 0 0 1 45 Good 65% cancer in marked area 
Table 45. Table showing the information for each biopsy from each patient of the NWCOG-2 trial. For some patients multiple biopsies were taken. This table shows the 
patient number and biopsy number for each sample along with information on the approximate percentage of dysplastic and cancerous nuclei in the samples, and an overall 
tumour nuclei percentage for the samples. Additional comments onto the quality of the block/sample and descriptions of specific types and grading of cancer and dysplasia 
are also shown in the table. 
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10 Appendix II: Chromatograms for the Sequencing of MRE11, CtIP, 
NBS1and RAD50 for the NWCOG-2 Patient Samples 
 
 
 
 
 
 
 
Figure 48. Chromatograms for the MRE11-E51V mutation in patient R11 from three separate 
sequencing reactions (forward and revers sequences from independent PCR products). This shows the A>T 
base change in the forward strand and the corresponding T>A base change in the reverse strand (as indicated 
by the arrows). The forward sequence chromatogram also shows a trace of the wild-type base (enlarged 
trace of the mutation shown) suggesting that either this trace may include sequence from nearby normal 
tissue, or that this mutation may be heterozygous. This figure also shows the chromatogram for the same 
region in the same patient from normal DNA extracted from the patient’s blood. This shows an absence of 
this mutation, indicating that this mutation has occurred somatically. 
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Figure 49. Chromatograms for the MRE11-S382N mutation in patient R11 from three separate 
sequencing reactions (forward and reverse sequences from independent PCR products). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequences show no trace of the wild-type base suggesting that this 
mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the same region 
in the same patient from normal DNA extracted from the patient’s blood. This shows an absence of this 
mutation, indicating that this mutation has occurred somatically. 
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Figure 50. Chromatograms for the MRE11-L446P mutation in patient R11 from three separate 
sequencing reactions (forward and reverse sequences from independent PCR products). This shows the T>C 
base change in the forward strand and the corresponding A>G base change in the reverse strand (as 
indicated by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-
type base suggesting that either this trace may include sequence from nearby normal tissue, or that this 
mutation may be heterozygous. This figure also shows the chromatogram for the same region in the same 
patient from normal DNA extracted from the patient’s blood. This shows an absence of this mutation, 
indicating that this mutation has occurred somatically. 
 
292 
 
 
 
 
 
 
 
 
  
Figure 51. Chromatograms for the MRE11-G569P mutation in patient R119 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR products). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequences show no trace of the wild-type base suggesting that this 
mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the same region 
in the same patient from normal DNA extracted from the patient’s blood. This shows an absence of this 
mutation, indicating that this mutation has occurred somatically. 
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Figure 52. Chromatograms for the MRE11-K682K mutation in patient R11 from three separate 
sequencing reactions (forward and reverse sequences from independent PCR products). This shows the A>G 
base change in the forward strand and the corresponding G>A base change in the reverse strand (as 
indicated by the arrows). The forward and reverse sequences show no trace of the wild-type base suggesting 
that this mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the 
same region in the same patient from normal DNA extracted from the patient’s blood. This shows an 
absence of this mutation, indicating that this mutation has occurred somatically. 
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Figure 53. Chromatograms for the MRE11-V684A mutation in patient R11 from three separate 
sequencing reactions (forward and reverse sequences from independent PCR products). This shows the T>C 
base change in the forward strand and the corresponding A>G base change in the reverse strand (as 
indicated by the arrows). The forward and reverse sequences show no trace of the wild-type base suggesting 
that this mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the 
same region in the same patient from normal DNA extracted from the patient’s blood. This shows an 
absence of this mutation, indicating that this mutation has occurred somatically. 
295 
 
 
 
 
 
 
 
 
  
Figure 54. Chromatograms for the CtIP-L286L mutation in patient R11 from three separate sequencing 
reactions (forward and reverse sequences from the same PCR product). This shows the G>A base change in 
the forward strand and the corresponding C>T base change in the reverse strand (as indicated by the arrows). 
The forward and reverse sequences show no trace of the wild-type base suggesting that this mutation may be 
homozygous or hemizygous. This figure also shows the chromatogram for the same region in the same 
patient from normal DNA extracted from the patient’s blood. This shows an absence of this mutation, 
indicating that this mutation has occurred somatically. 
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Figure 55. Chromatograms for the CtIP-Q293R mutation in patient R119 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the A>G 
base change in the forward strand and the corresponding T>G base change in the reverse strand (as indicated 
by the arrows). The reverse sequence chromatogram also shows a trace of the wild-type base suggesting that 
either this trace may include sequence from nearby normal tissue, or that this mutation may be heterozygous. 
This figure also shows the chromatogram for the same region in the same patient from normal DNA 
extracted from the patient’s blood. This shows an absence of this mutation, indicating that this mutation has 
occurred somatically. 
CtIP-Q293R 
P 
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Figure 56. Chromatograms for the CtIP-D548D mutation in patient R11 from three separate sequencing 
reactions (forward and reverse sequences from independent PCR products from the same initial multiplex 
PCR). This shows the T>C base change in the forward strand and the corresponding A>G base change in the 
reverse strand (as indicated by the arrows). The reverse sequence chromatogram also shows a trace of the 
wild-type base (enlarged trace of the mutation shown) suggesting that either this trace may include sequence 
from nearby normal tissue, or that this mutation may be heterozygous. This figure also shows the 
chromatogram for the same region in the same patient from normal DNA extracted from the patient’s blood. 
This also shows the mutation, and a trace of the wild-type base (enlarged trace of the mutation base shown) 
this shows that this mutation is germline heterozygous. 
298 
 
 
 
 
 
 
 
 
  
Figure 57. Chromatograms for the CtIP-F614F mutation in patient R119 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequences show no trace of the wild-type base suggesting that this 
mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the same region 
in the same patient from normal DNA extracted from the patient’s blood. This shows an absence of this 
mutation, indicating that this mutation has occurred somatically. 
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Figure 58. Chromatograms for the CtIP-K704K mutation in patient R135 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also show traces of the wild-type base 
(enlarged trace of the mutation shown) suggesting that either this trace may include sequence from nearby 
normal tissue, or that this mutation may be heterozygous. This figure also shows the chromatogram for the 
same region in the same patient from normal DNA extracted from the patient’s blood. This also shows the 
mutation, and a trace of the wild-type base (enlarged trace of the mutation base shown) this shows that this 
mutation is germline heterozygous. This mutation, with similar chromatograms, was also found for patients 
R133 and R139 (chromatograms not shown). 
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Figure 59. Chromatograms for the CtIP-L740S mutation in patient R11 from three separate sequencing 
reactions (forward and reverse sequences from the same PCR products). This shows the T>C base change in 
the forward strand and the corresponding A>G base change in the reverse strand (as indicated by the 
arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 60. Chromatograms for the NBS-L34L mutation in patient R18 from three separate sequencing 
reactions (forward and reverse sequences from the same PCR product). This shows the G>A base change in 
the forward strand and the corresponding C>T base change in the reverse strand (as indicated by the arrows). 
The forward and reverse traces show no trace of the wild-type base suggesting that this mutation may be 
homozygous or hemizygous. This figure also shows the chromatogram for the same region in the same 
patient from normal DNA extracted from the patient’s blood. This shows the presence of this mutation, 
showing that this mutation is germline. This mutation was also found in patients R7, R24, R60, R84, R93, 
R103, R115, and R139. This mutation was found to also be homozygous in patients R24, R60 and R103, 
and was found to be heterozygous in patients R7, R84, R93, R115 and R139. This mutation was found to be 
germline in all patients were blood DNA was available (no blood DNA available for patient R24). 
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Figure 61. Chromatograms for the NBS1-H149D mutation in patient R119 from three separate 
sequencing reactions (forward and reverse sequences from independent PCR products from the same initial 
multiplex PCR). This shows the C>G base change in the forward strand and the corresponding G>C base 
change in the reverse strand (as indicated by the arrows). The forward and reverse sequences show no trace 
of the wild-type base suggesting that this mutation may be homozygous or hemizygous. This figure also 
shows the chromatogram for the same region in the same patient from normal DNA extracted from the 
patient’s blood. This shows an absence of this mutation, indicating that this mutation has occurred 
somatically. 
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Figure 62. Chromatograms for the NBS-E185Q mutation in patient R18 from three separate sequencing 
reactions (forward and reverse sequences from the same PCR product). This shows the G>C base change in 
the forward strand and the corresponding C>G base change in the reverse strand (as indicated by the 
arrows). The forward and reverse traces show no trace of the wild-type base suggesting that this mutation 
may be homozygous or hemizygous. This figure also shows the chromatogram for the same region in the 
same patient from normal DNA extracted from the patient’s blood. This shows the presence of this mutation, 
showing that this mutation is germline. This mutation was also found in patients R7, R24, R84, R93, R103, 
R115, R133 and  R139. This mutation was found to also be homozygous in patients R24 and R103, and was 
found to be heterozygous in patients R7, R84, R93, R115, R133 and R139. This mutation was found to be 
germline in all patients were blood DNA was available (no blood DNA available for patient R24) 
NBS1-E185Q 
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Figure 63. Chromatograms for the NBS-D399D mutation in patient R18 from three separate sequencing 
reactions (forward and reverse sequences from the same PCR product). This shows the T>C base change in 
the forward strand and the corresponding A>G base change in the reverse strand (as indicated by the 
arrows). The forward and reverse traces show no trace of the wild-type base suggesting that this mutation 
may be homozygous or hemizygous. This figure also shows the chromatogram for the same region in the 
same patient from normal DNA extracted from the patient’s blood. This shows the presence of this mutation, 
showing that this mutation is germline. This mutation was also found in patients R11, R13, R24, R84, and 
R115. This mutation was found to also be homozygous in patients R24 and R115, and was found to be 
heterozygous in patients R11, R13, and R84. This mutation was found to be germline in all patients were 
blood DNA was available (no blood DNA available for patients R13 and R24). 
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Figure 64. Chromatograms for the RAD50-G36E mutation in patient R50 from two separate sequencing 
reactions (forward and reverse sequences from the same PCR products). This shows the G>A base change in 
the forward strand and the corresponding C>T base change in the reverse strand (as indicated by the arrows). 
The forward and reverse sequences show no trace of the wild-type base suggesting that this mutation may be 
homozygous or hemizygous. No blood DNA was available for this patient, therefore it is unknown if this 
mutation is somatic or germline. 
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Figure 65. Chromatograms for the RAD50-G39G mutation in patient R93 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR products). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 66. Chromatograms for the RAD50-R78R mutation in patient R93 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the A>G 
base change in the forward strand and the corresponding T>C base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 67. Chromatograms for the RAD50-Q524Q mutation in patient R12 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 68. Chromatograms for the RAD50-1703delG mutation in patient R50 from two separate 
sequencing reactions (forward and reverse sequences from independent PCR products). This shows the G 
base deletion in the forward strand and the corresponding C base deletions in the reverse strand (as indicated 
by the arrows). The forward and reverse sequences show a trace of the wild-type suggesting that this sample 
may contain DNA from nearby normal tissue or that the mutation is heterozygous. No blood DNA was 
available for this patient; therefore it is unknown if this mutation is somatic or germline.  
Patient: R50               1 bp deletion 
 
 
1 bp del 
1 bp del 
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Figure 69. Chromatograms for the RAD50-C680S mutation in patient R60 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the T>A 
base change in the forward strand and the corresponding A>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 70. Chromatograms for the RAD50-V733M mutation in patient R60 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 71. Chromatograms for the RAD50-T896I  mutation in patient R133 from two separate 
sequencing reactions. This shows the C>T base change in the forward strand (as indicated by the arrow). 
The forward sequences show no trace of the wild-type base suggesting that this mutation may be 
homozygous or hemizygous. This figure also shows the chromatogram for the same region in the same 
patient from normal DNA extracted from the patient’s blood. This shows an absence of this mutation, 
indicating that this mutation has occurred somatically. 
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Figure 72. Chromatograms for the RAD50-M1001K mutation in patient R93 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the T>A 
base change in the forward strand and the corresponding A>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 73. Chromatograms for the RAD50-Q1006R mutation in patient R60 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the A>G 
base change in the forward strand and the corresponding T>C base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequences show no trace of the wild-type base suggesting that this 
mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the same region 
in the same patient from normal DNA extracted from the patient’s blood. This shows an absence of this 
mutation, indicating that this mutation has occurred somatically. 
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Figure 74. Chromatograms for the RAD50-Q1011H mutation in patient R60 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the G>T 
base change in the forward strand and the corresponding C>A base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequences show no trace of the wild-type base suggesting that this 
mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the same region 
in the same patient from normal DNA extracted from the patient’s blood. This shows an absence of this 
mutation, indicating that this mutation has occurred somatically. 
 
316 
 
 
 
 
 
 
 
Figure 75. Chromatograms for the RAD50-E1084G mutation in patient R104 from two separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the A>G 
base change in the forward strand and the corresponding T>C base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous.  No blood DNA was available for this patient; therefore it is unknown if this mutation is 
somatic or germline. 
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Figure 76. Chromatograms for the RAD50-L1092F mutation in patient R72 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the C>T base 
change in the forward strand and the corresponding G>A base change in the reverse strand (as indicated by 
the arrows). The forward and reverse sequences show no trace of the wild-type base suggesting that this 
mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the same region 
in the same patient from normal DNA extracted from the patient’s blood. This shows an absence of this 
mutation, indicating that this mutation has occurred somatically. 
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Figure 77. Chromatograms for the RAD50-L1093X mutation in patient R72 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the C>T base 
change in the forward strand and the corresponding G>A base change in the reverse strand (as indicated by 
the arrows). The forward and reverse sequences show no trace of the wild-type base suggesting that this 
mutation may be homozygous or hemizygous. This figure also shows the chromatogram for the same region 
in the same patient from normal DNA extracted from the patient’s blood. This shows an absence of this 
mutation, indicating that this mutation has occurred somatically. 
319 
 
 
 
 
 
 
 
Figure 78. Chromatograms for the RAD50-V1187V mutation in patient R12 from three separate 
sequencing reactions (forward and reverse sequences from the same PCR product). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 79. Chromatograms for the RAD50-V1187V mutation in patient R61 from three separate 
sequencing reactions (forward and reverse sequences from independent PCR products). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 80. Chromatograms for the RAD50-E1275E mutation in patient R12 from three separate 
sequencing reactions (forward and reverse sequences from independent PCR products). This shows the G>A 
base change in the forward strand and the corresponding C>T base change in the reverse strand (as indicated 
by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-type base 
suggesting that either this trace may include sequence from nearby normal tissue, or that this mutation may 
be heterozygous. This figure also shows the chromatogram for the same region in the same patient from 
normal DNA extracted from the patient’s blood. This shows an absence of this mutation, indicating that this 
mutation has occurred somatically. 
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Figure 81. Chromatograms for the RAD50-S1280F mutation in patient R61 from two separate 
sequencing reactions (forward and reverse sequences from independent PCR products). This shows the C>T 
base change in the forward strand and the corresponding G>A base change in the reverse strand (as 
indicated by the arrows). The forward and reverse sequence chromatograms also shows traces of the wild-
type base suggesting that either this trace may include sequence from nearby normal tissue, or that this 
mutation may be heterozygous.  No blood DNA was available for this patient; therefore it is unknown if this 
mutation is somatic or germline. 
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11 Appendix III: Fluorescent Fragment Analysis Electropherograms for 
NWCOG-2 Patient Samples 
11.1 MRE11 
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Figure 82. Example electropherograms for the fluorescence fragment analysis of the region of MRE11 
that contains the poly(T)11 tract, which is subject to mutation in MSI+ cancers for each of the initial 25 
patient samples of the NWCOG-2 trial. Fluorescent fragment analysis for MRE11 not carried out on patients 
R7, R51 and R84 due to insufficient DNA. 
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11.2 CtIP 
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Figure 83. Example electropherograms for the fluorescence fragment analysis of the region of CtIP 
that contains the poly(A)9 tract, which is subject to mutation in MSI+ cancers for each of the initial 25 
patient samples of the NWCOG-2 trial. 
 
